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It is widely acknowledged that maternal obesity and metabolic disorder during 
pregnancy may trigger long-lasting cardiovascular dysfunction in the mother. In 
obese pregnancy, there is progressive insulin resistance and a systemic inflammatory 
end-organ structure and function. Emerging evidence suggests that the offspring may 
also be subject to these metabolic changes and endure these long-lasting effects. 
The ‘Developmental Origins of Health and Disease’ (DOHaD) model suggests that 
exposure to an abnormal environment in utero, such as in obese or diabetic 
pregnancy, may set a trajectory of greater offspring adiposity throughout the life-
course. This is demonstrated by the fact that exposure to maternal adiposity during 
pregnancy is associated with higher offspring birthweight and greater adiposity 
through childhood and into adulthood. Offspring of mothers with diabetes or 
hypertensive disorders of pregnancy (HDP), such as pre-eclampsia (PE), may also 
adopt a greater risk of cardiovascular disease in later life. This cycle is then 
perpetuated when the affected offspring become pregnant and extend this 
exponential risk profile onto the next generation. Epigenetic modification has been 
proposed in the pathogenesis of disease but shared familial lifestyle and behaviours 
may also be causal. With the increasing prevalence of childhood obesity and 
metabolic disorders, such as non-alcoholic fatty liver disease (NAFLD), there is a 
greater need to examine these causal relationships and determinants of the fetal 





Adipokines have both endocrine and paracrine function and are secreted by adipose 
tissue, as well as the placenta. Leptin is required for the regulation of maternal 
appetite and despite high levels during pregnancy, pregnancy induces a state of 
leptin resistance. Leptin is also a valid biomarker of neonatal fat mass and may be 
used as a proxy for neonatal anthropometry. Adiponectin has an opposing function 
to leptin during pregnancy and correlates with fasting insulin levels. Low adiponectin 
amongst obese adults is associated with metabolic dysfunction and systemic insulin 
resistance.  
 




and Children (ALSPAC), analysis of 5011 cord blood samples was performed for the 
purpose of this thesis. Offspring biomarkers and birthweight were examined in 
relation to obese, diabetic and hypertensive disordered pregnancy. Since biomarkers 
have shown evidence of tracking in later life, repeat measures at serial time points 
from birth (referred to as ‘like for like’ measures), using data available from the 
offspring at later time points, were also examined. Lastly, cord blood adipokines and 
birthweight were examined in relation to later obesity or development of NAFLD 
amongst the offspring to determine the impact of fetal over-nutrition, as 
demonstrated by higher cord blood leptin for example, on the long-term metabolic 
function of the offspring.  
 
This study has demonstrated that maternal body mass index (BMI), rather than 
appropriate GWG, was more consistently associated with a wider range of offspring 
cardio-metabolic markers at birth. Whilst there was limited evidence of GDM 
influencing cord blood at birth, offspring of mothers with pre-eclampsia displayed 
higher cord blood leptin and lipids.  
 
There was limited evidence of tracking of cord blood measures from birth into 
adolescence, however. Specifically, gamma-glutamyl transferase (GGT) and 
adiponectin correlated with repeat measures taken at birth and age 9. Whilst the 
association with adiponectin was lost in later childhood,  this study has shown that 
GGT may track from birth to age 17. Lastly, this study has demonstrated that cord 
blood leptin was weakly, and adiponectin strongly related to adiposity in childhood 
and adolescence respectively. As cord blood leptin may be used as a reflection of 
fetal fat mass, the positive association with adiposity in later life demonstrates that 
the offspring may be ‘programmed’ at birth and set on a trajectory of enhanced 
adiposity in later life. Neither birthweight, nor adiposity at birth were related to 
offspring markers of liver structure or function in adolescence, however. This 
suggested that behavioural and environmental factors may have contributed to the 
pathogenesis of NAFLD, and similar disorders, rather than exposure to an adverse 
perinatal environment itself.  
 
In conclusion, this study has demonstrated a limited association between disordered 




biomarkers being used as clinical predictors of disease may be the focus of future 
research, they are already established biomarkers of neonatal anthropometry. Given 
the direction of the association between cord blood leptin and birthweight with later 
offspring adiposity, exposure to over-nutrition in pregnancy may therefore have a 
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This thesis will examine the relationship between the intrauterine environment, as 
measured by cord blood analytes (reflecting maternal metabolic health and the 
environment to which the offspring was exposed during pregnancy) on offspring 
cardio-metabolic function at birth and in later life. By examining the relationship 
between these cord blood indices and long-term offspring outcomes, including 
adiposity and disease relating to metabolic dysfunction (such as non-alcoholic fatty 
liver disease), their relationship in the causal pathway is examined. Disordered 
metabolism in pregnancy, namely excessive gestational weight gain (GWG), diabetic 
and hypertensive disorders, may also influence the intrauterine environment and 
provide abnormal exposure to the offspring. The extent to which these maternal 
conditions influence cord blood analytes, reflecting potential programming of 
offspring metabolism at birth will also be determined. Finally, this thesis will 
examine the extent to which this biochemical imprint at birth tracks throughout the 
life course by examining metabolic analytes at serial time-points and comparing 
repeated measures of analytes (‘like for like’ measures)  at serial time points from 
birth to adolescence.   
 
 
Several reviews and publications have highlighted the need for large long-term 
follow-up studies examining the true effect of the intrauterine environment over 
environmental and familial factors influencing adiposity later in life (Debbie A. 
Lawlor et al., 2012; Lawlor, 2013). Using data obtained by the large prospective 
cohort - the Avon Longitudinal Study of Parents and Children (ALSPAC) - in addition 
to novel data created for this thesis from analyses of 5011 cord blood samples, it 
provides an overview of the biochemical influences of the maternal environment, 
offspring cardio-metabolic function at birth and the impact this may have on the 





1.1 Maternal metabolism in pregnancy 
 
 
Maternal metabolism alters significantly throughout each stage of pregnancy as 
energy requirements change accordingly. Accrual of lipid is characteristic of the first 
trimester, while insulin sensitivity remains under normal pre-gravid regulation 
(Franz, 1978; Catalano et al., 1999). This accretion of fat is to provide reserve 
energy stores required for late pregnancy where the demands are greater as the 
fetus grows and the mother prepares for birth and subsequent breastfeeding. With 
advancing gestation, the mother becomes progressively insulin resistant (Catalano 
et al., 1991) and there is compensatory hyperinsulinemia (Spellacy and Goetz, 
1963). This process triggers the release of free fatty acids and gluconeogenesis so 
that the increasing energy requirements of the developing fetus may be met, 
particularly during the third trimester. This is thought to be secondary to hormones 
produced by the placenta at this late stage, namely human placental lactogen and 
leptin. The degree of insulin sensitivity is inversely proportional to placental and 
birthweight and is,, therefore, a significant adaption in the growth of a healthy fetus 
(Catalano, Drago, and Amini, 1995). The HAPO study highlights the importance of 
good glycaemic control in pregnancy and demonstrated that maternal glucose levels 
are strongly associated with pregnancy outcomes. Birthweight, for example, 
correlated positively with maternal glucose levels, even where glucose levels did 
not meet the threshold for gestational diabetes (GDM) (Metzger et al., 2008). As 
such, it is becoming increasingly apparent that the maternal health and intrauterine 
environment that the fetus is exposed to in utero may have a significant impact on 















Defined by the World Health Organisation (WHO) in 2000, obesity is characterised 
by an ‘abnormal or excessive fat accumulation that may impair health’. This is 
further classified by the International Classification of Disease (ICD-10), recognising 
extreme obesity (E66.8) as a subgroup of its own.   
 
 
In keeping with the global health pandemic, the incidence of obesity in the UK 
continues to increase. In 2015, 58% of females and 68% of males were classified as 
overweight or obese, with a BMI of greater than30kg/m2 (World Health Organization, 
2018). Whilst there is some evidence to suggest that the incidence of obesity in the 
US may have plateaued (Ogden et al., 2014), the prevalence of obesity in the UK has 
risen dramatically from 15% in 1993 to 27% in 2015, with morbid obesity increasing 
three-fold during this time (World Health Organization, 2018). Despite considerable 
public health campaigns, particularly in pre-school children (Department of Health, 
Physical Activity, 2011), this phenotype appears to be trans-generational as 
currently 1 in 3 primary school children in England are classed as overweight or obese 
(World Health Organization, 2018). Being overweight at age 7 or 13 is positively 
associated with overweight in adulthood as well as the risk of type 2 diabetes 
(Bjerregaard et al., 2018). Childhood adiposity is also associated with metabolic 
dysfunction with elevated cholesterol, triglyceride, glycosylated haemoglobin, 
systolic blood pressure, and low-density lipoprotein cholesterol (LDLc) (Skinner et 
al., 2008, 2015). 
 
 
The rise in obesity, particularly in adolescents and younger age groups (Flegal et al., 
2010; Ogden et al., 2016), has particular concern during childbearing years as almost 
one-third of women aged 20 or over in the US are obese (Flegal et al., 2016). In 
keeping with national trends in the UK, maternal BMI at first midwife appointment 
(booking) is rising. In a large retrospective analysis of births between 1989 and 2007, 




appointment (Barber, Rankin, and Heslehurst, 2017). Cross-sectional data from the 
UK in 2015 however demonstrates that 45% of women fulfil these criteria (Health & 
Social Care Information Centre (HSCIC), 2015) and there is a disturbing trend to 
morbid obesity (BMI ≥40kg/m2) (Heslehurst et al., 2010). Whilst highlighting the 
current obesogenic climate, this also emphasises the need to limit escalating trends 
in obesity amongst women of childbearing age and address the impact on both 
mother and child (Deierlein et al., 2012) in the short and long-term.   
 
 
1.1.2 Adipose tissue, obesity, and insulin resistance 
 
 
Over-expansion of adipose tissue in obesity causes local and systemic dysfunction. 
Locally, there is dysregulation of adipose function and abnormal secretion of 
adipokines and pro-inflammatory cytokines as their pathways are upregulated. 
Leptin and adiponectin for example are expressed differently and the systemic 
metabolic response to them significantly altered. There are also widespread 
multisystem effects of obesity. Targeting the liver, skeletal muscle, pancreas, and 
brain specifically, this will clinically manifest as systemic insulin resistance and the 
pathophysiological features associated with obesity vascular dysfunction. 
Collectively this may lead to diabetes, hypertension, development of metabolic 
syndrome, and ultimately greater cardiovascular risk.   
 
 
An excess supply of free fatty acid in the liver (due to reduced storage capacity of 
adipose resulting from insulin resistance) contributes to greater intracellular lipid 
levels. Excess free fatty acid in conjunction with lipogenesis also contributes to 
greater production of very-low-density lipoprotein cholesterol (VLDLc) (Lewis et al., 
2002). Collectively they compound the greater risk of cardiovascular disease such as 
atherosclerosis. Locally, greater lipid levels lead to greater oxidative stress which 
may lead to hepatotoxicity and stimulation of hepatic inflammation (Sanyal et al., 
2001). Whilst obesity is a recognised risk factor for fatty liver disease, genetic 




et al., 2008). Within the lean population, there is a recognised group that has 
metabolic dysfunction but normal weight. It is thought that the greater proportion 
of mat mass may contribute to this predisposition. In this subset of the population, 
low physical activity was the main aggravator for the development of this phenotype 
(Karelis et al., 2004). Conversely, among the obese population, not all subjects have 
metabolic dysfunction and insulin resistance although many display early 
atherosclerotic changes and vascular abnormalities even in the absence of insulin 
resistance (Bonora et al., 1998; Karelis et al., 2004).  
 
 
Accrual of ectopic intracellular fat  is also associated with insulin resistance, 
independent of BMI or total body fat content (Korenblat et al., 2008). Whilst 
bariatric surgery and weight loss may reduce liver fat and lessen insulin resistance 
(Petersen et al., 2005; Vitola et al., 2009; Lim et al., 2011; Rossi et al., 2012), 
exercise alone has even been shown to improve hepatic fat content irrespective of 
the outcome on body weight (Hallsworth et al., 2011). Hepatic fat content, 
therefore, plays a key role in hepatic glucose production and insulin sensitivity.  
 
 
Obesity induces dysregulation of metabolic pathways and stimulates inflammatory 
processes which have a local and systemic effect. Clinically these may manifest in 
disease associated with disturbed end-organ structure and function. This cycle is 
then perpetuated by an obese-state and consequent dysfunction of normal 
metabolism. Pregnancy, with its progressive insulin resistance and fat deposition 
with increasing gestation, therefore carries a greater risk of worsening metabolism 





1.2 Adipose tissue 
 
1.2.1 Anatomical function of adipose tissue 
 
 
In humans’, there are three types of fat depots – brown, white, and beige adipose 
tissue. Adults have mostly white adipose tissue, and it is this tissue that increases in 
obesity. In contrast, brown adipose tissue is found mostly in the fetus and neonate 
with its role mainly in thermogenesis. It has been shown to generate significantly 
more heat than any other organ in the body (Symonds, Pope, and Budge, 2015) via 
its unique uncoupling protein (UCP1) that allows free passage of protons across the 
mitochondrial membrane (Cannon and Nedergaard, 2012). Brown adipose tissue is 
activated at birth as a result of cold exposure to the ex-utero environment, 
endocrine stimulation, and increase in UCP1 at birth that occurs during this time. It 
has been shown that although it may have a role in energy homeostasis in adult 
humans, it represents less than 1% of the total adipose tissue (Cypess et al., 2009). 
Although it, therefore, has a relatively minor role in adults, it remains responsive to 
sold stimuli (Virtanen et al., 2009) and the amount of brown adipose tissue is 
inversely proportional to BMI. This may support less of a requirement for non-
shivering thermogenesis in obese humans or reflect the inability in obese subjects 
to dispose of excess calories and therefore gain even more adipose tissue (Cypess et 
al., 2009).  
 
 
Beige adipose tissue is a more recent discovery and although it contains less UCP1 
than brown adipose tissue it resides in white adipose tissue, which has greater mass 
than any other adipose tissue and therefore has potential for more functional 
significance (Sepa-Kishi and Ceddia, 2018) 
 
 
Adipose tissue is a highly active organ of the endocrine system and has a specific 
function according to its anatomical site. As an organ of mesodermal origin, it is 




triglyceride. Its role however has emerged to be more complex and multifaceted as 
it is emerging that it is a highly active endocrine organ rather than an inert lipid 
storage organ. While fetal adipose tissue is composed of both brown and white 
adipose tissue, adults tend to have mostly white adipose tissue. Lymph nodes are 
also found within adipose tissue and the stromal cells found within demonstrate a 
localised immune cell response. In combination with the adipocytes found within 
adipose tissue, macrophages, fibroblasts, and endothelial cells activated during the 
immune cell response form the majority of the secretory products of adipose tissue.  
 
 
In contrast, white adipose tissue is widespread and found mainly subcutaneously and 
viscerally. Muscle and bone marrow are also thought to contain some white adipose 
as well. Composed of mainly adipocytes mainly derived from mesenchymal cells, 
white adipose tissue begins to form in the second trimester of pregnancy although 
most of the accrual and deposition of fetal adipose tissue occurs in the third 
trimester (Symonds et al., 2003). White adipose tissues’ function is mainly in 
supporting stromal cells and the vascular network.  
 
 
There may be regional differences in the characteristics and function of adipose 
depots as the site and size of the adipose depot confers  specific metabolic risk. The 
more metabolically active visceral depots, which include intra-abdominal adipose 
tissue, are associated with greater cardiovascular and metabolic risk. Visceral 
adipocytes tend to be smaller in size compared to subcutaneous depots and there is 
greater stromal cell infiltration into visceral depots, especially in obesity (Harman-
Boehm et al., 2007) thus contributing to the greater metabolic risk associated with 
visceral adipose tissue. Subcutaneous depots in contrast, despite comprising 80% of 
total body adipose, tend to confer less cardiovascular and metabolic risk. Its role 





1.2.2 Biochemical function of adipose tissue 
 
 
Under endocrine regulation, one of the main roles of adipocytes within adipose 
tissue is energy storage. Depending on whether the subject is in an energy-requiring 
or energy-replete state, determines the relative rate of lipid synthesis and lipolysis.  
Chylomicrons or  VLDLc circulate bound to protein and are hydrolysed by lipoprotein 
lipase and are bound to the endothelial surfaces of adipose tissue capillaries. The 
non-esterified fatty acid is then bound to protein and converted to fatty acid 
coenzyme A. It is then re-esterified with glycerol – 3 – phosphate to form 
triacylglyceride (TAG) in the endoplasmic reticulum. Hence lipid is stored in the 
form of TAG as a single anhydrous lipid droplet in the cytoplasm of the adipocyte. 
During fasting conditions, hormone-sensitive lipase is phosphorylated and relocates 
from the cytoplasm to the surface of the lipid droplet (Brasaemle et al., 2000). 
Triglyceride is then hydrolysed, and one molecule of glycerol and three molecules 
of fatty acid are released into the circulation. The free fatty acid is released to the 
plasma membrane from the lipid droplet bound to the fatty acid-binding protein 
(Baar et al., 2005). The free fatty acid is then bound to albumin and transported to 
the liver where they undergo beta-oxidation whereas glycerol is exported and used 
as a substrate for gluconeogenesis in the liver.  
 
 
Insulin is the principal hormone involved in enhanced lipid storage as it promotes 
lipid esterification and inhibition of lipolytic enzymes. It also promotes translocation 
of the Glucose Transporter 4 to the cell surface which in turn increases glucose 
uptake. Glucocorticoids (cortisol) also promote lipid storage by limiting lipolysis.  
Glucose is then phosphorylated and enters the lipid synthesis pathway. In contrast, 
catecholamines (adrenaline and noradrenaline) are mainly responsible for the 
release of lipids via lipolysis. Acting via adrenoceptors beta 1 and beta 2, they 






1.2.3 Endocrine function of adipose tissue 
 
Adipose tissue is a highly active endocrine organ and its role in lipid storage is only 
one element of its function. Adipokines are hormones with endocrine and paracrine 
functions. They are secretory products of adipose tissue. They form a group of 
hormones that include adipokines leptin and adiponectin, as well as inflammatory 
cytokines interleukin-6 and tumour necrosis factor-alpha. In obesity, the synthesis 
and secretion of inflammatory products become dysregulated although their role in 
the physiological control of adipose tissue is unclear. Whilst leptin has been shown 
to correlate with insulin sensitivity in some studies, leptins’ counterpart, 
adiponectin, may be more closely associated with this (Kirwan et al., 2002; 
McLachlan et al., 2006).  
 
 
Leptin has an important role in pregnancy for both the mother and the fetus. High 
levels of leptin in pregnancy are thought to be for the regulation of maternal 
appetite. Leptin is a 16kDa hormone that is mainly produced by white adipose tissue 
(Zhang et al., 1994) but it is also produced by the ovary (Cioffi, 1997), pituitary (Jin 
et al., 2000), and by the placenta in pregnancy (Masuzaki et al., 1997; Jin et al., 
2000). Subcutaneous adipose specifically is thought to be the main contributor to 
circulating leptin concentrations and leptin mRNA is greater in subcutaneous 
compared to omental adipose tissue (Montague et al., 1998). Leptin has a diverse 
role as it has pleiotropic effects on multiple organs. It is involved in the regulation 
of appetite (suppression), satiety, reproductive function, body mass, and immune 
regulation (Friedman and Halaas, 1998; Chan et al., 2006; Kelesidis et al., 2010). 
Circulating levels of leptin are proportional to fat mass (Maffei et al., 1995; 
Considine et al., 1996; Rönnemaa et al., 1997) and correlate inversely with insulin 
sensitivity independently of fat mass (Silha et al., 2003).  
 
 
In obesity, there are high levels of leptin (Maffei et al., 1995; Considine et al., 1996). 
Although leptin enhances insulin-sensitive pathways, in severe obesity there is often 




This may reflect end-organ insensitivity to leptin in obese subjects causing reduced 
hypothalamic signalling in response to leptin. In human pregnancy, the placenta is a 
major source of leptin (Masuzaki et al., 1997). In contrast, mouse studies show that 
leptin is mainly produced by adipose tissue in pregnancy and not by the placenta at 
all (Malik et al., 2005). In humans, circulating leptin levels correlate with hormones 
human chorionic gonadotrophin (hCG) and oestradiol and with insulin sensitivity 
(McLachlan et al., 2006). As such, serum leptin levels are consistently higher in 
pregnant women compared to non-pregnant women (Highman et al., 1998; Hendler, 
Blackwell, et al., 2005; McLachlan et al., 2006). Leptin levels continue to rise with 
advancing gestation, in keeping with fetal and placental development (Sattar et al., 
1998; Melczer et al., 2003), until around the third trimester of pregnancy. It is 
around this stage that leptin levels may begin to plateau or even fall, as placental 
leptin transcript levels  are  significantly lower at term compared to the first 
trimester (Sattar et al., 1998; Henson and Castracane, 2006). This reflects the trend 
in fat mass accumulation although leptin levels are still higher in the third trimester 
than in the non-pregnant state (Eriksson et al., 2010). 
 
 
The rise in serum leptin in pregnancy  is lesser in obese women compared to lean 
women  (Misra and Trudeau, 2011) which may also be in keeping with obese women 
gaining less fat mass, but also supporting the hypothesis that other tissues, 
supplementary to adipose tissue, may also account for the upregulation of leptin 
production with advanced gestation. These studies are however limited due to the 
inaccuracies of measuring fat mass and leptin in pregnancy. Fat mass, for example, 
is difficult to accurately quantify in a pregnant woman because of the distribution 
of fat and the gravid uterus. Measurement of serum leptin in obese versus lean 
women in pregnancy may also lead to inaccuracy as obese women have a larger 
circulating volume. The same mass of leptin will equate to a greater volume of 
distribution  and therefore a lower concentration of leptin in obese women.  
 
 
Pregnancy, whilst a state of hyperleptinemia, is also a state of relative leptin 




therefore eat excessively, stimulating more fat stores. Infusion of leptin in rats 
failed to suppress maternal appetite (Ladyman and Grattan, 2004). In ob/ob mice, 
withdrawal of leptin at different points throughout gestation appeared to influence 
maternal appetite and weight gain (Mounzih et al., 1998). In pregnant rats, there is 
also increased leptin binding protein (Seeber, Smith and Waddell, 2002) and 
downregulation of leptin receptors in the hypothalamus (Ladyman and Grattan, 
2004) thereby limiting the supply and uptake of leptin centrally. Pregnancy is 
therefore a state of relative maternal leptin (and insulin) resistance despite the 
development of hyperleptinemia due to increasing fat stores and placental secretion 
with advancing gestation. Greater maternal adiposity may alter leptin levels in 
pregnancy as obesity (along with greater maternal fat mass) is associated with 
maternal hyperleptinemia as well as reduced amino acid transport and uptake by 
the placenta (Farley et al., 2009). Intracerebroventricular infusion of leptin in 
pregnant rats, for example, does not suppress appetite unlike in non-pregnant rats 
(Ladyman and Grattan, 2004). There is also increased levels of leptin binding protein 
in pregnant rats (Seeber, Smith and Waddell, 2002), and downregulation of leptin 
receptors in the hypothalamus (Ladyman and Grattan, 2004) contributing to reduced 
availability of leptin to the brain. Once released into the maternal circulation, 
placental leptin (Linnemann et al., 2000) may regulate the energy supply to the 
fetus via altered amino acid uptake pathways (despite very little placental leptin 
being released to the fetal side of the placenta) (von Versen-Höynck et al., 2009). 
Collectively, increased fat stores, as well as placental secretion of leptin, may lead 
to a state of hyperleptinemia in pregnancy. Relative leptin resistance may ensue 
during pregnancy as shown in animal models which may perpetuate the process of 
laying down fat stores in pregnancy.  
 
 
Adiponectin is a 30kDa hormone protein that is secreted by adipocytes (Scherer et 
al., 1995) as well as salivary gland epithelial cells (Katsiougiannis et al., 2006), 
leucocytes (Crawford et al., 2010), skeletal muscle (Liu et al., 2009) and also by the 
placenta (Caminos et al., 2005; Lappas et al., 2005; Chen et al., 2006). Circulating 
in the plasma in a multimeric (high molecular weight) form, adiponectin takes on an 




is inversely associated with fat mass, especially in men (Zhang et al., 2005). In obese 
subjects, there is reduced expression and secretion of adiponectin from adipose 
tissue (Arita et al., 1999).  
  
 
In contrast to placental leptin, adiponectin correlates more closely with fasting 
insulin levels, reflecting insulin sensitivity (Hotta et al., 2000; Weyer et al., 2001; 
Catalano et al., 2006). Since adiponectin itself is insulin-sensitising, reduced levels 
of the hormone in obesity may in fact compound the insulin resistance seen in obese 
subjects. Out-with pregnancy, adiponectin has insulin-sensitising effects but as 
adiponectin levels fall in pregnancy, women develop relative insulin-resistance 
(Catalano et al., 2006; Nien et al., 2007). In those that meet the criteria for GDM, 
adiponectin levels are further suppressed compared to weight-matched non-diabetic 
pregnant individuals (Retnakaran et al., 2004; Williams et al., 2004). Overweight 
women, who already have lower baseline adiponectin levels, demonstrate 
maintenance of circulating adiponectin and there is less of an impact of the pregnant 
state than that seen in normal-weight pregnant individuals (Nien et al., 2007). As 
such, treatment with adiponectin can reverse the insulin resistance phenotype of 
obesity in mice and reduces hepatocyte gluconeogenesis (Yamauchi et al., 2001, 
2002). Treatment with adiponectin has also been proposed in adult human subjects 
(Achari and Jain, 2017). 
 
 
Targeting a variety of tissues, adiponectin’s function is also site-dependent. In 
skeletal muscle, adiponectin upregulates the expression of fatty acid transporter 
proteins and stimulates metabolic oxidation (Myeong et al., 2006). In addition, it 
stimulates glucose uptake by increasing GLUT4 translocation (Ceddia et al., 2005) 
and enhances mitochondrial biogenesis (Qiao, Kinney, et al., 2012). In the liver, 
adiponectin is insulin-sensitising (Qiao, Kinney, et al., 2012) and adiponectin levels 
are, as aforementioned, negatively associated with glucose production (Stefan et 






In pregnancy, circulating adiponectin levels remain, like leptin, fairly constant in 
the first trimester, but decline with advancing gestation and are lowest in the third 
trimester. As with adiponectin in the non-pregnant state, circulating adiponectin 
levels in pregnancy correlate with insulin sensitivity. With reduced expression and 
secretion of adiponectin, it may assume a specific role in contributing to pregnancy-
induced insulin resistance (rather than insulin resistance developing due to 
dysregulation of maternal metabolism and greater fat mass that occurs during 
pregnancy). Adiponectin may also alter placental function in pregnancy by 
negatively regulating placental amino acid transport, collectively altering the 
placental response to insulin and placental transport of the hormone (Jones, Jansson 




Adiponectin, therefore, plays a direct role in the development of insulin resistance 
during pregnancy although this will be multifactorial and will be influenced by the 
dysregulation of other metabolic processes that also occur during pregnancy.  
 
 
Whilst other maternal hormones, namely pro-inflammatory cytokines, sex steroids 
(oestrogens and progesterone), and the maternal pituitary hormone prolactin have 
all been implicated, placental adiponectin (and resistin) appear to be key in the 
development of the insulin resistance that occurs during pregnancy. In contrast, 
placental leptin is more strongly associated with fetal growth and placental 
function. Collectively, the expression of these adipokines by the placenta 
demonstrates their complex role in fetal development and physiological adaptions 






1.3 Obesity in pregnancy 
 
 
1.3.1 Maternal Effects of obesity in pregnancy 
 
 
Obesity in pregnancy has implications for weight gain during pregnancy, metabolic 
and vascular dysfunction, as well as a greater risk of adverse outcomes of labour and 
delivery. Obese pregnancy has implication s for both mother and baby both in the 
short and long term (Poston et al., 2016). Whilst the long-term impact obesity may 
have on offspring's cardiovascular and metabolic health throughout the life-course 
is starting to emerge, there is also a greater appreciation of the impact it may have 
on the mother herself. In Chapter 3,the impact of maternal GWG in pregnancy on 
cord blood biomarkers and birthweight, as well as maternal characteristics and GWG 
during each gestational period.  
 
 
Whilst maternal obesity is a recognised risk factor for developing GDM (Q. Wang et 
al., 2013), with progressive insulin resistance exacerbated in obese pregnancy, it 
also poses a greater risk of developing multi-system disorders such as pre-
eclampsia (PE) (Z. Wang et al., 2013). These disorders in pregnancy will be 
examined in Chapters 4 and 5, where the prevalence of diabetic and hypertensive 
disorders in pregnancy, the maternal offspring characteristics, as well as the 
impact of such metabolic disorders on offspring birthweight and offspring 
metabolism at birth, will be examined. Endothelial dysfunction, inflammation, 
dyslipidaemia, and oxidative stress are all characteristic of obesity-related 
hypertensive disorders in pregnancy. Chronic or essential hypertension may not 
have been recognised prior to pregnancy and may simply be detected at the onset 
of pregnancy; pregnancy-induced hypertension may develop during the pregnancy 
itself (Duckitt and Harrington, 2005). Obese pregnant women are at much greater 
risk of developing any hypertensive disorder of pregnancy (HDP) and there is 
around a 2-fold increased risk in developing PE in obese pregnant women 




Whilst weight gain in pregnancy may be less in obese compared to lean women 
(Soltani and Fraser, 2000; Ehrenberg, Huston-Presley and Catalano, 2003), accrual 
may be more central than subcutaneous and it is this central adiposity that confers 
greater risk in pregnancy, such as the greater risk of GDM, hypertension and PE and 
preterm delivery (Ebrahimi-Mameghani et al., 2013). The distribution of fatness 
appears to convey greater maternal risk as even non-obese women with a central 
distribution of fat (‘apple-shaped’ women) have a greater pro-inflammatory 
response at pregnancy booking compared to non-obese women with a lower body 
fat distribution (‘pear-shaped’ women) (E. Jarvie et al., 2010). Combining this 
central distribution at the beginning of pregnancy with its accrual actually during 
pregnancy in an already obese woman may be the trigger of greater metabolic 
dysfunction, greater insulin resistance, and consequently GDM in obese pregnant 
women (Chu et al., 2007).  
 
Obesity amongst women of child-bearing age impacts fertility from conception 
through to the postnatal period. It adversely affects ovulation and thus 
conception, such as in polycystic ovarian syndrome, commonly known as PCOS. In 
those that do manage to conceive, the risk of miscarriage and pregnancy loss is 
greater (Poston et al., 2016; Koh et al., 2017). During pregnancy itself, women 
may develop co-morbidities which range from minor nuances in pregnancy to 
maternal death. Symphysis pubis disorder (SPD), oesophageal reflux disease, carpal 
tunnel syndrome, and chest infections all feature more frequently in those with 
obesity in pregnancy (Denison et al., 2008). As discussed, in normal pregnancy, 
there is also progressive insulin resistance with compensatory hyperinsulinemia 
(Spellacy and Goetz, 1963). In obese pregnant women, there is an impaired beta-
cell function and impaired insulin response to glucose. In a prospective multi-
centre study, The UK Pregnancies Better Eating and Activity Trial (UPBEAT), 1555 
obese women were recruited between 2009 and 2004. From this 64% of obese 
women developed complications during pregnancy of which GDM was the most 






Obesity in pregnancy may also have a negative effect on parturition and the delivery 
may be more complex. Individuals are more likely to require induction of labour and 
instrumental or operative delivery (Sebire et al., 2001; Arrowsmith, Wray, and 
Quenby, 2011). More complex deliveries in obese pregnant women were also 
recognised by UPBEAT, as an emergency caesarean section was the most common 
delivery-related complication amongst obese women included in the study (Vieira et 
al., 2017). Greater caesarean section rates may be due to a greater risk of induction 
of labour as obese women are less likely to labour spontaneously and require post-
date induction of labour. Induction is also more likely to fail amongst obese women 
due to inefficient myometrial contractility but for those who did establish labour, 
they were less likely to progress in labour, thus requiring emergency caesarean 
section (Sherrard et al., 2007; Denison et al., 2008, 2014; Maged et al., 2018).  
 
 
Greater intervention in labour, resulting in operative delivery, is also associated with 
a greater risk of sepsis and post-partum complications including wound infections 
and thromboembolism. According to the recent report from Mothers and Babies: 
Reducing Risk through Audit and Confidential Enquiries across the UK (MBRRACE-UK), 
34% of mothers who died between 2013 and 2015 were obese and 19% were 
overweight (Koh et al., 2017). Venous thromboembolism and subsequent 
thromboembolic events remained the leading cause of direct maternal deaths during 
this triennium (Koh et al., 2017). As previously discussed, obesity may also impair 
myometrial contractility and as a result, there may be a greater risk of atonic 
postpartum haemorrhage (Sebire et al., 2001; Blomberg, 2011). Anaesthetic 
complications also feature more frequently. Difficulty inserting regional anaesthesia 
may result in women requiring a general anaesthetic and there is a greater risk of 
Mendelson syndrome. Collectively these complications prolong hospital stay and 
present a significant burden on the NHS (Denison et al., 2014; Solmi and Morris, 
2018). Whilst it is clear that greater maternal adiposity poses a significant risk to 







1.3.2 Fetal effects of obesity in pregnancy 
 
 
Maternal obesity adversely affects fetal health throughout the entire gestational 
period and there is emerging evidence to support a long-lasting impact on the 
offspring. Offspring of obese mothers are at greater risk of obesity themselves 
(Whitaker, 2004; Oken et al., 2007; Perng et al., 2014) although the interpretation 
of the relationships drawn from these studies are complex and are limited by 
environmental and lifestyle factors which may play a significant role in the causal 
pathway. Shared dietary patterns and activity levels within families, for example, 
may all contribute to the development of obesity in the offspring. Metabolic 
dysfunction in these offspring,, has potential for transfer of this dysfunction across 
generations as highlighted in epigenetic studies (Drake and Walker, 2004; Aagaard-
Tillery et al., 2008; Davis et al., 2008; Waterland et al., 2008; Li et al., 2012). Whilst 
it is recognised that interventions are required to prevent the propagation of 
obesity-related disease to subsequent generations, specific treatment options are 
limited due to the complex physiological processes that occur in pregnancy that are 
susceptible to environmental influences.  
 
 
In early pregnancy, there is a greater risk of fetal demise amongst obese pregnant 
women (Lashen, Fear, and Sturdee, 2004). There is also a greater risk of congenital 
anomalies (Institute of Medicine and National Research Council Committee to 
Reexamine IOM Pregnancy Weight Guidelines, 2009; Stothard et al., 2009; Mills et 
al., 2010; Zhu et al., 2018). This may be due to the poor quality of the oocyte at 
the peri-conceptual stage of pregnancy. Murine models suggest that there is an 
excess accumulation of lipid in oocytes of those fed a high-fat diet (Wu et al., 2010) 
which is associated with maternal mitochondrial dysfunction and impaired ability to 
maintain a pregnancy (Igosheva et al., 2010; Wu et al., 2010). Whilst this may 
account for subfertility in obese women, it may also implicate this peri-conceptual 
stage in translating this adverse metabolic environment onto the embryo which may 
develop abnormally. Congenital anomalies in the offspring of obese mothers may 




dysfunction (Ramsay et al., 2004), folate deficiency due to inadequate dietary 
intake and absorption of folate (Kaidar-Person et al., 2008), as well as decreased 
sensitivity of antenatal screening tests such as ultrasound (Eastwood et al., 2017). 
 
 
With advancing obese pregnancy, there is a greater risk of large for gestational age 
(LGA) offspring and fetal macrosomia (Yu et al., 2013). Maternal hyperglycaemia, as 
a result of maternal obesity, triggers diffusion of nutrients, such as glucose (but not 
insulin), along a concentration gradient from the maternal to the fetal circulation 
via the placenta. LGA and fetal macrosomia occur in offspring of these mothers, 
particularly if they have developed GDM, as there are relative hyperglycaemia and 
compensatory fetal hyperinsulinemia (Skyler, O’Sullivan, and Holsinger, 1980; 
Catalano et al., 2009; Modi et al., 2011) as well as placental fatty acid transport 
dysfunction (Dubé et al., 2012).  
 
 
The impact of maternal obesity on the fetus is not only restricted to the duration of 
pregnancy itself as labour and delivery are more likely to sway from the ‘normal’ 
delivery pathway. Obese women are less likely to labour spontaneously (Hendler, 
Goldenberg, et al., 2005) as discussed previously. They are also more likely to 
deliver pre-term (McDonald et al., 2010; Denison et al., 2014). This may be 
iatrogenic as there is a greater risk of preterm induction of labour (Hendler, 
Goldenberg, et al., 2005) as a result of medical complications arising in pregnancy 
such as PE and GDM.  Deliveries are more complicated as a result of fetal 
macrosomia, and there are consequent adverse outcomes for the fetus such as 
shoulder dystocia. With this, there is a greater risk of hypoxic-ischaemic 
encephalopathy, brachial plexus, or bony injury and stillbirth. Fetal monitoring 
during labour may technically be more challenging, heightening the risk to the fetus. 
Collectively, offspring of obese mothers are more likely to require admission to the 
neonatal unit (Denison et al., 2014).  
There is also evidence demonstrating that maternal obesity adversely affects the 
long-term health of the offspring. An adverse maternal metabolic environment, such 




reflected by dysregulation of adipokines and insulin (Catalano et al., 2009). Neonatal 
offspring of obese mothers, even in the absence of GDM, are also predisposed to 
greater adiposity (Sewell et al., 2006). This may extend though child into adulthood 
as greater birthweight is associated with offspring obesity throughout the life-course 
(Curhan et al., 1996; Whitaker, 2004). This is examined further in Chapters 6 and 7 
which explore how cord blood markers track through childhood into adolescence as 
well as how cord blood analytes  relate to later offspring adiposity. Not all infants 
born to obese mothers are however of large birthweight.  Adult central obesity, as 
previously discussed a risk factor for cardiovascular disease, can be associated with 
low birthweight (Kuh et al., 2002), as are hypertension, diabetes, and cardiovascular 
disease (Curhan et al., 1996) and there is evidence to show that placental 
dysfunction, in keeping with maternal obesity, may induce fetal growth restriction 
instead (McDonald et al., 2010). Nevertheless, there is evidence to suggest the 
offspring of obese mothers, even in the case of low or high birthweight, are 
predisposed to metabolic dysfunction. 
 
 
Animal models demonstrate the association between maternal nutritional status and 
adverse offspring phenotype. In primate models, greater offspring adiposity was 
seen in those of obese baboons (Farley et al., 2009) and obese macaques (McCurdy 
et al., 2009). Whilst the offspring of rats fed a high-fat diet in pregnancy were of 
low birthweight, the offspring became obese later in life (Howie et al., 2009; Nivoit 
et al., 2009). Dysregulation of rodent offspring insulin and leptin levels as well as 
fat mass and blood pressure have also been described (Khan et al., 2004; Samuelsson 
et al., 2008). Furthermore, the offspring of rats fed a high-fat diet in pregnancy 
demonstrated greater weight gain compared to offspring of lean dams, despite no 
difference in pup birth weight between the groups (Shankar et al., 2008).  
 
 
Animal models have also been used to show the association between an adverse 
maternal environment and adverse offspring metabolism. The offspring of diet-
induced obese rats demonstrated adipocyte hypertrophy and dysregulation of 




may also lead to overexpression of adipokines leptin and adiponectin, among other 
lipogenesis-stimulating hormones (Muhlhausler, Duffield and McMillen, 2007). 
Finally, alteration of thalamic neurotransmitters has also been implicated in the 
translation of this adverse maternal metabolic profile onto the offspring (Chang et 
al., 2008; Kirk et al., 2009; Sullivan et al., 2010).  
 
 
Collectively it is clear that maternal diet, distribution, and degree of adiposity, 
albeit peri-conceptually or during pregnancy, may adversely influence the 
offspring’s metabolic profile and phenotype at birth and this has the potential for 




1.4 Fetal programming 
 
 
1.4.1 The intrauterine environment and long-term programming of offspring 
 
 
Distinguishing between the concept of programming in utero and environment-
induced developmental modelling is complex. Examining the outcomes of one 
mechanism without the other is a challenging process, with many co-variables to 
consider. Acting via distinct or converging pathways, both theories imply that the 
individual is at increased risk of adverse health conditions later in life via altered 
growth trajectories and metabolic disruption. By identifying biomarkers at birth and 
recognising periods of greatest developmental modelling and impact on the 
phenotype there is potential to put in place stratified intervention models that 
generate positive changes in health. In doing so, there may be significant economic 
benefit by treating disease early on or even avoid the need for treatment altogether 
by preventing the onset of disease (Gluckman et al., 2008).  
 
 
1.4.2 Developmental Origins of Health and Disease   
 
 
The intrauterine environment is a critical time to ‘determine’ the offspring 's risk 
pathway for later life. The Developmental Origins of Health and Disease (DOHaD) 
concepts encompass mechanisms and early life exposures that create a ‘memory’ 
and fetal adaption to an abnormal early life environment which is then retained in 
later life 4). Several processes have been proposed to account for this DOHaD 
hypothesis, including maternal over as well as undernutrition, epigenetic changes, 
and abnormal environmental exposures.  
 
 
During this process, mal-adaption, and long-lasting changes in the morphological 




may predispose to a greater risk of non-communicable disease in later life such as 
cardiovascular and metabolic dysfunction. Fetal exposure to maternal obesity in 
pregnancy, for example, may set an abnormal trajectory of offspring health and 
predispose that individual to ill health in later life. This then in turns continues 




Barkers’ hypothesis (Barker and Osmond, 1986; Barker et al., 1989, 1993; Barker, 
2007), first proposed in 1986, demonstrated a direct link between prenatal nutrition 
and late-onset coronary artery disease. This hypothesis has not only demonstrated 
that fetal programming exists, but also that it significantly contributes to the origin 
of type 2 diabetes, metabolic syndrome, and cardiovascular disease. Historically, 
heart disease was thought to be solely accounted for by lifestyle and genetic factors. 
Whilst genetic variations have been directly associated with type 2 diabetes, it is 
thought that they only account for around 10% of primary constitutional type 2 
diabetes hence there are major aetiological factors involved in the origin of type 2 
diabetes that remain  unexplained (Ahlqvist, Ahluwalia and Groop, 2011). There is 
therefore potential for early life exposures to act as determinants of type 2 diabetes 
and its sequelae.  
 
 
Heart disease in adult life was also more prevalent amongst individuals with low 
birthweight. Replicated worldwide, the offspring are thought to have permanently 
adapted in utero to the abnormal environment and the physiology continues to 
respond in this abnormal way once born. While maternal undernutrition is more 
apparent in low-income countries, metabolic programming is thought to be more 
prevalent in any population with the greatest maternal exposure to underweight. 
The intrauterine environment, as determined by external exposures such as 
maternal obesity, acts as a ‘taster’ for what life may be like ‘ex-utero’ but this may 
be disproportionate to the world of birth. This world at birth may vary dramatically 
from the conditions the fetus was exposed to in utero. Nutritional resources for 




became accustomed to in utero. The adaptions made by the fetus may be long lasting 
and the physiological response of the fetus may not be appropriate or meet the new 
demands of the new environment outside the womb. GDM may reflect an early 
manifestation of type 2 diabetes and is associated with low (and high) birthweight 
offspring as a result of an abnormal intrauterine environment. Pregnancy is 
therefore a window of opportunity to prevent type 2 diabetes in both the mother 
and their offspring. This is a public health issue as the global diabetes epidemic 
continues to grow as a result of the propagation of maternal over-nutrition and 
physical inactivity and decreased birthweight in their offspring who are predisposed 
to metabolic dysfunction (NICE (National Institute for Health and Care Excellence), 
2011; National Institute for Health and Care Excellence, 2015).  
 
 
1.4.3 Developmental undernutrition 
 
 
Developmental undernutrition, also known as the ‘thrifty phenotype’, describes a 
low nutrient supply in utero, occurring in malnourished and mothers with a low BMI. 
The fetus adapts in utero to a low nutritional supply during the gestational period 
and maybe small for gestational age or growth-restricted at birth. In childhood, 
however, and with the supply of processed foods containing low nutritional and high 
calorific content, the offspring sustains permanent disruption to the regulation of 
glucose and insulin pathways hence greater predisposition to metabolic disease such 
as type 2 diabetes. This thrifty phenotype, and its association with developmental 
organ plasticity, has been proposed as the most plausible hypothesis for the 
aetiological development as well as the molecular mechanisms in the origin of type 
2 diabetes.  
 
 
A low birth weight itself, although a crude marker of the intrauterine environment, 
has repeatedly been associated with type 2 diabetes in later life, as demonstrated 
by population-based studies  (Ahlqvist, Ahluwalia, and Groop, 2011). This is of 




syndrome. Prematurity, which is independent of birthweight has also been 
independently linked to the development of type 2 diabetes, however, it is evident 
that growth velocity within the first and second trimesters have the greatest impact 
on the development of the metabolic syndrome in later life, rather than growth 
trajectory in a later gestational period (Vielwerth et al., 2008). 
 
 
Dutch Famine Birth Cohort Study demonstrated the permanent fetal adaption to a 
suboptimal intrauterine environment (Roseboom, de Rooij, and Painter, 2006). From 
1944-1945, the blockade of the Netherlands meant that no food was reaching the 
Dutch population and a famine ensued. The population, which included pregnant 
women, became severely malnourished. This study found that offspring born to 
these mothers were at greater risk of diabetes, cardiovascular disease, obesity, and 
other non-communicable diseases (Roseboom, de Rooij, and Painter, 2006). 
Exposure to famine at any gestational period, in the first, second, or third trimester, 
or throughout the entire gestational period predisposed the offspring to glucose 
intolerance in later life. The fetus is most vulnerable during the first trimester 
however as maternal exposure to famine during this period was also associated with 
cardiovascular disease and a more atherogenic profile in the offspring.  
 
 
Whilst organ dysfunction and cellular re-modelling (reflecting organ plasticity) 
involving cardiac, pancreatic, and hepatic tissues have been demonstrated in 
response to fetal under-nutrition studies, the structure of the kidney may be 
permanently altered by exposure to an abnormal intrauterine environment. 
Nephrons are developed in utero and a deficit created in this early gestational period 
has long-lasting effects. Low birthweight and prematurity, as influenced by maternal 
BMI, may lead to inadequate kidney development in utero and predispose the 
offspring to hypertension and risk of chronic kidney disease in later life (Luyckx et 
al., 2013). 
 
Twin studies also demonstrate the discordance in the development of diabetes 




as they are born of the same mother, but also removes variation in the gestational 
age at delivery and its association with offspring development of type 2 diabetes. 
Twins born with a lower birthweight were at greater risk of type 2 diabetes 
compared to their ‘normal weight’ and genetically identical co-twin, as found in 
monozygotic twins, but also dizygotic twins (Poulsen et al., 1997). 
 
 
1.4.4 Developmental overnutrition 
 
 
The DOHaD hypothesis also supports developmental overnutrition as a mechanism 
for translating metabolic dysfunction onto future generations. This is of particular 
relevance with the maternal population getting heavier and the prevalence of 
maternal diabetes in pregnancy greater. Normal physiological adaptions that occur 
during ‘healthy’ pregnancy include the development of some insulin resistance and 
elevated circulating glucose levels. This occurs to meet the demands of the 
developing fetus. There is a linear relationship between maternal glucose levels and 
offspring birthweight, even out with the diagnosis of maternal diabetes (Metzger et 
al., 2009). This risk however extends into childhood as maternal glucose 
concentration has also been shown to be related to childhood adiposity  (Ehrlich et 




Maternal obesity, compounded by maternal diabetes in pregnancy, may lead to fetal 
growth restriction (via the development of placental insufficiency), or fetal over-
growth (via greater in utero exposure to glucose). This is demonstrated by the fact 
that exposure to maternal adiposity during pregnancy is associated with higher 
offspring birth weight and greater adiposity through childhood and adult life (Nelson, 
Matthews, and Poston, 2009). The greater this degree of adiposity, the greater the 
transplacental passage of nutrients (glucose and fatty acids) are transferred to the 
fetus (Fraser et al., 2010; Lawlor et al., 2011). As a result, there is excessive 




development of larger babies with greater fat mass. The offspring born to obese 
mothers are not only at greater risk of adiposity but the metabolic disruption extends 
from childhood to adult life as offspring are at greater risk of cardiovascular-related 
death (Gaillard et al., 2013; Godfrey et al., 2017). Whilst accounting for 
environmental and shared lifestyle factors may be challenging, the DOHaD concept 
is further strengthened by the fact that offspring born to mothers before and after 
bariatric surgery had a greater risk of adiposity when the maternal BMI was greater 
(Smith et al., 2009). In addition, higher maternal weight gain in pregnancy is also 
associated with greater childhood adiposity, highlighting the intrauterine period as 
a key period of offspring programming (Godfrey et al., 2017). The fetus may be at 
risk from as early as the peri-conception stage as there is also mounting evidence 
that maternal obesity at the time of conception may adversely affect the metabolic 
health of the offspring (Lillycrop and Burdge, 2012; Fleming et al., 2018). 
 
 
It was first considered in 1980 that fetal exposure to obesity and ‘fuel mediated 
teratogenesis’ would cause long-lasting effects on the offspring (Freinkel, 1980). As 
demonstrated by Pima Indian population, offspring born to mothers with diabetes 
were at greater risk of obesity and early-onset type 2 diabetes in later life compared 
to non-diabetic mothers  (Dabelea et al., 2000). This Study also compared siblings 
within the family unit which also showed discordance in their risk when born before 
and after maternal development of diabetes in pregnancy (Dabelea et al., 2000). A 
Study of Indian children born to mothers with GDM also showed that the offspring 
had a greater risk of obesity, as well as higher glucose and insulin concentrations 
compared to those born to non-diabetic mothers (Krishnaveni et al., 2010).  
 
 
The phenotype at birth is well known to be related to long-term outcomes and this 
concept is strengthened by observations that birth weight is positively associated 
with the mean infant, childhood, and adulthood BMI, and adiposity (Pietiläinen et 
al., 2001). This is explored further in Chapter 6. It is also proposed that this 
increased birthweight may result in irreversible changes to the neuroendocrine 




is a greater degree of adiposity throughout life (Oken and Gillman, 2003; Taylor and 
Poston, 2007; Lawlor et al., 2011). This pathway is perpetuated when female 
offspring who then become pregnant pass over the cycle of developmental over-
nutrition onto subsequent generations (Ebbeling, Pawlak and Ludwig, 2002; Symonds 
et al., 2003; Taylor and Poston, 2007).  
 
 
The neuroendocrine feedback loop, the adipo-insular axis, encompasses the 
pancreas, adipose tissue, and the brain and regulates hunger and fat storage by 
controlling insulin and leptin. As insulin is adipogenic, it stimulates the production 
and secretion of leptin. Leptin, the satiety hormone, acts by suppressing energy 
intake and suppressing insulin secretion. Disruption to the neuroendocrine axis via 
fetal overnutrition (including maternal obesity and diabetes), causes altered energy 
and appetite regulation and disrupted adipocyte metabolism. From this, there is 
potential to induce greater fetal and neonatal adiposity as well as predispose the 
offspring to metabolic dysfunction in later life, such as type 2 diabetes and 
cardiovascular disease (Kieffer and Habener, 2000).  
 
 
Evidence from within sibling studies, comparisons of maternal and paternal 
exposures, and the use of genetic variants as proxies for the maternal exposures 
support developmental overnutrition causing greater adiposity in offspring at birth 
(Debbie A. Lawlor et al., 2012; Lawlor, 2013). However, studies to date have been 
unable to determine the extent to which greater fat mass at birth tracks into later 
life and explain the association or whether any longer-term impact is irrespective of 
fatness at birth. This is because the provision of excessive nutrients facilitates an 
increase in fetal fat mass, with the assessment of birth weight unable to distinguish 







There is increasing awareness of the impact of epigenetic changes in the 
developmental origins of disease. These changes occur as a result of intrauterine 
adaptions that have a long-lasting impact on the offspring's physiological responses. 
Epigenetics encompasses the study of heritable phenotypes that do not involve 
changes in the DNA sequence. The prefix ‘epi’ suggests that these changes are in 
addition to genetic changes and account for differentiation in gene expression and 
activity.  Predetermined epigenetics describes a predictable developmental change 
and is in contrast to probabilistic epigenetics, which describes alterations to 
structure and function as a result of environmental exposures. Epigenetics 
encompasses novel ideas and mechanisms that may underlie the development of 
organ dysfunction relevant to insulin resistance and type 2 diabetes and include 
changes in DNA methylation, histone modification and regulation, and non-coding 
micro RNA’s.  
 
 
DNA methylation, or differential methylation, occurs during key developmental 
periods, particularly in fetal life but also in early childhood and puberty. The 
‘methylome’ is determined mainly in utero and follows a period between 
fertilisation and implantation in which DNA in the fertilised egg (other than 
imprinted genes) is ‘demethylated’.  This accounts for differentiation in the cell 
types in the fetus with varying gene expression. This process may be influenced by 
maternal diet and the exposed environment as demonstrated by maternal famine 
during pregnancy, as previously discussed, as well as the season of conception. 
Consequently, varying offspring phenotypes ensue and may lead to offspring 
development of cardiovascular disease, obesity, hypertension, insulin resistance, 
and altered leptin and lipid profile. 
  
 
Altered methylation of the pro-opiomelanocortin (POMC) gene, which contributes to 




famine in a study conducted in The Gambia (Kühnen et al., 2016). This Study 
highlights the peri-conceptual phase as a critical period of epigenetic change and 
developmental plasticity. Offspring conceived during the rainy ‘hungry’ season had 
greater methylation of the POMC gene and overall greater offspring BMI and risk of 
obesity compared to those conceived during the dry season where nutrition was 
more plentiful (Kühnen et al., 2016).  
 
 
Epigenetic modifications and their association with low birthweight have been 
demonstrated in both animal and human models. Transcriptional regulation by 
promoter DNA methylation and histone modifications of the key pancreatic 
proliferation and transcription factor Pdx1 as a result of fetal undernutrition (Park 
et al., 2008). Furthermore, there is an increased expression of MiR-483-3p in 
subcutaneous adipose tissues from humans with low birthweight and from rats that 
were protein undernourished in utero. Collectively they have demonstrated a 
greater risk of lipotoxicity and organ dysfunction, culminating in a greater risk of 
type 2 diabetes in the offspring (Ferland-Mccollough et al., 2012). 
 
 
1.4.6 Other causes  
 
 
It is not only maternal and fetal over or undernutrition that may permanently 
influence the physiology of the offspring. Environmental exposures via shared 
lifestyle factors and familial dietary patterns may also account for the positive 
associations between maternal obesity in pregnancy for example, and offspring 
adiposity. Hormonal disruption may also contribute to this, as inadequate thyroid 
control and supply in pregnancy may lead to abnormal brain development, 
particularly during the first trimester (before the fetus starts to produce endogenous 
thyroid hormone). Chronic under-exposure to thyroid hormone in utero can lead to 
neurological conditions in later life. Furthermore, the maternal mental state may 
‘expose’ the offspring to mental health disorders. Maternal anxiety and depression 




stress, which may accompany these conditions, may lead to preterm labour and 
resulting low birthweight baby, which then inherently predisposes the offspring to 
metabolic dysfunction in later life.  
 
 
Intrauterine exposure to toxins, particularly during critical periods of fetal 
development may also permanently alter the hypothalamic-pituitary axis. 
Transplacental passage of alcohol for example alters the neuroendocrine, 
metabolic, and physiological responses of the offspring as demonstrated in fetal 
alcohol spectrum disorder. In addition, smoking may contribute to a greater risk of 
preterm labour and small for gestational age offspring with resultant altered lung 
development and potential for greater childhood obesity in the offspring (Rayfield 
and Plugge, 2017). Differentiating confounding factors, such as mothers who smoke 
in pregnancy may vary in socioeconomic status compared to mothers who don’t 
smoke, and the shared lifestyle in childhood and beyond may alone account for the 
greater predisposition in the offspring to obesity. Animal studies however have 
shown that pregnant rats given nicotine in pregnancy are associated with greater fat 
in the pups suggesting a causal relationship between the exposure and the offspring 
outcome (Behl et al., 2013).  Maternal consumption of medication, such as certain 
beta-blockers and angiotensin receptor enzyme inhibitors (ACEI), may also 
contribute to impaired fetal growth, especially in the context of maternal 





1.5 Programming of offspring metabolic dysfunction 
 
 
1.5.1 Gestational weight gain (GWG) in pregnancy on offspring metabolic markers  
 
 
Chapter 3 will focus on the impact of maternal obesity and GWG, reflecting maternal 
over (and under) nutrition in pregnancy and their role in the causal pathway on 
offspring birthweight and metabolic markers. The accumulation of adipose tissue 
leading to weight gain varies between individuals in pregnancy with average weight 
gain between 10 and 12kgs. Of which, around 3kg is due to an increase in adipose 
tissue. Approximately 3-4kg weight gain is due to the developing fetus, 0.5kg due to 
the placenta, 0.8kg due to amniotic fluid, 1.2kg from blood, 1kg due to the enlarged 
uterus, and 1.5kg due to extracellular extravascular fluid (Hytten and Leitch, 1971). 
There is evidence to suggest that obese pregnant women tend to gain less weight 
than lean women (Soltani and Fraser, 2000; Ehrenberg, Huston-Presley and 
Catalano, 2003), however, accrual tends to be more central than subcutaneous 
(Sohlstrom, Wahlund and Forsum, 1993; Sohlstrom and Forsum, 1995; Stevens-Simon 
et al., 2001), which as previously discussed may carry greater metabolic risk. 
Guidelines for weight gain in pregnancy were developed by the Institute of Medicine 
(IOM) in 2009 as weight gain greater than the recommended thresholds have been 
associated with adverse outcome (Crane et al., 2009; Institute of Medicine and 
National Research Council Committee to Reexamine IOM Pregnancy Weight 
Guidelines, 2009).  
 
 
Greater maternal adiposity, due to elevated pre-pregnancy BMI or excessive GWG, 
are well recognised ‘risk factors’ for adverse maternal and offspring outcomes in the 
perinatal period (Viswanathan et al., 2008; Poston, Harthoorn and Van Der Beek, 
2011). The ‘risk’ to the offspring appears to extend well beyond the neonatal period, 
however, as GWG has not only been strongly positively associated with birthweight 
(Fraser et al., 2010; Ludwig and Currie, 2010), but also with body mass index (BMI) 




(Mamun et al., 2009; Hochner et al., 2012). GWG has also been linked to elevated 
triglyceride and leptin and reduced high-density lipoprotein cholesterol (HDLc) 
levels in child and adulthood (A. Lawlor et al., 2010; Fraser et al., 2010; Hochner et 
al., 2012), but, as yet there is limited evidence of the effect of inappropriate GWG 
on the offspring’s cardio-metabolic profile at birth. Evidence does however support 
a greater association between GWG in already obese mothers and offspring adiposity 
(Oken et al., 2008). Pregnancy is therefore a crucial window of opportunity for 
optimising weight gain as there is increasing potential for the translation of the 
phenotype and potential inherent metabolic dysfunction onto the offspring.   
 
 
1.5.2 Institute of Medicine (IOM) Guidance on GWG 
 
 
The 2009 IOM guidance was devised to advise pregnant women on appropriate GWG 
according to their pre-pregnancy BMI, so that offspring growth patterns and the 
trajectory of metabolic health may be optimised (Rasmussen, Catalano and Yaktine, 
2009). By gaining weight appropriately, the guidance aimed to minimise the risk and 
potential health consequences for both mother and baby that are associated with 
low or excessive maternal weight gain during pregnancy. Appropriate GWG, for 
example, is associated with better obstetric outcomes (Olson, 2008; Langford et al., 
2011). More than half of pregnant Americans gained inadequately or excessively, 
which highlighted the need for a guideline and to standardise care and provide 
individualised advice before and during pregnancy (Institute of Medicine and 
National Research Council Committee to Reexamine IOM Pregnancy Weight 
Guidelines, 2009). Their focus was to examine both the short and long-term 
outcomes for both the mother and fetus. Specifically, the  guidance aimed to better 
advise on optimal weight gain to reduce the risk of a small or LGA fetus, reduce the 
need for unexpected caesarean section, and limit excessive maternal weight 
retention. The recommendations were to be used ‘in concert with good clinical 
judgement as well as a discussion between the mother and her prenatal care 
provider about diet and exercise’ (Institute of Medicine and National Research 




Recommendations on weight gain were first issued in 1990 (IOM, 1990) and vary 
dramatically from the current 2009 guidance available. Primary objectives were 
similar however and included reducing the risk of preterm birth, reducing the rate 
of non-scheduled caesarean section delivery, as well as reducing the risk of low 
offspring birthweight. Both have found that weight gain  above the guidance was 
associated with higher caesarean section rates (Institute of Medicine and National 
Research Council Committee to Reexamine IOM Pregnancy Weight Guidelines, 2009), 
and higher weight gain overall was associated with greater maternal post-partum 
weight and greater birthweight. One of the main recommendations from both 
publications was however to encourage a normal weight at the time of conception 
as this then has implications for the duration of the pregnancy and remains a large 
determinant of pregnancy outcome (Institute of Medicine and National Research 
Council Committee to Reexamine IOM Pregnancy Weight Guidelines, 2009; 
Rasmussen, Catalano and Yaktine, 2009).  
 
 
There was the need for these 1990 guidelines to be revised and updated for several 
reasons. Firstly, changing demographics incorporating a heavier, more obese 
maternal population with more chronic health conditions. Populations are more 
culturally diverse and in addition, maternal age at first index pregnancy has risen, 
as has the number of multiple pregnancies. Secondly, the BMI thresholds used in 
1990 were not  following World Health Organisation (WHO) cut-offs of BMI, as these 
had not yet been determined at this stage (‘Physical status: the use and 
interpretation of anthropometry. Report of a WHO Expert Committee.’, 1995). For 
example, ‘normal’ weight was defined as 19.8-26.0 kg/m2 and differs from current 
BMI thresholds, seen in Table 1.1 and Chapter 2, Table 2.1. Furthermore, the 
recommendation of weight gain for obese women was only a minimal weight gain 
but there was no upper limit specified. Lastly, its recommendations, based on 
observational data, drew conclusions that if maternal weight gain was within the 
recommendations issued in 1990, the pregnancy outcomes would be overall better. 
Pregnancy outcomes however are multi-factorial and consideration should also be 




in the current IOM guidance to account for these factors which may influence GWG, 
thereby influencing the pregnancy outcome.  
 
 
The current guidance on GWG however also has its limitations, which are more 
apparent in the contemporary population. Several publications have documented 
the association of GWG on gestational health conditions, such as GDM and HDP (Yee 
et al., 2011; Siegel et al., 2015; Egan and Dunne, 2018). Not all studies however 
account for the duration of pregnancy, likely to be shortened in the presence of PE 
for example, or the weight gain before the actual diagnosis of diabetes in pregnancy 
(Institute of Medicine and National Research Council Committee to Reexamine IOM 
Pregnancy Weight Guidelines, 2009). The latter being of particular importance in 
GDM where the diagnosis of the condition, and implementation of dietary changes 
or the addition of an anti-glycaemic agent, may limit the GWG thereby introducing 
bias. Furthermore, the current 2009 guidance does not account for maternal short 
stature, young age (adolescents), or specific ethnic groups which may all influence 
GWG. Weight gain in Asian women for example may have varying impact on 
pregnancy or fetal outcome compared to Western populations, in which the 2009 
recommendations were based. The recommendations were also limited to wide 
ranges of BMI, in particular for extreme obesity as it does not give guidance 
specifically on Class II (BMI: 35-39.9 kg/m2) or III obesity (BMI: 40 kg/m2), also shown 
in Table 1.1. Conversely, the guidance did not provide any recommendations on 
weight loss in pregnancy as the safety and implications of this have not yet been 
determined. As discussed, weight loss before pregnancy, to achieve optimal pre-
conceptual weight, is however widely recommended but with most pregnancies 
being unplanned, may not be applied in daily practice. Collectively, these factors 
highlight the need to revise the current 2009 guidance, with specific 
recommendations for a more diverse and obese contemporary population.  
 
 
There is a wide variety of literature available on the interventions adopted in 
pregnancy to encourage women to achieve optimal GWG (Polley, Wing, and Sims, 




weight gain during pregnancy, and providing support and counselling. Many have 
limited statistical power however to draw assumptions on the pregnancy outcome. 
They conclude however that models of care should be available for all women of 
childbearing age, and not simply to those ‘planning a pregnancy’ (as discussed, as 
most pregnancies are unplanned), in addition to being available throughout 
pregnancy as well as in the postpartum period. By optimising the weight gain in 
pregnancy, according to the 2009 guidance, it lowers the obstetric risk, normalises 
offspring birthweight, improves the long-term health outcomes, reduces the 
postpartum weight retention risk of obesity in subsequent pregnancies as well as 
reducing the risk of childhood obesity (Institute of Medicine and National Research 
Council Committee to Reexamine IOM Pregnancy Weight Guidelines, 2009).  
 
 
Table 1.1 IOM Recommended levels of GWG according to pre-pregnancy BMI 
categories (Institute of Medicine and National Research Council Committee to 
Reexamine IOM Pregnancy Weight Guidelines, 2009)  
 
 
Pre-pregnancy BMI (kg/m2) Recommended absolute weight gain 
(kg) 
<18.5 (Underweight)  12.5-18.0 
18.5-24.9 (Health weight) 11.5-16.0 
25.0-29.9 (Overweight) 7.0-11.5 






1.5.3 Maternal diabetes in pregnancy  
 
 
Whilst GWG and maternal obesity, and their role in the causal pathway, in relation 
to offspring birthweight and metabolic markers, are the focus in Chapter 3, Chapter 
4 will examine the impact of maternal diabetes in pregnancy, and fetal overnutrition 
in pregnancy. GDM is a common complication of pregnancy and accounts for 90% of 
all maternal diabetes in pregnancy (National Institute for Health and Care 
Excellence, 2015). Evidence from human studies suggests there is a possible linear 
(causal) association between elevated maternal glucose levels in utero and greater 
offspring birthweight and metabolic dysfunction (Metzger et al., 2008; Poston, 
Harthoorn and Van Der Beek, 2011; Thaware et al., 2015). Both leptin and insulin 
are higher in babies of mothers with GDM, as a result of fetal overnutrition as well 
as a consequence of leptin resistance or altered leptin signalling, so the offspring 
become less able to control weight gain (Simmons, 2011). It has been proposed that 
these offspring outcomes may be worsened by excessive GWG as it enhances the 
insulin-resistant state present during pregnancy and diabetes (Egan et al., 2014). As 
the 2009 IOM guidelines on GWG in pregnancy were devised for a general obstetric 
population, it is as yet unclear if they are relevant to higher risk groups, such as 
those with diabetes mellitus (Institute of Medicine and National Research Council 
Committee to Reexamine IOM Pregnancy Weight Guidelines, 2009). It also remains 
uncertain as to whether regulating GWG limits the translation of this metabolic 
dysfunction onto the offspring at birth.  
 
 
The large, multicentre study, Hyperglycaemia and Adverse Pregnancy Outcomes 
(HAPO) revolutionised clinical management of diabetes in pregnancy as it showed a 
clear association between maternal glycaemia, offspring birthweight, and cord 
blood c-peptide (Metzger et al., 2008). A more recent report from this study however 
has shown that the relationship between mild, untreated hyperglycaemia in 
pregnancy (that does not meet the criteria for GDM) and offspring adiposity in 
childhood is limited (Thaware et al., 2015). It has been proposed that the effect of 




adolescence as they transition through puberty. The Exploring Perinatal Outcomes 
among Children (EPOCH) study demonstrated this by showing higher BMI at age 10 
to 13 in the offspring of mothers who developed GDM during pregnancy (Crume et 
al., 2011). Undoubtedly, maternal diabetes emphasises the fetal overnutrition 
hypothesis with the offspring, and mothers, at substantial long-term risk.   
 
 
C-peptide is a short chain of amino acids that are released into the circulation as a 
byproduct of the formation of insulin from biologically inactive proinsulin in the 
pancreas. Both insulin and c-peptide are released in equimolar amounts but as 
insulin has a short half-life it is cleared quicker and therefore more prone to 
fluctuations,  making it difficult to measure from peripheral venous samples (Nesbitt 
et al., 2006; Metzger et al., 2008). In addition, c-peptide does not appear to be 
altered by haemolysis, unlike insulin which shows signs of degradation (O’Rahilly et 
al., 1987). As around 15% of all venous samples show signs of haemolysis, c-peptide 




1.5.4 Hypertensive disorders in pregnancy (HDP) 
 
 
HDP is increasingly prevalent amongst the current obstetric population and includes 
pre-eclampsia (PE) and gestational hypertension (GH).  Chapter 5 will examine the 
association of HDP in pregnancy and offspring birthweight and metabolic markers. 
PE is of unclear origin but is thought to be a two-stage disorder, as shown in Figure 
1.1 (Roberts and Hubel, 2009). Firstly, there is abnormal implantation and invasion 
by the trophoblast leading to insufficient spiral artery re-modelling and ultimately 
decreased placental perfusion, thereby limiting the passage of nutrients to the 
developing fetus (Pijnenborg, Vercruysse and Hanssens, 2006; Roberts and Hubel, 
2009). Following this, there is an exaggerated maternal systemic inflammatory 
response and oxidative stress. Altered vascular endothelial function ensue which 




and biochemical disruption that is associated with greater maternal adiposity may 
be the ‘maternal milieu’ that leads to this second stage in PE or may indeed trigger 
the onset of the first stage. Overweight and obesity are associated with a chronic 
low-grade inflammatory state and elevated C-reactive protein (CRP), as well as some 
inflammatory cytokines, have been demonstrated in such a population. There is also 
systemic inflammation as shown by elevated neutrophils, that release toxic 
compounds, which may adversely affect the integrity of the endothelium and may 
also contribute to the development of PE. 
 




Current guidance for women at high risk of developing pre-eclampsia is to commence 
low-dose Aspirin from 12 weeks’ gestation (NICE, 2010). As shown in Table 1.2, those 
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with one or more high-risk factors or women with two or more moderate risk factors 
should be advised to commence therapy during pregnancy. This treatment given to 
those at moderate to high risk of PE can reduce their risk of developing PE by 15% 
(Duley, 2009).  
 
 
Table 1.2: Risk factors for PE according to NICE guidelines (NICE, 2010) 
 
 
High risk Moderate risk 
History of hypertension in a previous 
pregnancy 
Nulliparous 
Chronic renal disease Age ≥40 
Autoimmune disease e.g. 
Antiphospholipid syndrome 
Pregnancy interval more than 10 
years 
BMI ≥35 at the first visit 
Type 1 or 2 diabetes mellitus Family history of PE 




PE in particular has well documented long-term sequelae for the mother, such as 
chronic hypertension, cardiac and cerebrovascular disease (Bellamy et al., 2007; 
Fraser et al., 2010; McDonald et al., 2010). Dyslipidaemia in the maternal serum has 
also been reported (Khatua et al., 1989; Vanessa A. Rodie et al., 2004; Ophir et al., 
2006; Catarino et al., 2008). Fewer extreme cases of PE are seen prior to 28 weeks’ 
gestation, with only 0.5% of all nulliparous women delivering before 34 weeks as a 
result of developing the severe disease (NICE, 2010).  
 
 
HDP may also contribute to an altered metabolic risk profile in the offspring. This 




al., 2008) in the offspring of those with PE, or from the pronounced endothelial 
dysfunction (Tenhola et al., 2003) and dyslipidaemia (Ophir et al., 2006; Catarino 
et al., 2008; Akcakus et al., 2010) that may ultimately lead to higher blood pressure 
(BP) and greater risk of cerebrovascular disease (Kajantie et al., 2009) in the 
offspring. As greater maternal BMI and excessive GWG are risk factors for developing 
HDP, it is unclear as to whether appropriate GWG may mitigate any additional 
metabolic risk in the offspring of mothers with HDP. There is also limited evidence 
on how these disorders during pregnancy influence the biochemical imprint at birth, 
as measured by cord blood adipokines and lipids.  
 
 
Women who develop PE are counselled about their recurrence risk and the risk of 
future cardiovascular disease. Whilst PE may recur in future pregnancies, the 
phenotype tends to be less severe. From those that had developed PE, there is a 13% 
increased risk of GH in a future pregnancy and a 16% risk of re-developing PE (NICE, 
2010). This may increase to 55% however if the original PE led to delivery before 28 
weeks’ gestation (NICE, 2010). In terms of lifetime risk, a 3.7-fold increased risk of 
hypertension, as well as a 2.2-fold increased risk of coronary heart disease and a 




1.5.5 Tracking of cord blood analytes  
 
 
Whilst cord blood measures may be used to describe the intrauterine environment 
at birth, it remains uncertain whether these markers track throughout the life 
course. It has also yet to be established whether these cord blood measures may be 
used at birth for predictive purposes, due to the lack of longitudinal studies 
examining these associations.  Chapter 6 will examine biomarkers in the cord blood 
at birth with subsequent repeat ‘like for like’ analyte measures  obtained in 
childhood and adolescence. A 12-year follow-up study has shown that serum 




2003), even though there is evidence from another that lipids positively correlate 
with cardiovascular disease in later life (Klag et al., 1993; Raitakari et al., 2003). 
Furthermore, liver function tests (LFT’s) have shown evidence of tracking in 
adulthood (Patel et al., 2007), as has leptin measured in childhood and 3 years later 
(Nishimura et al., 2009; Volberg, Heggeseth, et al., 2013). Cord blood leptin is also 
positively associated with leptin at age 3, unlike cord blood adiponectin which 
wasn’t associated with adiponectin at age 3 (Mantzoros et al., 2009). Studies from 
birth using cord blood indices are limited however and it is,, therefore, difficult to 
determine whether they may be used as predictors of long-term metabolic health. 
Should this be possible, it has significant therapeutic and health implications as 
‘higher risk’ individuals may be identified even before the onset of the disease. 
Certainly, the associations between lipids and later life cardiovascular events give 
promise to the concept that early detection of analytes may herald the early onset 
of metabolic disease.  
 
 
1.5.6 Adipokines and fetal programming  
 
 
Whether or not it is the maternal health and degree of adiposity in pregnancy that 
triggers a disruption in cord blood measures and resultant higher offspring birth 
weight or fact cord blood analytes act independently of maternal health is unclear. 
It has been proposed that it is the maternal health status that has the most 
significant impact on levels of fetal adipokines such as leptin and adiponectin in 
utero. From this, a ‘pathway’ may be created passing the maternal susceptibility to 
obesity and insulin resistance onto the fetus (Luo et al., 2013). Another mechanism 
may be that obese mothers may produce large for gestational age offspring which 
may then lead to increased adiposity later in life. These may however be all 
secondary mechanisms to the dominant cause which is shared lifestyle and genes 
that create an obesogenic environment for the offspring throughout late life (Debbie 
A. Lawlor et al., 2012). In Chapter 7, the associations between cord blood adipokines 




examined and account for variables such as maternal BMI which, as  previously 
discussed, are also associated with greater offspring adiposity.  
 
 
The key role that adipokine leptin plays in regulating energy homeostasis is well 
documented. Circulating cord blood leptin will likely be influenced by maternal 
adiposity (Geary et al., 1999; Karakosta et al., 2011). This in turn is positively 
associated with an increase in cord blood leptin (Helland et al., 1998). Leptin is 
present at significant levels in the cord blood making it a reliable biomarker to 
measure (Tamura et al., 1998; Schubring et al., 1999). The role leptin plays in fetal 
programming however remains relatively unknown (Karakosta et al., 2013). There is 
a vast amount of research demonstrating the link between leptin and the 
development of the fetus in utero through to the neonatal period. It is thought to 
act as a ‘growth-promoting signal for fetal development. It correlates positively with 
anthropometric markers of fetal growth in utero, increasing gestational age and 
birth weight (Tamura et al., 1998; Geary et al., 1999; Nakano, Itabashi and 
Maruyama, 2009; Tung et al., 2009; Karakosta et al., 2011, 2013). In particular, 
umbilical cord blood leptin is strongly related to birthweight (Laml, Hartmann, et 
al., 2001; Laml, Preyer, et al., 2001; Domali and Messinis, 2002) and is a true 
reflection of neonatal fat mass (Schubring et al., 1999; Schulz, Häckel and Weise, 
2000; Pighetti et al., 2003; Hauguel-de Mouzon, Lepercq and Catalano, 2006). Leptin 
is also related to the ponderal index in the neonatal period (Bellone et al., 2004). 
From this, it may be deduced that leptin may be used as a biomarker of fetal and 
neonatal adiposity which has the potential to programme the degree of adiposity in 
later life (Varvarigou, Mantzoros, and Beratis, 1999; Hauguel-de Mouzon, Lepercq 
and Catalano, 2006). 
 
 
Evidence of the long-term effects of fetal programming, as measured by tracking fat 
mass from the neonatal period into adulthood for example, and its relationship to 
cord blood leptin is limited as studies are mainly confined to the neonatal period, 
rather than later in the life-course (Mantzoros et al., 2009; Nakano, Itabashi and 




primarily reflects the availability of prospective birth cohorts with cord blood 
samples (N=56-580) and detailed measures of offspring adiposity as well as potential 
maternal and offspring confounders. Despite the robust positive association of cord 
blood leptin with birth weight, skin-folds and neonatal fat mass (Mantzoros et al., 
2009; Kaar et al., 2014), lower cord blood leptin has been associated with faster 
growth and infant weight gain in the first year (Mantzoros et al., 2009; Kaar et al., 
2014) and a higher BMI at 3 and 7 years (Mantzoros et al., 2009; Boeke et al., 2013). 
In contrast, from age 7 years through to adult life, higher circulating leptin predicts 
greater subsequent weight gain, BMI, and fat mass (Savoye et al., 2002; Fleisch et 
al., 2007). These contrasting directions of association with subsequent adiposity for 
cord blood leptin and childhood and adult leptin have been principally interpreted 
as reflecting distinct periods of leptin sensitivity (Blüher and Mantzoros, 2009; 
Mantzoros et al., 2009). In animal models, neonatal exposure to exogenous leptin 
matures the hypothalamic neurons responsible for appetite balance, thereby 
moderating subsequent energy balance and the trajectory of weight gain (Vickers et 
al., 2005). In adult mice exposure to exogenous leptin has little impact on 
subsequent weight gain, suggesting a loss of central sensitivity (Halaas et al., 1997). 
In humans, equivalent age-dependent periods of leptin sensitivity have been 
proposed (Mantzoros et al., 2009). However, the accuracy of circulating leptin even 
in cord blood as a measure of central leptin sensitivity as compared to its established 
role as an indicator of neonatal fat mass is unknown. In the offspring of mothers 
with type 1 diabetes, a classical model of developmental overnutrition (Pettitt et 
al., 1983), a higher cord blood leptin was associated with greater neonatal fat mass 
and higher BMI at age 7 years (Lindsay et al., 2010). Fundamentally if there is a 
positive correlation between cord blood leptin and growth and development later in 
life, cord blood leptin may be used as a surrogate marker for adiposity in future 
health intervention studies.  
 
 
The adipocyte-derived hormone adiponectin has also been shown to be related to 
birth weight and neonatal fat mass (Inoue et al., 2008). Its role in fetal physiology 
and programming is less clear, as maternal adiponectin does not cross the placenta 




growth as well as having insulin-sensitizing effects in adults. Adiponectin is also 
present in high levels in the cord blood which aids accurate measurement of the 
analyte (Tsai et al., 2004). Neonatal levels are approximately 4 to 7 times higher 
than maternal levels, and in contrast to maternal circulating concentrations,  where 
adiponectin is inversely associated with BMI, higher levels of cord blood adiponectin 
are associated with anthropometric parameters of adiposity, including increased 
birth weight and fat mass in some (Inoue et al., 2008; Mantzoros et al., 2009; Teague 
et al., 2015) but not all studies (Nelson et al., 2008; Lindsay et al., 2010). This shift 
in the association is evident in childhood where low serum levels of adiponectin have 
been associated with childhood obesity (Araki et al., 2006). The large longitudinal 
study of women and children, Project Viva, however, demonstrated high maternal 
and cord blood leptin and low cord blood adiponectin to be associated with lower 
offspring adiposity in childhood from age 3 to 13 years (Li et al., 2018). Adiponectin, 
therefore, exhibits different directions of association with adiposity in the neonate 
as compared to later on in life. That these higher cord blood adiponectin 
concentrations might reflect increased fat mass is suggested by mouse studies where 
transgenic over-expression of fetal adiponectin increased the size of fat depots in 
early life, while adiponectin knockout fetuses, with adiponectin deficiency, display 
lower body weight and lower fat content  (Qiao, Yoo, et al., 2012). This effect 
however was lost on the 15th postnatal day suggesting that adiponectin may not have 
a significant role in programming the degree of long-term offspring adiposity. These 
differing directions of associations highlight the complex role that adiponectin plays 
in early fetal life but suggest that the strength of their effect may diminish with 
time (Li et al., 2018). Collectively, from this established and emerging evidence 
examining the role of adipokines in pregnancy, it is clear that the hormonal status 
of the intrauterine environment may induce significant changes in growth patterns 




1.5.7 Lipids and fetal programming  
 
 
During early pregnancy, there is deposition and hypertrophy of maternal adipocytes, 
with increased expression of insulin receptors, enabling maternal glucose to meet 
the increased metabolic demand of the fetus (Herrera, 2002). With rising insulin and 
progesterone, there is subsequent lipogenesis and lipolysis, thereby increasing 
circulating lipids and enhancing transplacental passage of lipids to the fetus. With 
advancing gestation, there is further dysregulation of metabolic pathways, in 
particular the lipid pathway. Normal pregnancy is characterised by 
hypertriglyceridemia and hypercholesterolemia (Eslamian et al., 2013) as a result of 
disruption to lipid transport and metabolism. By the third trimester, triglyceride 
levels may be up to four times higher than that of pre-pregnancy levels (Hadden and 
McLaughlin, 2009). The disrupted lipid profile is also characterised by smaller, 
denser LDLc particles, which are thought to be more atherogenic (Belo et al., 2004). 
Elevated HDLc and lipoprotein-A, which peak in the second trimester, also feature 
in normal pregnancy. HDL offers vasodilatory, anti-inflammatory, anti-oxidant, and 
anti-thrombotic effects and thus protection against endothelial damage (Wan 
Sulaiman et al., 2016). 
 
 
Co-morbid conditions during pregnancy, such as PE and GDM, may also exaggerate 
the disruption to lipid profile during pregnancy and present additional risk to the 
mother and baby. In mild PE, high triglyceride and cholesterol levels (especially 
during the second trimester) feature, whereas lower LDLc may be seen in more 
severe disease (Baker et al., 2009). Reduced levels of HDL have also been reported 
in PE and may account for the vascular dysfunction that ensues (Wan Sulaiman et 
al., 2016).  
 
 
Maternal diabetes exaggerates this disruption of lipid profile and is also associated 
with altered lipoprotein levels, hence greater cardiovascular risk. This was evident 




elevated triglyceride and decreased HDL levels compared to controls (Dubé, Ethier-
Chiasson, and Lafond, 2013). In contrast, overweight or obese women with GDM had 
lower total cholesterol and LDLc levels compared to controls (Dubé, Ethier-Chiasson 
and Lafond, 2013). It is difficult to ascertain the metabolic risk adopted by the 
offspring, however. While offspring of diabetic mothers displayed elevated cord 
blood triglyceride and LDLc and lower HDLc levels, their associations were not 
significant compared to offspring of non-diabetic mothers (Dubé, Ethier-Chiasson 
and Lafond, 2013; Eslamian et al., 2013). Another study showed elevated 
triglyceride in mothers with GDM, higher fat mass in their offspring but lower 
triglyceride levels in the cord blood (Ortega-Senovilla et al., 2013). A further study 
showed that whilst maternal diabetes has been consistently associated with higher 
offspring glucose and insulin levels in adolescence, it was not associated with 
offspring lipids at all, nor was it associated with other metabolic markers including 
offspring blood pressure or CRP (Patel et al., 2012).  
 
 
Maternal obesity in pregnancy may also feature more atherogenic lipid profiles, 
which are associated with adverse pregnancy outcomes (Meyer et al., 2013; Barrett 
et al., 2014). In obese pregnancy triglyceride levels increase, and the anti-
inflammatory properties of HDL may be diminished. Combined with a rise in LDLc, 
these changes may account for decreasing vascular function and adverse pregnancy 
outcomes that are associated with obesity in pregnancy (Meyer et al., 2013). 
Dyslipidaemia is also a feature of pregnancies delivered pre-term, as well as the 
growth-restricted pregnancy, whose offspring assume greater cardiovascular risk in 
later life (Gluckman et al., 2008; Pecks et al., 2012).  
 
 
Despite evidence of lipids tracking through life from childhood (Raitakari et al., 
2003), their role, if any, in contributing to long-term offspring adiposity is unknown. 
HDL has been inversely related to fetal growth and BMI at age 9 (Nayak, Agarwal and 
Nayak, 2013), whereas triglycerides have been positively associated with neonatal 
anthropometry and BMI at age 9 (Nayak, Agarwal and Nayak, 2013; Volberg, Harley, 




been associated with lower adiposity in children at age 3 years (Donahue et al., 
2011). Recent mendelian randomization studies however did not support a causal 
association between maternal triglyceride, HDL, or adiponectin levels and offspring 
birth weight or ponderal index (Tyrrell et al., 2016).   
 
 
Whilst normal pregnancy features disruption to the maternal lipid profile, the extent 
of offspring dyslipidaemia may be subject to the maternal health status of the 
mother during pregnancy, and as yet there is conflicting evidence to support 
abnormal lipid profiles in pregnancy causing a long-lasting adverse clinical impact 
on the offspring.  
 
 
1.5.8 Non-Alcoholic Fatty Liver Disease in the offspring  
 
 
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease 
in children and adults in the developed world (Younossi et al., 2011). The increasing 
prevalence of the disease in childhood and adolescence has led to further 
investigation into potential fetal origins of the disease and developmental 
overnutrition has been proposed in its pathogenesis (Brumbaugh et al., 2013). 
Associations to date however have been mixed. Increasing maternal adiposity and 
greater GWG may both contribute to the adverse environmental exposure in utero 
and thus ‘programme’ the offspring to a greater predisposition to the disease. 
Maternal BMI has also been positively associated with increased intrahepatocellular 
lipid content in neonatal offspring (Modi et al., 2011). Animal models of a maternal 
high-fat diet during pregnancy equally display greater adiposity and elevated hepatic 
lipid accumulation in their offspring (McCurdy et al., 2009; Oben et al., 2010). 
Conversely, lower birth weight has also been associated with elevated liver 
transaminases and NAFLD in adolescence and adulthood (Nobili et al., 2006; Fraser 
et al., 2008; Faienza et al., 2013; Anderson et al., 2014), which is thought to be as 
a result of impeded organ development (Andersen and Osler, 2004; Nobili et al., 




birth have been linked to neonatal fat mass and anthropometric measurements in 
early life, their association with childhood NAFLD remains unclear. In Chapter 8, the 
associations between cord blood adipokines, lipids, and birthweight, and structural 








This thesis aims to explore the impact of the intrauterine environment, as a 
reflection of maternal health in pregnancy, on the offspring’s health in the short 
and long-term. Emerging and established evidence suggests that the intrauterine 
environment plays a considerable role in offspring development and by utilising cord 
blood indices from the large prospective cohort, ALSPAC, this may be examined 
further. As  few epidemiological studies address the long-term impact of adverse 
metabolism in utero, this Thesis will aim to provide an overview of the relationship 
between altered maternal metabolism, offspring biomarkers at birth, and their 
association with later life anthropometry.  
 
 
Maternal ‘ill health’ may be determined by a wide range of physiological processes. 
Maternal obesity and inappropriate GWG may lead to dysregulation of adipose tissue, 
disruption to circulating adipokines, and may stimulate systemic pro-inflammatory 
responses which collectively may result in multi-system effects on the mother and 
baby. Metabolic complications in pregnancy, such as GDM, may arise as a result of 
an inadequate response to increased circulating glucose with resultant systemic 
insulin resistance. In addition, HDP may develop as a result of widespread vascular 
dysfunction. Collectively, these may influence fetal growth and development in 




Although birthweight is a recognised anthropometric marker that is positively 
associated with adolescent adiposity, it has yet to be established whether 
biomarkers at birth, such as cord blood leptin and adiponectin, track throughout the 
life course. Whilst positive associations have been established between repeat 
measures of adipokines, lipids, and liver function in later life, this Thesis aims to 
examine the direction of associations and degree of tracking between cord blood 




surrogate of measured fat mass, by identifying evidence of tracking throughout the 
life course, there is potential to use leptin measurements, from cord blood at birth 
for example, as an indicator of the fat mass in the offspring in later life.  
 
 
Lastly, given the associations established in later life, the  aim is to establish 
whether a higher cord blood leptin, as a surrogate for greater neonatal fat mass, 
would be associated with greater adiposity in late childhood and adolescence. 
Conversely, acknowledging the direct effect of adiponectin on body composition and 
specifically enhancing fat deposition, and the different direction of associations in 
infancy compared to adulthood, this study aims to determine whether adiponectin 








1.7 Hypothesis  
 
 
This study was designed with the aims of addressing:  
 
 
a) How a dysregulated intrauterine environment, such as in maternal diabetes, 
hypertension, or in abnormal GWG, may influence cord blood lipids, 
adipokines, and birthweight. Specifically, it was hypothesised that greater 
maternal BMI or GWG would be positively associated with cord blood leptin 
and lipids and negatively associated with cord blood adiponectin, given the 
direction of association that existed amongst obese adult subjects. In 
addition, it was proposed that maternal diabetes in pregnancy was not 
associated with elevated cord blood lipids levels, as associations in childhood 
previously reported by ALSPAC were null. It was also proposed that cord blood 
adiponectin specifically would be lower in the offspring of diabetic mothers, 
given the inverse relationship that has existed between adiponectin and 
maternal diabetes. As maternal PE has previously been associated with 
disturbed lipid profile in the offspring, this study also hypothesised that the 
presence of PE would be associated with higher cord blood triglyceride and 
LDLc, as well as lower HDL levels.  
 
 
b) How the baseline measures of cord blood lipids, adipokines, and liver function 
tests, reflecting the offspring’s cardio-metabolic profile at birth, may track 
from birth to adolescence. As positive associations have previously been 
demonstrated between LFTs, lipids, and adipokines in later life, it was 
hypothesised that cord blood measures would also be positively associated 
with repeat measures of the analyte in childhood and adolescence.   
 
 
c) How birthweight and cord blood adipokines, reflecting the intrauterine 
environment at birth, may be associated with long-term metabolic function 




by the presence of NAFLD in late adolescence. Given the positive associations 
that have existed between cord blood leptin and fat mass at birth and in early 
childhood, as well as the direct effect adiponectin has on body composition 
and fat deposition, it was hypothesised that higher cord blood leptin and 
lower cord blood adiponectin, would be associated with greater adiposity in 
later childhood and adolescence. In addition, it was hypothesised that cord 
blood leptin and lipids would be positively, and adiponectin negatively 
associated with NAFLD in adolescence, given the already established 
associations between these measures and presence of NAFLD activity in later 






Specific Hypothesis for each Chapter 
 
Chapter 3:    Greater maternal adiposity (as measured by higher maternal BMI and 
greater or excessive GWG) would be positively associated with offspring birthweight, 
cord blood leptin, and lipids (higher cord blood cholesterol and triglycerides and 
lower cord blood HDLc) and lower cord blood adiponectin.  
 
Chapter 4: Maternal diabetes in pregnancy would be positively associated with 
offspring birthweight, negatively associated with cord blood adiponectin, and 
limited or no impact on cord blood lipids.  
 
Chapter 5: Elevated blood pressure in pregnancy would be negatively associated 
with offspring birthweight and cord blood adiponectin and positively associated with 
cord blood leptin and lipids (elevated cord blood cholesterol, triglyceride and lower 
HDLc).  
 
Chapter 6: Cord blood LFTs (AST, ALT, and GGT), lipids (cholesterol, triglyceride 
and HDLc), CRP, and leptin would track positively, and cord blood adiponectin track 
negatively when repeat measures of each analyte were obtained at ages 9 (LFTs, 
lipids, leptin, and adiponectin), 15 (lipids and CRP) and 17 (LFTs, lipids and CRP).    
 
Chapter 7:  Cord blood leptin would be positively, and cord blood adiponectin 
negatively associated with offspring birthweight and BMI, waist circumference, and 
fat mass at ages 9 and 17.  
 
Chapter 8:  Cord blood leptin, lipids, and birthweight would be positively, and cord 
blood adiponectin negatively associated with an ultrasound (measured by liver 
stiffness, volume, and presence of a fatty liver) and biochemical (measured by ALT, 





Chapter 2: General Methods 
 
 
2.1 The Avon Longitudinal Study of Parents and Children (ALPSAC) 
 
 
2.1.1 Study population and ethical approval 
 
 
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective birth 
cohort study investigating the health and development of children (Boyd et al., 
2013; Fraser, Macdonald-wallis, et al., 2013). The study website contains details of 
all the data that is available through a fully searchable data dictionary; 
http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/. ALSPAC 
had sought prior ethical approval from the ALSPAC Law and Ethics Committee 
(Institutional Review Board 00003312) and the National Health Service local ethics 
committee. Participants provided written consent to participate in the study, 
including information from medical records to be abstracted.  Written informed 
consent was obtained from parents/guardians providing consent for offspring up to 
age 16 years, with offspring providing consent thereafter.  
 
 
A total of 14,541 women were initially enrolled, with expected dates of delivery 
between 1st April 1991 and 31st December 1992. Of those recruited, there were 5011 
mother-offspring pairs with a cord blood sample.  
 
 
2.1.2 Obstetric and perinatal data  
 
 
Six trained research midwives from ALSPAC extracted data from obstetric medical 
records.  There was no between midwife variation in the mean values of data 





consistently less than 1%, as previously reported by ALSPAC (Fraser, Macdonald-
wallis, et al., 2013). This data included maternal age, GWG, complications during 
pregnancy (hypertensive or diabetic disorders), gestational age at birth, mode of 
delivery, offspring’s sex, and birthweight. Maternal pre-pregnancy height and 
weight, smoking status (defined as never smoked, smoked before but not during 
pregnancy and smoked during pregnancy), parity, occupational social class, and 
highest educational attainment were obtained from questionnaires completed by 
the mothers in early and advanced stages of pregnancy. Self-reporting of pre-
pregnancy weight correlated highly with weight at the first antenatal visit (Geelhoed 
et al., 2010). The occupation was used to allocate social class groups using the 1991 
British Office of Population and Census Statistics classification. To quantify GWG 
during pregnancy, maternal weight was recorded by research midwives at regular 
intervals during the pregnancy (median 10, IQR 8, 10) along with the corresponding 
gestational age and date. Although the exact models of confounder adjusted analysis 
are discussed later and according to each Chapter, maternal confounders obtained 
from data extraction by ALSPAC included age, smoking, parity, occupational social 
class, education, and pre-pregnancy BMI. Further analysis included adjusting for 
pregnancy confounders obtained from ALSPAC and accounted for gestational age at 
birth, mode of delivery, gestational weight gain, hypertensive disorders, and 
diabetic disorders of pregnancy.  
 
 
Gestational age was included as a confounder in the models of analysis as it was 
proposed that a longer duration of pregnancy may influence the circulating 
metabolites within the intrauterine environment. Literature supports increasing 
circulating leptin levels with advanced gestational age, in particular in those who 
are already overweight or obese (Misra, Straughen and Trudeau, 2013).  Cord blood 
adiponectin also rises with advanced gestational age, particularly from 24 weeks’ 
gestation (Kajantie et al., 2004). Greater gestational age would also likely be 
associated with greater maternal GWG, which has also been positively associated 
with higher maternal and offspring leptin levels (Logan et al., 2017). Also in keeping 
with advanced gestational age is larger offspring birthweight and evidence supports 





offspring birthweight (Farias et al., 2017). As leptin is additionally secreted by the 
placenta during pregnancy, advanced gestation and therefore a larger placenta is 
likely to yield higher circulating leptin levels (Masuzaki et al., 1997). There is also 
the risk of placental dysfunction and consequent metabolic dysfunction with very 
advanced gestational age. Collectively this may have influenced the circulating 
levels of adipokines and lipids and justifies including gestational age as a cofounder, 
and mediator, in the analysis. However, for most individuals included in the Study, 
delivery was around ‘term’ (40 weeks) and was unlikely to exceed 42 weeks, which 
reflects obstetric practice throughout the UK. Conversely, deliveries before 37 
weeks (pre-term pregnancies) were not well represented in this Study for several 
reasons. The pre-term umbilical cord would be less likely to yield sufficient blood 
volume to be included in the study, partly because the cord would have been 
narrower and technically more difficult to access the umbilical vein, but also 
because the cord would have contained less blood volume. In addition, pre-term 
deliveries were also encouraged to allow passive flow of cord blood into the baby 
following delivery (and before clamping of the cord) to increase delivery of red blood 
cells to the preterm offspring, therefore limiting the abundance of available cord 
blood. As a result of the impact gestational age may have on the offspring and the 
circulating analyte concentrations, it was therefore adjusted for in the analysis.  
 
 
Mode of delivery was also adjusted for in the analysis, owing to its influence on cord 
blood adipokines at birth. Vaginal birth has been associated with higher cord blood 
leptin levels compared to caesarean section deliveries (Yoshimitsu et al., 2000). This 
finding however has not been demonstrated by all, with one study concluding that 
leptin was associated with duration of labour rather than the mode of delivery alone 
(Logan et al., 2016) and another study demonstrated that adiponectin was not 
associated with mode of delivery (Kajantie et al., 2004).   
 
 
Mediator adjusted analysis has also been also described within the analysis in 
Chapters 3 and 4, as maternal BMI or GWG may have influenced the cord blood 





potential mediating factors when examining maternal diabetes and its offspring cord 
blood analytes. In this case, maternal diabetes and its association with GWG may 
have positively influenced offspring birthweight which may then have also 
influenced the cord blood adipokine levels, justifying their inclusion as potential 
mediators. These variables may also have been examined as potential confounders 
however as there was progressive glucose dysregulation with advancing gestational 
age. Furthermore, in Chapter 7, offspring height and fat mass in the preceding age 
group feature in the causal pathway and were accounted for in the analysis. In 
Chapter 8, where offspring liver outcomes were examined in relation to cord blood 
measures, the offspring’s height and weight were also accounted for given the 
associations with offspring anthropometry in adolescence, which may in turn have 
influenced the risk of metabolic dysfunction, as measured by offspring NAFLD.  
 
 
2.1.3 Offspring data 
 
 
Offspring were followed up at specified clinics and anthropometric measurements 
were obtained by ALSPAC, as previously reported (Boyd et al., 2013). Specific details 
on offspring variables have been listed according to each Chapter. Identical 
protocols were used at all ALSPAC follow-up clinics. At each clinic assessment 
participants’ age in months was recorded and their weight and height were 
measured in light clothing and without shoes. Weight was measured by ALSPAC to 
the nearest 0.1kg using Tanita scales. Height was measured by ALSPAC to the nearest 
0.1cm using a Harpenden stadiometer. Dual-energy X-ray absorptiometry (DEXA) 
scans were used by ALSPAC to measure total fat mass. Waist circumference was 
measured by ALSPAC to the nearest 1mm at the midpoint between the lower ribs 
and the pelvic bone with a flexible tape and with the child breathing normally. BMI 
was represented by z-scores, adjusted for age and sex according to the 1990 British 
Growth Charts (Cole et al., 2000). Offspring obesity was classified using BMI and 






For the purpose of this Thesis, offspring birthweight was examined as an exposure 
variable. In Chapter 7, relations between birthweight (the exposure) and offspring 
adiposity outcomes have been addressed and in Chapter 8, birthweight was further 
analysed as an exposure in relation to offspring liver outcomes. Birthweight, 
however, has also been acknowledged as an outcome of the ‘exposed’ intrauterine 
environment. As discussed in Chapter 1, umbilical cord blood leptin has been widely 
recognized as an accurate biomarker for neonatal fat mass (Hauguel-de Mouzon, 
Lepercq and Catalano, 2006) with its concentration at birth proportional to 
birthweight. In animal studies, overexpression of adiponectin has been associated 
with greater fat depots in early life, and in contrast, adiponectin knockout fetuses 
have lower fat content and body weight (Qiao, Yoo, et al., 2012). Birthweight has  
also been related to maternal BMI (Stamnes Koepp et al., 2012), uncontrolled GDM 
(Gillman et al., 2003), and GWG (Stamnes Koepp et al., 2012), highlighting 
birthweight as a product of the intrauterine environment rather than simply the 
primary exposure for that individual.  
 
 
2.1.4 Body Mass Index (BMI) 
 
 
Body Mass Index (BMI) is the most commonly used method to quantify adiposity. It is 
easily reproducible, simple to calculate, and is used universally so that data can be 
calculated and compared between studies globally. By assessing weight relative to 
height, BMI is expressed in kg/m2 and is calculated as weight (kg) / (height (m) 2. 







Table 2.1: BMI as defined by the World Health Organisation (WHO) 
 
 
Category BMI Range (kg/m2) 
Underweight <19.9 
Normal 20.0 - 24.9 
Overweight 25.0 – 29.9 
Obese Class I 30.0 – 34.9 
Obese Class II 35.0 – 39.9 
Obese Class III >40.0 
 
 
Whilst the use of BMI is adequate in general population studies, it may have its 
limitations. As it is a simplistic measurement of total body fatness, it assumes that 
relative proportions of muscles, water, and fat mass remain constant. BMI or 
adiposity may be overestimated in athletes for example, with a greater proportion 
of lean body mass. The distribution of the fat may also determine the risk of 
cardiovascular disease and as discussed in Chapter 1, it has been proposed that 
central (or abdominal) adiposity poses a greater risk (Eleanor Jarvie et al., 2010). 
The categories of BMI may also vary according to ethnicity as the relative 
cardiovascular risk may be greater at lower thresholds of BMI in South East Asian and 
Japanese populations (Razak et al., 2007). In these populations, a BMI of >23.0 kg/m2 
may be considered overweight and at greater cardiovascular risk compared to their 
European counterparts, where a BMI of >25.0 kg/m2 would meet this criterion.  
 
 
For the purpose of this study, childhood BMI was represented by z-scores, adjusted 







In order to assess body composition and distribution of fatness, direct and indirect 
methods were employed. BMI is an example of an indirect method, in addition to 
anthropometric measurements such as waist-hip ratio (WHR), waist circumference 
(WC) and skinfold thickness. Direct methods include DEXA, computerised 
tomography (CT) and magnetic resonance imaging (MRI).  
 
 
2.1.5 Indirect Methods: Anthropometric measurements 
 
 
The WHR is the simplest measurement of body distribution and assesses the ratio of 
waist circumference to hip circumference. A WHR >0.85 has been shown to 
demonstrate greater central adiposity and therefore cardiovascular disease and type 
II diabetes mellitus (Kannel et al., 1991). For the purpose of this thesis WC in the 
offspring was measured by ALSPAC. 
 
 
Skinfold thickness is a more detailed measurement of fat distribution. It is a means 
of quantifying total body fat as a percentage of total body weight. With the use of 
callipers to gauge fatness at specific anatomical sites, namely subscapular, biceps, 
triceps, and supra-iliac locations. At birth, skinfold thickness is considered the best 




Implementation of the WHR or skinfold thickness has major advantages in larger-
sized studies in that they are low cost, easily accessible, and acceptable by patients 
involved in the study.  As the method of measurement is not exactly entirely 
reproducible, however, identifying the correct site for measurement as well as 
employing the use of the calipers will vary according to each operator which will 
lead to a lot of variation. Whilst repetition and training may lower this variation, 





they be of extremes of weight in the Gaussian curve. It is however a good method 
of assessing body composition in longitudinal studies over a long period.  
 
 
2.1.6 Direct methods: Imaging 
 
 
DEXA, CT and MRI compose the main imaging techniques used to measure body fat 
content as well as providing an assessment of fat distribution. For the purpose of 
this thesis, we have also used data obtained by ALSPAC on offspring fat mass using 
DEXA. DEXA makes use of the differential attenuation of X-ray radiation by bone, 
adipose, and non-adipose soft tissue. It was relatively operator-independent and it 
was a quick method to perform. Other advantages were that as well as providing 
information on total adipose tissue, it also reported specific sites of adipose 
deposits. Body composition, using the 4-compartment model, was also measured 
more accurately with the measurement of bone mass. These 4 compartments 
included fat mass, and fat-free mass including bone mass, body water, and protein 
or muscle mass. Disadvantages however included the expense of the assessment and 
exposure to ionising radiation. Although radiation exposure with X-ray is low, it did 
however limit its usefulness as it was not suitable in pregnant women or children.  
 
 
Whole-body CT is an alternative to DEXA but it was a more expensive option and 
would have exposed the individual to significantly more X-ray radiation. MRI has the 
advantage that it avoids radiation exposure. It provides a detailed assessment of 
adipose tissue and organ lipid content due to its increased resolution of soft-tissue 





2.1.7 Cord blood samples  
 
 
Cord blood samples were collected and prepared by ALSPAC at the time of 
delivery. Specimens were separated into 1ml aliquots of cord blood plasma along 
with 500µl of heparin and stored at -70°C. The samples were transferred frozen 
from ALSPAC to the University of Glasgow (British Heart Foundation building), 
where all of the cord blood sample analyses were performed for the purpose of 
this thesis. Cord blood leptin and adiponectin were measured using commercially 
available ELISA (Enzyme-Linked ImmunoSorbent Assay) kits (Quantikine human 
leptin immunoassay, R&D systems, Quantikine human adiponectin immunoassay, 
R&D systems). Cord blood total lipids (cholesterol, triglyceride, HDLc and non-
high-density lipoprotein cholesterol (non-HDLc), LFT’s and CRP were measured 
using Roche Cobas C311 auto-analyser using enzymatic reagents for lipid 
determination. Non-HDLc was calculated as total cholesterol minus HDLc. Cord 
blood c-peptide was measured using Roche Cobas E411 auto-analyser. This is 
summarised in Table 2.2. Analysis of the cord blood was completed within a 
maximum of three freeze-thaw cycles, over twelve months, and remained at -80°C 









Table 2.2: Materials used for laboratory analysis 
 
 
Cord blood analyte Manufacturer 










Cholesterol Cobas C311 auto-analyser Roche CHOL2 




Cobas C311 auto-analyser Roche HDLC3 
C-reactive protein 
(CRP) 
Cobas C311 auto-analyser Roche CRP 
Alananine 
transaminase (ALT) 




Cobas C311 auto-analyser Roche AST/GOT 
Gamma-glutamyl 
transferase (GGT) 
Cobas C311 auto-analyser Roche GGT 
C-peptide Cobas E411 auto-analyser Roche CPEP 
 





2.2.1 Analyte Assays 
 
 
Types of ELISA and procedure protocol 
 
 
ELISA is an immunoassay used to detect the presence of proteins or other antibodies, 
known as 'antigens'. Commercially available ELISA kits were used for leptin and 
adiponectin quantification (R&D Systems, UK) for the purpose of this thesis. This 
method has previously been used for the quantification of both cord blood leptin 
and adiponectin (Teague et al., 2015; Logan et al., 2017), and this study will also  
later directly compare the precision of two separate ELISA kits. In ELISA, the capture 
antibody or protein, specific to the target analyte, was bound to each well so that 
many samples could be analysed and processed simultaneously. The ELISA assay 
typically entailed a 96-well microplate that enabled efficient analysis of the samples 
of interest. A conjugated detection antibody was then used to bind to the epitope 
on the target analyte. This was followed by the addition of a substrate solution which 
reflected the amount of analyte bound by releasing a signal in proportion to it. The 
presence of a signal meant that the antigen of interest was present.  
 
 
ELISA is the widely preferred method of examining and quantifying specific protein 
levels in biological samples. Whilst there are other methods available, including 
Western Blots and other immunoassay platforms, they are not as specific or as 
sensitive tests and do not produce entirely quantitative results. The binding 
characteristics of the antibodies, the amplification process involved in some, as well 
as the display system for the signal produced all contributed to the highly sensitive 
nature of the ELISA process. Furthermore, ELISA is a robust method that can 
withstand various buffers or pre-treatments already used. As the signal produced 
was specific for the amount of analyte of interest present within the sample, 
detection or amplification of other proteins not being examined was unlikely. When 





and there was also the option to add in an additional amplification step to aid the 
sensitivity of the analyte.  
 
 
There are four different types of ELISA: direct, indirect, sandwich, and competitive 
ELISA. The advantages and disadvantages are described in Table 2.3  
 
 
Table 2.3: Advantages and Disadvantages of Four Types of ELISA 
 
 





Protocol easy to follow (only one 
antibody used) 
 
Less specific and less sensitive 
Risk of interference 
Indirect  A secondary antibody is used 
allowing greater amplification of 
the analyte 
Risk of cross-reactivity 
Sandwich Most specific and sensitive ELISA 
as two antibodies required to 
bind to the protein of interest 
ELISA takes longer 
More complex protocol 
Competitive Quantification of smaller 
molecules (using one antibody) 
Less specific 






Direct ELISAs are a preferred method of analysis where rapid processing is required 
as it only uses one antibody. As a result of this, however, they are less specific than 





examining antibody affinity and specificity or when assessing blocking or inhibitory 
interactions. During this process, the antigen or sample is immobilized directly on 
the plate and a conjugated primary detection antibody binds to the target protein 
(antigen). With the addition of the substrate solution, the amount of analyte in the 






Indirect ELISAs are typically used when examining endogenous antibodies. They 
differ from the Direct ELISA due to the addition of an extra amplification step to 
detect the immobilized antigen. As a result, Indirect ELISAs take longer. Similar to 
the direct ELISA, the antigen is immobilized on the plate using an unconjugated 
primary detection antibody. In contrast to the direct ELISA, a conjugated secondary 
antibody is then added and is directed against the host species of the primary 
antibody. Finally, with the addition of the substrate solution, a signal proportional 
to the amount of antigen bound in the well is then released. As the desired antigen 
may be present in very low quantities compared to the proportion of other proteins 
present in the sample, Indirect ELISA may not be able to detect the presence of the 
antigen in the sample. Whilst Indirect ELISA may be more sensitive than Direct ELISA, 






Sandwich ELISAs were used in the current study and examined the concentration of 
an analyte in a biological sample. They were therefore the most common type of 
ELISA. The process took longer and the protocol more complex to follow as it used 
two specific antibodies to ‘sandwich’ the antigen. As a result of this, they are highly 
specific assays. With the ‘capture’ antibody coated on the microplate, the addition 





followed by the addition of a conjugated-detection antibody which bound to an 
additional epitope on the target protein. As displayed by the other types of ELISA, a 
signal was produced that reflected the amount of the analyte within the sample 






Competitive ELISAs use only one antibody and are used for the detection of small 
molecules and hormones. In this case, the protein of interest cannot be ‘sandwiched’ 
effectively as it is too small, so a conjugated antigen is used to bind to the antigen 
in the sample. With greater quantities of antigen within the sample, the less 
conjugated antigen will bind to the capture antibody. Similar to the other types of 
ELISAs, a substrate solution is then added but in contrast, the signal produced in 




2.2.2 A comparison of leptin ELISA kits 
 
 
A comparison was performed between leptin ELISA kits from 2 different 
manufacturers: Meso Scale Diagnostics (MSD) and R&D systems. This was required 
to determine which method would provide sufficient reliability results. Using the 
MSD platform, 10 plates were analysed, and using the R&D systems platform, 43 
plates were analysed. Inconsistency in the results was demonstrated early on in 
the study, justifying why only 10 plates from the MSD manufacturer were used. 
The inter-and intra-assay coefficients of variability (CVs) were consistently better 
using the R&D systems kits which led to their use for the entirety of the Study 







Table 2.4: Inter and intra-assay CVs between MSD and R&D leptin ELISA kits 
 
 
      
MSD 
(10 plates)   
R+D 
(43 plates) 
                
Inter-assay Mean (ng/ml) 9.72   11.53  
   St dev (ng/ml) 3.61   1.10  
   CV  0.37   0.096  
          










In order to identify the presence of systematic differences and possible outliers 
between measurements in the R&D and the MSD groups, a Bland Altman plot was 
developed. Figure 2.2 shows poor agreement between the two methods of leptin 
ELISA. The x-axis represents the mean of the two measurements, whereas the y-



















means of evaluating bias between the mean differences. This method of examining 
the data was explicitly different from examining relationships between values. In 
correlation studies, for example, one value is compared to another rather than 
examining the actual difference between the two groups. Based on this assessment 
of two different commercially available kits, R&D ELISA kits were used for the 
analysis of the cord blood samples for the purpose of this thesis.  
 
 
Figure 2.2: Bland Altman plot showing poor agreement between leptin assays 
 
Mean (bias): 2.01 ng/ml 
SD: 10.9 ng//ml 
Upper limit of agreement: 23.4 ng/ml 
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2.2.3 Leptin procedure protocol: 
 
 
Reagents and samples were brought to room temperature before use and the assay 
was performed according to manufacturers’ instructions. Samples were diluted 100-
fold prior to the assay. The reagents were prepared to produce a substrate solution, 




100 µL of Assay Diluent was added to each well on the 96-well plate. Then, 100 µL 
of sample or control was also added to each well of the pre-coated plate. The plate 
was covered and left to incubate for 2 hours at room temperature. The incubation 
process enabled the antigen to be adsorbed entirely to the well surface.  
 
 
The plate was then aspirated, and each well was washed in an automated plate 
washer 4 times. For this, a phosphate-buffered saline with Tween detergent (PBS-T) 
was used. This process removes unbound or poorly bound protein and leaves the 
protein being assayed bound to the plate. 200 µL of Conjugate was then added to 
each well. The plate was then again covered and left to incubate at room 
temperature for 1 hour. A secondary detection antibody conjugate, which had been 
biotinylated and was specific to the protein being assayed, was then added. This 
ensured that the primary antibody bound non-specifically to the well.  
 
 
The samples were then aspirated and each well was washed in an automated plate 
washer 4 times, again removing any unbound detection antibody. The protein being 
assayed was then anchored to the primary and secondary antibodies. 200 µL of 
Substrate Solution was then added to each well in the plate following which, the 
plate was covered and incubated at room temperature for 30 minutes, ensuring its 






The Substrate Solution was composed of horseradish peroxidase-conjugated to 
streptavidin. It detected the antibody being quantified as streptavidin bound biotin 
(in the Conjugate) specifically. It released a blue coloured dye in response to 
peroxidase activity (3,3’,5,5’-tetramethylbenzidine becomes 3,3’,5,5’-
tetramethylbenzidine diamine), reflecting the amount of protein of interest 
detected. 50 µL of Stop Solution was then added to each well in the plate. Stop 
solution (sulphuric acid) was then added and caused a colour change in the wells 
from blue to yellow.  
 
 
The plate was then placed in the plate reader within 30 minutes of adding the Stop 
Solution. The plate reader used spectrophotometry to measure light absorption at 
450nm. The amount of absorption reflected the concentration of the yellow solution 
produced by adding the Stop Solution. This was directly proportional to the 





2.2.4 High and low molecular weight adiponectin 
 
 
Adiponectin circulates in the plasma in three distinct forms: 70 kDa low molecular 
weight (LMW) noncovalently-linked trimers, disulphide-linked medium molecular 
weight (MMW) hexamers, and high (>300 kDa) molecular weight (HMW) multimers 
(Ebinuma et al., 2007). Each has a specific function and action on individual target 
tissues. Circulating in peripheral tissues (Oh, Ciaraldi and Henry, 2007; Heidemann 
et al., 2008), the primary bioactive fraction of adiponectin resides in the form of 
HMW adiponectin (Hara et al., 2006). It is widely favoured for its best approach to 
measuring adiponectin concentrations. It is recognised for its insulin sensitising 
effects whilst being negatively associated with obesity, insulin resistance, and 
coronary artery disease. Repeatedly, HMW (and total) adiponectin have proven to 
be the more useful indicators of metabolic conditions as there are greater fold 
differences between HMW and downregulation of insulin-resistant states and in the 
extremes of BMI (Daimon et al., 2003; Nakashima et al., 2006; Zhu et al., 2010; Goto 
et al., 2014). HMW adiponectin however may be implicated more specifically in 
vascular dysfunction associated with obesity (Kobayashi et al., 2004). Furthermore, 
in studies examining high-risk populations, such as those with diabetes or 
demonstrable coronary artery disease, HMW adiponectin may be a more reliable 
marker of cardiometabolic risk than total adiponectin (Aso et al., 2006; Hara et al., 
2006). In these studies, HMW adiponectin displayed its association with (rather than 
its predictive value of) already established individuals with insulin resistance and 
cardio-metabolic dysfunction. In a healthy population, however, both total and HMW 
adiponectin have comparable predictive values of impending insulin resistance and 
metabolic dysfunction (Almeda-Valdes et al., 2010).  
 
 
Although the role of LMW adiponectin is less defined, there is growing evidence to 
also implicate LMW adiponectin in the control of glucose metabolism (Graessler et 
al., 2011; Goto et al., 2014). Found predominantly in cerebrospinal fluid (Ebinuma 
et al., 2007; Kusminski et al., 2007), LMW adiponectin is not as widely associated 





a Japanese population of diabetic patients with matched controls however LMW 
adiponectin, in addition to validated biomarkers total and HMW adiponectin, 
demonstrated an inverse association with diabetes (Goto et al., 2014).  
 
 
For the purpose of this thesis, total adiponectin rather than HMW adiponectin was 
measured as it would have required pre-treatment of the plasma sample with a 
specific protease enzyme so that the differential forms of the protein (trimers, 
hexamers) would be removed. Measurement of total adiponectin was therefore a 




2.2.5 Adiponectin procedure protocol 
 
Samples and controls were removed from the freezer and transferred to a rack to 
defrost to reach room temperature. The control used was pooled plasma EDTA 
from healthy individuals. 2 mls of calibrator diluent RD6-39 was added to the 
adiponectin standard. This produced a stock solution of 250ng/ml. The sample was 
mixed to ensure complete reconstitution and allowed to sit for a minimum of 15 
minutes prior to making dilutions. Within the assay plate, there were 78 specimen 
samples (labelled 1 to 78), 4 control samples (labelled C), and 7 calibrator samples 
(standards, labelled 1 (low) to 6 (high) and 7 (blank)).  
 
2ml of the calibrator diluent RD6-39 was pipetted into the tubes labelled 1-78 and 
then pipetted into each of the 4 controls. Once completely defrosted, 10µl of the 
sample was added to tubes 1-78, and each of the controls and mixed.  
 
Using a multichannel pipette, 100µl of the assay diluent RD1W was added to each 
well then 50µl of the standards, control, and sample were also added using a 





The plate was then covered with an adhesive strip and incubated for 2 hours at 
room temperature on a plate shaker. 
 
The wash buffer was prepared and mixed, to ensure there were no crystals in the 
sample. The wash buffer was then diluted in deionised water. It was used to 
aspirate and wash each plate 4 times on the automated washer. Excess wash 
buffer was then removed and 200µl of adiponectin conjugate was added to each 
well. The plate was then re-covered and incubated for 2 hours at room 
temperature on a plate shaker. 
 
The plate was then aspirated and washed again. The substrate solution was then 
prepared within 15 minutes of use and 200 µl was added to each well, ensuring 
that the plate was protected from light. This process turned the samples blue. The 
plate was then re-incubated for a further 30 minutes at room temperature. 
 
Finally, 50 µl of stop solution was added to each well. The plate was read at 450 










The Roche Cobas auto-analysers were employed for analysis of cholesterol, 
triglyceride, HDLc, CRP, ALT, AST, and GGT (C311 model) and c-peptide (C411 
model). They were selected for use within the study largely as they were already 
readily available within the lab, however, there were also demonstrable advantages 
to using them.  They are stand-alone molecular platforms that allowed convenient 
reagent and sample handling. With up to 45 tests onboard capacity, they allowed 
rapid processing of samples. The main benefit of these analysers was that they could 
process very small sample sizes, which was of particular importance when processing 
finite cord blood samples. Over 70% of all the reagents required sample volumes of 
less than 5µl so this minimised the volume of sample wasted or required for the 
sample to be processed. In addition, the analysers were able to check the integrity 
of the sample via highly sensitive pressure sensors and a clot detection system. This 
reduced the level of repeated errors and highlighted which samples possessed a 
significant amount of clot and could not be processed as a result. There were also 
advantages in terms of the use of the reagent provided. These reagents were already 
conveniently prepared, thereby minimising the handling of the reagent so overall 
reduced time and increased the throughput of the specimens. The reagent was 
stable for 3-month periods, so the long inter-calibration intervals reduced the time 
spent processing this.  
 
 
2.2.7 Quality control (CV) 
 
 
CV is the standardised measure of the frequency of distribution. It demonstrates 
the precision of the assay as well as signifies its repeatability. The CV was 
calculated as the standard deviation divided by the mean. The standard deviation 
must always be understood in the context of the mean and it quantified the 
amount of variability ie. if the standard deviation was low, the value was close to 





intra-assay CV demonstrated the CV within assays. The desired CV for biochemical 
analysis such as in this study was less than 10%. Both the inter-and intra-assay CVs 
met this criterion, as shown in Tables 2.5 and 2.6. The quality control data for all 
of the studies performed are displayed in the Appendix, Tables 1-3. Using the 
Roche C311 equipment to process the cord blood lipids and LFT’s, a standard 
control was used to detect lower concentration (ensuring that this remained within 
the range 1.5-2.46 ng/ml), as well as a higher concentration of analytes (ensuring 
that this remained in the range 7.35-12.00 ng/ml). An adult control sample was 
used as well on each plate in the analyser to ensure these remained within desired 
reference ranges, as shown in Table 3 in the Appendix.  
 
 
Table 2.5: Inter-assay CV  
 
 
Analyte Mean Standard 
deviation (SD) 
Coefficient of variability 
(CV, %) 
Leptin (pg/ml) 11.38 1.08 0.09 (9.0) 
Adiponectin (µg/ml) 14.41 0.47 0.03 (3.0) 
HDLc (mmol/l) 1.11 0.04 0.04 (4.0) 
Cholesterol 
(mmol/l) 
2.52 0.08 0.03 (3.0) 
Triglyceride 
(mmol/l) 
1.25 0.03 0.03 (3.0) 
ALT (u/l) 42.82 1.76 0.04 (4.0) 
AST (u/l) 50.03 1.77 0.04 (4.0) 
GGT (u/l) 51.56 1.30 0.03 (3.0) 






Table 2.6: Intra-assay CV 
 
 Intra-assay CV (%) 
Leptin ELISA 0.03 (3.0) 
Adiponectin ELISA  0.06 (6.0) 
Roche C311 
Lower concentration control 








2.3 Cord blood analyte reference ranges and stability with long-term storage 
 
 
The cord blood samples used within the study were originally obtained between 1991 
and 1992 and have been in freezer storage since. It was vital to examine the stability 
of the analytes included in the study over time in order to aid the interpretation of 
the results and ensure their validity in such prospective studies. Whilst preliminary 
studies encouraged the laboratory separation of the blood sample immediately after 
venesection to ensure greater accuracy of the assay (Diver et al., 1994), more 
contemporary studies have highlighted many additional factors that may contribute 
to analyte variability.  
 
 
The concentration of an analyte may be affected by the method of specimen 
collection, the conditions the sample was stored, or the number of freeze-thaw 
cycles prior to sample processing. Direct comparison of clinical studies needs this 
process to be standardised so that valid between sample analysis can be made. 
Variations may be present from the onset – from the fasting status of the patient to 
the time of day the sample was collected. In addition, the time that was taken for 
the sample to coagulate, the quantity or type of additive within the areceptacle, 
and the presence of sample haemolyisis may also influence the assay results. The 
time left to stand before processing and separating the sample, the method of 
centrifugation, and the type of storage vials used may also alter the outcome. The 
storage temperature of the sample could also range from the ambient temperature 
at the point of collection to the storage temperature in the biobank and there may 
be wide variations within these. Repeated freeze-thaw cycles may also contribute 




Whilst studies using cord blood samples were limited, there was more detailed 
availability of child and adult blood samples that have been used to examine the 





to degrade with long-term storage but in contrast, there did not appear to be the 
same degree of degradation with cord blood adipokines, lipids, or liver function tests 
included in this study, as demonstrated in Table 4 in the Appendix.  
  
 
Flower et al. examined specific variations in specimen collection by assaying leptin, 
and pro-inflammatory cytokines in 22 healthy subjects (Flower et al., 2000). Samples 
were allowed to stand at hourly intervals before or after sample separation and 
freezing at -70°C. The concentration of leptin was unchanged by allowing the 
specimen to stand for up to 6 hours (Flower et al., 2000). The study also examined 
the effect of using 3 different anticoagulants (lithium heparin, sodium citrate, and 
EDTA) or no anticoagulant in the specimen collection tubes. EDTA specimens 
demonstrated stability for both leptin and cytokines however there was wide 
variation in the analytes when alternative anticoagulants or no anticoagulant was 
used (Flower et al., 2000). The impact of freeze-thaw cycles was also addressed in 
this study by performing a series of freeze-thaw cycles prior to the analysis. This 
showed that leptin (along with IL-6) could withstand up to 6 freeze-thaw cycles 
(Flower et al., 2000). Another study demonstrated high reproducibility of leptin 
sampled 1 year apart (Stattin et al., 2004) and a further study has demonstrated its 
stability when taken 4 years apart (Chu et al., 2001).  
 
 
Leptin does not appear to vary according to fasting or non-fasting status in normal 
or obese subjects and was, therefore, a reliable biomarker to measure irrespective 
of recent dietary intake (Korbonits et al., 1997). Although there was demonstrable 
stability of leptin with storage, it did display a significant circadian rhythm (Sinha 
et al., 1996). For studies to be reproducible, leptin ideally would be sampled at the 
same time of day as the concentration doubles overnight compared to during the 
day (Sinha et al., 1996). It was unlikely, however, that the ALSPAC specimens were 
obtained outwith daytime hours. This further validated leptin as a robust analyte as 
it did not appear to degrade with storage, nor did it vary depending on recent dietary 
intake and it could withstand repeated freeze-thaw cycles without adversely 






In contrast to leptin, levels of pro-inflammatory cytokines, Interleukin-6 (IL-18) and 
TNF- α, as demonstrated by Flower et al. varied significantly if left unseparated for 
over 4 hours (Flower et al., 2000). These cytokines are strongly related to obesity 
and metabolic disorders. They are both secreted by adipocytes and are responsible 
for the induction of acute-phase proteins producing proteins including CRP, 
culminating in inflammatory states (Popko et al., 2010). Consequently, cord blood 
CRP was measured during this thesis and has previously demonstrated stability 4°C, 
-20°C, and -80°C over 3 months (Q. Li et al., 2013)(24). That the  findings were null 
(0), excluding CRP from the analysis, may reflect the very low levels of CRP expected 
in healthy pregnant women. Elevated levels may typically be found in those who 
have developed sepsis or an acute inflammatory state for example and therefore 
compose very small numbers within the study. These women may also have been 




The stability of adiponectin specifically has also been assessed in a small study by 
examining the effect of leaving the primary sample up to 36 hours before processing 
and repeating the sample 1 year later to assess reproducibility (Pischon, Hotamisligil 
and Rimm, 2003). Using both EDTA and sodium heparin products within the specimen 
tube, samples were processed at sequential intervals until 36 hours from the initial 
point of collection. There was no change in the concentration of adiponectin if left 
to stand for 36 hours before processing, compared to immediate analysis however 
the concentration increased if left for more than 24 hours in the EDTA sample. It has 
been proposed that this is either due to chance or that this observation may be a 
result of adiponectin's dissociation from polymeric and multimeric forms leading to 
a higher result (Pischon, Hotamisligil and Rimm, 2003). Overall the concentration of 
adiponectin decreased when stored at -150°C and was assayed again one year later. 
It has been proposed however that the individuals’ change in BMI over time may 
account for this. There was no significant difference in the concentration of 
adiponectin one year later following adjustment for BMI indicating that it is a highly 






There have been varying outcomes on the effect of storage on hepatic enzymes. 
LFT’s appeared stable when stored over 10 hours at 21°C (Henriksen et al., 2014) 
and again when LFT’s were examined over 56 hours and stored at 25°C in either 
unseparated or separated (into plasma and serum) form (Boyanton and Blick, 2002). 
Furthermore, analysis of rat serum has shown that transaminases were stable when 
stored in the fridge for up to 7 days and when they examined the samples over a 
longer period (Cray et al., 2009). They demonstrated that LFTs were stable for up 
to 90 days at -20°C in a frost-free freezer and up to one year at -70°C (Cray et al., 
2009). Other studies have supported this, reporting that both GGT and 
aminotransferases to be stable when stored at -20°C for 3 months and could 
withstand up to 10 freeze-thaw cycles (Cuhadar et al., 2013). In addition, Jung et 
al. found relative stability of hepatic enzymes, including ALT, AST, GGT, and alkaline 
phosphatase, over 10 months when stored at -196°C (liquid nitrogen) (Jung, Bader 
and Grutzmann, 1984). 
 
 
In contrast, others have shown that storage at ambient room temperatures or in the 
fridge prior to transport to the lab may adversely affect LFT concentration by up to 
46% on day 6 of storage at -20°C (Williams, Kline and Dodd, 1987). ALT determination 
in particular may be influenced by storage conditions. Analysis of rat serum showed 
50% demonstrable loss of the analyte when stored in a frost-free freezer at -20°C 
for up to 90 days (Cray et al., 2009) and they recommend that this degradation 
should be accounted for when interpreting results of future studies.  
 
 
Due to the conflicting evidence around the stability of AST, Niblock et al. analysed 
AST activity at room, fridge, and freezer conditions over 28 days. They demonstrated 
that AST was stable in ambient conditions for the first 24 hours, and at 4°C, -20°C, 
and -80°C for up to 28 days, and is in contrast to previous reports (Niblock, Leung 
and Henderson, 1986). An additional study concluded however that degradation of 
aminotransferases begins from initial venepuncture and encourages sample assay 





supported by others who have concluded that time from sample collection to 
analysis was more influential than the temperature it was stored at but that the rate 
of analyte decay was limited during lower storage temperatures (An and Park, 2014).  
 
 
There are limited studies observing the stability of hepatic enzymes over longer 
periods, whose conclusions could be transferable when examining analytes used in 
longitudinal studies. The Norwegian Mother and Baby biobank concluded that AST 
was stable over 2 years of storage at -80°C and could withstand up to thirty freeze-
thaw cycles (Paltiel et al., 2008). Overall it appeared that optimising conditions 
(such as at -80°C), along with improved sample collection, could minimise analyte 
decay during long-term storage periods (Williams, Kline and Dodd, 1987). 
 
 
The stability of lipids has also been examined over the short and long term. When 
stored in the very short term, over 10 hours at 21°C, lipid levels did not appear to 
deteriorate (Henriksen et al., 2014). Again, when lipids were examined over 56 hours 
and stored at 25°C in either unseparated or separated (into plasma and serum) form, 
there was no adverse effect on the variability of the samples (Boyanton and Blick, 
2002). Shih et al. examined the stability of lipids (Cholesterol, HDLc, and 
triglyceride) when stored at -70°C and demonstrated the reliability of the assay 
after one year. There was however some (<3%) deterioration in triglyceride and 
cholesterol levels over 5 and 7 years respectively (Shih et al., 2000). The Canadian 
Laboratory Initiative in Pediatric Reference Interval (CALIPER) study demonstrated 
the stability of all but one of the 57 routine biochemical markers assayed over a 10 
to 13 month period stored at -80°C, with up to one freeze-thaw cycle (Brinc et al., 
2012). In addition, cholesterol and HDLc have been examined following storage at -
20°C over 3 months and also for up to 10 freeze-thaw cycles and stability of both 
analytes has been observed (Cuhadar et al., 2013). Further studies have 
demonstrated that cholesterol and triglycerides may withstand up to thirty freeze-
thaw cycles over 2 years of storage at -80°C as there was no demonstrable difference 
from the analyte observed at baseline (39). Collectively there did appear to be 





C-peptide is a 3kDA hormone and is formed when insulin and propeptide are cleaved 
to form the active hormone. As it has a longer half-life than insulin it is a useful 
measure of insulin secretion. Insulin is not a reliable biomarker with longer-term 
storage as demonstrated over 4 years (Chu et al., 2001). Being a small polypeptide, 
however, c-peptide is also susceptible to attack from proteases and endopeptidase 
degradation of c-peptide has previously been described (Melles et al., 2004).  
 
 
The Janus Serum Bank was established in 1972 and is a population-based biobank for 
prospective systematized serum collection in Norway. Its primary aim was for the 
identification of specific biomarkers relevant to certain cancers however due to the 
long-term nature of the samples being stored (at -25°C), it has also been used to 
demonstrate analyte stability or degradation over varying timeframes. Samples were 
largely collected from men attending for routine cardiovascular health assessments 
and from male blood donors. The study included only males as this limited biological 
hormonal influence on the specimens collected and was made up of a mainly 
Caucasian population. A detailed description of the Janus Serum Bank Cohort, its 
data, and its establishment, has already been published (Langseth et al., 2017). 
From this study, examining the stability of serum components, comparing analytes 
from fresh (obtained within 1 month) and samples that had been in long-term 
storage, they found marked differences in the concentration of c-peptide over time 
(Gislefoss, Grimsrud and Mørkrid, 2009). It displayed significant decay when assayed 
one year later (Stattin et al., 2004), and there was a complete loss of the analyte 
after 25 years of storage (Gislefoss, Grimsrud and Mørkrid, 2009). This would suggest 
that c-peptide may degrade significantly with time and as a result introduce bias 
within future studies.  
 
 
Although cord blood c-peptide was measured as the preferred index of fetal glucose 
exposure, the concentration of the analyte was much lower (median 0.1 ng/ml) than 
fresh cord blood c-peptide levels obtained during other studies (Metzger et al., 2008; 
Regnault et al., 2011; Hou et al., 2014; Rifas-Shiman et al., 2017), as shown in Table 





methods of cord blood sample collection and variation in quantities of freeze-thaw 
cycles, methods of analysis, and duration and conditions of storage.  
 
 
Both insulin and c-peptide are highly susceptible to glucose metabolism and will vary 
significantly according to fasting status. Although the fasting status of individuals 
from the cohort was not recorded, women in labour for example are likely to be in 
a near fasted state indicating that high levels of c-peptide would be significant for 
these individuals. That this study demonstrated very low or no c-peptide results 
indicated that the sample had degraded significantly and perhaps may reflect the 
near-fasted state of the ALSPAC cohort.  
 
 
It is clear that specimen collection and the storage conditions and duration can vary 
dramatically between and even within studies. For epidemiological and clinical 
studies to be truly comparable, standardised operating procedures should be 
reproduced and adhered to. Comparing study outcomes and analyte concentration 
according to certain diseases for example may be misleading and not reliable if there 
was such variation in practice. There was limited literature or documentation from 
the process of the cord blood collection in ALSPAC which was also acknowledged 
when analysing the study outcomes. Many of the studies discussed were small in 
sample size and the duration of the storage period may be limited. In order to 
validate the results from ALSPAC, immediate analysis of the cord blood followed by 
the assessment of the specimen at timely intervals would have yielded significant 
information on the stability of analytes measured within a large cohort, over a long 
period. This would have been limited or not possible however due to the very small 
cord blood sample size obtained initially and also due to changing method of sample 
analysis and advancement in technology during this time frame.  
 
 
Collectively, there does appear to be sufficient evidence to exclude any of the 
analytes assayed, except cord blood c-peptide and CRP, from this study but further 





additional evidence for this. Most of the studies reported some assay variability 
which may be attributed to changes in the analyte concentration over time rather 
than significant degradation of the analyte.  
 
 
2.4 Statistical analysis 
 
 
All statistical analyses were performed using Stata (version 13.0) software (Stata 
Inc., College Station, TX.).  A detailed description of analyses undertaken has been 
displayed according to each Chapter.  
 
 
2.4.1 Regression Analysis 
 
 
Regression analysis was used in each of the Chapters to examine the relationship 
and effect of the association between a dependent variable, the ‘outcome’ and an 
independent variable, the ‘exposure’. Linear regression analysis has relied on the 
following assumptions: linearity, homoscedasticity, the absence of collinearity, and 
finally a normal distribution of the residuals. Consequently, the data were examined 
to ensure there was a linear relationship between the dependent and independent 
variables, that the data values for each had equal variance, that there was no 
correlation between two or more independent variables, and that the data were 
normally distributed. In certain cases, such as offspring WC and fat mass, the data 
were log-transformed to produce approximately normal distributions of residuals. 
BMI was assessed via BMI z-scores in children and therefore BMI z scores were created 
using the UK 1990 British growth reference (Cole, Freeman and Preece, 1998). To 
further validate the study, sex exposure interactions were tested for and included 







Chapters 3 to 5 used complete case data sets, including only those with a complete 
set of data variables. In Chapter 3, GWG was examined as a continuous variable (per 
1kg increase) and according to IOM criteria (Institute of Medicine and National 
Research Council Committee to Reexamine IOM Pregnancy Weight Guidelines, 2009). 
Chapter 4 further explored the association of GWG and pre-pregnancy weight (PPW) 
according to maternal diabetic status on cord blood analytes and the regression 
analysis additionally adjusted for potential confounders and mediators. In addition, 
this Chapter examined the association between maternal diabetic status and cord 
blood biomarkers, and offspring birthweight. Chapter 5 examined HDP in pregnancy 
using continuous measures during pregnancy in relation to cord blood biomarkers 
and birthweight.  
 
 
In Chapter 7, multiple imputation methods were used to perform linear (offspring 
BMI, WC, and fat mass) and logistic (offspring obesity) regression models in order to 
examine the associations between birth weight and cord blood measures and 
offspring BMI, WC, fat mass, and obesity at age 9 and 17 years. A series of regression 
models were created and accounted for maternal and offspring confounders, as 
detailed in Chapter 7.  
 
 
In Chapter 8, multiple imputation methods were employed again. Multivariable 
linear and logistic regression models were used to examine the associations between 
cord-blood measures, birthweight and fatty liver, liver volume, fibrosis, and liver 
function tests at age 17 years.  
 
 
2.4.2 Missing Data and Multiple Imputation Methods 
 
 
Missing data, particularly among large data sets occurs frequently. First described 
by Rubin in 1972, multiple imputation (MI) is a specific statistical technique used for 





as a result of limited responses in surveys, thereby limiting the data that could be 
analysed. Values may be missing if there was a deletion of the case or data or if it 
was omitted or indeed was never available. Missing data may introduce bias (and 
therefore influence the outcome or representation of the result) and may make the 
data difficult to handle and examine.   
 
 
The main objective in using MI was to enable handling of the missing data to allow 
valid statistical inferences, rather than to simply re-create the absent values as close 
as possible to the true ones (Rubin, 1978, 1996). The imputation process replaced 
the missing data with estimated values based on all the other values available and 
the imputed value is not a random number or simulated value.  
 
 
In complete case analysis, values, and observations are excluded with any missing 
variable. In smaller data sets, for example, missing data removed from the analysis 
may have had a substantial impact on the overall outcomes. In contrast, missing 
data in much larger datasets may have had less impact. By maximising the number 




Missing data can be missing at random (MAR), completely missing at random (CMAR), 
and missing not at random (MNAR). MAR values describe data that were missing but 
the probability of the data being missing did not depend on unobserved data but 
may have depended on observed data. MCAR data accounts for data that was missing 
but the reason for it being missing was unrelated to the study itself. In this case, the 
probability of the data missing did not depend on observed or unobserved data. For 
example, the patient agreed to take part in the Study and had routine maternal and 
neonatal observations were taken but she moved away and she or her child did not 
attend for follow-up of the study.  The missing data were therefore simply missing 
at random so that there was consistent disregard of any missing values in subsequent 





missing should be accounted for. For example, the participant was very unwell at 
the time of delivery so obtaining a blood sample for Study purposes was not 
appropriate at that time and therefore no result was available.  
 
 
MI uses a pre-defined number of imputations, known as M. There has been conflicting 
evidence on the number of M required to achieve optimal inferences. Historically, 
founders of the technique felt that M should equal five to achieve valid imputed 
data (Rubin, 1972; Van Buuren, Boshuizen and Knook, 1999). It was commonly 
accepted however that the actual number of imputations required depended on the 
amount of missing data as well as the analysis model used. As many variables as 
possible were recommended to be included particularly when there was a wide range 
of observations. The impact of a mis-specified imputation model depended on the 
quantity of observed versus imputed data. For example, in a case where there was 
a large number of observations with complete data, few incorrectly imputed values 
were unlikely to influence outcomes significantly. Overall, twenty imputations were 
acceptable in order to minimise the sampling error due to MI although other studies 
suggested that more imputations may have been required to obtain plausible results 
(Horton and Lipsitz, 2001). Some literature was available however on the sampling 
error of the MI estimates and the accuracy of the outcomes according to the number 




In the current study, there were small amounts of missing data on some covariables 
included in the multivariable models, as detailed in Chapters 7 and 8. In Chapter 7, 
twenty imputation datasets were generated by chained equations (White, Royston 
and Wood, 2011), with all cord exposures, birth weight, covariates, and the 
measurements from the 11-year clinic and 15-year clinic informing imputation of 
missing values in the 9-year clinic and 17-year clinic, respectively (hereafter 
referred to as 9 and 17 years). Again, to deal with the missing data in Chapter 8, 
twenty imputation data sets were generated by chained equations (White, Royston 





imputation of missing values in the 17-year clinic respectively. This imputation 
process generated up to 541 data sets for all participants with a liver scan and paired 
cord sample and up to 1037 for all participants with LFTs and paired cord samples. 
The distributions of observed (complete confounders) and imputed variables were 
also examined to ensure comparable results.  This added strength to the outcomes 
of the current study and validated the use of MI analysis compared to using the 






2.4.3 Structural Equation Modelling (SEM) 
 
 
In Chapter 6: Programming of offspring cardio-metabolic risk: tracking analytes from 
birth to adolescence, Dr. Smith used multivariate statistical analysis to analyse 
structural relationships in form of structural equation modelling (SEM).  It examined 
the structural relationship between measured or observed variables and unobserved 
constructs, known as latent variables. As blood analytes were obtained at varying 
time points (at birth (cord blood), aged 9 and aged 17), and their concentration may 
have depended on the participants' age for example as well as external factors, SEM 
was useful for describing the underlying mechanism and to why a relationship 
existed. Multiple factors may be accounted for in a single analysis and it 
incorporated independent variables, such as the cord blood analyte measure at 
birth, and the dependent variable such as the variable measure at age 17.  
 
 
As SEM assumes normally distributed data, skewed values, including leptin and CRP, 
were log-transformed to ensure normally distributed data. In Figure 2.3, the direct 
association is demonstrated simplistically between cord blood and age 9 (i), cord 
blood and age 17 (ii), and between analytes measured at age 9 and age 17 (iii). In 
each case, the analyte is measured at the specified time points and the association 
is described between repeated measurements of the same  variable. The direct 
effect bypasses the effect of any mediator and simply displays the effect of the 
exposure on the outcome via processes that do not involve the mediator. The 
indirect association between cord blood and the same analyte at age 17 additionally 
accounts for the direct association between cord blood and the analyte at age 9 and 
then the association between age 9 and age 17 (i x iii), thereby accounting for the 
mediator in the causal pathway. The total (cumulative, iv) effect of association is 
more complex as it encompasses the direct as well as the indirect effect (i x iii + ii). 
Mediation analysis is used to separate the total effect of the exposure on the 





































(i x iii) 
Total 





2.4.4 Mediation Analysis  
 
 
Mediation analysis was also used and described in Chapters 3 to 5. This method 
examined the effect of an independent ‘predictor’ variable on a mediator variable, 
which then, in turn, may have influenced the dependent or ‘outcome’ variable. First 
described in 1986 (Baron and Kenny, 1986), mediation analysis provided an account 
of the mechanism or process that underlay the observed relationship between the 
independent and dependent variables. The mediator, or the ‘intervening’ variable, 
essentially mediated the relationship between the predictor and the outcome. This 
was of value, particularly when these main variables may not have any automatic 




In contrast to confounding variables, which may affect both the independent and 
the dependent variables, mediators were part of the causal pathway. Regression 
analysis provided an estimate of the correlation between the independent and the 
dependent variable, but this process did not test for causality. In mediation analysis, 
the aim was to determine the extent to which an association between an exposure 
and an outcome operated through the mediator of interest.  
 
 
2.4.5 Linear Spline Multilevel Modelling 
 
 
Linear spline multilevel models were used to describe the shape of change of a 
variable over time and are readily interpretable. In handling longitudinal data, there 
were many challenges encountered including the time points where the 
measurement was taken and the total number of observations per participant 
obtained. Multilevel modelling overcame these challenges by adding flexibility to 
the data structure, as values did not need to be obtained at the same time points. 





(Steele, 2008). Anyone with one or more observations could be included in the model 
under the assumption that data were missing at random ie. the probability of the 
missing observations were related to other observed variables for that participant 
and did not depend on the actual number of the missing value (Little and Rubin, 
2002). This added power to the data, particularly if there was attrition during 
participant follow-up.  
 
 
Linear spline modelling involved a series of ‘knot points’ that were used to model 
growth trajectories at specific time points. This methodology has previously been 
applied to ALSPAC data to study childhood growth (Howe et al., 2016). Traditional 
methods for the analysis of child growth, such as z-scores for childhood BMI (Cole, 
2004), may have been employed however they didn’t demonstrate the true shape of 
the observations or growth patterns observed. In addition, measurement error could 
have affected the results and may have differed with age. In contrast, linear spline 
multilevel modelling estimated average and person-specific linear growth rates 
across periods of time defined by ‘knot points.’  Specific ‘knot points’ were 
identified using fractional polynomial curves to enable a smooth function of the 
curve and this determined the position of the knots (Ben-Shlomo et al., 2008; Howe 
et al., 2012).  
 
 
In Chapter 8, average shape trajectories already devised by ALSPAC encompassed 
fractional polynomial curves and described trajectories of blood pressure 
measurements during pregnancy. During the gestational period, specific time points 
were identified and trajectories of the changes in blood pressure during pregnancy 
were summarised. From this, three-knot points were identified with changes in 
blood pressure identified over 4 gestational periods (MacDonald-Wallis et al., 2011; 
Macdonald-Wallis et al., 2014). The baseline BP was set by ALSPAC at 8 weeks’ 
gestation as few participants had BP recorded prior to this. The best-fitting linear 
spline models had three knots at 18, 30, and 36 weeks and from 36 weeks until 
delivery (MacDonald-Wallis et al., 2011).  There were therefore 4 gestational 





30-36 weeks, and >36 weeks. These already established models from ALSPAC then 
allowed for a series of multivariable regression models to be formulated and 
confounders and mediators to be adjusted for using complete case analysis. It also 
allowed for the rate of change in maternal SBP or DBP according to each gestational 
period to be examined as well as the cord blood measures according to the presence 
of a hypertensive disorder of pregnancy.  
 
 
2.4.6 Directed Acyclic Graph (DAG) 
 
 
Directed Acyclic Graphs (DAGs) were used as directed graphs with no directional 
cycles and displayed the relationships amongst variables. In diagram format, they 
highlighted which variables were being examined and which variables were 
confounders or mediators. They incorporated a priori knowledge and clearly stated 
the assumptions. Typically, all common causes of exposure and disease of interest 
were included in the causal diagram. A DAG has been created for each Chapter to 
display the variables of interest and the potential confounding factors and mediators 








Chapter 3: Gestational weight gain (GWG) in pregnancy: association with cord 
blood lipids, adipokines and birth weight 
  
 
3.1 Introduction  
 
 
Maternal obesity in pregnancy is of public health concern. It poses a significant risk 
of medical complications during pregnancy, such as thromboembolism and pre-
eclampsia, and there is a greater risk of complex caesarean section deliveries 
(Poston, Harthoorn and Van Der Beek, 2011; Poston et al., 2016). There is also three 
times greater risk of developing GDM during obese pregnancy, but the risk may be 
even higher than this (Chu et al., 2007). Fetal complications and poorer neonatal 
outcomes are also seen more frequently in the presence of maternal obesity, 
including pre-term birth, macrosomia, and stillbirth (Gaillard et al., 2017). There is 
mounting evidence that maternal obesity in pregnancy can have a long-lasting 
impact on the offspring as well (Godfrey et al., 2017), with systematic review 
demonstrating up to 3 times greater risk of offspring overweight when the mother 
was obese pre-pregnancy (Yu et al., 2013).  
 
 
Emerging evidence suggests that gestational weight gain (GWG) in pregnancy, 
independently or in addition to higher pre-pregnancy BMI, may also contribute 
significantly to this risk of greater offspring adiposity. A significant positive 
association has been identified between GWG and offspring birthweight, as observed 
in one large-scale retrospective study (Ludwig and Currie, 2010) and by ALPSAC 
(Fraser et al., 2010). GWG has also been positively associated with BMI in childhood 
(Oken et al., 2007; Fraser et al., 2010; Ludwig and Currie, 2010; Ludwig, Rouse and 
Currie, 2013), adolescence (Oken et al., 2008; Schack-Nielsen et al., 2010) and 
adulthood (Mamun et al., 2009; Schack-Nielsen et al., 2010; Hochner et al., 2012), 
culminating in a greater risk of adult obesity (Schack-Nielsen et al., 2010). 
Associations between GWG and offspring birthweight, as previously reported by 





associated with a wider range of offspring cardio-metabolic markers (Fraser et al., 
2010). Some studies suggest the risk of GWG on offspring overweight or obesity 
appears to increase with advancing age (Voerman et al., 2019), even accounting for 
repeated measurements throughout childhood (Oostvogels et al., 2017; Zalbahar et 
al., 2017). It has therefore been proposed that in order to address the worldwide 
trend to increasing prevalence of obesity over past decades, including extreme 
obesity, (Brandkvist et al., 2019), there is a need to examine the causal relationship 
between maternal BMI and GWG and offspring adiposity and the impact on their 
cardio-metabolic health both in the short and long-term.  
 
 
As discussed in Chapter 1, the fetal overnutrition hypothesis suggests that increased 
offspring exposure to nutrients in utero may lead to persistent adaptations in the 
structure and function of adipose tissue, appetite regulation, and energy 
metabolism, leading to an increased susceptibility to later obesity. It is unclear 
however whether epigenetic processes may account for these associations. Changes 
in DNA methylation have been identified as a plausible mediating mechanism (Sharp 
et al., 2015). Shared fetal-maternal genes, shared socioeconomic and lifestyle 
factors have also been implicated in the transgenerational passage of obesity 
(Silventoinen et al., 2016; Tyrrell et al., 2016). 
 
 
The impact of GWG may not be limited to the degree of offspring adiposity, however. 
Since GWG has also been positively associated with blood pressure in the child (Oken 
et al., 2007) and adulthood (Mamun et al., 2009), there is growing evidence to 
support the adverse effect of inappropriate GWG on the offspring cardiovascular risk 
profile at birth. GWG throughout pregnancy has been positively associated with cord 
blood leptin (Karakosta et al., 2013; Karachaliou et al., 2015; Lemas et al., 2015). 
This may be because higher leptin levels have been demonstrated in mothers with 
greater maternal BMI and GWG and maternal and cord blood leptin levels have been 
positively correlated (Li et al., 2018), greater GWG may influence cord blood leptin 
levels. Evidence suggests that greater GWG does not appear to impact adiponectin 





inverse relationship between adiponectin and maternal obesity during pregnancy 
(Haghiac et al., 2014). In addition, lower adiponectin levels are also evident with 
obesity and progressive insulin resistance (Arita et al., 1999; Hotta et al., 2000). As 
umbilical cord blood leptin is widely recognised as an accurate biomarker for 
neonatal fat mass (Hauguel-de Mouzon, Lepercq and Catalano, 2006), the lack of 
association between GWG and cord blood adiponectin suggests that abnormal GWG 
has no bearing on offspring adiposity at birth. Greater GWG has however been 
associated with elevated maternal triglycerides throughout pregnancy (Shen et al., 
2016), and with dyslipidaemia in the offspring at age 9, 20, and 32 years, as 
demonstrated by elevated triglyceride and leptin and reduced HDLc levels (Fraser 
et al., 2010; Hochner et al., 2012). This may reflect the more atherogenic lipid 
profile overweight and obese mothers have at the start of pregnancy (Scifres, Catov 
and Simhan, 2014), who develop greater small dense LDLc, elevated leptin levels, 
and hypoadiponectinemia with advancing gestation and accumulating GWG (Farias 
et al., 2016; Li et al., 2018). 
 
 
The 2009 IOM guidance recommends that GWG is modified according to pre-
pregnancy BMI to optimise offspring growth patterns and the trajectory of 
metabolic health (Institute of Medicine and National Research Council Committee 
to Reexamine IOM Pregnancy Weight Guidelines, 2009), as discussed in Chapter 
1. Whilst GWG for normal-weight women may vary between 6 and 18kg, the degree 
of weight gain varies between individuals and is often dependent on the pre-
pregnancy weight (PPW) (Institute of Medicine and National Research Council 
Committee to Reexamine IOM Pregnancy Weight Guidelines, 2009). Although there 
is limited evidence of the impact of inappropriate GWG on the cardio-metabolic 
profile of the offspring at birth, there is concern that excessive GWG poses a 
significant risk of offspring overweight and obesity (Gaillard et al., 2017). Up to 
30-40% risk of overweight has also been reported in the offspring of mothers who 
gained weight excessively during their pregnancy (Nehring, Lehmann and Von 
Kries, 2013; Mamun, Mannan and Doi, 2014; Tie et al., 2014), although the risk 
may be even higher than this (Voerman et al., 2019). As one study has shown, only 





that excessive GWG may induce a persisting susceptibility to an obesogenic 
environment, (Schack-Nielsen et al., 2010). excessive GWG has also demonstrated 
a positive association with cord blood leptin levels (Karakosta et al., 2013; 
Karachaliou et al., 2015). 
 
The adverse impact of excessive GWG on the offspring may only be short-lived, 
however. Whilst increased overweight in 3 to6-year-old offspring of mothers with 
excessive GWG has been reported, beyond this only half of the offspring who 
remained overweight were born to obese mothers who also gained weight 
excessively (Guo et al., 2015). This is supported by the fact that weight 
management intervention studies in the second or third trimesters had little or no 
impact on birth outcome or offspring body fat composition (Thangaratinam et al., 
2012; Poston et al., 2015; Dodd et al., 2016). Furthermore, a lifestyle intervention 
study in pregnancy showed no impact on offspring BMI at age 5 (Ronnberg, Hanson, 
and Nilsson, 2017). Providing advice to mothers on appropriate GWG, or tracking 
and recording weight during pregnancy may also be of limited value to the mother 
(Ferrari and Siega-Riz, 2013; Power et al., 2018). This is in keeping with the fact 
that patterns of GWG in mothers over ten years since the IOM guidance was 
launched have not changed, despite a general acceptance of the 
recommendations. The same proportion of women with excessive GWG have been 
observed, even accounting for a rising background BMI during this time (Power and 
Schulkin, 2017).  
 
 
Assessment of the timing of GWG and accrual of adiposity may also be crucial for 
the mother and the offspring. Pre- or early pregnancy obesity may reflect poor 
nutritional status, fat accumulation, and low-grade inflammation, whereas GWG in 
late pregnancy may additionally reflect fluid expansion, growth of the fetus, 
placenta, and uterus as well as the accumulation of amniotic fluid. The degree of 
GWG within the first trimester is important however as it may signify the final GWG 
category, according to the IOM recommendations (Logan et al., 2017), and high GWG 





GDM, especially amongst normal-weight women (Chu et al., 2007). As early as the 
first and second trimesters of pregnancy, maternal GWG may also positively 
influence fetal growth, as measured by ultrasound scan and fetal length at birth 
(Neufeld et al., 2004). In addition, mid-pregnancy excessive GWG has been 
associated with decreased HDLc levels in 9-year old offspring from the ALSPAC 
cohort (Fraser et al., 2010).  It has therefore been proposed that early or mid-
pregnancy GWG may have a significant impact on the translation of adverse cardio-
metabolic health onto the offspring.  
 
 
Collectively,  the extent to which GWG may contribute to the degree of offspring 
adiposity remains unclear and the underlying mechanisms involved are not fully 
understood (Voerman et al., 2019). The fact that maternal pre-gravid BMI has been 
shown to attenuate the adverse association between GWG and offspring BMI and 
HDLc at age 10 years (Kaar et al., 2014) suggests that GWG has a limited role in the 
causal pathway. It has therefore been proposed that GWG may be a modifiable risk 
factor for offspring adiposity and future cardiometabolic health, but that optimising 
GWG may not minimise the risk entirely for the offspring of women who were already 
overweight or obese mothers (Gaillard et al., 2013; Robinson et al., 2014).  
 
 
In this Chapter, the impact of fetal overnutrition, as demonstrated by greater 
maternal BMI and GWG, on offspring birthweight and cardiometabolic outcome at 
birth was explored. With greater maternal adiposity, higher cord blood leptin and 
lower cord blood adiponectin, reflecting disruption to adipokines in the presence of 
maternal obesity, was anticipated. Offspring dyslipidaemia, characterised by 
elevated levels of cord blood cholesterol, triglyceride, and lower levels of HDLc, 
reflecting the maternal lipid profile in obese pregnancy, was also expected. By 
examining GWG during specific gestational periods, as well as the impact of 
excessive GWG, according to the IOM guidelines, the aim was to establish whether 
early or mid-pregnancy GWG (as previously demonstrated by ALSPAC on later 
offspring outcomes) or excessive GWG may have contributed to greater offspring 







3.2.1 Study Population 
 
There were 5011 mother-offspring pairs from the ALSPAC cohort with a cord blood 
sample. Multiple pregnancies and those that were delivered before 37 weeks’ 
gestation were excluded as this would likely influence birthweight and 
concentration of cord blood analytes. In total, there were 3479 mother-offspring 
pairs with a recorded maternal pre-pregnancy weight and height so that the BMI 
and GWG variables could be created.  
   
 
Details of cord blood sample collection and analysis are presented in Chapter 2: 
General Methods. Details of obstetric and perinatal abstraction of data from patient 
case-notes and questionnaires completed are presented in Chapter 2: General 
Methods.   
 
3.2.2 GWG  
 
As discussed in Chapter 1, the 2009 Institute of Medicine guidelines on (GWG) were 
used to categorise women into inadequate, appropriate and excessive GWG 
(Institute of Medicine and National Research Council Committee to Reexamine IOM 
Pregnancy Weight Guidelines, 2009).  In order to allocate women according to these 
categories, maternal weight was obtained by ALSPAC from obstetric notes, who 
subtracted the first (<18 weeks) from the last (≥37 weeks) weight  measurement in 
pregnancy to derive the variable absolute weight gain, as previously reported. This 
was further classified using the IOM criteria so that weight gain was either less, equal 
to or more than the recommendations, irrespective of BMI. As also discussed in 
Chapter 1, BMI was calculated as weight (kg)/height(m2) and categorised according 
to World Health Organisation categories (underweight <18.5 kg/ m2, normal 18.5 
24.9 kg/ m2, overweight 25.0-29.9 kg/ m2, obese 30 kg/ m2). All pregnancy weight 
measurements (median number of repeat measurements per woman, 10; range, 1, 





(with 2 levels: woman and measurement occasion) relating maternal weight (the 
outcome) to gestational age (the exposure) (Fraser et al., 2011). There were high 
levels of agreement between estimated and observed weights and full details of 
statistical modelling have previously been published. In this multilevel model, 
specific knots were identified at 18 and 28 weeks. This model was then used by 
ALSPAC to predict maternal weight at 0 weeks (hereafter referred to as ‘pre-
pregnancy weight’) and GWG per week from 0-18 weeks (‘early pregnancy GWG’), 
19-28 weeks (‘mid pregnancy GWG’), and 29 weeks to delivery (‘late pregnancy 
GWG’). PPW and gestational weight change were modified by ALSPAC to be clinically 
meaningful so that the variation in offspring outcomes could be examined per 
additional 1 kg of maternal weight at conception and per 400-g gain per week of 
gestation for GWG (the recommended rate of weight gain in pregnancy for women 
with a normal BMI) (Institute of Medicine and National Research Council Committee 
to Reexamine IOM Pregnancy Weight Guidelines, 2009).  By examining GWG in early, 
mid, and late pregnancy, this enabled specific gestational periods of GWG to be 
examined in relation to the cord blood or birthweight outcome. 
  
 
3.2.3 Statistical Analysis  
 
 
Cord blood cholesterol, triglyceride, HDLc and non-HDLc, leptin, adiponectin, and 
birthweight were log-transformed to produce approximately normal distributions of 
residuals. Linear regression models were used to examine the associations between 
GWG and cord blood lipids (cholesterol, triglyceride, HDLc, and non-HDLc), 
adipokines (leptin and adiponectin),  and birthweight using complete case analysis. 
GWG was examined as a continuous variable (per 1kg increase) and as categorised 
according to IOM criteria. Using these recommendations, adequate GWG was 
classified as: 12.5-18kg for underweight women, 11.5-16kg for normal-weight 
women, 7-11.5kg for overweight women, and 5-9kg for obese women. Those gaining 
less than these ranges within each BMI category were defined as having inadequate 
GWG (<) and those gaining more as having excessive GWG (>). Maternal BMI was also 





blood analytes and birthweight. Sex-exposure interactions were tested for and as 
there was no evidence to support these, results are reported for male and female 
offspring combined.   
 
 
A series of incremental analyses  was performed in order to adjust for potential 
confounders and mediators, as discussed in section 4. The basic model (model 1) 
adjusted for offspring sex. In model 2 birthweight was additionally adjusted for 
(birthweight was not included where the outcome was birthweight), as was 
gestational age. In the fully adjusted model (model 3) maternal and pregnancy 
confounders (age, smoking, parity, occupational social class, education, BMI, 
ethnicity, mode of delivery, and diabetes in pregnancy) were also adjusted for. 
Where the rate of GWG was examined for each gestational period (0-18, 19-28, ≥29 
weeks) GWG in the previous period was also adjusted for.  
 
 
3.2.4 Assessment of confounders and mediators 
 
 
As shown in Figure 3.1: DAG, potential confounder and mediator variables were 





















7) Occupational social class 
 
GWG (per 1kg) 

















Model 1: offspring sex 
Model 2: Offspring confounder/mediator 
adjusted 
Model 3: Additional adjustment for pregnancy 
and maternal confounders/mediators  
 
BMI (kg/m2)  
8)   Education 
9)   BMI 
10)  Ethnicity 
11)  Mode of delivery 
12)   Presence of diabetes 
 
Mediators 
Birthweight, gestational age, BMI/GWG in 
previous period, mode of delivery and 








Lower GWG in pregnancy has been shown to occur with female offspring more than 
male offspring (Navara, 2014). At delivery, male offspring may be on average 100g 
heavier than female offspring, thus contributing to the overall maternal weight 
gain (Tamimi et al., 2003). Indeed, the rate of growth may also differ between 
sexes, with male offspring growing at a faster rate in the first and second 
trimesters before there is a comparable rate of growth between the sexes in the 
third trimester (De Zegher, Devlieger and Eeckels, 1999), and this may influence 
the GWG observed during each trimester. Offspring sex was also introduced as a 
confounder as higher leptin levels have been demonstrated in the cord blood of 
female compared to male offspring (Helland et al., 1998; Kayemba-Kay’s et al., 
2008) although some studies have not identified any gender difference for leptin 
(Iñiguez et al., 2004). Lower adiponectin levels have also been identified in 
females compared to male offspring at age 2 years and adiponectin has also been 






GWG is positively correlated with offspring birthweight (Fraser et al., 2010; Ludwig 
and Currie, 2010), as is BMI across all ranges (Stamnes Koepp et al., 2012). 
Birthweight may directly influence GWG or cord blood adipokines or lipids, indeed 
GWG may also be moderated by birthweight. Even though there is a strong 
correlation between maternal leptin and cord blood leptin, it appears that only cord 
leptin is directly associated with offspring birthweight and so maternal leptin was 













Gestational age was accounted for as a potential confounder as shorter duration of 
pregnancy limits the time frame for potential GWG. Deliveries of less than 37 weeks 
were also excluded and therefore adjusting for gestational age would have only 
considered those beyond 37 weeks’ gestation. Gestational age may also mediate 
offspring birthweight by limiting the time for accrual of fat mass leading to a higher 
birthweight. In addition, the length of gestation positively influences cord blood 
leptin (Kayemba-Kay’s et al., 2008) and is associated with progressive dysregulation 
of lipids (Sattar et al., 1997), with elevated triglyceride levels from as early as the 
first trimester in particular associated with adverse pregnancy outcome (Vrijkotte 
et al., 2012). Gestational age is also a mediator as greater or lesser GWG may 
adversely affect the length of gestation since extremes of GWG or maternal BMI may 
influence the timing of delivery. Women with low BMI, for example, may labour 
earlier, compared to women with high GWG who may fail to labour spontaneously 
(Han et al., 2011; N. Li et al., 2013). 
 
 
Maternal Age  
 
 
Younger maternal age has been associated with excessive GWG (Restall et al., 2014) 
as well as earlier deliveries, thereby limiting the opportunity for GWG (Aliyu et al., 
2010). More recently, however, younger age at conception has been associated with 
GWG less than recommended, although this association was weak (Power et al., 














Smoking, during pregnancy, has been associated with excessive GWG in one study 
(Gaillard et al., 2013), even when smoking has stopped by 14-16 weeks (Restall et 
al., 2014). Maternal smoking is also consistently associated with lower birthweight 
in the offspring (Kayemba-Kay’s et al., 2008). Smoking is also associated with 
adipokine and cardio-metabolic disruption. Smoking cessation, for example, may 
lead to elevated leptin levels, possibly reflecting the changes in fat distribution after 
stopping smoking (Kryfti et al., 2015). Smoking also induces dyslipidaemia and 







Higher parity is associated with maternal obesity as well as excessive GWG (Gaillard 
et al., 2013). This finding is not universal, however, and a large retrospective study 
demonstrated that GWG above the recommendations was associated with lower 
parity and GWG below the recommendations associated with higher parity (Power 
et al., 2018). Higher parity is also associated with progressively higher infant 
birthweight and risk of macrosomia (Ørskou et al., 2003). 
 
 
Occupational social class and education 
 
 
Lower education levels are associated with maternal obesity (Gaillard et al., 2013) 
but it has also been associated with GWG out with the recommended guidance during 
pregnancy (O’Brien, Alberdi and McAuliffe, 2018). There are inconsistent results 
when exploring social class as well as education as a risk factor for overall GWG. In 





educated normal-weight women specifically, rather than lesser educated obese 
women (Bjermo, Lind and Rasmussen, 2015). Overall higher education appears to 
protect against excessive GWG (C.K. et al., 2013) whereas there does not appear to 
be the same or any association between social class and GWG (Fraser et al., 2011; 






One study showed that women that gain weight excessively in pregnancy are more 
likely to be already overweight or obese (Restall et al., 2014). In a study across nine 
obstetric units in Canada, more than half of women with a BMI greater than 25 kg/m2 
(ie. overweight or obese women) gained weight excessively and the risk of excessive 
GWG increased exponentially according to BMI category (Morisset et al., 2017). In 
addition, a large retrospective study of 18,217 women between 2006 and 2015, 
showed that more than half of women who were overweight or obese gained more 
than the recommended weight - in contrast to underweight women - who were more 
likely to gain less than recommended (Power et al., 2018).  Despite the threshold 
for exceeding the recommendations, GWG itself however declined with advancing 
BMI, suggesting that obese women gain less weight than lean women even though 
they may exceed the recommended GWG limit. They also highlighted the third 
trimester as the stage of pregnancy for most GWG (Gluckman et al., 2008) and so 
GWG in the previous trimester (as well as pre-pregnancy BMI) were also accounted 
for in the analysis. 
 
 
Overweight and obese mothers have more atherogenic lipid profiles during 
pregnancy, in addition to higher leptin and lower adiponectin levels (Scifres, Catov 
and Simhan, 2014; Farias et al., 2016; Li et al., 2018). As higher maternal leptin, 
reflecting higher maternal BMI, correlates with higher cord blood leptin (Li et al., 
2018) it was therefore appropriate to adjust for BMI in the mediation analysis of 







European ethnicity has been associated with excessive GWG (Gaillard et al., 2013) 
and more recently this has been demonstrated amongst the Caucasian population 
when compared to other ethnicities (Guo et al., 2019). Observing GWG amongst 
diverse ethnicities across three continents, a recent systemic review indicated that 
women in the United States and Europe have a higher prevalence of GWG above IOM 
recommendations and lower rates of GWG below the recommendations than women 
in Asia (Goldstein et al., 2018). Despite this, during pregnancy (and out with), Asian 
women also have a greater cardio-metabolic and diabetes risk profile at a lower BMI 
compared to Caucasian women (Deurenberg, Deurenberg-Yap and Guricci, 2002; Li 
et al., 2002). Regulation of adipokines may therefore vary according to ethnicity, 
with lower adiponectin and higher leptin levels demonstrated amongst a South Asian 




Mode of delivery 
 
 
In one small study, cord blood leptin was higher amongst those who delivered 
vaginally compared to those who were delivered by caesarean section (Yoshimitsu 
et al., 2000), suggesting that placental leptin release is augmented by advanced 
labour. Another study did not find any difference between the mode of delivery and 
that cord blood leptin was associated with the duration of labour alone (Logan et 
al., 2016). Vaginal delivery has also been associated with fetal lipid dysregulation as 
demonstrated by elevated cord blood fatty acid levels compared to those undergoing 
caesarean section (Yoshimitsu et al., 1999). Weight loss amongst obese women in 
pregnancy may reduce the risk of caesarean section delivery, compared to those 
who gained weight according to the IOM recommendations (Blomberg, 2011), 







Presence of diabetes 
 
 
GDM is associated with higher maternal BMI and GWG (National Institute for Health 
and Care Excellence, 2015). Higher maternal GWG may exaggerate the progressive 
insulin resistance during pregnancy, overall contributing to the risk of GDM.  One 
recent retrospective study showed that women who were diagnosed with GDM were 
less likely to exceed the recommendations on GWG which may reflect the greater 
intervention such as counselling and dietician input in this patient group (Davis et 
al., 2015; Power et al., 2018). In contrast, excessive GWG prior to the diagnosis of 
GDM increased the odds of developing GDM, with similar strength of effect for 
normal-weight compared to overweight or obese women (Brunner et al., 2015). GDM 
is also associated with higher maternal and cord blood leptin, perhaps as a result of 
higher leptin mRNA expression, as well as lower adiponectin (Meller et al., 2006; 
Desoye and Hauguel-De Mouzon, 2007), and elevated triglyceride levels which have 





3.3 Results  
 
Figure 3.2 demonstrates the ALSPAC participant flow chart, the inclusion and 
exclusion criteria as well as introducing the demographics of the cohort.  
 






Core ALSPAC cohort 
14541 pregnancies 
14676 offspring 
4797 offspring with paired 
cord blood sample 
Exclusions 
13 triplet and 
quadruplet 
pregnancies 
9866 cord blood 
sample unavailable 
214 pregnancies re-
engaged in cohort follow 
up 
4741 ‘term’ singletons 
3811 with maternal 
BMI recorded 
 
Total 4947 singletons 
 
3479 with maternal gestational weight gain recorded 
 
Underweight (BMI<18.5 kg/m2): 161 (4.6%) 
Normal weight (BMI 18.5-24.9 kg/m2): 2590 (74.4%) 
Overweight (BMI 25.0-29.9 kg/m2): 544 (15.6%) 





64 twin pairs 
Exclusion 
206 delivered <37 
weeks’ gestation 
Exclusion 
930 without maternal 
BMI recorded 
Exclusion 
332 without maternal 






Table 3.1 summarises the characteristics of the entire cohort with GWG 
recorded and according to IOM criteria.  
 
 
The median age was 28 years (25, 31 years). Women were mostly nulliparous (44.8%) 
and had never smoked (69.8%). Most mothers left school at 16 years old (63.8%) and 
few had gone on to further education. Less than 20% were socially disadvantaged, 
categorised as Class IIIb or below. The cohort consisted of a mainly Caucasian 
population (97.4%) with minimal ethnic diversity. Most women in the study had a 
normal BMI (74.4%), with only 5.3% of women classified as obese. The median GWG 
was 12 kg (9.6, 15.5kg). Most women achieved a vaginal birth (77.7% had a 
spontaneous vaginal delivery, SVD), with only 5.8% undergoing caesarean section. 
There were a similar number of male (50.6%) and female (49.4%) babies delivered 
and the median birthweight was 3.5 kg (3.2, 3.8kg) and 40 weeks’ gestation. Table 
3.1 also displays the median (and IQR) cord blood levels including leptin (6.6 (3.8, 
12.2) pg/ml), adiponectin (77.2 (54.9, 100.0) µg/ml), cholesterol (1.7 (1.4, 2.0) 
mmol/ml), triglyceride (0.5 (0.4, 0.6 ) mmol/l), HDLc (0.5 (0.4, 0.7) mmol/ml) and 









Entire cohort <   = > 
N (%)  Median (IQR)  N (%)  Median (IQR)  N (%)  Median (IQR)  N (%)  Median (IQR) 
Age  3479 28 (25, 31) 1191  29 (25, 32)  1305  28 (25, 31)  983  27 (25, 30) 
Smoking  











   
807 (68.8)  
62 (5.3)  
 
 
304 (25.9)  
    
938 (73.0)  
98 (7.6)  
 
  
249 (19.4)  
    
640 (66.7)  
95 (9.9)  
 
 
224 (23.4)  
 
BMI (kg/m2)  3479 22.2  
(20.5, 24.4) 
1191  21.5  
(20.0, 23.1)  
1305  21.8  
(20.5, 23.7)  
951  24.0  
(21.7, 26.7) 
<18.5  161 (4.6)        


















   
450 (39.3)  
430 (37.5)  
186 (16.2)  
60 (5.2)  
20 (1.7)  
    
577 (45.5)  
485 (38.3)  
150 (11.8)  
45 (3.6)  
11 (0.9)  
    
472 (50.6)  
311 (33.4)  
114 (12.2)  
29 (3.1)  
6 (0.7)  
 
Education    
Left school  
at 16  







   
731 (64.4)  
 
251 (22.1)  
154 (16.6)  
    
756 (60.1)  
 
317 (25.2)  
184 (14.5)  
    
641 (67.4)  
 
214 (22.5)  
96 (10.9)  
 
Social Class  





   
59 (6.3)  
303 (32.3)  
    
56 (5.2)  
363 (33.9)  
    
34 (4.2)  








Entire cohort <   = > 
N (%)  Median (IQR)  N (%)  Median (IQR)  N (%)  Median (IQR)  N (%)  Median (IQR) 
IIIa   








400 (42.6)  
70 (7.5)  
87 (9.3)  
19 (2.0)  
468 (43.7)  
75 (7.0)  
88 (8.2)  
21 (2.0)  
361 (44.4)  
69 (8.5)  
88 (10.8)  
6 (1.5)  
Ethnicity  
White Caucasian  
Black Caribbean  
Black African  












   
1112(97.7)  
4 (0.4)  
1 (0.1)  
2 (0.2)  
6 (0.5)  
4 (0.4)  
3 (0.3)  
    
1234 (98.6)  
2 (0.2)  
1 (0.1)  
5 (0.4)  
3 (0.2)  
0 (0.0)  
3 (0.2)  
    
928 (98.3)  
6 (0.6)  
1 (0.1)  
3 (0.3)  
1 (0.1)  
1 (0.1)  
1 (0.1)  
 
Pregnancy Characteristics           
 
GWG(kg) 
















9.0 (6.8, 10.2)  1305 
56 (34.8) 
1060 (40.9)  
152 (27.9) 
37 (20.1) 
13.2 (12.0, 14.5)  983 















   
1151(96.6)  
4 (0.3)  
7 (0.6)  
29 (2.4)  
    
1252 (95.9)  
2 (0.2)  
5 (0.4)  
46 (3.5)  
    
3341(96.0)  
8 (0.2)  
16 (0.5)  












   
 
974 (82.0)  
11 (0.9)  
102 (8.6)  
    
 
1013 (77.9)  
10 (0.8)  
111 (8.5)  
    
 
708 (72.4)  
5 (0.5)  








Entire cohort <   = > 







49 (4.1)  
42 (3.5)  
10 (0.8)  
70 (5.4)  
81 (6.2)  
16 (1.2)  
83 (8.5)  
69 (7.1)  
13 (1.3)  
Gestational age 
at birth (weeks)  
3479 40 (39, 41) 1191  40 (39, 40)  1305  40 (39, 41)  983  40 (39, 41) 








   
608 (51.1)  
583 (49.0)  
    
646 (49.5)  
659 (50.5)  
    
505 (51.4)  
478 (48.6)  
 
Birthweight 
(kg)   
3448 3.5 (3.2, 3.8) 1177  3.3 (3.0, 3.6)  1292  3.5 (3.2, 3.8)  979  3.6 (3.3, 4.0) 
Cord blood 
leptin (pg/ml)   












3421 0.5 (0.4, 0.6) 1171  0.5 (0.4, 0.6)  1286  0.5 (0.4, 0.6)  964  0.5 (0.4, 0.7) 
Cord blood 
HDLc (mmol/l)  




3360 1.1 (0.9, 1.4) 1146  1.1 (0.9, 1.4)  1262  1.1 (0.9, 1.4)  952  1.1 (0.9, 1.4) 
< represents GWG less than recommended, = represents GWG within recommendations, > represents GWG more than 





Table 3.1 also describes the cohort according to those who gained weight less than, 
within or  more than the IOM recommendations on GWG. Of these women, 4.6% were 
underweight, 74.4% were normal weight, 15.6% were overweight and 5.3% were 
obese. More than half of overweight (58.1%) or obese (57.1%) women exceeded the 
recommendations on GWG, even though obese women gained overall less weight 
(mean GWG was 9.6kg in obese women and 12.9kg in normal-weight women), 
compared to only 21% of normal-weight women who also exceeded the 
recommendations on GWG.  
 
 
In contrast to those with GWG within the recommendations, mothers with GWG less 
than recommended were older (median 29 years old compared to 28 years old), more 
likely to smoke during pregnancy (25.9% compared to 19.4%) although maternal BMI 
was comparable between these groups (median 21.5 kg/m2 and 21.8 kg/m2 
respectively). They had the highest rate of SVD (82%) compared to 77.9% of healthy 
women although the rate of caesarean section was similar between groups.   
Offspring birthweight was lowest among women with inadequate GWG (3.3kg 
compared to 3.5kg in those that gained within the recommendations). Although cord 
blood cholesterol, triglyceride, HDLc, and non-HDLc were similar between each of 
the groups, those that gained less than the recommended weight during pregnancy 
had offspring with lower cord blood leptin (5.7 pg/ml compared to 7.0 pg/ml), and 
similar adiponectin levels (76.4 µg/ml compared to 77.5 µg/ml).  
 
 
Characteristics of those that exceeded, in contrast to those that gained within, the 
GWG recommendations are also presented in Table 3.1. Overall, they were slightly 
younger (median 27 years old), more likely to smoke either before (9.9%) or during 
pregnancy (23.4%), and have a higher pre-pregnancy BMI (24 kg/m2). Exceeding the 
GWG recommendations also included more nulliparous women (50.6% compared to 
45.5 % of nulliparous who gained within the recommendations) who were least 
educated (67.4% left school at 16 years old compared to 60.1% of those who gained 
within the GWG recommendations). This group also had the lowest rate of SVD 





also had higher offspring birthweight (3.6kg compared to 3.5kg), cord blood leptin 
(8.0 pg/ml compared to 7.0 pg/ml), and cord blood adiponectin (78.2 µg/ml 
compared to 77.5 µg/ml) levels were also higher in those with excess GWG 
compared those who gained within the recommendations. Again, cord blood 
cholesterol, triglyceride, HDLc, and non-HDLc were comparable between groups.     
 
 
Characteristics of the ALSPAC cohort are displayed in Figures 3.3 to 3.5. Figure 3.3 
presents the GWG IOM category according to BMI; Figure 3.4 presents the mode of 
delivery according to the IOM category and Figure 3.5 shows the concentration of 
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%
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Figure 3.5: Concentration of cord blood leptin and offspring birthweight 












< Within > IOM recommendations on GWG
Leptin (pg/ml) Birthweight (kg)





















SVD Breech Caesarean section Forceps Vacuum Other





The association between the entire range of GWG (per 1kg) and BMI (per kg/m2) 
and cord blood leptin, adiponectin, lipids, and birthweight is shown in Table 3.2 
Both GWG and BMI were weakly positively associated with cord blood leptin 
(coefficient 0.01 (0.00, 0.02), p=0.002 and 0.02 (0.02, 0.03), p=0.000 respectively) 
in the fully adjusted analysis. GWG and BMI were also weakly positively associated 
with birthweight (coefficient 0.01 (0.01, 0.01), p=0.000 and 0.01 (0.01, 0.01), 
p=0.000). There was no significant association between GWG and cord blood 
adiponectin, cholesterol, HDLc, or non-HDLc. BMI however displayed weak positive 
association with cord blood triglycerides (coefficient 0.01 (0.01, 0.02), p=0.000) 
and a weak negative association with cord blood HDLc (coefficient -0.01 (-0.01, 





Table 3.2: Association between GWG (per 1kg) and BMI (per kg/m2) and cord blood measures and birthweight  
 
Outcome   Model 1  Model 2  Model 3  
   Coefficient (95% CI)  p  Coefficient (95% CI)  p  Coefficient (95% CI)  p  
Cord blood leptin  
(pg/ml)  
N=2695  
GWG 0.03 (0.02, 0.03) 0.000 0.01 (0.00, 0.02)  0.006 0.01 (0.00, 0.02)  0.002  
BMI 0.04 (0.03, 0.04) 0.000 0.02 (0.02, 0.03) 0.000 0.02 (0.02, 0.03) 0.000 
Cord blood adiponectin  
(µg/ml)  
N=2669  
GWG 0.00 (0.00, 0.01)  0.572 0.00 (-0.01, 0.00)  0.684 0.00 (-0.01, 0.00)  0.369  
BMI 0.00 (-0.01, 0.00) 0.339 -0.01 (-0.02, 0.00) 0.103 0.00 (-0.01, 0.00) 0.142 
Cord blood cholesterol  
(mmol/l)  
N=2657  
GWG 0.00 (0.00, 0.01)  0.236 0.00 (0.00, 0.01)  0.171 0.00 (0.00, 0.01)  0.316  
BMI 0.00 (0.00, 0.00) 0.869 0.00 (0.00, 0.01) 0.732 0.00 (0.00, 0.01) 0.515 
Cord blood triglyceride  
(mmol/l)  
N=2645  
GWG 0.00 (0.00, 0.01)  0.097 0.01 (0.00, 0.01)  0.004 0.00 (0.00, 0.01)  0.060  
BMI 0.01 (0.00, 0.01) 0.014 0.01 (0.01, 0.01) 0.000 0.01 (0.01, 0.02) 0.000 
Cord blood HDLc  
(mmol/l)  
N=2595  
GWG 0.00 (0.00, 0.01)  0.593 0.00 (0.01, 0.00)  0.854 0.00 (0.00, 0.01)  0.805  
BMI 0.01 (-0.01, 0.00) 0.040 -0.01 (-0.01, 0.00) 0.004 0.01 (0.01, 0.00) 0.011 
Cord blood 
non-HDLc (mmol/l)  
n=2595  
GWG 0.00 (0.00, 0.01)  0.276 0.00 (0.00, 0.01)  0.104 0.00 (0.00, 0.01)  0.355  
BMI 0.00 (0.00, 0.01) 0.430 0.00 (0.00, 0.01) 0.182 0.00 (0.00, 0.01) 0.119 
Birthweight † (g)  
N=2696  
GWG 0.01 (0.01, 0.01)  0.000 0.01 (0.01, 0.01)  0.000 0.01 (0.01, 0.01)  0.000  
BMI 0.01 (0.01, 0.01) 0.000 0.01 (0.01, 0.01) 0.000 0.01 (0.01, 0.01) 0.000 
 
Models adjusted for 1: offspring sex, 2: offspring sex, birthweight, and gestational age, 3: offspring sex, birthweight, gestational 
age, maternal age, smoking, parity, social class, education, BMI (for the GWG analysis)/GWG (for the BMI analysis), ethnicity, 
mode of delivery and presence/absence of diabetes in pregnancy. †Birthweight not included as a confounder in models 2 and 3 





Displaying the association between GWG in those that gained weight excessively 
(according to the IOM criteria) and cord blood leptin and birthweight, Table 3.3 
shows that the association was strongest for obese women who also gained weight 
excessively during pregnancy, although the association with birthweight was 
attenuated in the analysis (coefficient 0.06 (0.01, 0.12), p=0.034 for cord blood 
leptin and 0.01 (0.00, 0.16), p=0.052 for birthweight).  
 
 
Table 3.3: Association between GWG in those that gained weight excessively 
according to the IOM criteria and cord blood leptin and birthweight 
  
  
Outcome  Maternal BMI category   GWG (kg)  
    N  Coefficient (95% CI)  p 
Cord blood 
leptin pg/ml 
Normal  434  0.04 (0.00, 0.07)  0.033  
Overweight  244  0.00 (-0.03, 0.03)   0.835   
Obese  77  0.06 (0.01, 0.12)  0.034  
Birthweight  
(g)  
   
Normal  434  0.01 (0.00, 0.01)  0.022  
Overweight  245  0.00 (0.00, 0.01)  0.037  
Obese  77  0.01 (0.00, 0.16)  0.052  
  
 
Adjusted for offspring sex, birthweight, gestational age, and maternal age, 
smoking, parity, social class, education, BMI, ethnicity, mode of delivery, and 
presence/absence of diabetes in pregnancy. †Birthweight not included as a 








Table 3.4 shows the categorical association between GWG (classified as less or 
more than recommended) and cord blood leptin and birthweight. Gaining less 
weight than recommended was negatively associated with lower cord blood leptin 
and birthweight (-0.10 (95% CI -0.18, -0.02), p=0.012 and coefficient 0.054 (95% CI 
-0.07, -0.04), p=0.000 respectively) in the fully adjusted analysis. Excessive GWG 
was associated with higher offspring birthweight (0.03,(95% CI 0.02), 0.04, 
p<0.001). Excessive GWG was also associated with higher cord blood leptin but the 
association attenuated to null after adjusting for confounders. GWG categorised 





Table 3.4: Association between GWG (per 1kg) (according to IOM categories) and cord blood leptin and birthweight  
  
 
Outcome  IOM Category  Model 1  Model 2  Model 3  





< Recommended  
= Recommended  
> Recommended  
-0.23 (-0.31, -0.15)  
Reference (null, 0)  




-0.11 (-0.19, -0.04) 
Reference (null, 0) 




-0.10 (-0.18, -0.02)  
Reference (null, 0)  





† (g)  
N=2696  
< Recommended  
= Recommended  
> Recommended  
-0.06 (-0.07, -0.05)  
Reference (null, 0)  




-0.05 (-0.07, -0.04) 
Reference (null, 0) 




-0.05 (-0.07, -0.04)  
Reference (null, 0)  






Models 1: adjusted for offspring sex, 2: additionally adjusted for birthweight and gestational age, 3: additionally adjusted for 
maternal age, smoking, parity, social class, education, BMI, ethnicity, mode of delivery, and presence of diabetes in pregnancy. 





The association between GWG during specific gestational periods (0-18 weeks 
‘early’, 19-28 weeks ‘mid’ and >28 weeks ‘late’ pregnancy) and cord blood leptin, 
adiponectin, lipids, and birthweight are shown in Table 3.5. Early GWG was 
associated with cord blood leptin, but this attenuated to the null when adjusted 
for in the analysis. Mid pregnancy GWG was weakly positively associated with cord 
blood leptin (coefficient 0.12 (95% CI 0.03, 0.20), p=0.010) and the association 
strengthened in late pregnancy (coefficient 0.14 (95% CI 0.05, 0.23), p=0.002). Mid 
pregnancy GWG was also weakly positively associated with triglyceride (coefficient 
0.05 (95% CI 0.01, 0.10), p=0.025) but this association was lost during late 
pregnancy. There was no other significant association between early, mid, or late 
pregnancy GWG and cord blood cholesterol, HDLc or non-HDLc. GWG throughout 
each gestational period was positively associated with birthweight, with mid-
pregnancy GWG demonstrating the strongest association (coefficient 0.06 (95% CI 







Table 3.5: Association between early, mid-, and late pregnancy GWG* and cord blood measures and birthweight  
  GWG (per 400g/wk change) *  
   0-18 wk ‘early’ 19-28 wk  ‘mid’ ≥29 wk ‘late’ 
 Outcome  Model   Coefficient (95% CI)  p Coefficient (95% CI)  p  Coefficient (95% CI)  p  





 0.09 (0.02, 0.17)  
0.01 (-0.07, 0.08)  




0.21 (0.13, 0.28)  
0.08 (0.01, 0.16)  




0.23 (0.16, 0.30)  
0.15 (0.08, 0.21)  









 -0.03 (-0.08, 0.01)  
-0.05 (-0.09, 0.02)  




0.01 (-0.05, 0.04)  
-0.02 (-0.07, 0.03)  




0.03 (-0.01, 0.08)  
0.04 (-0.02, 0.07)  









 0.03 (0.01, 0.06)  
0.03 (0.00, 0.07)  




0.02 (-0.01, 0.06)  
0.03 (-0.01, 0.07)  




0.00 (-0.03, 0.03)  
0.00 (-0.03, 0.03)  









 0.00 (-0.04, 0.04)  
0.03 (-0.01, 0.07)  




0.02 (-0.02, 0.07)  
0.06 (0.02, 0.10)  




0.00 (-0.04, 0.03)  
0.04 (0.00, 0.07)  









 0.05 (0.00, 0.09)  
0.03 (-0.01, 0.07)  




0.03 (-0.02, 0.07)  
0.01 (-0.04, 0.05)  




0.03 (-0.03, 0.04)  
-0.02 (-0.06, 0.02)  









 0.02 (-0.02, 0.06)  
0.03 (-0.01, 0.07)  




0.01 (-0.03, 0.05)  
0.03 (-0.01, 0.07)  




-0.01 (-0.04, 0.03)  
0.01 (-0.03, 0.04)  









 0.04 (0.03, 0.05)  
0.05 (0.03, 0.06)  




0.06 (0.05, 0.07)  
0.06 (0.05, 0.07)  




0.04 (0.03, 0.05)  
0.05 (0.04, 0.06)  




Models 1: adjusted for offspring sex, 2: additionally adjusted for birthweight, 3: additionally adjusted for maternal age, smoking, parity, 
social class, education, BMI, GWG in the previous period, ethnicity, mode of delivery, and presence of diabetes. †Birthweight not included 
as a confounder in where birthweight is the outcome. * A 400g per week change is the recommended rate of GWG in women with a normal 





3.4 Discussion   
 
 
In this Chapter, GWG was examined in relation to cord blood leptin, adiponectin, 
lipids, and birthweight as well as the characteristics of women with inadequate and 
excessive GWG. Amongst this relatively lean Caucasian population, more than half 
of overweight or obese women gained weight excessively during pregnancy, 
compared to one-fifth of normal-weight women, even though obese women gained 
less weight overall. Excessive GWG occurred in younger, less educated, nulliparous 
women with a higher BMI, compared to women within the GWG recommendations. 
They also had offspring with higher birthweight, which may reflect the lower rate 
of vaginal birth and higher cord blood leptin and adiponectin levels. This study has 
shown that both GWG and BMI were positively associated with cord blood leptin and 
offspring birthweight, with the strongest association for cord blood leptin seen in 
obese women who gained excessive weight during pregnancy. BMI was also positively 
associated with cord blood triglyceride and negatively associated with cord blood 
HDLc, unlike GWG which showed a positive association with cord blood triglyceride 
during mid-pregnancy only. Whilst GWG throughout pregnancy was positively 
associated with both birthweight cord blood leptin, mid-pregnancy GWG 
demonstrated the strongest association with birthweight whereas late pregnancy 
GWG showed a stronger association with cord blood leptin.   
 
 
Maternal pre-pregnancy weight and BMI have been more consistently and historically 
associated with offspring adiposity and cardiovascular risk factors than GWG alone 
(Fraser et al., 2010; Poston, Harthoorn and Van Der Beek, 2011; Voerman et al., 
2019). This is supported by the current study whereby  maternal BMI was associated 
with a wider range of cord blood biomarkers, and this has also been demonstrated 
by previous ALSPAC reports (Fraser et al., 2010). GWG however has also been 
considered significant in contributing to offspring overweight and obesity (Lau et 
al., 2014; Goldstein et al., 2017). It remains unclear if these effects are causal and 
the underlying mechanistic influence of both BMI and GWG is not yet fully 





triglyceride and birthweight and negatively associated with cord blood HDLc. This is 
in contrast to GWG which was positively associated with cord blood leptin and 
birthweight alone (other than a weak positive association with cord blood 
triglyceride during  mid-pregnancy GWG).  GWG has also demonstrated a positive 
correlation with leptin at birth in other reports  (Lemas et al., 2015), and the 
association between GWG and leptin appears to track across the life-course as 
evident in child and early adulthood (Fraser et al., 2010; Hrolfsdottir et al., 2015). 
 
 
Both elevated cord blood leptin and birthweight represent markers of fetal 
overnutrition as a result of higher maternal BMI or greater GWG. Umbilical cord 
blood leptin increased with advancing gestation, due to increased production by the 
placenta, and is an established biomarker of neonatal fat mass (Hauguel-de Mouzon, 
Lepercq and Catalano, 2006), with elevated leptin levels reflecting greater neonatal 
fat mass. Birthweight is also a crude marker of offspring anthropometry at birth that 
correlates positively with child and adult adiposity (Evensen et al., 2017). As well as 
reflecting neonatal fat mass, leptin plays a central role in early life fetal 
programming, thereby altering adipocyte function (Thakali et al., 2014) and as such, 
influences the propensity to greater adiposity throughout the life course. It has 
therefore been proposed that fetally-programmed adipokine levels may play a role 




Emerging evidence highlights the importance of maternal BMI in pregnancy in 
relation to leptin gene expression and its effect on offspring body composition. 
Decreased methylation near the transcription start site of the leptin gene has been 
strongly associated with greater maternal BMI during pregnancy (Kadakia et al., 
2017). Consequently, enhanced expression of the leptin gene and overall greater 
leptin levels in infancy may have a long-lasting effect on the offspring. It is suggested 
that such offspring may adopt a leptin-resistant state from early on with subsequent 
dysregulation of metabolism and satiety leading to greater adiposity throughout 





of offspring overweight or obesity, it is becoming more evident that each 
incremental rise in maternal BMI has a greater effect on offspring adiposity 
compared to GWG (Voerman et al., 2019). The current study has demonstrated this 
by displaying similar increased strength of effect when maternal BMI, rather than 
GWG, was considered. Examining excessive GWG, according to the IOM 
recommendations, it was felt that the additional risk of this is minimal and maternal 
BMI is the overriding factor. Accounting for greater offspring birthweight and leptin 
at birth, and the long-term implications of these findings, maternal BMI may account 
for the translation of the obesity epidemic across generations. Chapters 6 and 7 
explored how these cord blood measures at birth tracked throughout childhood and 
into adolescence and how the phenotype at birth reflected the degree of adiposity 
in later life as well. Recent analysis has demonstrated that greater maternal pre-
pregnancy BMI and GWG displayed the strongest effects on offspring adiposity in late 
childhood, rather than at birth (Voerman et al., 2019), which suggested that 
maternal obesity had potential for long term programming of the offspring and the 
effects were not fully evident at birth or simply short-lived.  
 
 
There was no association identified between GWG or BMI and cord blood adiponectin 
in the current study. This may be due to the fact the cohort included a relatively 
lean population and higher adiponectin levels are seen out-with pregnancy in obesity 
and Type 2 diabetes. Whilst one study found no difference between adiponectin in 
pregnant and non-pregnant controls, they did however identify lower adiponectin 
levels amongst those with GDM and PE (Cortelazzi et al., 2007). They also reported 
no correlation between fetal and maternal adiponectin levels, even though fetal 
adiponectin is lower in the offspring of GDM mothers (Cortelazzi et al., 2007). In 
addition, whilst adiponectin has been positively associated with offspring 
birthweight, no association was identified between cord blood adiponectin and 
maternal BMI (Sivan et al., 2003). Since fetal adiponectin is significantly higher than 
maternal adiponectin, collectively this highlights that maternal and fetal 
adiponectin are distinct and that fetal adiponectin has an independent regulatory 






The 2009 IOM guidance on GWG, as discussed in Chapter 1, was devised in order to 
guide pregnant women on appropriate weight gain in pregnancy and minimise their 
obstetric risks (Institute of Medicine and National Research Council Committee to 
Reexamine IOM Pregnancy Weight Guidelines, 2009). Offspring of obese women with 
excessive GWG were considered to be at greatest risk, as demonstrated by the 
strength of association with birthweight and cord blood leptin, and this highlights 
the importance of optimising maternal BMI before pregnancy as well as optimising 
GWG during pregnancy. Despite this, obese women in the current study gained less 
weight overall than normal-weight women, which has been demonstrated in previous 
reports suggesting that early pregnancy BMI was associated with significant 
differences in GWG (Bergmann et al., 1997; Cedergren, 2006), and may be due to 
the utilisation of fat stores during the third trimester when fetal energy 
requirements are greater. In the current study, over half of obese or overweight 
women exceeded the recommendations however and whilst GWG has been inversely 
related to pre-pregnancy BMI (Viswanathan et al., 2008), it is clear that most women 




ALSPAC has previously reported on the metabolic impact of excessive GWG on 9-
year-old offspring (Fraser et al., 2010). Offspring were at greater risk of obesity 
(Fraser et al., 2010) and overweight in childhood (Nehring, Lehmann and Von Kries, 
2013) due to excessive GWG. Greater fat mass, leptin, and HDLc have also been 
reported in the offspring of mothers with excessive GWG (Fraser et al., 2010; Logan 
et al., 2017), as has higher maternal leptin immediately following delivery (Logan 
et al., 2017). The Rhea group further demonstrated a positive association between 
excessive weight gain in pregnancy and cord blood leptin levels (Karakosta et al., 
2013; Karachaliou et al., 2015). Whilst excessive GWG alone has been shown to 
result in heavier and longer babies who grow more slowly in the first year of life (N. 
Li et al., 2013; Diesel et al., 2015), a more adipose maternal population (who also 
gained weight in pregnancy excessively) not only had babies that were heavier and 
longer, they also had greater growth trajectories in infancy (Deierlein et al., 2012). 





associated with offspring BMI, the risk of offspring overweight doubled when the 
mother was overweight or obese and gained weight excessively (Guo et al., 2015). 
Studies have concluded therefore that greater maternal PPW is associated with a 
wider range of cardiovascular risk factors and posed a greater risk of offspring 
adiposity overall (Fraser et al., 2010). This was supported by the lack of association 
seen with GWG on offspring outcomes in the current study, although the association 
with birthweight was weakly positive throughout all BMI categories. Given the 
positive association between GWG in mothers that were already obese in pregnancy 
and offspring birthweight and cord blood leptin, this current study suggests that it 
was the offspring of mothers who not only exceed the GWG recommendations but 
also have a greater pre-gravid BMI that were at greatest risk of life-long adiposity 
and these findings add to previous reports on this (Robinson et al., 2014).  
 
 
GWG within the recommendations for BMI has however been shown to attenuate the 
adverse effect of maternal adiposity (Kaar et al., 2014) and this may also be the 
focus of future research. Whilst GWG less than the recommendations has been 
associated with lower birthweight (Viswanathan et al., 2008) and levels of adiposity 
in 9-year-old offspring, it has been reported that childhood cardio-metabolic profile 
did not differ from offspring of mothers who gained weight appropriately during 
pregnancy (Fraser et al., 2010). This current study has demonstrated a similar lack 
of association with cord blood adiponectin or lipids is in keeping with this and 
emphasises the role of developmental overnutrition rather than undernutrition in 
programming offspring adiposity and cardio-metabolic dysfunction.   
 
 
Although obese women may gain less weight during pregnancy overall compared to 
lean women, lean mothers may fail to lose the extra weight accrued during 
pregnancy for example before they become pregnant again. One study found that 
one-third of women with a normal pre-pregnancy BMI became overweight or obese 
by one year post-partum (Endres et al., 2015).  Greater rate of change in rising 
cholesterol and LDLc in normal-weight women has also been reported during 





atherogenic lipid profile at the start of pregnancy and this may reflect the greater 
overall weight gain amongst normal-weight women (Scifres, Catov and Simhan, 
2014). It has therefore been proposed that interventions to support appropriate GWG 
(rather than excessive GWG) should be encouraged for all ranges of BMI (Schack-
Nielsen et al., 2010). Recent intervention studies, to limit GWG to an appropriate 
level, have had varying outcomes. Involving obese women in pregnancy, group-based 
weight management sessions with changes in diet and physical activity observed 
lower GWG during pregnancy compared to a control group (Vesco et al., 2014). 
Despite also observing lower mean GWG in those that received dietary counselling 
and exercise classes, another study concluded that most women still exceeded the 
recommendations despite the intervention (Sagedal et al., 2017). They also 
suggested that the proportion of women that exceeded the guidance on GWG did 
not vary according to BMI and proposed that a  more intense, individualized approach 
to weight management during pregnancy is recommended (Sagedal et al., 2017). 
Whilst brief exposure to an intervention study based on an energy balance model, 
aimed at promoting better eating habits, behaviour and exercise, did not show any 
change in overall GWG although they did demonstrate positive changes in healthy 
eating and exercise during pregnancy. This study highlighted that more intense 
programmes may be of benefit and the limited impact on total GWG was perhaps 
restricted by the short duration of the intervention (6 weeks) (Pauley et al., 2018).   
 
 
The period in which GWG occurred may also be significant. Whilst first trimester 
weight gain reflects fat deposition and expansion of maternal tissues, late pregnancy 
GWG is closely related to fat-free mass and is attributable to increased circulating 
volume, growth of the fetus and placenta, and accumulation of amniotic fluid (Van 
Raaij et al., 1988; Fraser et al., 2010). Early GWG is important as it has been 
positively associated with later development of GDM, particularly amongst normal-
weight women (Cho, Hur and Lee, 2015), as well as positively associated with fetal 
growth and infant length at birth (Neufeld et al., 2004), and cord blood leptin levels 
(Logan et al., 2017).  Expansion of maternal fat stores due to GWG during this time 
results in increased circulating glucose, amino acid, and free fatty acids along with 





GWG in early pregnancy may be a critical time for transmission of cardio-metabolic 
disease to the offspring.  Second or third-trimester GWG has been associated with 
cardio-metabolic dysfunction in childhood (Fraser et al., 2010; Karachaliou et al., 
2015), as well as higher maternal leptin levels (Logan et al., 2017). Greatest strength 
of association with birthweight was demonstrated during mid-pregnancy GWG, 
positive association with cord blood triglycerides during mid-pregnancy GWG only, 
and greatest strength of association with cord blood leptin during late pregnancy 
GWG emphases these critical periods of fetal cardio-metabolic modelling during 
pregnancy. Although birthweight was positively associated with GWG throughout the 
entire gestational period, in keeping with previous reports (Tobi et al., 2009; Fraser 
et al., 2010), it is this peak during mid-pregnancy that may be of greatest 
significance to the offspring. Mid pregnancy GWG has also been associated with 
higher childhood BMI and fat mass, with loss of association with third-trimester GWG 
(Hivert et al., 2016). By contrast, ALSPAC has previously reported that mid-
pregnancy GWG was only positively associated with offspring adiposity aged 9 when 
the mother had excessive GWG during this time, although there was a linear positive 
association evident between first-trimester GWG and offspring adiposity (Fraser et 
al., 2010).  
 
 
In contrast to studies examining GWG and fetal over nutritional effect, the Dutch 
famine study demonstrated metabolic changes in the offspring of those exposed to 
famine. Maternal undernutrition in mid or late gestation, as a result of famine, 
displayed different cord blood metabolic profiles compared to those exposed in early 
gestation (Roseboom et al., 2001). Changes in DNA methylation, as aforementioned, 
may occur due to changes in maternal BMI, may also occur as a result of weight gain 
during specific periods in pregnancy, and may also account for resultant offspring 
metabolic dysfunction (Tobi et al., 2009). Given that the associations were seen 
with GWG during specific periods during pregnancy, targeted intervention during key 







In keeping with a smaller contemporary cohort (n=753), GWG was not consistently 
associated with cord blood lipids at birth (Lemas et al., 2015). Associations with 
offspring lipids in later life have also been inconsistent. Whilst GWG between 14 and 
36 weeks was positively and linearly associated with adverse lipid profile in the 
offspring at age 9, associations were mediated by offspring adiposity (Fraser et al., 
2010). Similarly, another study reported that associations with LDLc, HDLc, and 
triglycerides were attenuated to the null when adjusting for offspring BMI at age 32 
(Hochner et al., 2012). Although there were no consistent associations demonstrated 
between GWG and cord blood lipids, maternal pre-gravid BMI was however 
associated with offspring higher cord blood triglyceride and lower cord blood HDLc, 
indicating that maternal adiposity (rather than GWG alone) may alter the 
mechanisms involved in cholesterol transport and metabolism. This may be 
attributable to the more atherogenic profiles obese women have at the start of 
pregnancy. Higher maternal BMI is associated with higher cholesterol and 
triglycerides and lower HDLc levels at the start of pregnancy compared to normal-
weight women, even though the rate of change of maternal lipids, as previously 
discussed, is lower during obese pregnancy than normal-weight women (Scifres, 
Catov and Simhan, 2014). The resulting disruption to the offspring’s lipid profile that 
occurs in obese pregnancy may account for the vascular dysfunction and consequent 
predisposition to cardiovascular risk later in life (Cole, Freeman and Preece, 1998; 
Meyer et al., 2013). This emphasises the value of maintaining a healthy PPW and 
supports weight management initiatives aimed at women of reproductive age.  A 
positive association between mid-pregnancy GWG and cord blood triglycerides 




When examining GWG according to categories of appropriate weight gain, 
associations with lipids have also been inconsistent. Whilst one study showed that 
appropriate GWG may attenuate the inverse relationship between maternal BMI and 
offspring HDLc at age 10 (Kaar et al., 2014), another showed that the negative 
association between maternal pre-gravid BMI and HDLc at age 9 remained in those 





cardio-metabolic profile, as measured by cord blood lipids, is therefore foremost 
determined by maternal pre-gravid BMI. This may be moderated by GWG, 
particularly during pregnancy, rather than determined by GWG alone.  
 
 
This study has a number of strengths including the size of the cohort and the 
availability of data on a range of maternal, pregnancy, and social characteristics as 
well as being one of few studies with detailed recordings of maternal GWG and cord 
blood. Multiple pregnancies and deliveries <37 weeks were excluded as these would 
have influenced birthweight and cord blood measures. Potential confounders and 
mediators including maternal parity, ethnicity, smoking, and age were adjusted for 
in the analyses, enabling a more robust evaluation of the associations, as previously 
described. Pre-pregnancy BMI was also included as a confounder as it was inversely 
associated with GWG (Viswanathan et al., 2008).   
 
 
Limitations of the study should also be acknowledged. A mainly Caucasian population 
was included, so it is not possible to translate the findings across other ethnicities 
with a greater, or lesser predisposition to weight gain, which, as previously discussed 
is also a limitation of the IOM guidance. The maternal obesity rate in the current 
study is 5.3%, much lower than the contemporary population. Whilst it has been 
highly correlated with weight at the first antenatal visit (Geelhoed et al., 2010), 
self-reporting maternal weight may have led to under-representation of BMI within 
the cohort. Maternal weight gain (last minus first weight measurement in pregnancy, 
kg) may be a more accurate reflection of the exposure as it is calculated using the 
first measured weight (around 10 weeks) and maternal weight (within 12 hours of 
delivery) as previously described (Fraser et al., 2010; Lawlor et al., 2011). This 
avoids contributions from the fetus, placenta and amniotic fluid (as in GWG) and 
reflects fat accrual instead. However, GWG is a more widely published exposure and 
was easier to classify according to the IOM guidelines (Institute of Medicine and 
National Research Council Committee to Reexamine IOM Pregnancy Weight 
Guidelines, 2009). It was also useful to include GWG in the previous gestational 





gain up until the reference point of examining GWG. This GWG may be due to 
increasing fat depots during pregnancy, mainly during the second trimester, as on 
average women gain between 2 and 5kg fat mass during pregnancy (Ehrenberg, 
Huston-Presley and Catalano, 2003). Whilst the gold standard assessment of body 
fat composition uses DEXA, this was not suitable during pregnancy as it uses ionising 
radiation. Alternative measures to assess fat mass include using water displacement, 
anthropometric measurement and bioelectrical impedance techniques. It is difficult 
to validate these as an assessment of fat mass in pregnancy however as they cannot 
be compared to DEXA. As such, maternal weight, and BMI instead of fat mass were 
examined for the purpose of this study.  
 
 
We have used birthweight and umbilical cord blood leptin (reflecting neonatal fat) 
as surrogate markers of intrauterine growth and development and as direct measures 
of offspring anthropometry at birth. Recent studies however have used whole-body 
air-displacement plethysmography (PEA POD, Life Measurement) (Lemas et al., 
2015) and MRI (Kaar et al., 2014) to quantify fat mass in infancy and childhood 
respectively. Whilst these were not readily available or universally suitable for 
infants they may be the focus of future research, providing a more accurate 
assessment of neonatal fat mass. In addition, glucose or insulin levels were not 
measured, unlike other studies (Lemas et al., 2015). Significant cord blood sample 
degradation of c-peptide (the preferred index of fetal glucose exposure) was evident 
with long-term storage and this phenomenon has also been reported by others 
(Gislefoss, Grimsrud and Mørkrid, 2009), as previously discussed in Chapter 2.   
 
 
In this current Chapter, BMI, but not GWG, was associated with a wider range of 
cardiometabolic risk factors at birth. Both BMI and GWG were however positively 
associated with offspring birthweight and cord blood leptin, reflecting greater 
offspring anthropometry at birth. With over half of overweight or obese mothers 
exceeding the recommendations, this work supports healthy weight gain initiatives 
aimed at obese mothers, whose offspring are at the greatest risk of adopting this 





maintaining a healthy pre-pregnancy BMI, as this was a more significant predictor of 
offspring cardio-metabolic profile at birth. By optimising weight gain during 
pregnancy, offspring may therefore adopt a lower risk of adiposity or cardio-
metabolic dysfunction at birth. In addition, changes in dietary and lifestyle patterns 
during pregnancy may benefit the family unit longer term so pregnancy may be 






Chapter 4: Diabetic disorders in pregnancy: association with cord bloods lipids, 




As discussed in Chapter 1, and examined in the previous Chapter (Chapter 3), the 
DOHaD paradigm suggests that exposure to an adverse intrauterine environment may 
lead to irreversible re-programming of fetal physiological systems (Barker, 2007). 
This abnormal intrauterine environment may be evident in maternal diabetes and 
obesity as insulin signalling pathways are disrupted due to chronic inflammation 
(Thakali et al., 2014). As this inflammatory environment adversely affects the 
maternal-fetal interface, maternal insulin-resistance (exacerbated by GWG), 
exhibits a causal programming effect in utero (Poston, 2010), leading to offspring 
with a greater propensity to cardio-metabolic dysfunction. In addition, fetal 
exposure to maternal diabetes increases the offspring’s risk of obesity also via 
intrauterine mechanisms, which is not solely accounted for by maternal pre-gravid 
BMI (Lawlor, Lichtenstein and Långström, 2011; Phillips et al., 2014). This 
association is not universal however as studies have shown that mild hyperglycaemia 
(falling short of the threshold for diagnosis of GDM), as well as those diagnosed with 
GDM, are not directly at increased risk of obesity in childhood (Pettitt et al., 2010; 
Thaware et al., 2015). The association between maternal glycaemia and offspring 
cardiovascular risk in early and later life however remains unclear. There was 
therefore the need for a detailed assessment of maternal diabetes, reflecting over 




GDM is one of the most common complications of pregnancy, defined as a 
carbohydrate intolerance identified in pregnancy (National Institute for Health and 
Care Excellence, 2015). Of the 5% of all pregnancies complicated by diabetes, 88% 
are recognised as GDM, 7.5% as Type 1 and 5%, and Type 2 (National Institute for 
Health and Care Excellence, 2015). Such pregnancies are deemed ‘high risk’ due to 





risk of miscarriage, GH, pre-term labour, caesarean section and worsening diabetic 
retinopathy throughout the gestational period (National Institute for Health and Care 
Excellence, 2015). The maternal risk extends beyond the pregnancy, however, as 
mothers face greater co-morbidity in later life such as obesity, type 2 diabetes, and 
cardiovascular disease (Catalano et al., 2003; Egan et al., 2014; Gante et al., 2015).  
 
 
Fetal risks during pregnancy include a greater risk of stillbirth, congenital 
malformations, large for gestational age, birth injury, and perinatal mortality. 
Evidence supports a direct causal role for exposure to maternal diabetes in utero in 
determining offspring's long-term greater adiposity and adverse cardio-metabolic 
health.  GDM, for example, is associated with over a four-fold greater risk of 
offspring macrosomia, with birthweight over 4kg (A. Lawlor et al., 2010). The HAPO 
study of over 23,000 pregnant women, as discussed in Chapter 1, found that the odds 
ratio for offspring birthweight greater than the 90th centile was 2.19 for non-obese 
women with GDM, 1.73 for obese women without GDM, and 3.62 for women with 
both obesity and GDM (Catalano et al., 2012). This suggested that whilst maternal 
diabetes and maternal obesity may impact independently on fetal growth, the risk 
of the conditions combined had an additive and compounding effect on the offspring.  
The pathophysiology of macrosomia may be explained by the modified Pedersen’s 
hypothesis in which exposure to maternal hyperglycaemia leads to fetal 
hyperinsulinemia and greater glucose utilisation resulting in greater fetal adipose 
tissue, as demonstrated in Figure 4.1 (Pedersen, 1952). Circulating glucose crosses 
the placenta but insulin does not and as a result, the fetal pancreas will secrete 
insulin in response to the hyperglycaemic environment. A combination of both fetal 
hyperinsulinemia and hyperglycaemia leads to anabolic accrual of greater fat and 



























The presence of maternal obesity in maternal diabetes is of concern. As discussed 
in Chapter 3, the risk of developing GDM is 3 times greater in maternal obesity 
(Tamimi et al., 2003). A retrospective study of 2773 women showed that 46% of 
those with pre-gestational diabetes (PGDM) and 18.3% of those with GDM 
demonstrated GWG above the 2009 IOM recommendations (Institute of Medicine and 
National Research Council Committee to Reexamine IOM Pregnancy Weight 
Guidelines, 2009; Egan and Dunne, 2018), as discussed in Chapter 3. Amongst those 
with excessive GWG, most women were either already overweight or obese  (Egan 
and Dunne, 2018). The risk of macrosomia, especially for those with PGDM, was also 
higher amongst diabetic mothers with excessive GWG (Yee et al., 2011; Harper et 
al., 2013; Parellada et al., 2014; Scifres et al., 2014; Siegel et al., 2015; Egan and 
Dunne, 2018). Excessive GWG, even amongst women with a normal BMI may still, 
however, impose a greater risk of LGA infants of mothers with Type 1 diabetes 
(Scifres et al., 2014), suggesting that fetal overnutrition and hyperglycaemia may 
act independently of maternal BMI.  
 
Maternal   Placental unit   Fetal 
↓Insulin release      Birth weight ↑ 
                          
 ↓Glucose utilisation     Lipid ↑ Glycogen ↑ 
                                Insulin ↑ 
 Hyperglycaemia      Hyperglycaemia 
    
  







Greater risk of caesarean section and poorer neonatal condition at birth have also 
been reported amongst those with excessive GWG in some (Yee et al., 2011; Harper 
et al., 2013) but not all studies (Siegel et al., 2015). Maternal outcomes at delivery 
however do not appear to be consistently adversely affected amongst mothers with 
excessive GWG and GDM (Harper et al., 2013). 
 
 
It is therefore becoming increasingly apparent that the insulin-resistant state in 
diabetes may be exaggerated by pregnancy weight gain, thereby worsening the 
obstetric and perinatal outcomes (Egan et al., 2014; Gante et al., 
2015). Intervention studies suggest these outcomes or offspring metabolic risk may 
be modified as dietary and lifestyle changes in diabetic pregnancies, and therefore 
limiting GWG may moderate the translation of obesity and cardio-metabolic 
programming onto the offspring (Retnakaran et al., 2013). A recent multicentre 
study of obese women with GDM reported that only a third of women achieved GWG 
within the recommendations (Gante et al., 2015), although this has been reported 
as low as 10.9% in women with PGDM (Siegel et al., 2015). Achieving appropriate 
GWG amongst this high-risk population will therefore be challenging. Gaining less 
than recommended amongst women with GDM is however not recommended as the 
benefits have yet to be established, as discussed previously, and the neonatal 
condition or the risk of caesarean section did not differ from those with GDM gaining 
within the recommendations on GWG (Harper et al., 2013). 
 
 
This risk of maternal hyperglycaemia and offspring adiposity may also extend into 
early childhood and there is a positive, albeit weak, correlation between maternal 
glucose levels at 28 weeks’ gestation and offspring obesity at aged 2 years, (Pettitt 
et al., 2010) although the association with offspring BMI or obesity was not 
independent of maternal BMI in the 5 to 7-year-old offspring (Thaware et al., 2015). 
This association has been described in recent systematic review and meta-analysis, 
where GDM is a risk factor for childhood offspring overweight or obesity that is not 
independent of maternal BMI, even though maternal BMI itself is a risk factor for 





Voerman et al., 2019). There is also the reported risk of greater offspring adiposity 
in later life. Maternal GDM has been associated with overweight and obesity in 9-11-
year-old offspring, as previously reported by ALPSAC, and in adolescence, although 
the effect of GDM on offspring overweight or obesity may only partially be explained 
by its effect on birthweight as there was evidence of maternal BMI attenuating this 
association (Gillman et al., 2003; A. Lawlor et al., 2010). The association between 
maternal glycosuria, demonstrated by at least 2 episodes of 2+ glucose in urine 
during pregnancy in the absence of PGDM or GDM, did however show greater odds of 
overweight or obesity in the adjusted analysis of 9-11-year-old offspring (A. Lawlor 
et al., 2010). In the ‘Growing Up Scotland Study’ of 4 and 6-year-old offspring, GDM 
was positively associated with childhood obesity, although the association 
attenuated to the null in the PGDM group (Abraham et al., 2015). This indicates that 
disruption to maternal and fetal glucose metabolism in pregnancy may therefore 
play a modest role in the development of offspring obesity and that its role in the 
causal pathway is not simply accounted for by maternal pre-pregnancy BMI alone.  
 
 
This metabolic risk not only applies to a greater risk of obesity in later-life, however. 
Diabetes in pregnancy poses a further risk of metabolic dysfunction in the offspring 
as demonstrated by human studies suggesting that maternal glycaemia exhibits a 
causal programming effect in utero and so may be used as a predictor of metabolic 
disorders as well in the offspring (Poston, 2010). The inflammatory and 
hyperglycaemic environment present in GDM may adversely affect the fetal-
placental unit and disrupt the adipo-insular axis in early and late gestation, thereby 
establishing an adverse trajectory of metabolic health in the offspring (Dubé, Ethier-
Chiasson and Lafond, 2013; Li, Chen and Li, 2013; Thakali et al., 2014), although the 
exact mechanisms involved are not clear. As previously discussed, epigenetic 
modification of fetal genes in utero is of concern and have been suggested as a 
mediator on the pathways from maternal pregnancy diabetes to long-term offspring 
outcomes, including  the transgenerational transmission of diabetic disorders in the 







The effect of GDM on offspring insulin resistance was demonstrated by a small study 
of Chinese pregnant women in which cord blood insulin, proinsulin, and homeostasis 
model assessment of insulin resistance (HOMA-IR) levels were significantly higher in 
the offspring of GDM mothers compared to a control group (Q. Wang et al., 2013). 
ALSPAC has also previously reported that both PGDM and GDM were positively 
associated with 15-year-old fasting glucose levels and that maternal glycosuria, not 
maternal diabetes, was positively associated with fasting insulin in the 15-year-old 
offspring (Patel et al., 2012).  
 
 
There have been inconsistent reports of disruption to the offspring’s lipid, however. 
As discussed in Chapter 3, obese pregnant women display a more atherogenic lipid 
profile compared to normal-weight women. Higher cholesterol, LDLc, and 
triglycerides, as well as lower HDLc, have been reported in obese pregnant women 
compared to normal-weight pregnant women who develop GDM (Bozkurt et al., 
2016). Overweight or obese women however display significantly different 
trajectories (slower) of lipids with advancing pregnancy compared to normal-weight 
mothers (Bozkurt et al., 2016). Amongst diabetic mothers, higher cord blood 
triglyceride and LDLc and lower HDLc have been reported (Dubé, Ethier-Chiasson 
and Lafond, 2013). In the UK Pregnancies Better Eating and Activity Trial (UPBEAT), 
a multicentre randomised controlled trial of a complex lifestyle intervention in 
obese pregnant women, there was marked dyslipidaemia (elevated lipids and 
lipoprotein constituents in VLDL subclasses) in mothers at least 10 weeks prior to 
the diagnosis of GDM (White et al., 2017). This is thought to be due to greater insulin 
resistance in adipose tissue and reduced suppression of lipolysis with advancing 
pregnancy (Catalano et al., 2002). There is less consistent evidence of GDM 
impacting the lipid profiles of the offspring, however. Whilst LDLc 
hypercholesterolaemia in the cord blood of mothers with GDM has been reported 
(Eslamian et al., 2013), ALSPAC has previously demonstrated that neither PGDM, 
GDM, or maternal glycosuria were associated with offspring lipids, or other 
metabolic markers such as CRP or blood pressure in 15-year-old offspring (Patel et 






In addition, there is also limited evidence of the effect of maternal diabetes on 
offspring adipokines. As previously discussed, adiponectin is an adipocyte-derived 
hormone that is inversely associated with circulating insulin and insulin resistance, 
BMI, lipids, and type 2 diabetes in non-pregnant women (Cnop et al., 2003; Yadav 
et al., 2013). Women who are more insulin resistant prior to pregnancy may also 
have a concomitantly low adiponectin level, due to hyperinsulinemia, and as they 
become progressively more insulin resistant in pregnancy have a greater tendency 
to developing GDM (Iliodromiti et al., 2016). Low levels of adiponectin prior to 
pregnancy may be used to predict the development in GDM in subsequent pregnancy 
and indeed there is growing evidence to support adiponectin testing in early 
pregnancy to detect those at high or low risk (Hedderson et al., 2013; Iliodromiti et 
al., 2016). In a healthy pregnancy, cord blood adiponectin levels correlate with 
maternal adiponectin levels (Ballesteros et al., 2011; Retnakaran et al., 2013). In 
GDM pregnancy, maternal adiponectin levels are lower than control groups, 
especially amongst obese women with GDM (Retnakaran et al., 2013; Iliodromiti et 
al., 2016). Maternal adiponectin in GDM pregnancy does not however correlate with 
offspring adiponectin levels at birth and there was no difference in adiponectin 
levels in 1-year-old offspring of mothers with GDM compared to offspring of healthy 
mothers (Ballesteros et al., 2011; Retnakaran et al., 2013). Collectively, the lack of 
consistent associations between maternal diabetes and a range of cardio-metabolic 
markers suggests that maternal diabetes may have a limited impact on the cardio-
metabolic health of the offspring. 
 
 
In contrast to maternal adiponectin, maternal leptin has been inconsistently 
associated with GDM. Whilst elevated leptin levels have been identified in those 
with GDM amongst (Kautzky-Willer et al., 2001; Chen et al., 2010; Fasshauer, Blüher 
and Stumvoll, 2014), this was not reproduced in the UPBEAT study, where leptin was 
not associated with GDM in the obese women and may reflect chronically elevated 







By examining associations between maternal diabetes (PGDM, GDM, and glycosuria) 
and offspring cord blood adipokines, lipids, and birthweight, the aim of this study 
was to identify whether fetal exposure to intrauterine hyperglycaemia, reflecting 
fetal overnutrition, poses a significant metabolic risk to the offspring at birth. 
Specifically, and as previously discussed, lower cord blood adiponectin in the 
offspring of diabetic mothers was anticipated, with limited or no effect on cord 
blood lipids of these offspring. By examining maternal weight in each of the diabetic 








4.2.1 Study Population  
 
 
There were 5011 participants with a paired cord blood sample. Multiple pregnancies 
and those without GWG or BMI recorded were excluded. Therefore, there were 3629 
mother-offspring pairs included in the study. Women were categorised into one of 
four mutually exclusive categories of no diabetes or glycosuria (hereafter referred 
to as ‘healthy’ women), PGDM, GDM, and glycosuria. Details of cord blood sample 
collection and analysis are presented in Chapter 2. 
 
 
4.2.2 Obstetric and Perinatal Data  
 
 
Data were abstracted from obstetric medical records and questionnaires by 
ALSPAC. Full details of the study have been previously published (Fraser, Macdonald 
wallis, et al., 2013) and are discussed in Chapter 2. Information on pre-pregnancy 
diabetic status was obtained from the patient questionnaire at the time of 
recruitment. A standard protocol was used by research midwives to obtain 
information on GDM and glycosuria (recorded as none, +, ++ and +++) for the index 
pregnancy from the participant’s antenatal and postnatal records. Glycosuria is a 
valid marker of maternal glycemia as it positively associates with birth size and 
macrosomia (A. Lawlor et al., 2010). All women were offered urine tests for 
glycosuria at each antenatal visit. Glycosuria in the current study was defined as a 
record of at least ++ (equal to 13.9mmol/l or 250mg/100ml) on at least two 
occasions at any time during the pregnancy in the absence of PGDM and GDM. 
Glycosuria below 250mg/100ml may occur in pregnancy as a result of normal 
physiological processes that lead to a greater glomerular filtration rate 
(Buhling et al., 2004) and therefore testing for GDM below this level was not 





and those with glucose greater or equal to 7.0 mmol/l or greater or equal to  9.0 
mmol/l respectively were diagnosed with GDM.  
 
 
At the time that this study was undertaken, screening for GDM was not universal and 
was selective to only those with established risk factors. These factors included 
established glycosuria in the index pregnancy, maternal obesity, family history of 
diabetes, personal history of GDM or macrosomic baby, and south Asian ethnicity. 
PGDM was defined as diabetes occurring prior to pregnancy and encompassed both 
‘type 1’ and ‘type2’ diabetes mellitus. Offspring of PGDM mothers are universally 
at risk of impaired glucose tolerance so defining the type of maternal diabetes was 






GWG was recorded, as detailed in Chapters 2 and 3. This enabled the variable 
absolute weight gain to be created (Fraser et al., 2010), which was then classified 
according to the IOM criteria (Institute of Medicine and National Research Council 
Committee to Reexamine IOM Pregnancy Weight Guidelines, 2009). ALSPAC has 
previously created a multilevel model (Fraser et al., 2010, 2011; Fraser, Macdonald 
wallis, et al., 2013) relating gestational age to maternal weight so that pre- 
pregnancy weight (0 weeks), early (0-18 weeks), mid (19-28 weeks), and late (>29 
weeks until delivery) pregnancy GWG could be examined. PPW was examined per 1 
kg additional maternal weight at conception and rate of GWG was examined per400g 
GWG per week (the recommended rate of weight gain in pregnancy for women with 
a normal BMI) (Institute of Medicine and National Research Council Committee to 









4.2.4 Statistical Analysis 
 
 
Cord blood cholesterol, triglyceride, HDLc and non-HDLc, leptin, adiponectin and 
birthweight were log-transformed to produce approximately normal distributions 
of residuals. Differences in the distribution of participant characteristics (maternal, 
obstetric and offspring co-variables) in relation to maternal diabetes or glycosuria 
status were also examined. These relations were tested using chi2 tests for 
categorical variables and one-way anova or ttests for continuous variables, as 
previously reported by ALSPAC (Fraser et al., 2010, 2011). These analyses tested for 
the null hypothesis of no difference between the four exposure groups so that there 
was no assumption of a linear trend across the exposure categories of healthy, 
PGDM, GDM, and glycosuria.  The examination of PPW in the PGDM group was limited 
due to the small sample size. The power calculation, to determine the minimal 
detectable effect size suggested that the numbers were too small although it was 




A series of multivariable regression models were formulated to examine the 
association of maternal diabetes or glycosuria with offspring outcomes and to 
examine the impact of adjusting for potential confounding and mediating 
characteristics on these associations. For each outcome, only participants with 
the complete data (complete case analysis) were included in each of the 
multivariable analysis models, and therefore the number of participants (N) varied 
between models. Associations did not differ for male and female offspring, and there 
was no statistical evidence of interaction with sex. Therefore, all results were 
presented with males and females combined. Maternal diabetic status was examined 
as a categorical variable in relation to cord blood measures and in the confounder 
adjusted model maternal age, social class, smoking, parity, and BMI were 
additionally adjusted for whereas potential mediation by birthweight, mode of 






Linear regression analysis was performed to examine pre-pregnancy weight (PPW, 
per 1kg) and GWG (per 1 kg) as a continuous variable in relation to cord blood 
adipokines, lipids, and birthweight. Again, potential offspring confounding or 
mediation by birthweight and gestational age were adjusted for. Where PPW was 
the exposure, maternal height replaced maternal BMI. Power calculation, to 
determine the minimal detectable effect size, and to minimise any errors in the 
effect size seen, suggested that the number of women with PGDM with PPW 
recorded, as well as all the co-variables included in the study, were too small. It 
was however possible to perform the analysis for GWG as there were fewer missing 
variables in this group, although the reproducibility of the effects demonstrated this 






4.2.5 Assessment of confounders and mediators 
 
 
As shown in Figure 4.2: DAG, baseline offspring confounders (sex, birthweight, and 
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Similar confounders and mediators were included as those discussed in Chapter 3 
since maternal diabetes, as well as maternal BMI and GWG, may reflect fetal 
overnutrition and be therefore considered in relation to offspring birthweight and 
cord blood adipokines and lipids. As an extension of the assessment of confounders 






Male offspring of GDM mothers have demonstrated lower birthweight and lower 
neonatal fat mass indicating greater responsiveness to treatment of diabetes in 
pregnancy (Bahado-Singh et al., 2012). Offspring sex was therefore additionally 
considered as a confounder as well as a mediator in the analysis as it may potentially 
influence not only the birthweight, but also cord blood leptin as a reflection of 




There is at least double the risk of offspring macrosomia in the presence of GDM, 
although this is even higher particularly in the presence of maternal obesity (A. 







Gestational age was adjusted for as women become more insulin resistant with 
advancing gestation as well as the fact that women with diabetes tend to be 





preterm delivery (Lepercq et al., 1998), and even in the presence of good glycaemic 
control and appropriate fetal growth, mothers with GDM will be advised to deliver 
by 40 weeks and not beyond this.  
  
 
Maternal Age  
 
 
Greater maternal age is associated with a greater risk of developing GDM (Kuo et 
al., 2017) which may display low adiponectin levels as a result, partly due to the 
progressive insulin resistance that occurs with advancing age but also due to physical 
inactivity displayed in older adults. In keeping with this, advancing age may also be 
associated with a more atherogenic baseline lipid profile which may influence the 






Whilst smoking does not appear to influence the risk of GDM, it is associated with 
lower GWG and lower offspring birthweight and it may also influence cord blood 
lipids at birth. The diagnosis of GDM in pregnancy, along with the lifestyle and 
dietary modifications offered, may however encourage women to stop smoking and 






The recurrence risk of GDM is greater with higher parity, partly because of greater 
baseline BMI but also because of advancing age, and therefore maternal parity was 






Occupational social class and education 
 
 
Lower socioeconomic class is a risk factor for developing Type 2 diabetes and may 
confer the same risk to women in pregnancy (NICE (National Institute for Health and 





High maternal BMI carries a greater risk of developing GDM. However, severity of 
GDM may also be moderated by optimising BMI during pregnancy (National Institute 
for Health and Care Excellence, 2015) and so it was important to account for this in 





Women from a minority ethnic background may be more predisposed to developing 
GDM than Caucasian women (National Institute for Health and Care Excellence, 
2015). This may be due to the greater visceral fat, particularly amongst the South 
East Asian community, and a greater propensity to cardiovascular disease at a lower 
BMI than the Caucasian population, as discussed in Chapter 2. Asian women may also 
have smaller birthweight babies, partly due to placental insufficiency. Ethnicity was 
therefore included as a confounder for the risk of developing GDM but also 
considered for the impact on birthweight and cord blood adipokines and lipids.  
 
 
Mode of delivery 
 
 
Women with GDM are more likely to require a caesarean section and so mode of 





glucose control in pregnancy warranting an emergency delivery (National Institute 





4.3 Results  
 
 
Figure 4.3 shows the inclusion and exclusion criteria of the ALSPAC participants 
included in the study.  
 
 







Core ALSPAC cohort 
14541 pregnancies 
14676 offspring 
4797 offspring with paired 
cord blood sample 
Exclusions 
13 triplet and 
quadruplet 
pregnancies 
9866 cord blood 
sample unavailable 
214 pregnancies re-
engaged in cohort follow 
up 
4271 with GWG recorded 
3629 with diabetic status, GWG and BMI 
recorded 
 
No diabetes/glycosuria: 3480 (95.9%) 
Existing diabetes: 11 (0.3%) 
Gestational diabetes: 18 (0.5%) 
Glycosuria: 120 (3.3%) 
 
Total 4947 singletons 
Exclusion 
64 twin pairs 
Exclusion 
676 without GWG 
recorded 
Exclusion 






Table 4.1 summarises the cohort characteristics, according to their diabetic status 
in pregnancy. Age, parity (most nulliparous), ethnicity, education, and social class 
were comparable across all groups. Amongst the healthy women, 22.9% smoked 
during pregnancy, in contrast to 9.1% of those with PGDM or 5.6% of those with GDM. 
More women who developed GDM however smoked before, but not during, pregnancy 
(22.2%), which was higher than any other group. Maternal BMI was highest among 
mothers with PGDM (25.8kg/m2) and lowest in the healthy (22.1kg/m2) and GDM 
groups (23.9kg/m2). GWG varied between groups with healthy mothers and those 
with glycosuria gaining the most (12.4kg) and mothers with GDM gaining the least 
(9.8kg). Most women gained either within or less than the recommendations on GWG 
although 33.3% of those with glycosuria exceeded these recommendations compared 




Table 4.1 also demonstrates that the offspring birthweight was lowest among those 
with PGDM (3.2kg), perhaps due to the earlier gestation at delivery (37 weeks), 
and highest among those with glycosuria (3.6kg), who were delivered at 40 weeks’ 
gestation. The offspring of mothers with GDM were of similar birthweight to 
offspring of the healthy mothers (3.5kg) and were delivered at 39 and 40 weeks, 
respectively. There were more male offspring amongst those with GDM (66.7%), 
and offspring sex was similar for males and females among all other groups. The 
caesarean section rate was much higher amongst women with diabetes with 18.2% 
of those with PGDM and 11.1% of those with GDM requiring a caesarean delivery, in 






Table 4.1: Summary of cohort characteristics according to diabetic groups 
  
 
 Healthy (n=3480)  PGDM (n=11)  GDM (n=18) Glycosuria (n=120)   
  N (%)  Median (IQR)  N (%)  Median (IQR)  N (%)  Median (IQR)  N (%)  Median (IQR)  P 
Maternal Characteristics  
Age  3480   28 (25, 31)  11   29 (24, 31)  18   28 (25, 35)  120   28 (25, 32)  0.345  
Smoking  






2381 (69.7)  
254 (7.4)  
  
781 (22.9)  
    
10 (90.9)  
0 (0.0)  
  
1 (9.1)  
    
13 (72.2)  
4 (22.2)  
  




82 (68.3)  
10 (8.3)  
  
28 (23.3)  
   
0.117 
BMI (kg/m2)  3480  22.1  
(20.5, 24.4)  
11  25.8  
(22.7, 29.4)  
18  23.9  
(21.5, 25.7)  
120  22.8  









1502 (44.9)  
1223 (36.5)  
455 (13.6)  
130 (3.9)  
37 (1.1)  
    
7 (63.6)  
4 (36.4)  
0 (0.0)  
0 (0.0)  
0 (0.0)  
    
8 (44.4)  
6 (33.3)  
1 (5.6)  
3 (16.7)  




55 (46.6)  
35 (29.7)  
20 (17.0)  
6 (5.1)  
2 (1.7)  
   
0.786  
Education    
Left school at 
16  
A level   
Degree  
  
2128 (63.6)  
785 (23.5)  
433 (12.9)  
    
4 (40.0)  
4 (40.0)  
2 (20.0)  
    
8 (50.0)  
6 (37.5)  
2 (12.5)  
    
75 (67.6)  
24 (21.6)  
12 (10.8)  
   
0.538  




IIIa   
  
143 (5.1)  
  
932 (33.0)  
1224 (43.4)  
    
1 (9.1)  
  
2 (18.2)  
5 (45.5)  
    
1 (8.3)  
  
3 (25.0)  
5 (41.7)  
    
9 (9.4)  
  
23 (24.0)  
45 (46.9)  






 Healthy (n=3480)  PGDM (n=11)  GDM (n=18) Glycosuria (n=120)   




217 (7.7)  
254 (9.0)  
52 (1.8)  
0 (0.0)  
2 (18.2)  
1 (9.1)  
1 (8.3)  
2 (16.7)  
0 (0.0)  
4 (4.2)  
11 (11.5)  




Black Caribbean  
Black African  






3274 (98.2)  
12 (0.4)  
4 (0.1)  
9 (0.3)  
11 (0.3)  
4 (0.1)  
7 (0.2)  
13 (0.4)  
    
11 (100.0)  
0 (0.0)  
0 (0.0)  
0 (0.0)  
0 (0.0)  
0 (0.0)  
0 (0.0)  
0 (0.0)  
    
16 (88.9)  
0 (0.0)  
0 (0.0)  
0 (0.0)  
0 (0.0)  
0 (0.0)  
0 (0.0)  
0 (0.0)  
    
110 (97.4)  
0 (0.0)  
0 (0.0)  
1 (0.9)  
1 (0.9)  
0 (0.0)  
0 (0.0)  
1 (0.9)  
  0.994  
Pregnancy characteristics 
GWG (kg)  
 
= Recommend  
< Recommend   
> Recommend  
3480  
  
1294 (37.2)  
1224 (35.2)  
962 (27.6)  
12.4  
(9.5, 15.4)  
11  
  
3 (27.3)  
5 (45.5)  
3 (27.3)  
10.6  
(6.2, 11.7)  
18  
  
6 (33.3)  
8 (44.4)  
4 (22.2)  
9.8  
(5.5, 14.5)  
120  
  
48 (40.0)  
32 (26.7)  
40 (33.3)  
12.4  












2705 (78.0)  
28 (0.8)  
305 (8.8)  
204 (5.9)  
190 (5.5)  
36 (1.0)  
    
 
4 (36.4)  
0 (0.0)  
5 (45.5)  
2 (18.2)  
0 (0.0)  
0 (0.0)  
    
 
8 (44.4)  
0 (0.0)  
8 (44.4)  
2 (11.1)  
0 (0.0)  
0 (0.0)  
    
 
91 (75.8)  
1 (0.8)  
15 (12.5)  
2 (1.7)  
7 (5.8)  
4 (3.3)  
  0.000  
Gestational age 
at birth (weeks)  











1767 (50.8)  
1713 (49.2)  
    
6 (54.6)  
5 (45.5)  
    
12 (66.7)  
6 (33.3)  
    
62 (51.7)  
58 (48.3)  
   
0.594  
Birthweight 
(kg)   
3448  3.5  
(3.2, 3.8)  
11  3.2  
(3.1, 7.8)  
18  3.5  
(3.2, 4.1)  
119  3.6  
(3.2, 4.0)  
0.000 
Cord blood 
leptin (pg/ml)   
3477  6.3  
(3.6, 11.8)  
11  8.3  
(5.4, 13.9)  
18  5.8  
(2.3, 11.6)  
120  7.9  





3477  76.6  
(54.4, 99.8)  
11  71.8  
(36.1, 105.6)  
18  63.8  
(37.5, 84.3)  
117  67.0  





3436  1.7  
(1.4, 2.0)  
10  2.2  
(1.6, 2.6)  
18  1.6  
(1.2, 1.9)  
118  1.6  





3422  0.5  
(0.4, 0.6)  
10  0.6  
(0.5, 0.6)  
18  0.4  
(0.3, 0.6)  
118  0.4  
(0.4, 0.6)  
0.000  
Cord blood 
HDLc (mmol/l)  
3365  0.5  
(0.4, 0.7)  
10  0.6  
(0.4, 0.8)  
18  0.6  
(0.3, 0.7)  
115  0.5  
(0.4, 0.6)  
0.142  
Cord blood non-
HDLc (mmol/l)  
3365  1.1  
(0.9, 1.4)  
10  1.4  
(1.1, 1.8)  
18  1.1  
(0.9, 1.2)  
115  1.1  
(0.9, 1.4)  
0.010  
 





GWG according to the IOM recommendations for each diabetic group is displayed in 
Figure 4.4.  
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The concentration of cord blood leptin was highest (8.3pg/ml) amongst women 
with PGDM and lowest among those with GDM (5.8pg/ml). In contrast, cord blood 
adiponectin from both PGDM and GDM groups had the lowest values (71.8µg/ml 
and 63.8µg/ml respectively). Cord blood cholesterol was highest among those with 
PGDM (2.2mmol/l), as was cord blood triglyceride (0.6mmol/l) and non-HDLc 
(1.4mmol/l). The concentration of cord blood analytes according to diabetic status 
is displayed in Figure 4.6. 
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Table 4.2 shows the multivariable associations between maternal diabetic status 
(compared to the healthy reference group) and cord blood adipokines, lipids, and 
birthweight. PGDM was associated with cord blood cholesterol (0.31, 95% CI 0.07, 
0.54, p=0.011), triglyceride (0.28, 95% CI 0.02, 0.54, p=0.036) and non-HDLc (0.34 
95% CI 0.10, 0.61, p=0.009) after adjusting for potential confounding and mediation. 
PGDM was also associated with lower birthweight although the confidence interval 
included the null and was mediated by gestational age. GDM was associated with 
lower cord blood adiponectin in the simplest model but this was attenuated to the 
null when maternal co-variables were considered. GDM was associated with higher 
offspring birthweight (0.10, 95% CI 0.03, 0.16, p= 0.004) in the fully adjusted 
analysis, but not with any other variable. Glycosuria was associated with lower cord 
blood cholesterol (-0.09, 95% CI -0.17, -0.00, p=0.040) and triglyceride (-0.11, 95% 
CI -0.208, -0.02, p=0.021) and higher offspring birthweight (0.03, 95% CI 0.00, 0.05, 





Table 4.2: Multivariable models for the association between maternal diabetes/glycosuria status and offspring cardio-






















Models 1: adjusted for offspring sex, 2: additionally adjusted for maternal age, social class, smoking, parity, and BMI, 3: 
additionally adjusted for birthweight, mode of delivery, and gestational age †Birthweight not included as a confounder in 
models 2+3 where birthweight is the outcome
    PGDM  GDM  Glycosuria  




Model 1  4258  0.09 (-0.40, 0.58) 0.716 0.22 (-0.16, 0.60) 0.262  0.26 (0.11, 0.41)  0.001   
Model 2  3097  -0.15 (-0.65, 0.35) 0.557 0.17 (-0.29, 0.64) 0.472  0.15 (-0.03, 0.33)  0.107   




Model 1  4218  -0.19 (-0.48, 0.10) 0.194 -0.26 (-0.49, -0.03) 0.027  -0.05 (-0.14, 0.04)  0.292   
Model 2  3069  -0.18 (-0.49, 0.12) 0.236 -0.18 (-0.47, 0.10) 0.206  -0.06 (-0.17, 0.05)  0.318   




Model 1  4203  0.25 (0.03, 0.05) 0.024 -0.02 (-0.19, 0.14) 0.789  -0.06 (-0.13, 0.00)  0.061   
Model 2  3057  0.29 (0.05, 0.52) 0.016 -0.03 (-0.24, 0.18) 0.767  -0.07 (-0.15, 0.01)  0.079   




Model 1  4188  0.13 (-0.13, 0.39) 0.324 -0.11 (-0.30, 0.09) 0.294  -0.08 (-0.15, 0.00)  0.049   
Model 2  3045  0.07 (-0.20, 0.35) 0.595 -0.01 (-0.25, 0.23) 0.945  -0.11 (-0.21, -0.02)  0.019   




Model 1  4124  0.23 (-0.04, 0.50) 0.088 0.03 (-0.18, 0.23) 0.780  -0.06 (-0.14, 0.03)  0.175   
Model 2  2993  0.28 (0.00, 0.56) 0.053 -0.11 (-0.36, 0.14) 0.399  0.08 (-0.174 0.03)  0.142   




Model 1  4124  0.27 (0.02, 0.51) 0.033 -0.06 (-0.24, 0.13) 0.535  -0.06 (-0.13, 0.02)  0.135   
Model 2  2993  0.29 (0.03, 0.55) 0.029 -0.01 (-0.25, 0.22) 0.906  -0.070 (-0.16, 0.02)  0.143   
Model 3  2955  0.34 (0.09, 0.61) 0.009 0.03 (-0.21, 0.26) 0.826  -0.08 (-0.17, 0.01)  0.096   
Birthweight † 
(g)  
Model 1  4221  -0.10 (-0.19, -0.02) 0.015 0.06 (0.00, 0.13) 0.059  0.04 (0.01, 0.06)  0.008   
Model 2  3072  -0.11 (-0.19, -0.03) 0.007 0.06 (-0.02, 0.14) 0.121  0.02 (-0.01, 0.05)  0.171   





Table 4.3 shows the multivariable association of PPW (per 1kg) and GWG (per 1kg) 
and cord blood adipokines, lipids, and birthweight. Assessment of PPW in the PGDM 
group and cord blood adipokines, lipids, and birthweight were limited due to the 
small sample size, where 7 to 8 out of the 11 women with PGDM had complete 
confounders available. For the remaining groups, there were complete confounder 
sets available for 2599 to 3167 out of 3480 in the healthy group, 15 out of 18 of 
those with GDM, and 88 to 110 out of 120 women with glycosuria. PPW was weakly 
positively associated with cord blood leptin (0.01, 95% CI 0.00, 0.01, p=0.000) in 
healthy women and weakly negatively associated with cord blood leptin in the 
glycosuria group (0.01, 95% CI 0.00, 0.02, p=0.016). PPW was also weakly 
negatively associated with cord blood HDLc (-0.01, 95% CI -0.02, 0.01, p=0.000) in 
the glycosuria group. PPW was not associated with cord blood adipokines, lipids, or 
birthweight across diabetic groups. 
 
 
GWG was weakly positively associated with cord blood leptin and triglyceride in the 
healthy groups (0.01, 95% CI 0.01, 0.02, p=0.00) but there was not any association 
identified between GWG and cord blood leptin, adiponectin, cholesterol, HDLc, or 
non-HDLc in any of the diabetic groups. GWG was however weakly positively 
associated with birthweight in the offspring of healthy mothers (0.01, 95% CI 0.01, 
0.01, p=0.000), and in those with GDM (0.01, 95% CI 0.00, 0.03, p=0.035) and 






Table 4.3: Association between pre-pregnancy weight (PPW) (per 1kg) and GWG (per 1kg) and cord blood measures and 
birthweight according to diabetic group   
 
     Model 1 Model 2 Model 3 




Healthy  PPW 3325 0.01 (0.01, 0.01) 0.000 3296 0.01 (0.00, 0.01) 0.000 3167 0.01 (0.00, 0.01) 0.000 
GWG 347 0.03 (0.02, 0.03) 0.000 3446 0.01 (0.00, 0.02) 0.007 3314 0.01 (0.01, 0.02) 0.000 
PGDM  PPW 8 0.01(-0.06, 0.08) 0.823 8 0.02 (-0.09, 0.12) 0.640    
GWG 11 0.07 (-0.10, 0.24) 0.364 11 0.06 (-0.15, 0.27) 0.533 11 0.02 (-0.95, 1.00) 0.925 
GDM  PPW 15 0.02 (-0.06, 0.10) 0.551 15 0.01 (-0.06, 0.08) 0.726 15 0.01 (-0.19, 0.21) 0.902 
GWG 18 0.09 (-0.01, 0.19) 0.062 18 0.01 (-0.10, 0.11) 0.877 18 -0.03 (-0.20, 0.40) 0.684 
Glycosuria PPW 113 0.02 (0.01, 0.03) 0.001 112 0.01 (0.00, 0.02) 0.026 110 0.01 (0.00, 0.02) 0.016 





Healthy  PPW 3295 0.00 (0.00, 0.00) 0.265 3265 0.00 (0.00, 0.00) 0.027 3137 0.00 (-0.01, 0.00) 0.072 
GWG 3447 0.00 (0.00, 0.01) 0.045 3415 0.00 (0.00, 0.00) 0.831 3284 -0.01 (-0.01, 0.00) 0.765 
PGDM  PPW 8 -0.02 (-0.09, 0.05) 0.570 8 -0.03 (-0.12, 0.06) 0.336    
GWG 11 0.01 (-0.10, 0.13) 0.789 11 0.01 (-0.15, 0.17) 0.858 11 0.06 (-0.71, 0.82) 0.786 
GDM  PPW 15 -0.01 (-0.05, 0.03) 0.699 15 -0.02 (-0.06, 0.02) 0.373 15 0.03 (-0.05, 0.10) 0.374 
GWG 18 0.04 (-0.01, 0.09) 0.094 18 0.03 (-0.01, 0.02) 0.589 18 0.06 (-0.03, 0.15) 0.145 
Glycosuria PPW 111 0.01 (-0.01, 0.00) 0.615 110 0.00 (-0.01, 0.01) 0.851 108 0.00 (-0.01, 0.01) 0.906 





Healthy  PPW 3284 0.00 (0.00, 0.00) 0.654 3254 0.00 (0.00, 0.00) 0.597 3125 0.00 (0.00, 0.00) 0.761 
GWG 3436 0.00 (0.00, 0.00) 0.427 3404 0.00 (0.00, 0.00) 0.388 3272 0.00 (0.00, 0.01) 0.378 
PGDM  PPW 7 0.00 (-0.13, 0.17) 0.925 7 0.06 (-0.59, 0.70) 0.743    
GWG 10 -0.06 (-0.17, 0.04) 0.198 10 -0.07 (-0.21, 0.08) 0.275 10 -0.14 (-1.28, 1.00) 0.353 
GDM  PPW 15 0.01 (-0.02, 0.03) 0.640 15 0.01 (-0.02, 0.04) 0.618 15 -0.02 (-0.07, -0.03) 0.260 
GWG 18 -0.02 (-0.05, 0.02) 0.381 18 -0.01 (-0.06, 0.04) 0.712 18 -0.01 (-0.07, 0.06) 0.856 
Glycosuria PPW 112 0.00 (-0.01, 0.00) 0.377 111 0.00 (-0.01, 0.00) 0.179 109 0.00 (-0.01, 0.00) 0.208 





Healthy  PPW 3271 0.00 (0.00, 0.00) 0.023 3241 0.00 (0.00, 0.00) 0.000 3112 0.00 (0.00, 0.01) 0.000 
GWG 3422 0.01 (0.00, 0.01) 0.001 3390 0.01 (0.00, 0.01) 0.000 3258 0.01 (0.00, 0.01) 0.001 
PGDM  PPW 7 -0.02 (-0.13, 0.08) 0.551 7 0.09 (-0.34, 0.52) 0.464    
GWG 10 -0.04 (-0.15, 0.06) 0.353 10 -0.04 (-0.17, 0.09) 0.435 10 -0.07 (-1.43, 1.29) 0.627 





     Model 1 Model 2 Model 3 
Outcome     N Coefficient (95% CI) p N Coefficient (95% CI) p N Coefficient (95% CI) p 
GWG 18 0.00 (-0.05, 0.05) 0.946 18 0.02 (-0.05, 0.08) 0.617 18 0.02 (-0.05, 0.09) 0.589 
Glycosuria PPW 112 0.01 (0.00, 0.01) 0.032 111 0.01 (0.00, 0.01) 0.002 109 0.01 (0.00, 0.01) 0.005 




Healthy  PPW 3213 0.00 (0.00, 0.00) 0.361 3183 0.00 (0.00, 0.00) 0.025 3056 0.00 (0.00, 0.00) 0.005 
GWG 3365 0.00 (-0.00, 0.00) 0.908 3333 0.00 (-0.01, 0.00) 0.382 3203 0.00 (-0.01, 0.00) 0.471 
PGDM  PPW 7 0.01 (-0.07, 0.08) 0.841 7 -0.02 (-0.39, 0.36) 0.872    
GWG 10 -0.05 (-0.11, 0.02) 0.124 10 -0.06 (-0.13, 0.01) 0.082 10 -0.12 (-0.28, 0.05) 0.072 
GDM  PPW 15 -0.01 (-0.04, 0.02) 0.660 15 -0.01 (-0.04, 0.03) 0.715 15 -0.03 (-0.12, 0.05) 0.390 
GWG 18 -0.01 (-0.05, 0.03) 0.611 18 -0.01 (-0.06, 0.05) 0.834 18 -0.02 (-0.11, 0.07) 0.660 
Glycosuria PPW 109 -0.01 (-0.02, -0.01) 0.000 108 -0.01 (-0.02, -0.01) 0.000 106 -0.01 (-0.02, 0.01) 0.000 




Healthy  PPW 3213 0.00 (0.00, 0.00) 0.342 3183 0.00 (0.00, 0.00) 0.095 3056 0.00 (0.00, 0.00) 0.119 
GWG 3365 0.00 (0.00, 0.01) 0.277 3333 0.00 (0.00, 0.01) 0.127 3164 0.00 (0.00, 0.01) 0.113 
PGDM  PPW 7 -0.01 (-0.15, 0.13) 0.901 7 0.08 (-0.63, 0.79) 0.664    
GWG 10 -0.07 (-0.19, 0.05) 0.229 10 -0.07 (-0.23, 0.10) 0.336 10 -0.15 (-1.57, 1.28) 0.414 
GDM  PPW 15 0.01 (-0.02, 0.04) 0.549 15 0.01 (-0.02, 0.04) 0.521 15 -0.02 (-0.09, -0.05) 0.490 
GWG 18 -0.01 (-0.05, 0.03) 0.490 18 -0.01 (-0.06, 0.05) 0.831 18 0.01 (-0.06, 0.07) 0.854 
Glycosuria PPW 109 0.00 -0.00, 0.01) 0.862 108 0.00 (0.00, 0.00) 0.974 106 0.00 (-0.01, 0.01) 0.956 
GWG 115 0.01 (0.00, 0.02) 0.177 114 0.01 (-0.01, 0.02) 0.456 112 0.00 (-0.01, 0.02) 0.621 
Birthweight † 
(g)  
Healthy  PPW 3297 0.00 (0.00, 0.00) 0.000 3297 0.00 (0.02, 0.00) 0.000 2599 0.00 (0.00, 0.00) 0.000 
GWG 3448 0.01 (0.01, 0.01) 0.000 3448 0.01 (0.01, 0.01) 0.000 3316 0.01 (0.01, 0.01) 0.000 
PGDM  PPW 8 0.01 (-0.01, 0.02) 0.416 8 0.01 (-0.01, 0.02) 0.420    
GWG 11 0.02 (-0.02, 0.06) 0.280 11 0.02 (-0.01, 0.04) 0.244 11 0.03 (-0.04, 0.09) 0.302 
GDM  PPW 15 0.00 (-0.01, 0.01) 0.299 15 0.00 (-0.01, 0.01) 0.493 15 0.00 (-0.01, 0.01) 0.284 
GWG 18 0.01 (0.00, 0.03) 0.040 18 0.01 (0.00, 0.02) 0.010 18 0.01 (0.00, 0.03) 0.035 
Glycosuria PPW 112 0.00 (0.00, 0.00) 0.002 112 0.00 (0.00, 0.00) 0.002 88 0.00 (0.00, 0.01) 0.017 
GWG 119 0.01 (0.00, 0.01) 0.002 119 0.01 (0.00, 0.01) 0.001 117 0.01 (0.00, 0.01) 0.000 
 
Models 1: adjusted for offspring sex, 2: additionally adjusted for offspring sex, birthweight and gestational age at birth, 3: 
additionally adjusted for maternal age, parity, smoking status and BMI (for GWG), and maternal height (for pre-pregnancy 





4.4 Discussion   
 
 
This Chapter examined the impact of fuel-mediated teratogenesis, as displayed in 
diabetic pregnancy, on mothers and their offspring in a mainly Caucasian population. 
Maternal, pregnancy, and offspring characteristics of each diabetic group (mothers 
with PGDM, GDM, and glycosuria) have been described, and the association between 
maternal PPW and GWG, previously described indiscriminately in Chapter 3, on cord 
blood leptin, adiponectin, lipids and birthweight have also been examined.  
 
 
Mothers with PGDM had higher pre-pregnancy BMI than any other group, were 
delivered earlier, and had the highest caesarean section rate. Offspring of mothers 
with PGDM had the lowest birthweight and displayed higher cord blood leptin, 
cholesterol, triglyceride, and non-HDLc and lower adiponectin than any other group, 
although the association was only significantly positive for cord blood cholesterol, 
triglyceride, and non-HDLc.  
 
 
Mothers with GDM had a lower BMI at booking, and many were smokers prior to but 
not during pregnancy. Overall, they had lower GWG and lower caesarean section 
rates than those with PGDM. GDM and GWG within this group were positively 
associated with offspring birthweight, even though birthweight was a similar normal 
weight to the offspring of healthy mothers. Mothers with GDM displayed the lowest 
levels of cord blood leptin and adiponectin compared to any other group, but this 




Amongst mothers with glycosuria during pregnancy, GWG and offspring birthweight 
were the highest, and yet the caesarean section rate was lowest. Glycosuria was 





PPW, in those that developed glycosuria, was weakly negatively associated with cord 
blood leptin and HDLc.  
 
 
Offspring birthweight in the GDM group was unexpected and of similar ‘normal’ value 
to the healthy group, and the group with the highest offspring birthweight was 
among those with glycosuria. This may partly be explained by lower pre-pregnancy 
BMI (which itself is independently associated with lower offspring birthweight) 
amongst those with GDM and greater intervention following the diagnosis of GDM 
such as dietician input, lifestyle modification, or pharmaceutical intervention 
(consequently limiting GWG, as demonstrated previously (Retnakaran et al., 2013)). 
Treatment of GDM has demonstrated a reduction in offspring birthweight and 
neonatal fat mass, even in the presence of mild hyperglycaemia (Landon et al., 
2009). GWG was lowest among women with GDM, which may have limited fetal 
growth, and fewer women with GDM gained weight excessively than any other group 
which is in contrast to previous reports (Gante et al., 2015). The lower birthweight 
among offspring of GDM mothers may also be explained by the fact that these 
offspring were delivered 1 week earlier than the ‘healthy’ or the glycosuria offspring 
(further limiting maternal opportunity for GWG and limiting fetal accruing of fat). 
As more women smoked prior to, but not during pregnancy, this may have instead 
led to higher GWG amongst this group of GDM mothers due to compensatory eating 
habits however this was not the case but may explain the lower pre-pregnancy BMI 
in this group.  
 
 
In contrast, those with glycosuria had a higher baseline BMI than those with GDM 
(already predisposing the offspring to higher birthweight), and as they were not 
‘diabetic’ they were not offered any intervention or diabetes management (and 
therefore were unlikely to have adjusted their dietary or lifestyle habits). This group 
gained more weight overall during pregnancy partly because of the longer duration 
of pregnancy and lack of lifestyle changes (and one-third of women exceeded the 
recommendations on GWG, more than any other group), so there was more 





glycosuria had offspring with higher birthweight. In addition, there were more male 
offspring amongst women with GDM than any other diabetic or non-diabetic 
category, and whilst this did not reach significance, may additionally explain the 
unexpectedly ‘normal’ birthweight in offspring of GDM mothers. Treatment of GDM 
in mothers carrying male offspring has been shown to yield lower offspring 
birthweight and lower neonatal fat mass that was only significant amongst male 
offspring (Bahado-Singh et al., 2012). This may be because GDM is characterised by 
increased oxidative stress, which in turn is also associated with lipogenesis (Sekiya 
et al., 2008), male offspring are more susceptible to the insults of oxidative stress 
and therefore may be more responsive to improved glycaemic control in pregnancy  
(Brandes and Mügge, 1997; Malorni et al., 2008; Bahado-Singh et al., 2012).  
 
 
The pathophysiology of GDM involves many complex maternal, fetal, and placental 
factors that are interrelated and lead to fetal insulin resistance.  Firstly, the fetal 
placental unit plays an important role in the development of GDM. With advancing 
gestation and the growing placenta, there is a greater release of the hormones 
oestrogen, progesterone, cortisol, and human placental lactogen (HPL) (which is ten 
times higher in pregnancy) into the maternal circulation (Ryan and Enns, 1988). HPL 
is an insulin antagonist in pregnancy and acts by increasing lipolysis and promoting 
free fatty acid transmission to the mother in order to preserve glucose and amino 
acid for the developing fetus (Buchanan and Xiang, 2005). With this, insulin 
resistance ensues from 20-24 weeks’ gestation. The fact that once delivery has 
occurred, the placental hormone production stops and GDM resolves in most cases, 
suggests that these placental hormones are responsible for the progressive insulin 
resistance in GDM pregnancy (Buchanan and Xiang, 2005).  
 
 
Secondly, adipose tissue also plays an additional important role in the development 
of GDM. As discussed in Chapter 1, adipose tissue produces adipokines, including 
leptin, adiponectin, and TNF-α, which have been implicated in developing insulin 
resistance in pregnancy (Briana and Malamitsi-Puchner, 2009). Maternal obesity or 





abundance of adipose tissue, thus predisposing women to the condition. High first-
trimester GWG, particularly amongst normal-weight women, has been strongly 
associated with the development of GDM in later pregnancy (Chu et al., 2007). The 
resulting offspring of diabetic mothers display a unique pattern of fetal overgrowth 
with the accrual of fat centrally leading to wider shoulders and increased abdominal 
circumference, hence the greater risk of birth injury.   
 
 
An early manifestation of offspring exposed to hyperglycaemia, as a result of 
maternal GDM, is macrosomia. Accelerated growth patterns may be detected in GDM 
pregnancy, and may even pre-date the diagnosis of the disease (Sovio, Murphy and 
Smith, 2016). There is at least double the risk of offspring macrosomia in the 
presence of GDM, although this is even higher particularly in the presence of 
maternal obesity (which itself is an independent risk factor for higher birthweight) 
(A. Lawlor et al., 2010; Catalano et al., 2012). Maternal obesity may itself be a 
stronger predictor of large for gestational age babies than hyperglycaemia, as 
demonstrated in Chapter 3, where BMI and GWG were positively associated with 
offspring birthweight. HAPO has previously reported that obesity alone doubles the 
risk of macrosomia in the presence or absence of GDM (Metzger et al., 2008). The 
limited number of women included in the current study with GDM, who were 
relatively lean,  may have only had a very mild manifestation of the disease and 
could also account for the lower birthweight amongst this group and lack of 
associations evident in this study. In addition, the prevalence of GDM may be 
inaccurate due to screening methods.  
 
 
A later manifestation of offspring exposed to GDM is demonstrated in a Pima Indian 
population in Arizona. Mothers, who either had Type 2 diabetes or GDM in pregnancy, 
had offspring that were LGA and heavier at 5 years of age compared to offspring of 
non-diabetic mothers (Pettitt et al., 2010) (Pettitt et al., 1993). In addition, the 
EPOCH study showed that exposure to GDM was associated with higher offspring BMI 
(and greater BMI growth trajectory), waist circumference, visceral and subcutaneous 





ALSPAC has previously reported higher offspring BMI and fat mass in the 9 to 11-year 
old (A. Lawlor et al., 2010) and 15-year old (Patel et al., 2012) offspring of mothers 
with diabetes or glycosuria (a marker of hyperglycaemia). Reporting similar strength 
of association at each age group suggested that intrauterine exposure to diabetes 
may induce long-lasting influence on adiposity on the offspring. The fact that an 
inverse relationship between GDM and birthweight has been identified suggests that 
GDM itself does not influence offspring anthropometry at birth and that perhaps the 
associations with adiposity become more apparent in later life. This is unexpected 
however as higher offspring birthweight is more prevalent in diabetic groups and 
may simply reflect the leaner cohort with limited GWG, as well as the impact of a 
diabetes treatment programme in pregnancy, thus lowering the offspring 
birthweight in this current cohort. The fact that there was a positive association 
between glycosuria and birthweight suggests that in untreated hyperglycaemia, 
which is under the threshold for diagnosis GDM, may still exhibit causal programming 
of the offspring in utero, particularly as birthweight was highest among this group. 
More recently, the Growing Up in Scotland (GUS) Birth Cohort has demonstrated 
greater risk of obesity at age 4 and 6 years amongst offspring of GDM mothers 
(Abraham et al., 2015), emphasising the impact GDM has on childhood offspring 
anthropometry. The association between maternal glucose and offspring adiposity 
however is not linear. HAPO has previously demonstrated that whilst maternal 
glucose positively correlated with offspring birthweight and cord blood c-peptide, 
they did not report any association between maternal glucose and offspring BMI z-
score at age 2 (Thaware et al., 2015). In addition, they did not identify any 
association between mild, untreated maternal hyperglycemia (falling short of the 
threshold for GDM) and offspring adiposity at age 5 to 7 (Pettitt et al., 2010).  
 
 
Maternal diabetes is associated with higher caesarean section delivery and this has 
been demonstrated in the current study, particularly amongst mothers with PGDM, 
even though they had a lower birth weight and earlier gestational at delivery than 
any other group. Anticipated large for gestational age infants detected at antenatal 
scan may promote this decision for caesarean delivery. Antenatal scanning, 





unnecessary earlier or surgical intervention, particularly amongst diabetic women 
(Hall, 1996). This may be either electively, in order to minimise the birth-related 
injury to the mother and baby of vaginal birth, or due to the unstable or 
malpresentation that can occur in fetal macrosomia and polyhydramnios, as 
displayed in uncontrolled diabetes. Similarly, an emergency caesarean section in the 
diabetic group may be higher due to failed induction of labour, perhaps due to 
iatrogenic preterm intervention (and PGDM group was delivered earlier than other 
groups) or failure to progress or poor descent in labour as a result of greater offspring 
birthweight.   
 
 
There is growing evidence demonstrating this transgenerational transmission of GDM 
and gene modification and epigenetic changes may account for this, although the 
exact mechanisms are unclear. The abnormal metabolic environment offspring are 
exposed to in utero impacts fetal development, by inducing changes in gene 
expression by epigenetic mechanisms of susceptible cells. This may lead to the 
development of diabetes in later life or GDM in a future pregnancy. This is a vicious 
cycle as the next generation of offspring are then exposed to this abnormal 
metabolic environment and adopt further epigenetic changes making them more 
prone to metabolic disease in later life. Decreased gene methylation may be 
responsible for these epigenetic modifications, and has previously been 
demonstrated in the placenta and cord blood of GDM pregnancy (El Hajj et al., 
2013). Epigenetic changes to adipokines have also been reported in GDM pregnancy. 
Specifically, lower placental adiponectin and leptin gene expression has been 
demonstrated in the presence of maternal insulin resistance (Bouchard et al., 2010, 
2012). The increased fetal need for insulin, in conjunction with exposure to 
hyperglycaemia in GDM pregnancy, maybe the trigger for these epigenetic changes 
in early pregnancy and lead to disruption in glucose and insulin regulation.    
 
  
There is limited evidence of cord blood lipids being examined in relation to maternal 
diabetic status. In addition, the influence of GDM on offspring lipids is difficult to 





of altered lipid transport and metabolism (Eslamian et al., 2013). Early lipogenesis 
followed by lipolysis with advancing gestation occurs in healthy pregnancy but there 
is more marked dyslipidaemia in obese pregnancy.  This is thought to result from 
enhanced insulin resistance in adipose tissue and reduced suppression of lipolysis in 
order to support fetal growth as well as meet the maternal energy demands for 
labour and the postpartum period (Catalano et al., 2002).  Recently, NMR has been 
employed to examine the maternal metabolome in pregnancy and from mid-
pregnancy, before the diagnosis of GDM, obese pregnant women display a markedly 
different metabolic profile to non-obese pregnant women (White et al., 2017). 
Placental lipoprotein lipase (LPL) DNA methylation dysregulation has been reported 
in GDM pregnancy and has been implicated in the translation of cardio-metabolic ill-
health onto the fetus (Houde et al., 2014). The impact of GDM on the lipid profile is 
not clear however and whilst aortic fatty streaks have been demonstrated in the 
fetal offspring of mothers with hypercholesterolaemia (Napoli et al., 1997), 
intervention studies suggest that offspring exposed to GDM were not at any greater 
cardiovascular risk (Retnakaran et al., 2013). Dube et al. examined maternal and 
cord blood lipids at birth in normal and overweight mothers with GDM (Dubé, Ethier-
Chiasson and Lafond, 2013). They found that normal-weight mothers with GDM had 
higher levels of triglycerides and lower levels of HDLc compared to overweight 
mothers with GDM, who had lower levels of cholesterol and LDLc. The offspring at 
birth however displayed higher free fatty acids with no other sign of disruption to 
their lipid profile (Dubé, Ethier-Chiasson and Lafond, 2013). Eslamian et al. did not 
show any association between GDM and cord blood cholesterol, HDLc, or 
triglycerides, although they did show lower LDLc in the cord blood of mothers with 
GDM (Eslamian et al., 2013). ALSPAC has also previously examined the association 
between maternal diabetes and adolescent offspring lipids but found no correlation, 
despite showing elevated insulin and glucose levels (Patel et al., 2012). This is 
reflected in the current study, whereby no association between GDM and cord blood 
lipids was identified, highlighting the limited impact GDM may have on the 







More variability amongst cord blood cholesterol and triglycerides were however 
demonstrated in the PGDM group. This may be because they had a more atherogenic 
lipid profile before pregnancy because of their pre-existing chronic disease or 
because maternal BMI was higher in this group and any GWG may have exaggerated 
the dyslipidaemia during pregnancy. In addition, this may also be because higher 
cord serum triglycerides are independently associated with small for gestational age 
babies (Hou et al., 2014), or babies born at an earlier gestation, as seen more 
frequently amongst the PGDM group. Conversely, the glycosuria group displayed a 
weak inverse association with cord blood cholesterol and triglyceride perhaps 
reflecting the limited cardio-metabolic dysfunction relayed in this group compared 
to those with PGDM which inherently pose a greater metabolic risk to the offspring.  
This highlights the role of greater pre-pregnancy maternal adiposity on a background 
of chronic metabolic disease, such as in PGDM, rather than any de novo condition 
such as GDM, in disrupting lipid metabolism and placenta transfer to the offspring. 
This is further supported by intervention studies, using glucose-lowering treatment 
and dietary changes in GDM pregnancies, which showed that the offspring 
cardiovascular risk at 1 year old is equivocal to offspring of mothers without GDM 
(Retnakaran et al., 2013). It remains unclear however whether this equivocal 
offspring cardio-metabolic risk to offspring risk from a healthy mother is due to 
moderation of maternal lifestyle or pharmacological input following a diagnosis of 
GDM, for example. It also questions whether the association between GDM and 
offspring cardio-metabolic dysfunction truly exists. Despite this, a positive 
relationship between maternal glucose and BMI z-score in infancy remains, 
indicating that intervention and appropriate management of GDM may not prevent 
adverse development of the cardio-metabolic profile entirely (Retnakaran et al., 
2013). In addition, even when maternal glycemia does not fulfil the criteria for GDM, 
certain studies have still identified an association between maternal hyperglycaemia 
and childhood offspring cardio-metabolic dysfunction (Ehrlich et al., 2012).   
 
 
Exposure to maternal hyperglycaemia in GDM pregnancy may also alter the control 
of adipokines, which are additionally subject to epigenetic modification (Retnakaran 





cord blood adipokines was demonstrated, even though cord blood leptin was higher 
in PGDM and lower in GDM and cord blood adiponectin was lower in both diabetic 
groups, suggesting that they are subject to confounding and mediation by co-
variables. Reports of maternal leptin in GDM have also been inconsistent, although 
most report an increase in pregnancy (Kautzky-Willer et al., 2001; Chen et al., 
2010). GDM is characterised by a pro-inflammatory environment and associated 
enhanced placental production of leptin has been reported in some studies (Lepercq 
et al., 1998; Lea et al., 2000). Leptin is insulin sensitising and regulates insulin 
secretion, the utilisation of glucose and glycogen synthesis as well as regulates the 
secretion of gonadotrophin-releasing hormone (GnRH) from the hypothalamus. High 
maternal plasma leptin at 13 weeks’ gestation has been associated with over four 
times increased risk of GDM with advancing pregnancy (Qiu et al., 2004). Similarly, 
leptin measured in amniotic fluid at 15-17 weeks has been directly associated with 
insulin and a greater risk of developing GDM (D’Anna et al., 2007). Other studies 
have reported a reduction (Festa et al., 1999) or equivocal (Simmons and Breier, 
2002) maternal leptin level in GDM pregnancy but differing severity of disease or 
ethnicity may have accounted for these findings. Overall it is likely that, since leptin 
increases in normal pregnancy, GDM pregnancy may aggravate this. As leptin itself 
is also pro-inflammatory, higher levels in GDM pregnancy have the potential to 
further enhance the inflammatory environment that the fetus is exposed to. In 
addition, as chronic insulin administration increases leptin secretion by adipocytes, 
(D’Anna et al., 2007), hyperinsulinemia in GDM pregnancy may further enhance 
leptin production, perpetuating the cycle. The fact that leptin levels were lowest 
amongst the GDM group suggests that temporary exposure to the condition may not 
have any lasting impact on the fetus, but it may also be accounted for if the severity 
of the condition or treatments offered were acknowledged. In contrast, cord blood 
leptin was highest among women with PGDM, suggesting that longer-term exposure 
to maternal hyperglycaemia may increase the production of leptin and deliver 
greater risk to the offspring. These findings were however subject to confounding 







In contrast, adiponectin is insulin sensitising and anti-inflammatory, decreasing 
hepatic glucose production and stimulating the uptake of glucose in skeletal muscle. 
The oxidative stress of normal pregnancy may be associated with the downregulation 
of adiponectin mRNA in the placenta and subsequent lower adiponectin levels with 
advancing gestation, and this may be even more apparent in diabetic pregnancy  
(Retnakaran et al., 2007; Fasshauer, Blüher and Stumvoll, 2014). As previously 
discussed, low adiponectin levels, from as early as the first trimester, may be used 
to predict GDM in later pregnancy (Lain et al., 2008; Iliodromiti et al., 2016). 
Offspring of GDM mothers also display lower adiponectin levels compared to 
offspring of non-diabetic mothers, even after adjustment for gestational age and 
birthweight (Lindsay et al., 2003; Cortelazzi et al., 2007). It is therefore clear that 
the low-grade inflammatory environment in pregnancy and GDM, as previously 
described, has a negative regulatory effect on adiponectin gene expression and as 
adiponectin is insulin sensitising, decreased levels may further aggravate insulin 
resistance. Furthermore, as insulin suppresses adiponectin production, this 
perpetuates this cycle of inflammation and poor metabolic environment that the 
offspring of a hyperinsulinaemic pregnancy is exposed to in utero (Fasshauer, Blüher 
and Stumvoll, 2014). Retnakaran et al. however found no clear association between 
GDM and offspring adiponectin in infancy. Despite this, they did demonstrate 
reduced adiponectin levels in diabetic mothers and that the correlation between 
adiponectin in mother-offspring pairs only existed in the non-diabetic group 
(Retnakaran et al., 2013). This loss of association in GDM mother-offspring pairs 
indicates that the offspring’s exposure to GDM may alter the protective role of 
adiponectin, culminating in greater cardiovascular risk in later life (Retnakaran et 
al., 2013). Whilst the study  did demonstrate that cord blood adiponectin levels were 
lowest amongst those with PGDM and GDM, they were subject to confounding and 
mediation, so the associations described may not be accounted for by the diabetic 
disorder alone.  
 
 
GWG and PPW were examined in relation to maternal diabetes and offspring cardio-
metabolic risk as women who develop GDM are more likely to be overweight or 





on weight gain, according to the IOM, as discussed previously in Chapter 3. These 
guidelines were first described for a general obstetric population and not for higher 
risk groups, such as those with diabetes in pregnancy and it is therefore difficult to 
advise diabetic women in pregnancy on appropriate GWG. Emerging evidence 
suggests that GWG less than 5kg should be recommended to women with GDM in 
order to optimise obstetric and neonatal outcomes (Gante et al., 2015). Although 
this is not current practice, nor was it at the time of the study, GWG was however 
lowest amongst mothers with GDM compared to any other group. The fact that there 
was no association identified between GWG across the entire gestational period and 
cord blood measures for any of the diabetic groups indicates that weight gain, when 
examined continuously in diabetic pregnancy, does not appear to adversely affect 
the cardio-metabolic profile at birth. GWG does appear to influence birthweight, 
however, although this association was only weakly positive in the GDM and 
glycosuria group. This adds further support to outcomes identified in Chapter 3, 
which showed that GWG positively influenced anthropometry at birth and that 
exaggerated fetal overnutrition, as demonstrated by GWG in GDM pregnancy, may 
moderate fetal growth. PPW was not associated with offspring adipokines, lipids, or 
birthweight in either of the diabetic groups but there was little variability in BMI 
amongst this lean population, with few numbers, and the weak positive association 
with cord blood leptin in the healthy group may be a chance finding. GWG (and 
weight gain in the first trimester) and maternal BMI  may therefore confer greater 
offspring risk in a general population, but have less bearing on the cord blood profile 
at birth amongst diabetic groups.  
 
 
As discussed in Chapter 3, the size of the cohort and the detailed measures of 
maternal, pregnancy, and social characteristics added to the strengths of the study. 
This was also one of the very few studies with detailed recordings of maternal 
diabetic status, GWG, and a paired with a cord blood sample. Multiple pregnancies 
were excluded as they are at greater risk of GDM and other obstetric complications, 
as well as pre-term delivery and lower offspring birthweight. Pre-pregnancy BMI was 
included as a confounder as it is inversely associated with GWG (Viswanathan et al., 





allowing adjustment for any potential confounding, as older mothers with higher 
parity (as well as higher BMI) are at greater risk of GDM whereas smoking may limit 
GWG. Women included in this study who gained weight excessively were younger, a 
finding previously reported by others (Egan et al., 2014; Gante et al., 2015), and it 
has been suggested that older women may be more informed and therefore more 
likely to comply with guidance on lifestyle in pregnancy (Gante et al., 2015). In 
addition, stopping smoking prior to or at the onset of pregnancy was more common 
in the GDM group. The timing of this may lead to excessive dietary intake in 
pregnancy and thus greater BMI at booking and greater, thereby increasing the 
overall incidence of GDM amongst these women. 
 
 
This study was however also subject to limitations. The incidence of GDM is 
increasingly prevalent in the current population, reflecting the global obesity 
pandemic. The ALSPAC cohort, however, displayed a much lower incidence of 
maternal diabetes (<1%) and obesity, compared to a contemporary cohort (5%) 
(National Institute for Health and Care Excellence, 2015). Participants were 
screened for GDM based on risk factors alone and the diagnostic criteria for GDM was 
different from current practice and therefore the prevalence of GDM in this cohort 
may under-represent the true prevalence of the condition. Contemporary screening 
practices are based on national guidelines and may have detected more women with 
GDM than in the current study as the threshold for diagnosis of GDM is lower 
(National Institute for Health and Care Excellence, 2015). Universal screening of 
pregnant women however would undoubtedly have detected a greater number of 
GDM mothers, as demonstrated by another cohort at a similar time (Koukkou et al., 
1995). Overall the numbers included in the study with GDM and glycosuria were 
small, but in keeping with previous ALSPAC reports on maternal diabetes and 
offspring metabolic risk (A. Lawlor et al., 2010; Patel et al., 2012). The numbers 
included in the study differed from Chapter 3 as only those with maternal diabetic 
status recorded were included whereas pre-term deliveries were not excluded which 
collectively may have contributed to the variability in the results in this chapter. In 
keeping with previous ALSPAC reports, participants with GDM also gained less weight 





Research Council Committee to Reexamine IOM Pregnancy Weight Guidelines, 2009), 
unlike other studies that frequently reported excessive GWG (Carreno et al., 2012). 
This may account for the lack of associations and it would be beneficial to repeat 
the study using a more contemporary cohort.  Self-reporting of maternal weight may 
have led to under-representation of BMI within the cohort although it has been highly 
correlated with weight at the first antenatal visit (Geelhoed et al., 2010). As 
previously discussed, the last minus the first weight measurement in pregnancy (kg) 
may be a more accurate reflection of weight gain in pregnancy (Lawlor et al., 2011) 
and would have avoided contributions from the fetus, placenta, and liquor. 
However, GWG was easier to classify according to IOM guidance (Institute of 
Medicine and National Research Council Committee to Reexamine IOM Pregnancy 
Weight Guidelines, 2009).  
 
 
This study included mainly a Caucasian population, and whilst it is not possible to 
translate findings across other ethnicities with a differing prevalence of maternal 
obesity and diabetes, it did not necessarily introduce additional bias. A greater 
prevalence of the disease however may have been identified by examining a more 
multi-ethnic population. Infants born prematurely (the earliest delivery being 34 
weeks) were not excluded, even though they have a greater risk of cardiovascular 
disease (Morrison et al., 2013). Gestational age however was adjusted for in the 
analyses and this enabled the number of participants in the study to be maximised. 
GWG is frequently associated with a greater risk of macrosomia and although the 
effect on birthweight as an outcome was examined, it may also have been 
worthwhile to examine the risk ratio for macrosomia, as we had done in Chapter 3.  
It was not possible to randomise women to gain a certain amount of weight so, like 
all studies of GWG, we were limited by observational data. Given the exclusion 
criteria and the number of confounders used in the analyses, selection bias may have 
been introduced but there is no reason to believe that the subjects excluded would 
be any different from the cohort used. Examination of PPW in the PGDM group was 
limited due to the small sample size. The power calculation, to determine the 
minimal detectable effect size and to minimise any error, suggested there were 





analysis for GWG as there were fewer missing variables in this analysis, repeating 
this study in a larger cohort of diabetic women may have yielded more reliable and 
reproducible associations. Whilst several maternal and offspring characteristics 
were adjusted for; this did not include physical activity or dietary intake (sodium) 
and there was missing data on maternal social class. This may have influenced the 
degree of GWG or the development of GDM and contributed to variability within the 
results. Similarly, the severity of diabetes or how well controlled it was during 
pregnancy were not accounted for. Popova et al. conducted a similar study of 
maternal diabetes in pregnancy on cord blood measures and birthweight but 
categorised subjects according to 1) tight control of diabetes, 2) less tight control 
of diabetes and 3) no diabetes (control) (Popova et al., 2018). This enabled 
interpretation of associations identified by the severity of disease which was not 
possible in the current study.   
 
 
As discussed previously, variation in the assays may also have occurred partly due to 
cord blood sample degradation although leptin and adiponectin do appear to be 
stable with long-term storage (Flower et al., 2000; Shih et al., 2000; Boyanton and 
Blick, 2002; Gislefoss, Grimsrud and Mørkrid, 2008; Paltiel et al., 2008). Whilst cord 
blood c-peptide reflects maternal insulin status (Dubé et al., 2012), it was not 
possible to quantify this measure due to sample degradation associated with long-
term storage, as previously reported (Gislefoss, Grimsrud and Mørkrid, 2009).   
 
 
This study highlights the complex associations between intrauterine exposure to 
maternal hyperglycaemia, maternal weight status (in particular, PPW weight and 
early pregnancy GWG), and offspring birthweight and cord blood cardio-metabolic 
profile. In conclusion, this study has demonstrated that GDM, as a marker of fetal 
overnutrition, exhibited a limited impact on the offspring’s cardio-metabolic health 
at birth. As GDM generally manifests during the third trimester, there is, therefore, 
a relatively short timeframe for disrupting lipids and adipokines and therefore the 
offspring of GDM may not adopt any greater cardiometabolic risk. In contrast, the 





dyslipidaemia, suggesting that PGDM may have a wider impact on the offspring’s 
metabolome at birth. The study did however demonstrate that GWG amongst GDM 
and glycosuria groups positively influenced offspring anthropometry, as measured 
by birthweight, even though this was not evident amongst those with PGDM. Despite 
this, mothers with GDM had offspring with birthweight that was still within a normal 
range and may reflect successful intervention in pregnancy to optimise glucose 
control. It may also reflect however the lean population within this cohort with low 
GWG which may limit the final birthweight. Finally, this study emphasises that whilst 
GDM may influence offspring birthweight, PGDM may impose a significantly more 





Chapter 5: Blood pressure in pregnancy: association with cord bloods lipids, 






As the effect of an abnormal intrauterine environment as a result of greater 
maternal adiposity (in Chapter 3) and diabetes in pregnancy (Chapter 4) has already 
been examined, this Chapter will focus on the impact of maternal blood pressure 
(BP) in creating an abnormal intrauterine environment and the impact this has on 
the offspring’s cardiometabolic profile at birth. Encompassing both both GH and PE, 
HDP may present long term metabolic risk to both the mother and offspring. 
Affecting 2-8% of women globally, HDP account for 8-10% of pre-term births and 5% 
of stillbirths (NICE, 2010). Whilst the rate of maternal death as a result of PE 
continues to fall within the UK (Knight et al., 2014), there is a stark contrast to the 
global burden of the disease (Duley, 2009; World Health Organization, 2018). 
 
 
PE is a condition of uncertain aetiology but is thought to be a result of abnormal 
placentation and abnormal immune response to the placenta leading to hypoxia, 
increased oxidative stress, and release of inflammatory mediators. It has 
multisystem effects on the liver, brain, and kidneys (Mustafa et al., 2012) and is 
characterised by a state of systemic inflammation, endothelial dysfunction, and 
insulin resistance (Sattar et al., 1997, 2003; Ness and Sibai, 2006; Catarino et al., 
2008). Abnormalities of the clotting cascade are well documented in women with PE 
(Brenner, 2002) and placental insufficiency may ensue as a result of thrombophilia-
induced micro and macrovascular thrombosis (Isermann et al., 2003). Abnormal lipid 
profiles are also characteristic of PE and result in increased oxidative stress. 
Regulators of lipid metabolism, lipoprotein lipase, and apolipoprotein E are 
produced by the placenta and have therefore been proposed in the origin of the 
disease as possible candidate genes (Kim et al., 2001; Descamps et al., 2005). Risk 





pregnancy, history of PE or pre-existing hypertensive disorder, diabetes and chronic 
kidney disease, autoimmune disease, antiphospholipid syndrome as described in 
Chapter 1. Epidemiological studies have also demonstrated a genetic link to PE. 
Numerous candidate genes have been proposed based on their underlying 
mechanisms relating to endothelial function, vasoactive proteins, thrombophilia, 
oxidative stress, lipid metabolism, and immunogenetics (Mütze et al., 2008). It is 
likely that the underlying cause for the disease may be due to complex interaction 
of predisposing environmental factors and numerous single nucleotide 
polymorphisms. Better understanding of these interactions and phenotypes is the 
focus of future research as this would enable targeted interventions in individuals 
at greater risk of the disease.  
 
 
Long-term maternal sequelae of PE culminate in greater cardiometabolic risk due to 
hypertension, hyperinsulinemia, elevated BMI, and dyslipidaemia (Fraser et al., 
2012). In particular, higher cholesterol, LDLc, and triglyceride, as well as lower 
HDLc, have been demonstrated in the maternal serum of those that developed PE 
(Khatua et al., 1989; V. A. Rodie et al., 2004; Ophir et al., 2006; Catarino et al., 
2008; Wan Sulaiman et al., 2016). As HDLc has anti-inflammatory, vasodilatory, and 
anti-oxidant properties, reduced levels of this, in particular, may contribute to the 
onset of vascular dysfunction and ultimately predispose the mother to greater risk 
of cardiac and cerebrovascular disease in later life (Bellamy et al., 2007; McDonald 
et al., 2008; Wan Sulaiman et al., 2016). 
 
 
The offspring of mothers with pre-eclampsia may also be at immediate and longer-
term risk. Perinatal outcomes are poorer in the offspring of those with PE (Friedman 
et al., 1995; Backes et al., 2011), which may be attributable in part to the lower 
associated birthweight, shorter gestational age, or preterm delivery and the 
associated placental dysfunction. Collectively these may give rise to inadequate 
organ development in utero (Levine et al., 2004). Offspring of mothers with GH 
disorders have also been shown to be at greater risk of overweight and obesity (Davis 





in contrast to maternal BMI itself which acts as an independent risk factor for 
offspring obesity (Patro Golab et al., 2018; Voerman et al., 2019) and cardio-
metabolic dysfunction at birth, as discussed in Chapter 3. These associations may be 
due to the elevated maternal leptin levels identified in maternal diabetes and PE 
(Miehle, Stepan and Fasshauer, 2012), but as discussed in Chapter 4 yield an inverse 
relationship with cord blood leptin in those with GDM. Elevated cord blood 
inflammatory markers and pronounced endothelial dysfunction present during PE 
(Catarino et al., 2008; Jayet et al., 2010) may also contribute to higher offspring BP 
throughout life (Tenhola et al., 2003, 2006; Ferreira, Peeters and Stehouwer, 2009; 
Geelhoed et al., 2010; Davis et al., 2012; Lawlor et al., 2012; Fraser, Nelson, et al., 
2013), greater aortic intima-media thickness (Akcakus et al., 2010) and greater risk 
of stroke (Kajantie et al., 2009).  
 
 
PE may also impact the offspring’s lipid profile. Altered placental lipid transport 
during pregnancy with PE may lead to dyslipidaemia and oxidative stress in the 
offspring (Romanowicz and Bańkowski, 2009), as higher triglyceride and LDLc, as 
well as lower HDLc levels, have been shown in the cord blood and neonatal offspring 
of mothers with pre-eclampsia. Disturbed lipid profile has also been reported in 5 to 
8-year old offspring of mothers with pre-eclampsia (V. A. Rodie et al., 2004; Ophir 
et al., 2006; Akcakus et al., 2010). Elevated total cholesterol levels have been 
identified in the offspring of mothers with pre-eclampsia, although there may be no 
effect on concentrations of LDLc, HDLc, and triglycerides (Kvehaugen et al., 2011). 
As HDLc has anti-inflammatory properties, lower levels of this in combination with 
higher LDLc, may contribute to the greater long-term metabolic risk in the offspring 
(Pecks et al., 2012) and greater need for closer follow up in later life (V. A. Rodie 
et al., 2004; Catarino et al., 2008). As PE may run in families due to genetic variants, 
this has potential to translate greater metabolic risk across generations. These 
findings however are inconsistent, with further studies including those from ALSPAC, 
showing no difference in lipids measured in the child or adolescent offspring of 
mothers with HDP (Tenhola et al., 2003; Lawlor et al., 2012; Fraser, Nelson, et al., 
2013). Indeed, previous reports have not shown an association between HDP and 





the impact of HDP on the offspring’s metabolic risk at birth (Kvehaugen et al., 2011; 
Lawlor et al., 2012). The rate of change in BP throughout pregnancy may also be 
significant, even if the BP does not reach the threshold for a diagnosis of HDP. Higher 
baseline systolic BP (SBP) and diastolic BP (DBP) in early pregnancy, as well as 
greater rate of change in both SBP and DBP between the second and third trimesters, 
have been associated with lower birthweight and a shorter gestational period and 
preterm birth (Bakker et al., 2011; Macdonald-Wallis et al., 2014).  
 
 
It is clear that PE and GH may induce adverse cardiovascular changes in the mother 
and changes seen in the offspring may also be evident from birth. By examining the 
associations between maternal BP in pregnancy and offspring birthweight, cord 
blood adipokines, and lipids, the aim of this study was to establish whether the 
altered intrauterine environment( as seen in HDP) adversely affects the offspring’s 
cardio-metabolic profile at birth. By examining the rate of change in BP across each 
gestational period according to HDP status, this study also aimed to identify specific 










5.2.1 Study Population  
 
 
There were 5011 participants with a paired cord blood sample. Multiple pregnancies 
and those with a diagnosis of hypertension prior to pregnancy. There were 4537 
mother-offspring pairs included in the study which were categorised into one of 
three mutually exclusive groups, according to BP status. 3810 women were classified 
as ‘healthy’ with no diagnosis of pre-existing hypertension, GH, or PE; 642 were 
classified as having GH and 85 were categorised as having PE. Details of cord blood 
sample collection and analysis are presented in Chapter 2. 
 
 
5.2.2 Obstetric and Perinatal Data  
 
 
Data were abstracted from obstetric medical records and questionnaires by ALSPAC 
as presented in Chapter 2: General Methods. Full details have been previously  
published by ALSPAC (Fraser, Macdonald-wallis, et al., 2013).  Using the definitions 
according to the International Society for the Study of Hypertension in Pregnancy 
(Davey and MacGillivray, 1988), participants were categorised by ALSPAC with pre- 
eclampsia or gestational hypertension. Pre-eclampsia was defined as hypertension  
(systolic BP 140mmHg or a diastolic blood pressure 90mmHg) measured on at least 2  
occasions after 20 weeks of gestation with accompanying proteinuria. Proteinuria  
was defined by ALSPAC as at least 1+ reading on dipstick tests (Albustix; Ames  
Company, Elkhart, IN) which equated to 30 mg/Dl (Davey and MacGillivray, 1988).  
GH was defined by ALSPAC as an equivalent measure of hypertension in the absence 
of proteinuria (Davey and MacGillivray, 1988).  
 
 





categories of no hypertensive disorder (healthy women), GH, or PE.  
 
 
Blood pressure was measured by ALSPAC in the supine position using an Omron M6 
monitor (Omron Healthcare UK Ltd, Milton Keynes, UK). A median number of 14 BP 
measurements were obtained (IQR 11-16) across the entire gestational period 
(MacDonald-Wallis et al., 2011).  
 
 
5.2.3 Statistical Analysis  
 
 
Cord blood cholesterol, triglyceride, HDLc and non-HDLc, leptin, adiponectin, and  
birthweight were log-transformed to produce approximately normal distributions of  
residuals. Differences in the distribution of participant characteristics (maternal,  
obstetric, and offspring co-variables) in relation to maternal hypertensive status  
were tested using chi2 tests for categorical variables and one-way anova or ttests for  
continuous variables, as shown in Table 5.1. These analyses tested for the null  
hypothesis of no difference between the three exposure groups so that there was no  
assumption of a linear trend across the exposure categories of healthy, GH, and PE.  
 
 
Fractional polynomial curves have previously been devised by ALPSAC to obtain 
average shape trajectories of SBP and DBP by gestational age (MacDonald-Wallis et 
al., 2011; Macdonald-Wallis et al., 2014). Changes in direction (slope) of linear 
splines were identified by ALSPAC in order to determine the approximate position 
of knots where SBP and DBP were examined as outcomes in relation to gestational 
age as the exposure. The baseline BP was set by ALSPAC at 8 weeks’ gestation as 
few participants had BP recorded prior to this. The best-fitting linear spline models 
had three knots at 18, 30, and 36 weeks and from 36 weeks until delivery 
(MacDonald-Wallis et al., 2011).  There were therefore 4 gestational periods where 
the rate of change in BP was assumed: from 8-18 weeks, 18-30 weeks, 30-36 weeks, 





adjust for potential confounders and mediators using complete case analysis. 
Associations did not differ for male and female offspring, and there was no statistical 
evidence of interaction with sex. Therefore, all results were presented with males 
and females combined. The relationship between baseline maternal SBP or DBP and 
the rate of change in maternal SBP or DBP according to each gestational period and 
cord blood measures according to HDP status were also examined. Maternal and 
offspring confounders were considered and adjusted for.  
 
 
5.2.4 Assessment of Confounders and Mediators 
 
 
In addition to the Assessment of Confounders in Chapters 3 and 4, potential 
confounding and mediating factors were considered when examining HDP in relation 




















6. Social class 




No hypertension: ‘healthy’ 
Gestational hypertension 
(GH) 


















Adjust for potential confounding 
using co-variables in 2 stages 1-7 
and 1-11. Adjustment for mediators 
including birthweight, gestational 
age, mode of delivery and BMI 
 
Systolic blood pressure 







10. Gestational age 








Adjustments were made for age, as PE is more prevalent amongst extremes of age 
and age can influence birthweight and maternal adipokines (including lower 
adiponectin), and dyslipidaemia may be more prevalent in older mothers. Smoking 
reduces the risk of PE but translates to greater cardiovascular risk so may influence 
cord blood measures and it may also limit the birthweight. PE is more common in 
nulliparous women and there is a trend for increasing birthweight with sequential 
pregnancies, so parity was also considered in the analysis (NICE, 2010).  
 
 
Greater maternal BMI is a risk factor for PE but may also lead to higher maternal  
leptin and cholesterol, lower adiponectin, and higher offspring birthweight so it was 
also important to account for BMI. In addition, BMI is independently associated with  
SBP and DBP throughout pregnancy (Farias et al., 2014). Similarly, the presence of 
PE may influence maternal BMI, partly due to lifestyle intervention once PE is 
diagnosed but also by limiting time for GWG due to earlier delivery and therefore 
limiting the BMI. Collectively this may influence the offspring’s birthweight or cord 
blood adipokines. Birthweight was considered a mediator when cord blood analytes 
were the outcome as PE influences birthweight which directly impacts cord blood 
adipokines, as previously discussed. HDP, especially in severe disease, may lead to 
shorter gestational age as a result of a medically indicated earlier delivery for 
example which may influence birthweight (lower) and cord blood adipokines (lower 
leptin as smaller, pre-term placenta may lead to less placental production of the 
adipokine).  In addition, severe HDP may warrant urgent caesarean section delivery 
which again may influence cord blood leptin concentration. Placental insufficiency 
of HDP may induce fetal growth restriction and resultant lower offspring birthweight 

























Core ALSPAC cohort 
14541 pregnancies 
14676 offspring 
4797 offspring with paired 
cord blood sample 
Exclusions 
13 triplet and 
quadruplet 
pregnancies 
9866 cord blood 
sample unavailable 
214 pregnancies re-
engaged in cohort follow 
up 
4676 singletons 
4537 with BP categorised 
Healthy: 3810 (84%) 
Gestational hypertension: 642 (14.2%) 
Pre-eclampsia: 85 (1.9%) 
  
Total 4947 singletons 
Exclusion 
64 twin pairs 
Exclusion 











Table 5.1 summarises the cohort characteristics according to BP status. There 
were 84% that remained ‘healthy’ and unaffected by GH or PE, 14.2% that 
developed GH, and 1.9% that developed PE.  
 
 
Women who developed PE during pregnancy were younger (median age 26 years) 
compared to the ‘healthy’ group (median age 28 years). They were also less likely 
to smoke during pregnancy (11.5%) compared to the ‘healthy’ group, where 25.4% 
smoked during pregnancy. Mothers who developed pre-eclampsia had a higher BMI 
at booking (23.5 kg/m2) compared to the healthy group (21.9 kg/m2). Most women 
who developed PE were nulliparous (73%), in contrast to the healthy group among 
whom 41.5% were nulliparous. Women who developed PE were less likely to achieve 
a spontaneous vaginal delivery (SVD), as 22.6% required caesarean section compared 
to only 7.8% of the healthy group. Women with PE were also delivered earlier 
(median 39 weeks) and had offspring with a lower birthweight (median 3.1kg) 
compared to the healthy group (40 weeks and 3.4kg respectively). Cord blood leptin 
and cholesterol were higher in mothers with pre-eclampsia (8.1 pg/ml and 1.8 
mmol/l respectively) compared to the healthy group (6.4 pg/ml and 1.6 mmol/l 
respectively). Whilst lower cord blood adiponectin was observed in HDP compared 
to the healthy group, this trend was not significant. 
 
 
Women who developed GH during pregnancy were also slightly younger (median age 
27 years) compared to the healthy group. Although most women with GH had never 
smoked (69.6%), 20.7% continued to smoke during pregnancy. Women that 
developed GH also had a higher BMI at booking (median 23.5 kg/m2) compared to 
the healthy group. Women with GH were more likely to achieve SVD (71.3%) than 
those with PE, although the rate of SVD was highest amongst the healthy group. 
Gestational age and birthweight were comparable amongst those with GH and the 
healthy group (median 40 weeks and 3.5kg respectively).  Higher cord blood leptin 
(7.1 pg/ml) and cholesterol (1.7mmol/l) were also observed in those with GH 





Table 5.1 also displays the blood pressures for each category of HDP. Both SBP and 
DBP were higher at booking in those who later developed PE (median SBP 
118.5mmHg, DBP 71.3mmHg) compared to the healthy group (SBP 111.0mmHg, 
DBP 65.3mmHg (p<0.001)). Although there was however a negative trend in SBP in 
between 8-18 weeks’ pregnancy, the BP rose beyond 18 weeks and both the SBP 
and DBP remained higher in those that developed PE compared to the healthy 
group. Between 30-36 weeks, there was also a steeper rise in the DBP in mothers 
with pre-eclampsia (1.03mmHg), compared to the healthy group. 
 
 
Both SBP and DBP were also higher at booking in those that later developed GH 
(median SBP 119.2mmHg, DBP 70.3mmHg), compared to the healthy group. A 
negative trend in BP was observed between 8-18 weeks in those who developed GH, 
followed by a rise in BP beyond 18 weeks, which remained greater than those in the 





Table 5.1: Summary of cohort characteristics according to BP status 
  
  Healthy (n=3810)  Gestational Hypertension 
(n=642)  
Pre-eclampsia (n=85)  P value 
 N (%)  Median (IQR)  N (%)  Median (IQR)  N (%)  Median (IQR)  
Maternal Characteristics  
Age  3810 (84.0)  28 (25, 31)  642 (14.2) 27 (24, 31)  85 (1.9) 26 (22, 29)  0.006  
Smoking  
Never   
Before, not during 
pregnancy   
During pregnancy  
  
2434 (67.3)  
264 (7.3)  
  
920 (25.4)  
    
430 (69.6)  
60 (9.7)  
  




58 (74.4)  
11 (14.1)  
  
9 (11.5)  
  0.001  








1472 (41.5)  
1320 (37.2)  
543 (15.3)  
159 (4.5)  
52 (1.5)  
    
331 (55.1)  
176 (29.3)  
62 (10.3)  
24 (4.0)  
8 (1.3)  
    
62 (73.0)  
13 (15.3)  
7 (8.2)  
1 (1.2)  
2 (2.4)  
  0.000  
Education    
Left school at 16  
A level   
Degree  
  
22663 (65.1)  
781 (22.5)  
432 (12.4)  
    
395 (67.0)  
125 (21.2)  




49 (65.3)  
20 (26.7)  
6 (8.0)  
  0.643  




IIIa   





144 (5.1)  
921 (32.7)  
1212 (43.0)  
212 (7.5)  
268 (9.5)  
64 (2.3)  
    
25 (5.1)  
138 (28.4)  
232 (47.7)  
35 (7.2)  
46 (9.5)  
10 (2.1)  
    
3 (4.8)  
22 (34.9)  
23 (36.5)  
7 (11.1)  
8 (12.7)  
0 (0.0)  





  Healthy (n=3810)  Gestational Hypertension 
(n=642)  
Pre-eclampsia (n=85)  P value 
 N (%)  Median (IQR)  N (%)  Median (IQR)  N (%)  Median (IQR)  
Ethnicity  
White Caucasian   
Black Caribbean  
Black African  






3374 (97.4)  
18 (0.5)  
4 (0.1)  
16 (0.5)  
16 (0.5)  
8 (0.2)  
9 (0.3)  
18 (0.5)  
    
583 (99.3)  
1 (0.2)  
0 (0.0)  
1 (0.2)  
0 (0.0)  
1 (0.2)  
0 (0.0)  
1 (0.2)  
    
73 (97.3)  
0 (0.0)  
0 (0.0)  
1 (1.3)  
1 (1.3)  
0 (0.0)  
0 (0.0)  
0 (0.0)  
  0.183  
SBP (mmHg) 
8 weeks  
8-18 weeks  
18-30 weeks  
30-36 weeks  








111.0 (107.2, 115.1)  
-0.17 (-0.30, -0.05)  
0.14 (0.01, 0.27)  
0.20 (-0.06, 0.46)  






 606   
  
119.2 (114.9, 123.6)  
-0.02 (0.18, 0.12)  
0.19 (0.03, 0.45)  
0.41 (0.05, 0.76)  








118.5 (113.9, 125.5)  
-0.08 (-0.22, 0.07)  
0.18 (-0.01, 0.33)  
0.71 (0.41, 1.09)  








8 weeks  
8-18 weeks  
18-30 weeks  
30-36 weeks  








65.3 (62.7, 68.1)  
-0.20 (-0.27, -0.13)  
0.08 (-0.01, 0.17)  
0.33 (0.10, 0.57)  








70.3 (67.1, 73.4)  
-0.17 (-0.25, -0.09)  
0.13 (0.02, 0.24)  
0.69 (0.35, 0.99)  








71.3 (68.4, 74.6)  
-0.20 (-0.26, -0.12)  
0.17 (0.08, 0.26)  
1.03 (0.69, 1.34)  







Pregnancy Characteristics  








3075 (81.0)  
30 (0.8)  
295 (7.8)  
173 (4.6)  
193 (5.1)  
31 (0.8)  
    
455 (71.3)  
6 (0.9)  
84 (13.2)  
47 (7.4)  
34 (5.3)  
12 (1.9)  
    
47 (56.0)  
0 (0.0)  
19 (22.6)  
10 (11.9)  
6 (7.1)  
2 (2.4)  





  Healthy (n=3810)  Gestational Hypertension 
(n=642)  
Pre-eclampsia (n=85)  P value 
 N (%)  Median (IQR)  N (%)  Median (IQR)  N (%)  Median (IQR)  
Offspring Characteristics               
Gestational age at 
birth (weeks)  





1937 (50.8)  
1873 (49.2)  
    
334 (52.0)  
308 (48.0)  
    
46 (54.1)  
39 (45.9)  
  0.729  
Birthweight (kg)   3774  3.4 (3.1, 3.8)  637  3.5 (3.2, 3.8)  83  3.1 (2.8, 3.6)  <0.001  
Cord blood leptin 
(pg/ml)   












3746  0.5 (0.4, 0.6)  631  0.5 (0.4, 0.7)  85  0.5 (0.4, 0.7)  0.000  
Cord blood HDLc 
(mmol/l)  
3688  0.5 (0.4, 0.7)  621  0.5 (0.4, 0.7)  85  0.5 (0.3, 0.7)  0.008  
Cord blood non-
HDLc (mmol/l)  
3688  1.1 (0.9, 1.4)  621  1.2 (0.9, 1.5)  85  1.2 (1.0, 1.5)  0.110  
  
Median (Interquartile range)  





Smoking according to HDP status is displayed in Figure 5.3.  
 





















SBP and DBP during each gestational period according to HDP status are displayed in 
Figure 5.4. 
 












8 weeks 8-18 weeks 18-30 weeks 30-36 weeks >36 weeks
BP mmHg
Gestational period





The concentration of each cord blood analyte according to HDP status is displayed 
in Figure 5.5. 
 

















Leptin (pg/ml) Adiponectin (µg/ml) Cholesterol (mmol/l)





Table 5.2 shows the multivariable models of the association between SBP and DBP 
(per 10mmHg rise at 8 weeks’ gestation and per 1mmHg rise per week between 8-
18 weeks, 18-30 weeks, 30-36 weeks, and >36 weeks’ pregnancy) and cord blood 
leptin, adiponectin, lipids, and birthweight according to HDP status. In the healthy 
group, every 10mmHg rise in SBP at 8 weeks’ gestation was negatively associated 
with cord blood HDLc (-0.04mmol/l (-0.07, 0.00), p=0.044). Following this, 1mmHg 
per week rise in DBP from 8 to 18 weeks and 1mmHg per week rise in SBP from 36 
weeks’ gestation was positively associated with cord blood leptin (0.28pg/ml (0.01, 
0.55), p=0.46 and 0.07pg/ml (0.01, 0.13) p=0.032 respectively). Between 30 and 36 
weeks, 1mmHg rise in DBP was positively associated with cord blood cholesterol 
(0.05mmol/l (0.00, 0.09), p=0.044). Also between 30 and 36 weeks, 1mmHg rise per 
week in SBP and DBP was negatively associated with birthweight (-0.02g (-0.03, 
0.00), p=0.014 and -0.05 (-0.08g, -0.01), p=0.010) in the healthy group. In those that 
developed PE, every 10mmHg rise in SBP at 8 weeks’ gestation was positively 
associated with cord blood HDLc (0.35mmol/l (0.02, 0.67), p=0.036), as was every 
1mmHg per week change in SBP between 30 and 36 weeks (0.51mmol/l (0.03, 0.98), 
p=0.038). In those that developed GH, between 30 and 36 weeks, 1mmHg rise in SBP 
and DBP was negatively associated with birthweight (-0.05g (-0.07, 0.02), p=0.000 
and -0.01 (-0.11, -0.05), p=0.001). These associations remained after adjustment for 
potential confounding, including maternal and offspring characteristics as well as 
accounting for potential mediation by offspring birthweight, gestational age, mode 
of delivery and BMI. There was minimal impact of mediators, such as gestational 





Table 5.2: Multivariable models for the association of SBP and DBP (per 10mmHg at 8 wks and per 1mmHg/wk change 




Healthy (n= 2200-2288)  Gestational Hypertension (n=368-381)  Pre-eclampsia (n=48)  
Model 1  Model 2  Model 1  Model 2  Model 1  Model 2  
β (95% CI)  p  β (95% CI)  p  β (95% CI)  p  β (95% CI)  p  β (95% CI)  p  β (95% CI)  p  














































































































Healthy (n= 2200-2288)  Gestational Hypertension (n=368-381)  Pre-eclampsia (n=48)  
Model 1  Model 2  Model 1  Model 2  Model 1  Model 2  





























































































































Healthy (n= 2200-2288)  Gestational Hypertension (n=368-381)  Pre-eclampsia (n=48)  
Model 1  Model 2  Model 1  Model 2  Model 1  Model 2  
β (95% CI)  p  β (95% CI)  p  β (95% CI)  p  β (95% CI)  p  β (95% CI)  p  β (95% CI)  p  




























































































































Healthy (n= 2200-2288)  Gestational Hypertension (n=368-381)  Pre-eclampsia (n=48)  
Model 1  Model 2  Model 1  Model 2  Model 1  Model 2  





























































































































Healthy (n= 2200-2288)  Gestational Hypertension (n=368-381)  Pre-eclampsia (n=48)  
Model 1  Model 2  Model 1  Model 2  Model 1  Model 2  
































































































































Healthy (n= 2200-2288)  Gestational Hypertension (n=368-381)  Pre-eclampsia (n=48)  
Model 1  Model 2  Model 1  Model 2  Model 1  Model 2  








































































































































Healthy (n= 2200-2288)  Gestational Hypertension (n=368-381)  Pre-eclampsia (n=48)  
Model 1  Model 2  Model 1  Model 2  Model 1  Model 2  
β (95% CI)  p  β (95% CI)  p  β (95% CI)  p  β (95% CI)  p  β (95% CI)  p  β (95% CI)  p  




























































































































Healthy (n= 2200-2288)  Gestational Hypertension (n=368-381)  Pre-eclampsia (n=48)  
Model 1  Model 2  Model 1  Model 2  Model 1  Model 2  
































































































































Healthy (n= 2200-2288)  Gestational Hypertension (n=368-381)  Pre-eclampsia (n=48)  
Model 1  Model 2  Model 1  Model 2  Model 1  Model 2  












































Confounder Model 1: adjusted for maternal age, social class, education, smoking status, parity, BMI, and BP in the previous 
period   









In this Chapter, the maternal and offspring characteristics of those that developed 
HDP have been described and the impact of exposure to HDP on cord blood 
adipokines, lipids, and offspring birthweight has been examined. Overall, those that 
developed PE were younger, nulliparous, less likely to smoke, and have a higher 
booking BMI. Greater maternal BP at booking, with a steeper rise in SBP and DBP 
from 18 weeks’ gestation, particularly in those with PE was also observed.  Women 
with HDP were less likely to deliver vaginally, with more women requiring caesarean 
section than those in the healthy group. Birthweight and gestational age at delivery 
was also lower in those with HDP. Higher cord blood leptin and cholesterol were 
observed in those with HDP, particularly those with PE. The change in BP during each 
gestational period was associated with the offspring’s metabolic profile at birth. In 
those that developed PE, a sequential increase in SBP at booking and during the 30 
to 36-week gestational period was positively associated with cord blood HDLc. DBP 
was also positively associated with cord blood cholesterol during the third trimester. 
Beyond 36 weeks’ gestation, however, SBP in the PE group was negatively associated 
with cord blood adiponectin. In those that developed GH, DBP during late pregnancy 
was negatively associated with cord blood leptin and birthweight.  
 
 
Maternal characteristics of those with HDP described in this Chapter reflect 
commonly identified risk factors displayed in National guidelines (NICE, 2010). 
Smoking is a well-documented protector of developing PE and reduces the overall 
risk of developing the condition (Conde-Agudelo et al., 1999), despite paradoxically 
increasing the risk of cardiovascular disease in later life (Mons et al., 2015). This has 
been demonstrated in the current study by the fact that there were more women 
who smoked during pregnancy amongst the healthy group. The fall in the number of 
smokers in recent years, including pregnant women, along with the rise in 
prevalence of PE and obesity amongst the contemporary population may also reflect 
this changing trend in smoking status. BMI is also a known modifiable risk factor for 





al., 2012) and this study has demonstrated higher BMI amongst mothers who 
developed HDP compared to the healthy group. First pregnancies are also at greater 
risk of PE and around 4% of nulliparous patients are affected (Hernández-Díaz, Toh 
and Cnattingius, 2009), which is in keeping with the findings of this study. Delivery 
by caesarean section was also more common amongst women with PE, as was lower 
birthweight and gestational age at birth. This may be iatrogenic due to worsening 
maternal disease warranting earlier surgical delivery or abnormal antenatal fetal 
monitoring requiring delivery in the fetal interest. Similarly, women who develop PE 
may also labour spontaneously earlier than reach the expected ‘due date’. NICE 
reports that 20-25% of preterm births and 14-19% of term births in women with PE 
are growth restricted (NICE, 2010), as a result of abnormal placental development 
in PE. Whilst the current study found that most women with HDP delivered around 
‘term’, it was not possible to account for the severity of the disease, nor was it 
possible to account for the condition of the offspring at birth or the health of the 
mother during this time which in current practice may have warranted earlier 
delivery. NICE have reported that 8-10% of all preterm births result from 
hypertensive disorders and half of the women with severe disease deliver preterm 
(NICE, 2010). These offspring are at greater future metabolic risk because 
prematurity itself has also been linked to lower levels of cord blood triglyceride 
(Kelishadi, Badiee and Adeli, 2007; Yonezawa et al., 2009), and lower birthweight 
and prematurity have also been independently linked to hypertensive and 
cardiovascular disease in the offspring (Martin et al., 2000). Lower birthweight 
amongst those with PE, but not with GH, was identified reflecting placental 
dysfunction associated with maternal toxaemia and the more wide-spread multi-
system effects of the disease.  
 
 
Maternal metabolic dysfunction may be detected during pregnancy affected by PE, 
as maternal serum has shown disruption to cholesterol, LDLc, HDLc, and 
triglyceride profiles, which may result in vascular dysfunction and confer greater 
cardiovascular risk (Khatua et al., 1989; V. A. Rodie et al., 2004; Ophir et al., 
2006; Catarino et al., 2008; Wan Sulaiman et al., 2016). Whilst the current study 





study, higher cord blood leptin in the offspring of mothers with HDP was 
identified. This suggest that neonatal leptin levels may mirror that of the mothers’ 
and implies in utero programming of the offspring during such pregnancies. 
Maternal blood pressure at booking and across each gestational period was also 
examined. In both GH and PE groups, it was identified that the blood pressure was 
higher at booking compared to the healthy reference group. This would indicate 
that those who developed HDP already had an underlying low-grade propensity to 
hypertension and potentially endothelial dysfunction prior to pregnancy itself. This 
is in keeping with previous reports from ALSPAC, as well as adding to evidence of 
greater long-term cardiovascular risk in mothers who developed PE during 
pregnancy (MacDonald-Wallis et al., 2011; Staley et al., 2015). It was also found 
that in those with GH and PE, the rate of increase in DBP was greater in the third 
trimester compared to the healthy reference group. This suggests that it is this 
late gestational period that is critical for monitoring the development of the 
disease. It is also in keeping with the fact that the onset of PE is most commonly 
beyond 28 weeks’ gestation, with few developing severe disease prior to this and 
less than 1% requiring delivery as a result of PE before 34 weeks (NICE, 2010).  
 
 
Whilst ALSPAC has previously demonstrated higher blood pressure in the offspring of 
mothers with HDP (Staley et al., 2015), the adverse impact of PE on endothelial 
function however has not been observed universally ( Lawlor et al., 2012), and there 
is conflicting evidence about the offspring’s cardiovascular risk, as measured by 
offspring adipokines, lipids, and birthweight. Elevated cord blood inflammatory 
markers and pronounced endothelial dysfunction in the offspring of mothers with 
pre-eclampsia have been reported by some (Jayet et al., 2010; Kvehaugen et al., 
2011), even contributing to a greater risk of stroke in the offspring (Kajantie et al., 
2009). Offspring of mothers with PE may also display marked dyslipidaemia and 
altered placental lipid transport resulting in increased oxidative stress (Romanowicz 
and Bańkowski, 2009). In some studies, higher cord and neonatal triglyceride and 
LDLc, as well as lower HDLc levels, have been reported in the offspring of mothers 
with pre-eclampsia (Ophir et al., 2006; Catarino et al., 2008; Akcakus et al., 2010). 





measured in the child or adolescent offspring of mothers with HDP (Tenhola et al., 
2003; Fraser et al., 2012; Fraser, Nelson, et al., 2013). In a small study by Tenhola 
et al., no difference in cholesterol, HDLc, or triglyceride was observed in the 12-
year old offspring of mothers with pre-eclampsia compared to a control group 
(Tenhola et al., 2003). In addition, there was no difference in the endothelial 
function of 5 to 8-year-old offspring of mothers with pre-eclampsia compared to a 
healthy cohort (Kvehaugen et al., 2011). Furthermore, in a previous study from 
ALSPAC, no difference in endothelial function, arterial stiffness, brachial distension, 
or diameter was identified, nor did they show any difference in serum lipids or 
inflammatory markers in the 9 to 12-year old offspring of mothers with HDP 
compared to a healthy cohort (Fraser et al., 2012). They did however show a positive 
association with offspring blood pressure (Fraser et al., 2012) as in the 17-year old 
offspring from ALPSAC, the SBP and DBP in the offspring of mothers with HDP were 
higher despite no adverse effect of HDP on offspring lipid levels being identified 
(Fraser, Nelson, et al., 2013).  
 
 
The association with offspring BP is inconsistent as The Northern Finland Birth 
Cohort, did not identify any association in blood pressure (or lipid concentration) in 
the 16-year old offspring of mothers with pre-eclampsia compared to a healthy group 
(Miettola et al., 2013). They did however find that offspring of those with GH had 
higher blood pressure (SBP and DBP) and cholesterol levels at age 16, suggesting that 
GH, rather than PE, led to a more unfavourable lipid profile. The Western Australia 
Pregnancy Cohort (Raine) reported on the clinical cardiovascular risk in 2868 
offspring of mothers with HDP. They found that PE and hypertension (leading to 
preterm birth) contributed to a 3-fold increased risk of hypertension at age 20 years 
(Davis et al., 2015). In the offspring of those with GH, the risk remained, albeit to a 
lesser degree, but these offspring were also at greater risk of overweight or obesity 
at age 20. They also observed that serum cholesterol, but not triglyceride or HDLc, 
levels were higher in 24-year old offspring born prematurely to mothers with PE 
(Lazdam et al., 2010). This positive association with serum cholesterol was mirrored 
in the aforementioned study by Kvehaughen et al which found serum cholesterol 





2011) compared to a healthy reference group. There was no significant association 
with offspring LDLc, HDLc, and triglyceride or inflammatory markers however 
between the groups. That higher cord blood leptin and cholesterol, but no difference 
in cord blood triglyceride or HDLc, in those with HDP was identified, suggests that 
HDP may exhibit some degree of cardio-metabolic programming in utero. Whist 
lower cord blood adiponectin levels in the offspring of HDP was identified, this trend 
was not significant, and although lower maternal adiponectin has been identified in 
PE pregnancy, the association was only evident amongst obese women (Thagaard et 
al., 2019), which was not prevalent in this current cohort. Elevated leptin levels 
have also been demonstrated amongst toxaemic mothers and a rise in the adipokine 
may even precede the onset of PE (Poston, 2002). This may be as a result of 
increased placental production of leptin with hypoxia and inflammatory mediating 
factors giving rise to this. With the greatest difference in cord blood leptin identified 
in those with PE compared to a healthy group, as well as the associated lower 
offspring birthweight and higher cord blood cholesterol levels, it further compounds 
the multi-system effects of PE compared to the manifestation of GH alone. As there 
is inconsistent evidence of the impact of maternal HDP on offspring BP, lipids, or 
adipokines in later life, the long-term implications of these disrupted cord blood 
profiles at birth however remain unclear.  
 
 
During this Chapter, maternal blood pressure throughout pregnancy in relation to 
offspring birthweight, and cord blood profiles was also examined. We observed 
amongst healthy and HDP groups a mid-pregnancy fall in BP followed by a progressive 
rise in BP and this pattern has been widely reported (MacDonald-Wallis et al., 2011; 
Grindheim et al., 2012; Farias et al., 2014). Changes in BP during pregnancy may 
not be specific to those diagnosed with PE however, as greater booking DBP and 
greater increases in SBP and DBP in the second and third trimesters, even if they did 
not reach the threshold for HDP, have been associated with shorter gestational age, 
preterm birth and lower birthweight (Steer et al., 2004; Bakker et al., 2011; 
Macdonald-Wallis et al., 2014). In this study, SBP at booking and changes in SBP in 
the third trimester were positively associated with cord blood HDLc in those that 





SBP during late pregnancy was negatively associated with cord blood adiponectin 
amongst those with PE. The association with higher cholesterol and lower 
adiponectin highlights the translation of metabolic dysfunction onto the offspring, 
particularly as lower adiponectin confers greater cardiovascular risk and reflects 
greater insulin resistance, as discussed in previous Chapters 3 and 4. In those with 
GH, DBP in the third trimester was negatively associated with cord blood leptin and 
birthweight. Collectively, this indicates that changes in blood pressure, particularly 
during the third trimester, may have the greatest impact on the cord blood profile 
at birth. Insulin resistance may be involved in the pathogenesis of PE (S. et al., 2013) 
and this may have added to the robustness of the data should it have been available. 
SBP and DBP have both been positively associated with cord blood leptin amongst 
those with PE (Rehman, Ahmad and Ullah, 2015), indicating that leptin may play a 
central role in the pathogenesis of PE. This may be secondary to sympathetic 
stimulation (Correia et al., 2001), the influence on the renin-angiotensin-angiogenic 
system (Adamczak, Kokot and Wiecek, 2000), or as a result of pro-inflammatory 
cytokine production (Loffreda et al., 1998). 
 
 
The long duration of follow-up and wide range of maternal and offspring variables 
and mediators added to the strength of the analyses within this Study. The standard 
international definition of PE and HDP as described by NICE (NICE, 2010) was adhered 
to and even though this updated guideline was not available at the time of the 
original recruitment and data collection phase of the study, the thresholds for 
diagnosis of each condition was the same. Previous publications and analyses by 
ALSPAC enabled maternal blood pressure in relation to cord blood analytes to be 
examined across different gestational periods (MacDonald-Wallis et al., 2011; 
Debbie Anne Lawlor et al., 2012; Fraser, Nelson, et al., 2013; Macdonald-Wallis et 
al., 2014; Staley et al., 2015).  
 
 
Limitations of the study may also be acknowledged. The diagnosis of ‘proteinuria’ 
was made by research midwives using urine dipsticks which may have led to some 





diagnosis of proteinuria is by urinary polymerase chain reaction (PCR) which was not 
available at the time of this study. The numbers of those included in the study with 
PE were limited (n=85) by the prevalence of disease at the time and by complete 
case analyses. Numbers included may be higher if repeated in a more contemporary 
cohort with a greater prevalence of risk factors for the condition (higher maternal 
age, obesity, etc). There may also have been some variability in blood pressure 
measurements. This was standardised however to some degree using Omron 
monitors rather than the traditional sphygmomanometers. PE perhaps wasn’t as well 
recognised a condition at the time of this study but the BP was measured at timely 
intervals during each pregnancy (mean 14 times) which suggests that even in the 
asymptomatic patient, PE or GH should have been detected if they had developed 
it (MacDonald-Wallis et al., 2011). PE has traditionally been diagnosed by using a 
combination of high blood pressure and proteinuria which together would warrant 
tertiary referral for further investigation (Milne et al., 2005). Other tertiary methods 
have been proposed or trialled in order to ‘diagnose’ the disease. For example, 
metabolomics and proteomics (Kenny et al., 2010; Navaratnam et al., 2013; 
Buhimschi et al., 2014), detection of angiogenic factors (Andraweera, Dekker and 
Roberts, 2012), and the measurement of radiographic features such as uterine artery 
pulsatility index (O’Gorman et al., 2016) have all been proposed but are fairly novel 
and specialised assessments and so were not available for this study.    
 
 
Medication, such as antihypertensive treatment or anti-convulsant therapy that the 
participant may have been receiving as a result of their HDP, were not accounted 
for. Whilst there is little evidence to suggest that these would have directly 
influenced the cord blood, well-controlled BP at the time of delivery (as a result of 
antihypertensive treatment) may have led to some variability in the cord blood 
measures. Similarly, it was not possible to account for women taking daily low-dose 
aspirin, as recommended by the NICE guidelines (NICE, 2010) as discussed in Chapter 
1, as these were not available at the time. Again, this may have also contributed to 
some variability since aspirin has been shown to reduce the risk of developing PE 
(Askie et al., 2007). This study cohort included a mainly Caucasian population. 





greater risk of CVD (Caughey et al., 2005). Should this population have been included 
in the study, more associations with the cord blood profile at birth may have been 
evident. It was not possible to account for the severity of the disease or exclude 
those who had extreme pathology. PE, for example, may have led to convulsions and 
a state of ‘eclampsia’ or HELLP syndrome (haemolysis, elevated liver enzymes, low 
platelets), which again may have led to some variability in the cord blood analytes. 
Early-onset, severe pre-eclampsia typically occurs before 28 weeks’ gestation. 
Lazdam et al. have previously demonstrated greater cardiometabolic risk in the 
offspring of those with severe, early-onset PE (Lazdam et al., 2010, 2012) and so it 
may therefore have been useful to examine the cohort according to the onset of 
disease to determine whether this affected the offspring’s cardiovascular risk. In 
addition, only live births were included in the study so that there was a viable paired 
cord blood sample. As PE accounts for 5% of all stillbirths in the absence of 
congenital abnormalities (NICE, 2010), such cases may not have been included in the 
study but given the small numbers, would not have been likely to influence the 
results.  
 
In conclusion, this study has demonstrated that women who developed HDP were 
younger, non-smokers, had a higher BMI, and were more likely nulliparous compared 
to those that did not develop HDP. These risk factors are in keeping with those 
displayed in national guidance (NICE, 2010). Blood pressure was higher at booking in 
those that developed HDP, with the DBP rising more sharply in the third trimester. 
PE was associated with lower birthweight and lower gestational age at birth, both 
of which are independent risk factors for future metabolic dysfunction. In those that 
developed HDP, higher cord blood leptin and cholesterol were also demonstrated. 
Changes in BP during the third trimester (>30 weeks) were more consistently 
associated with the offspring’s metabolic cord blood profile at birth, highlighting 
the importance of optimising BP control in later pregnancy. This study demonstrated 
that in the presence of HDP, the biochemical imprint at birth (as measured by cord 
blood adipokines, lipids, and birthweight) may be modified. As reported previously 
by others, including findings from ALSPAC, the long-term clinical consequences of 
these associations or the impact of HDP on the offspring longer-term remain unclear. 





an altered cardiometabolic profile at birth the trajectory of cord blood analytes was 
examined by tracking repeated measures of the same analyte through childhood and 





Chapter 6: Programming of offspring cardiometabolic risk: tracking analytes 





As previously described, fetal life is a critical period and has potential for the 
development of adult chronic disease, with epidemiological studies demonstrating 
associations between birthweight and neonatal adiposity and metabolic disorders in 
child and adulthood (Pietiläinen et al., 2001; Fraser et al., 2008; Anderson et al., 
2014). An abnormal intrauterine environment, via greater maternal adiposity, 
diabetes, or PE, as discussed in the previous Chapters, may adversely affect the 
offspring’s birthweight and cardio-metabolic profile at birth. There is growing 
evidence to suggest that not only are these cardio-metabolic profiles established at 
birth but that the trajectory of these cord blood measures is also determined in 
utero and that these pathways govern the metabolic health risk across the life course 
(Varvarigou, Mantzoros and Beratis, 1999; Hauguel-de Mouzon, Lepercq and 
Catalano, 2006; Gluckman and Hanson, 2007; Taylor and Poston, 2007).  
  
 
Serum lipoproteins have been shown to track through life, as demonstrated by a 12-
year follow-up programme in the Young Finns study (Porkka et al., 1994). They 
demonstrated significant tracking of repeated measures of cholesterol, LDLc, HDLc, 
and triglycerides, and this trend was evident even more in males. This study 
suggested that by measuring serum lipoproteins in childhood there may be potential 
in identifying familial lipoprotein disorders and stratifying future cardiovascular risk. 
Cord blood biomarkers have however yet to be established for predictive purposes, 
partly due to the lack of longitudinal studies examining these associations.  Although 
triglycerides have been inversely associated with fat mass (Ortega-Senovilla et al., 
2013), lipids have been positively correlated with cardiovascular disease occurring 





therefore act as surrogate markers of future cardiovascular risk, particularly as 
childhood obesity does not predict adult serum lipid levels (Porkka et al., 1994).   
  
 
LFTs have also displayed evidence of tracking of repeat analytes in adulthood (Patel 
et al., 2007). In the Bogalusa heart study, serum samples obtained from adults aged 
18 to 32 years showed that gamma-glutamyl transferase (GGT) and alanine 
transferase (ALT) biomarkers positively associated with repeated measures of the 
same analyte 12 years later. They also showed that high concentrations of these 
analytes were positively associated with markers of metabolic syndrome, including 
the risk of obesity, dyslipidaemia, type 2 diabetes, and hypertension (Patel et al., 
2007; Nguyen et al., 2011). It has also been suggested that GGT may also be used to 
positively predict the onset of diabetes and metabolic syndrome 7 years later 
(Nannipieri et al., 2005). In addition, ALT measured in the West of Scotland Coronary 
Prevention Study of men demonstrated that ALT may also positively predict T2DM 
over a 5-year follow-up in men (Sattar et al., 2004).   
  
 
There is limited evidence that adipokines, such as leptin, show evidence of tracking 
and it remains unclear if any such association begins in utero and persists throughout 
life. As previously discussed, leptin is a recognised biomarker of fat mass and 
ponderal index in the neonatal period (Hauguel-de Mouzon, Lepercq and Catalano, 
2006; Karakosta et al., 2011, 2013). In childhood, however, cord blood leptin 
inversely correlates with BMI but remains positively associated with leptin levels at 
age 3 (Mantzoros et al., 2009). This finding is not uniform however as others have 
failed to identify an association between cord blood leptin and leptin in childhood 
(Volberg, Heggeseth, et al., 2013). Associations in childhood have been more 
consistent as leptin measured on two separate studies at ages 2, 5, and 9 and at age 
9 to 10 demonstrated positive association with repeat measures at least 3 years 
later, with associations strengthening with advancing age. This suggested that the 
variable may be genetically determined and that leptin did display evidence of 
tracking (Nishimura et al., 2009; Volberg, Heggeseth, et al., 2013). Adiponectin has 





2009; Volberg, Heggeseth, et al., 2013) and has been reported as being both 
unrelated to (Lindsay et al., 2003)  and positively associated with birth weight and 
neonatal fat mass (Tsai et al., 2004; Inoue et al., 2008; Mantzoros et al., 2009). In 
one study, cord blood adiponectin however was not associated with BMI or 
adiponectin levels at 3 years of age (Mantzoros et al., 2009). In contrast, another 
study showed that neonatal adiponectin correlated with adiponectin levels at age 2, 
5, and 9 (Volberg, Heggeseth, et al., 2013). Again, the association with the repeated 
‘like for like’ measure of the analyte strengthened with time. This has also been 
further demonstrated, with adiponectin at age 9 to 10 remaining positively 
associated with adiponectin measures 3 years later (Nishimura et al., 2009).  
  
 
The lack of longitudinal studies to date has limited the potential use of cord blood 
measures as biomarkers of long-term metabolic health. Several reviews and studies 
have highlighted the need to examine the relationship between key analytes from 
birth until later life and to determine the clinical consequences of these (Varvarigou, 
Mantzoros and Beratis, 1999; Stamler et al., 2000; Hauguel-de Mouzon, Lepercq and 
Catalano, 2006; Gluckman and Hanson, 2007; Taylor and Poston, 2007). In this 
Chapter, the extent to which cord blood analytes track from birth (cord blood) into 
childhood and adolescence was examined. Specifically, given the associations 
described in later life, it was anticipated that there was tracking of repeated 







6.2 Methods  
  
 
6.2.1 Study Population  
  
There were 5011 mother-offspring pairs included with a cord blood sample available. 
Details of obstetric and perinatal abstraction of data from patient case-notes and 
questionnaires completed are presented in Chapter 2.  Details of cord blood sample 
collection and analysis are also presented in Chapter 2.  
 
 
6.2.2 Assessment of outcomes  
  
Identical protocols were used by ALSPAC at all follow-up clinics. Non-fasting blood 
was obtained by ALSPAC at the 7- and 9-year-old clinic. Fasting blood samples were 
obtained at the 15- and 17-year-old clinic. The samples were immediately spun and 
frozen at -80°C after the preparation of the sample. All the samples were assayed 
on behalf of ALSPAC at the University of Glasgow within 12 months of obtaining the 
sample and on the first thaw cycle. Cord blood lipid measures (cholesterol, 
triglyceride, HDLc, and consequently non-HDLc) were available at all four-time 
points whereas CRP was only available at age 9, 15, and 17. Leptin and adiponectin 
were available at age 9 and LFTs (GGT, ALT, AST) were available at age 9 and 17.  
  
 
6.2.3 Statistical Analyses (provided by Dr. Smith) 
  
 
As described in more detail in Chapter 2, SEMs were created for this study. Linear 
associations between analytes were assessed with a SEMs framework. Analytes 
measured in non-fasting participants at ages 7 and 9 were represented by a single 
latent variable, scaled to the measurement at age 9. Analytes measured at ages 15 
and 17 in fasting participants were represented by a single latent variable, scaled 





and age 9, and age 9 and age 17, regression coefficients were also calculated 
between cord blood and age 17. In doing so, adjustments were made for the possible 
mediating effect at age 9 to produce estimates of the direct effect of cord blood on 
age 17, and the indirect effect via the associations with age 9. As there was no 
evidence of sex interaction, results are presented combined for males and females.   
  
 
The first model adjusted for offspring sex. The second model adjusted for potential 
confounders of the association between cord blood and later measures (offspring 
birthweight and gestational age at birth and maternal age, education, occupational 
social class, parity, pre-pregnancy BMI, and smoking status prior to and during 
pregnancy). The association between age 9 and later measures was also adjusted 
using a latent variable representing BMI z-scores at age 7 and 9, scaled to age 9. 
Estimation of regression coefficients was by maximum likelihood, using all available 
measures rather than complete case analysis.   
  
 
As the SEM assumed that all variables were normally distributed, those that were 
skewed (CRP and leptin) were log-transformed. Some values were below the lower 
limit of detection (LLD) for GGT, ALT, and AST in the cord blood and at age 9. These 
were replaced with zero; the effect of this in the cord blood was investigated by 
repeating the analyses with these values fixed at the lower limit of detection, and 
age 9 by comparing complete case analyses with and without considering the 
measurement at age 9 to be a truncated variable. There were many values below 








6.3 Results  
 
Figure 6.1 summarises the number of participants included and excluded within 
the study. There were 4937 (range 4859-5008) cord blood samples available but by 
age 9 there were 1690 (range 1690-1703) samples available and by age 17 there 































Core ALSPAC cohort 
14541 pregnancies 
14676 offspring 
4797 offspring with paired 
cord blood sample 
Exclusions 
13 triplet and 
quadruplet 
pregnancies 
9866 cord blood 
sample unavailable 
214 pregnancies re-
engaged in cohort follow 
up 
5011 mother-offspring pairs with 
cord blood sample 
Total 4947 singletons 
Exclusion 
9866 cord blood 
sample unavailable  
Offspring age 7/9 years 
1690 cord blood samples 
available with repeat analyte 
measures (range 1690-1703) 
 
Offspring age 15/17 years 
1062 cord blood samples 
available with repeat analyte 





Table 6.1 summarizes the characteristics of the 5011 participants with a cord 
blood sample. Certain analytes were not assayed or sampled in all age groups. 
Leptin and adiponectin were not assayed at age 7, 15 or 17 and ALT, AST, and GGT 
were not assayed at age 7 or 15 either. Table 6.1 also displays the number and 
percentage (%) missing sample of each analyte in each age group compared to the 
cord blood sample availability.  
 
 
Table 6.1: Characteristics of mother-offspring pairs with cord blood samples 
 
 
 N obs (%) Median Interquartile Range (IQR) 
Maternal characteristics     
Age (years)  4797    28  6 
Social class  




















    
Education  
Age 16 qualification  
Post 16 qualification  


























    
BMI (kg/m2)  4034    22.2 3.9  










    
Analyte 
Triglyceride (mmol/l)  
Cord blood  
7 years (non-fasting)  
9 years (non-fasting) 
Number of missing 
samples at age 7-9 years 
15 years (fasting)  











































 N obs (%) Median Interquartile Range (IQR) 
Number of missing 
samples at age 15-17 
years 
2724 55.2 
Cholesterol (mmol/l)  
Cord blood  
7 years (non-fasting)  
9 years (non-fasting)  
Number of missing 
samples at age 7-9 years 
15 years (fasting)  
17 years (fasting)  
Number of missing 






































HDLc (mmol/l)  
Cord blood  
7 years (non-fasting)  
9 years (non-fasting)  
Number of missing 
samples at age 7-9 years 
15 years (fasting)  
17 years (fasting)  
Number of missing 






































Non-HDLc (mmol/l)  
Cord blood  
7 years (non-fasting)  
9 years (non-fasting)  
Number of missing 
samples at age 7-9 years 
15 years (fasting)  
17 years (fasting)  
Number of missing 






































GGT (u/l)  
Cord blood  
9 years  
Number of missing 
samples at age 9 years17 
years  
Number of missing 





























ALT (u/l)  
Cord blood  
  














1st quartile: LLD,  






 N obs (%) Median Interquartile Range (IQR) 
Number of missing 
samples at age 9 years 
17 years  
Number of missing 

















AST (u/l)  
Cord blood  
9 years  
Number of missing 
samples at age 9 years 
17 years  
Number of missing 





























CRP (mg/l)  
Cord blood  
9 years  
Number of missing 
samples at age 9 years 
15 years  
17 years  
Number of missing 


































Adiponectin (μg/ml)  
Cord blood  
9 years  
Number of missing 
samples at age 9 years 
Number of missing 





















Leptin (pg/ml)  
Cord blood  
9 years  
Number of missing 
samples at age 9 years 
Number of missing 


































Figure 6.2 Median number of samples available for each age range (cord blood 








The median concentration of each analyte in cord blood and 9-year-old offspring is displayed in Figure 6.3. Notably, the analyte 
ALT rose with repeat measures at advancing age (ALT in cord blood: 1.3 u/l, ALT at age 17: 14.8 u/l) whereas adiponectin, 
leptin GGT, and AST’s levels all fell with repeat measures at each advancing age.  
 





























1-Triglyceride (mmol/l) 2-Cholesterol (mmol/l) 3-HDL (mmol/l)
4-Non-HDL (mmol/l) 5-Leptin (pg/ml) 6-GGT (u/l)





To determine whether cord blood analytes correlated with repeat measures at age 
9 and 17, were examined, and potential confounders were accounted for (Table 
6.2, i and ii respectively, provided by Dr. Smith). Cord blood cholesterol, HDLc, 
non-HDLc, GGT, and adiponectin showed weak to moderate positive correlation 
with repeat measures of the same analytes at age 9 years (regression coefficients 
varied between 0.00 (GGT) and 0.19 (HDLc)). 
 
 
Table 6.2 also shows the associations between analytes measured at age 9 and then 
repeated at age 17 (iii).  There were strong associations between triglyceride, 
cholesterol, HDLc, non-HDLc, GGT, ALT, AST, and CRP at age 9 and repeat analytes 
at age 17, with regression coefficients between 0.24 (GGT) and 0.88 (cholesterol).    
 
 
The association between cord blood and repeat measures at age 17, accounting for 
the relations between analyte measures in cord blood and age 9 and between age 9 
and 17 (i.e. the indirect association), are presented in Table 6.2 (iv). Cord blood 
cholesterol, HDLc, and non-HDLc were indirectly associated with repeat analytes at 
age 17 with regression coefficients varying from 0.03 (cholesterol) and 0.15 (HDLc).   
 
 
To examine the total effect of associations between cord blood and like-for-like 
analytes at age 17, intermediate associations between cord blood and age 17 
analytes were adjusted for (Table 6.2, v). In doing so, the associations between 
analytes in cord blood and at age 9 and 17, and between age 9 and 17 were 
accounted for. There was a weak cumulative effect of the association between cord 
blood HDLc, non-HDLc, and GGT and repeat measures at age 17 years with regression 





Table 6.2: Associations between analyte measurements in cord blood and later blood samples    (provided by Dr. Smith) 
 
   Direct effect (i) Direct effect (ii) Direct effect (iii) Indirect effect (iv) Total effect (v) 
   Association between cord  
blood and age 9 
Association between 
cord blood and age 17 
Association between 
age 9 and age 17 
Association between 
cord blood and age 17 
Association between 
cord blood and age 17 
Analyte  Model β (95% CI) p β (95% CI) p β (95% CI) p β (95% CI) p β (95% CI) p 
Triglyceride  
(mmol/l)       
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HDLc   
(mmol/l)      
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GGT   
(u/l)           
                   












































ALT (u/l)   
  






























































































   Direct effect (i) Direct effect (ii) Direct effect (iii) Indirect effect (iv) Total effect (v) 
   Association between cord  
blood and age 9 
Association between 
cord blood and age 17 
Association between 
age 9 and age 17 
Association between 
cord blood and age 17 
Association between 
cord blood and age 17 
Log CRP 
(mg/l)          
  


























































       
     
Log Leptin 
(pg/ml)     












                 
  
Model 1: Associations with cord blood adjusted for sex  
Model 2: Associations with cord blood adjusted for sex, birthweight, gestational age at birth, and maternal age, parity, 
occupational social class, highest educational attainment, pre-pregnancy BMI, and smoking status before and during pregnancy. 





Cord blood GGT was also weakly positively associated with GGT at age 17 (regression 
coefficient 0.02), as shown in the simplest model in Figure 6.4.  
 
 
Figure 6.4: Associations between GGT in cord blood, at age 9 and age 17 using 
model 1 (provided by Dr. Smith) 
 
 









0.02 (0.01 – 0.03) 








Cord blood GGT was also weakly positively associated with GGT at age 17 (regression 




Figure 6.5: Associations between GGT in cord blood, at age 9 and age 17 


















0.00 (0.00 – 0.01) 0.24 (0.08 – 0.41) 
Age 9 BMI 
z-score 
Age 7 BMI 
z-score 









Liver function measurements below the lower limit of detection in the cord blood samples did not have a discernible effect on 
the analysis: the largest relative change in effect estimate was 0.8% when these values were replaced with the next smallest 
value, as shown in Table 6.3, provided by Dr. Smith.  
 
Table 6.3: Associations between LFT’s in cord blood and later blood samples, in 5011 participants with cord blood samples, 
where values below the lower limit of detection have been replaced with the next smallest value  (provided by Dr. Smith) 
 
 
  Direct effect (i)  Direct effect (iii)  Direct effect (ii)  Indirect effect  
(iv= i × iii)  
Total effect  
(v= i × iii + ii)  
 
  Association between cord 
blood and age 9  
Association between age 9 
and age 17  
Association between cord 
blood and age 17  
Association between cord 
blood and age 17  
Association between cord 
blood and age 17  
 
Analyte  β (95% CI)  p  β (95% CI)  p  β (95% CI)  p  β (95% CI)  p       
GGT (u/l)   
Model 1  
  
Model 2  
  
0.004   
(0.000, 0.008)  
0.004   






0.314   
(0.149, 0.479)  
0.244   






0.018   
(0.007, 0.030)  
0.020   






0.001   
(0.000, 0.003)  
0.001   






0.019   
(0.008, 0.031)  
0.021   






ALT (u/l)   
Model 1  
  
Model 2  
  
0.077   
(-0.076, 0.230)  
0.097   






0.360   
(0.267, 0.453)  
0.347   






-0.109   
(-0.270, 0.053)  
-0.059   






0.028   
(-0.028, 0.083)  
0.033   






-0.081   
(-0.245, 0.083)  
-0.025   






AST (u/l)   
Model 1  
  
Model 2  
  
0.000   
(-0.015, 0.016)  
0.001   






0.520   
(0.457, 0.583)  
0.541   






0.005   
(-0.008, 0.019)  
0.006   






0.000   
(-0.008, 0.008)  
0.000   




 0.945  
  
0.005   
(-0.008, 0.018)  
0.006   






Cord blood: Models 1: adjusted for sex, 2: adjusted for sex, birthweight, gestational age at birth, and maternal age, parity, 
occupational social class, highest educational attainment, pre-pregnancy BMI, and smoking status before and during pregnancy. 





Adjusting for truncation of 9-year liver function measurements below the lower limit of detection also did not have a discernible 
effect on the analysis and the results presented were similar (Table 6.4, provided by Dr. Smith).  
 
Table 6.4: Associations between liver function measurements in cord blood and later blood samples, in 5011 participants 
with cord blood samples (complete case analyses only), with and without adjustment for truncation below the lower limit 
of detection in the intermediate outcome (provided by Dr. Smith) 
 
  Direct effect (i) Direct effect (iii) Total effect (v) 
  Association between cord 
blood and age 9 
Association between age 
9 and age 17 
Association between cord blood  
and age 17 
Analyte  β (95% CI) p β (95% CI) p β (95% CI) p 
GGT (u/l) (n = 695)  
Without adjustment for 
truncation  




























ALT (u/l) (n = 700)   
Without adjustment for 
truncation  




























AST (u/l) (n = 697)   
Without adjustment for 
truncation  

































Table 6.5 shows the correlation between birthweight, cord blood adipokines, and 
cord blood LFTs and outcomes at age 17: LFTs, glucose, insulin, lipids, BMI, and fat 
mass. There was a weak positive association between cord blood GGT and insulin, 
triglycerides, and BMI at age 17. Conversely cord blood GGT was weak negatively 





Table 6.5: Spearman correlations between birthweight, cord blood leptin, adiponectin, LFTs and LFTs, glucose, insulin, 
lipids, BMI, and fat mass at age 17 (N obs, R)  
Cord blood       17 yr old offspring 
  Leptin  Adiponectin  GGT  AST  ALT  GGT  AST   ALT   Glucose  Insulin  Cholesterol  Triglyceride  HDL   BMI  FM  
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GGT at 17  
(u/l)  


















AST at 17  
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ALT at 17  
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Glucose at 17 
mmol/l)  












Insulin at 17  
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Cholesterol at 17 
(mmol/l)  








Triglyceride at 17 
(mmol/l)  






HDLc at 17  
(mmol/l)  










In the Appendix, Table 5 shows the rank correlations between birthweight and cord 
blood lipids, LFTs, and adipokines. Birthweight was positively associated with cord 
blood leptin and to a lesser extent, cord blood adiponectin. Birthweight was also 
weakly associated with cord blood lipids. Cord blood GGT was positively associated 
with cord blood cholesterol and HDLc.  Cord blood LFTs were all positively related 
to each other. In addition, Table 6 in the Appendix shows the associations between 
outcomes at age 17: BMI, fat mass, lipids, LFT’s and glucose. LFTs at age 17 were 
also positively related to each other. GGT at age 17 was positively associated with 





6.4 Discussion  
  
 
In this prospective birth cohort, cholesterol, HDLc, non-HDLc, GGT, and adiponectin 
were tracked positively from birth (cord blood) to age 9. GGT was the only analyte 
that continued to track positively from birth to age 17 when the associations were 
examined in the simplest form. Accounting for the correlations between analyte 
measures in cord blood and at age 9 and between age 9 and 17, there was an overall 
indirect association between cord blood cholesterol, HDLc, and non-HDLc and repeat 
analytes at age 17 (i.e. not GGT). There was also a weak cumulative effect of the 
association between cord blood and age 17 for HDLc, non-HDLc, and GGT, but not 
for cholesterol, when the associations between cord blood and repeat analytes at 
age 9 and 17, as well as the associations between analytes at age 9 and 17, were 
adjusted for.   
 
 
As there was no direct association between cord blood HDLc and non-HDLc and 
repeat measures at age 17, the association identified as the cumulative effect was 
therefore simply the product of the associations between cord blood and age 9, and 
age 9 and 17. Whilst there was a direct association between GGT in cord blood and 
at age 17, the variation in GGT at age 9 was unlikely to account for this association. 
Finally, this study has demonstrated that all measured metabolic biomarkers 
(triglyceride, cholesterol HDLc, non-HDLc, GGT, ALT, AST, and CRP) obtained at age 
9 tracked positively through to age 17. 
 
 
Given that analytes in childhood may be used as surrogate markers of long-term 
metabolic health, identifying those at risk at the earliest feasible time point, such 
as using cord blood measures from birth, may have a significant impact on disease 
prevention or prediction. Although it was only possible to demonstrate that cord 
blood GGT was related to GGT at age 17, this may have the potential for identifying 






In the current study, cholesterol, HDLc, and non-HDLc were tracked from birth (cord 
blood) to age 9 but the direct association was lost beyond this, despite strong 
correlations between measures at age 9 and 17. These findings mirror previous 
reports associating lipids measured in childhood and later life (Porkka et al., 1994; 
Raitakari et al., 2003). The Young Finns Study, in which participants’ age ranged 
from age 8-18 years, showed that total cholesterol, HDLc, and LDLc were tracked 
positively over a 12-year follow-up (Porkka et al., 1994). Similarly, in a younger 
cohort, lipids obtained at age 5-14 years have also demonstrated evidence of 
tracking positively over 12 years (Webber et al., 1991). This cohort demonstrated 
that tracking was more pronounced from age 9 onwards, also in keeping with the 
findings in the current study, as associations identified earlier in childhood were 
much weaker (Webber et al., 1991). Lipids have been shown to decrease in 
concentration around puberty which may account for the lack of direct association 
(between cord blood lipids and repeat analytes at age 17) seen in the current study. 
This may also explain the weaker associations identified between cord blood and 
age 9 compared to the stronger correlation between analytes at age 9 and age 17 
(Webber et al., 1991). Overall, stronger associations from age 9 to 17 for 
triglyceride, cholesterol, and HDLc were identified than demonstrated in the Young 
Finns Study, which may be due to the larger sample size and set time points for 
sample collection in the current study. 
 
 
Lipoprotein levels have been shown to have some predictive value, as not only are 
they higher in men, but men are also at greater risk of cardiovascular disease 
(Mahoney et al., 1996). Identifying analyte associations that become more 
pronounced over time supports the role of lipoproteins (measured in late childhood) 
as biomarkers of future cardiovascular disease. In particular, cholesterol and 
triglyceride measured at age 15 may be used as predictors of cardiovascular disease 
as their elevated levels were significantly related to coronary artery calcification 15 
to 20 years later (Mahoney et al., 1996). Furthermore, LDLc measured at age 12-18 
years strongly correlated with carotid intima-media thickness 21 years later 






Adipokines have also been shown to track through childhood into adolescence and 
correlated with later adiposity outcomes (Geary et al., 1999; Mantzoros et al., 2009; 
Nishimura et al., 2009; Volberg, Heggeseth, et al., 2013). Leptin secretion signals 
the nutritional state of the brain (Bellone et al., 2004) and may positively correlate 
with neonatal fat mass, birthweight, and gestational age (Bellone et al., 2004). At 
later time points, it may also be positively related to body weight and BMI (Bellone 
et al., 2004). Examining leptin across a wide age range (age 2-15) has shown that 
although the levels were overall low, they increased markedly with advancing age 
and adiposity in females, especially in the 13 to 15-year age group (Ong et al., 1999; 
Sharrock et al., 2008). This suggests that leptin becomes increasingly coupled with 
fat mass and perhaps energy status with age, particularly around puberty, and may 
reflect developmental changes in energy required for pregnancy and lactation 
(Sharrock et al., 2008). Leptin levels in men have also been shown to be consistently 
low across the age range although they did not correlate with BMI in any age group 
(Sharrock et al., 2008). This may be due to suppression of leptin by androgens around 
puberty, suggesting that leptin may be a poor signal of energy status in males 
(Böttner et al., 2004; Kuzawa, Quinn and Adair, 2007; Sharrock et al., 2008). In 
keeping with these reports, this study has shown consistently low leptin levels in 
cord blood and at age 9. It was however not possible to demonstrate any association 
between cord blood leptin and leptin at age 9. Overall low levels of leptin (reflecting 
lower birthweight in this specific cohort, compared to a contemporary population), 
the pre-pubertal status of the participants, or variations in the leptin and leptin 




Adiponectin, the counter-part to leptin, is protective against diabetes, 
atherosclerosis, and metabolic syndrome (Kumada et al., 2003; Spranger et al., 
2003). In the current study, adiponectin levels were highest at birth, and there was 
a weak positive association identified between cord blood adiponectin and 
adiponectin at age 9. Previously, this association was demonstrated to be stronger 
(Nishimura et al., 2009). This disparity may be due to a shorter duration of follow-





confounders in the analyses (Nishimura et al., 2009). Tracking of adiponectin from 
birth, irrespective of strength, could however suggest that adiponectin may be 
relatively unaffected by hormonal changes on the approach to puberty and 
unchanged by the degree of fat mass in childhood.  With advancing age however, 
adiponectin levels may decrease and relate inversely to pubertal stage, BMI and 
obesity, particularly in males (Böttner et al., 2004). This may account for the higher 
incidence of cardiovascular disease in males than females. It was not possible to 
examine associations in adolescence due to the absence of adipokine measures at 
this time and this may be a focus of future research.   
 
 
After birth, with the cessation of placental function, the neonatal liver must adapt 
to the new environment and assume several hepatic functions. The current study 
has shown that GGT, AST, and ALT were all positively related to each other in cord 
blood and when they were measured at age 17. GGT activity in neonates may be 
significantly higher than the upper limit of normal in adults so the reference ranges 
may be age-dependent (Davidson, McIntosh and Ford, 1976; Cabrera-Abreu and 
Green, 2002; Melkie et al., 2012). GGT is a very sensitive marker although its activity 
remains constant in healthy adults, normal pregnancy, and bone disorders (Davidson, 
McIntosh and Ford, 1976; Cabrera-Abreu and Green, 2002). It is therefore more 
specific for liver disorders in adults and children than other liver enzymes, such as 
alkaline phosphatase (Davidson, McIntosh and Ford, 1976; Cabrera-Abreu and Green, 
2002). Glucose and lipid levels may influence GGT activity, however (Whitfield, 
2001; Paolicchi et al., 2004), and as such, GGT levels may fluctuate during specific 
periods of growth in childhood and adolescence, such as puberty (due to altered 
insulin concentration) (Goran and Gower, 2001; Levy-Marchal et al., 2010). GGT may 
also increase as a result of oxidative stress as it is a marker of free radicle formation 
and inflammation (Karp, Shimooku and Lipsky, 2001). Furthermore, GGT rises earlier 
and persists longer in obstructive jaundice, cholangitis, and cholecystitis than 
aminotransferases (ALT and AST) (Cabrera-Abreu and Green, 2002). As an inducible 
enzyme, GGT levels may also be affected by a wide variety of medications and 
alcohol (Whitfield, 2001; Paolicchi et al., 2004). In the adolescent age group, 





GGT, making its value more difficult to interpret (Cabrera-Abreu and Green, 2002). 
In the current cohort, however, a minimal impact from such external factors at birth 
and in childhood would be expected. Consequently, GGT values may be more 
reliable to translate in clinical practice and thus justifying its role as a credible 
biomarker of metabolic disease than other blood-based liver function tests 
throughout the life-course (Fraser et al., 2009; Nguyen et al., 2011). 
 
 
Whilst transaminases are sensitive to hepatocyte injury, the concentration of AST, 
in particular, may also increase in cardiovascular disease, muscular injury, and 
haemolysis (Davidson, McIntosh and Ford, 1976). Haemolysis may occur due to 
difficulty obtaining the sample or poor sample handling (Davidson, McIntosh and 
Ford, 1976). Newborn babies may also show higher levels of AST than infants, as 
demonstrated in the current study, due to placental release of AST into the fetal 
circulation and in contrast to ALT, may be found in a variety of sources (Davidson, 
McIntosh and Ford, 1976; Melkie et al., 2012). A ‘U’- shaped pattern of enzyme 
concentration has been observed for ALT and levels may be higher during periods of 
increased gluconeogenesis, such as infancy (Melkie et al., 2012). ALT has been found 
predominantly in the liver and its concentration may rise in response to liver 
pathology or inflammation and oxidative stress (Salgado et al., 2014). In the current 
study, hepatic immaturity at birth, lack of liver inflammation and varying ALT 
isoforms may account for the low cord blood levels of ALT which may increase as 
the neonatal liver takes on a more central role in gluconeogenesis. Neonates, who 
may be deficient in vitamin b6 (pyridoxine), may also have abnormally low ALT levels 
(Davidson, McIntosh and Ford, 1976). As there was no evidence in the current study 
that transaminases tracked from cord blood to age 9, it was not possible to use them 
for any predictive value. Whilst ALT has previously been shown to positively predict 
new-onset T2DM in adult males over a 5 year follow-up period (Sattar et al., 2004), 
there was no evidence of this in the current study since the positive association 






Valuable clinical implications may be assumed from the negative associations that 
exist between GGT and birthweight, cord blood adipokines, and cord blood 
triglycerides. Larger weight babies for example, with a lower cord blood GGT (and 
higher leptin and adiponectin levels), may assume a lower cardiovascular risk at age 
17 as demonstrated by lower insulin and lipid levels and lower BMI and fat mass. As 
GGT in adulthood has been positively correlated with GGT and systolic blood 
pressure (Patel et al., 2007), type 2 diabetes (Nannipieri et al., 2005; Nguyen et al., 
2011), and the metabolic syndrome (Nannipieri et al., 2005) in later life, we would 
also have expected low cord blood GGT to be predictive of lower blood pressure and 
lower risk of type 2 diabetes in late adulthood. Its association with insulin resistance 
may be independent of age, gender, weight, BMI, or body fat (Ortega et al., 2006). 
This particular study population of Pima Indians was however at high risk of diabetes 
mellitus anyway and its findings may not reflect multi-cultural phenotypes (Ortega 
et al., 2006). In overweight and obese Korean children GGT, but not transaminases, 
has nevertheless also been positively associated with insulin resistance (Lee, Sung 
and Chang, 2013). In the current study, cord blood GGT associations were weak and 
inconsistent with markers of lipid and glucose homeostasis and adiposity outcomes 
at age 17 so its use as a metabolic marker may be limited. Overall though, GGT 
better reflects the dynamic changes in metabolic and insulin status as the child 
grows and develops compared to liver transaminases. Other factors such as 
differences in changes in DNA methylation and regulation of gene expression, more 
independence of what food you consume at age 17, and chance may also have 




Strengths of the study included the size of the cohort, duration of follow-up, and 
repeat measures at specified time points. The study also has its limitations. At age 
9, body composition and therefore serum lipid levels may not yet be affected 
significantly by puberty and this may have accounted for the associations identified 
between cord blood lipids (cholesterol, HDLc, and non-HDLc) and repeat measures 
at age 9. At age 17 however, the later stage in puberty may have accounted for the 





adolescence. Although offspring lifestyle factors were not accounted for, BMI at age 
9 was adjusted for and the analysis included assessment of the direct and cumulative 
associations between cord blood measures and measures at age 17.  
 
 
The number of children who were overweight or obese however was smaller than 
many contemporary populations. Another limitation of the study was the loss to 
follow-up. However, results would be biased only if associations were substantially 
different among excluded participants and while this cannot be tested directly, it is 
unlikely to be the case. Cord blood sample degradation may have contributed to the 
variability seen but leptin, adiponectin, and lipids do appear to be stable with long-
term storage (Shih et al., 2000; Boyanton and Blick, 2002; Gislefoss, Grimsrud and 
Mørkrid, 2008; Brinc et al., 2012). This study was limited by a lack of leptin and 
adiponectin measures at age 17. It was not possible to include cord b lood c-peptide, 
the preferred index of fetal glucose exposure, due to concerns regarding degradation 
with long-term storage, a phenomenon also previously reported by others (Gislefoss, 
Grimsrud and Mørkrid, 2009). 
 
 
In conclusion, this study has demonstrated that lipids and LFTs measured at age 9 
were strongly associated with repeat analytes at age 17. Novel correlations between 
cord blood cholesterol, HDLc, non-HDLc, GGT, and adiponectin, and repeat 
measures at age 9 have also been identified. Uniquely, this association for GGT 
persisted from birth to age 17. This adds to emerging evidence that cord blood 
analytes, reflecting the perinatal environment, may therefore be used as biomarkers 
of long-term programming and predictors of offspring metabolic health, with 





Chapter 7: Adiposity in late childhood and adolescence: association with birth 
weight and cord blood adipokines 
 
 
7.1 Introduction  
 
 
As previously discussed, exposure to maternal adiposity during pregnancy has been 
positively associated with higher offspring birth weight and greater adiposity through 
childhood and adult life (Nelson, Matthews and Poston, 2009). In this Chapter, the 
association between offspring adiposity in late childhood and adolescence and cord 
blood analytes and birthweight was examined.  Developmental overnutrition has 
been proposed as a mechanism, by which excessive transplacental passage of 
nutrients facilitates the development of larger babies with greater fat mass. 
Evidence from within sibling studies, comparisons of maternal and paternal 
exposures, and the use of genetic variants as proxies for the maternal exposures 
support developmental overnutrition causing greater adiposity in offspring at birth 
(Debbie A. Lawlor et al., 2012; Lawlor, 2013; Tyrrell et al., 2016). However, whether 
this causal effect extends to long-term offspring adiposity is unclear. A longer-term 
effect may occur as a result of tracking birth fatness across the life course. However, 
because birth weight is unable to distinguish relative contributions of lean vs fat 
mass (Sewell et al., 2006; Jain et al., 2016), few studies to date have been able to 
determine the extent to which greater fat mass at birth tracks into later life.   
  
 
As previously described, umbilical cord blood leptin is widely recognised as an 
accurate biomarker for neonatal fat mass (Hauguel-de Mouzon, Lepercq and 
Catalano, 2006). Maternal exposures, including maternal adiposity, which may cause 
developmental overnutrition, have been associated with increased cord leptin and 
neonatal adiposity at birth (Catalano et al., 2009; Lawlor et al., 2014). In animal 
models fetal leptin has also been proposed to contribute to the long-term 
programming of hypothalamic feeding circuits, thereby providing a means by which 





birth (Bouret, 2012). However, use of cord blood leptin in determining whether 
neonatal fat mass tracks across childhood has however been limited (Blüher and 
Mantzoros, 2009; Nakano, Itabashi and Maruyama, 2009; A. Lawlor et al., 2010; 
Lindsay et al., 2010; Boeke et al., 2013; Kaar et al., 2014). This primarily reflects 
the scarcity of large prospective birth cohorts with cord blood samples and detailed 
measures of offspring adiposity as well as potential confounders. Studies that have 
made some assessment of this to date have had relatively small sample sizes (N=56 
to 588) (Blüher and Mantzoros, 2009; Nakano, Itabashi and Maruyama, 2009; A. 
Lawlor et al., 2010; Lindsay et al., 2010; Boeke et al., 2013; Kaar et al., 2014), and 
there were no studies that followed children beyond age 7 years. These studies have 
reported inconsistent results, with higher leptin associated with both a lower  
(Mantzoros et al., 2009) and higher (Boeke et al., 2013) BMI at age 3 years, and a 
higher BMI at age 7 years (Lindsay et al., 2010). 
 
 
Neonatal levels of adiponectin, which has insulin-sensitizing effects in adults, are 
approximately 4-7 times higher than maternal levels. Furthermore, whereas 
maternal circulating concentrations of adiponectin are inversely associated with 
BMI, higher levels of cord blood adiponectin are associated with an increased birth 
weight (Mantzoros et al., 2009; Aye, Powell and Jansson, 2013). That higher cord 
blood adiponectin concentrations might reflect increased fat mass in neonates is 
suggested by mouse studies where over-expression of fetal adiponectin was 
positively related to the size of fat depots in early life, whereas adiponectin 
knockout fetuses display lower body weight and lower fat content (Qiao, Yoo, et al., 
2012). Given this direct effect of adiponectin on body composition, specifically 
enhancing fat deposition-enhancing effect in mice, and the known relationships of 
leptin in humans to far mass, it was hypothesised that both cord blood leptin and 
adiponectin would be positively associated with offspring adiposity in prepubertal 
children and adolescents. 
   
 
This study aimed to determine whether cord blood leptin and adiponectin were 





whether this is independent of maternal BMI. For comparison, associations of 









7.2.1 Study Population 
 
 
A detailed outline of the exclusion criteria for this analysis and numbers with missing 
data is provided in Figure 7.2, but notably, participants were included if they had 1) 
attended and completed assessments at either the 9 or the 11-year clinic 
assessment, or 2) attended the 15 or 17-year clinic assessment. The eligible cohort 
for the current analysis was 2775 mother-offspring pairs at age 9-11 years and 2138 
mother-offspring pairs at age 15-17 years. Details of cord blood sample collection 
and analysis have been presented in Chapter 2. Details of obstetric and perinatal 
abstraction of data from patient case-notes and questionnaires completed have also 
been presented in Chapter 2.  
 
 
7.2.2 Offspring Adiposity Measurements   
 
 
Identical protocols were used at all ALSPAC follow-up clinics. At each clinic 
assessment participants’ age in months was recorded and their weight and height 
were measured in light clothing and without shoes. Weight was measured by ALSPAC 
to the nearest 0.1kg using Tanita scales. Height was measured by ALSPAC to the 
nearest 0.1cm using a Harpenden stadiometer. DEXA scans were used by ALSPAC to 
measure total fat mass. Waist circumference was measured by ALSPAC to the nearest 
1mm at the midpoint between the lower ribs and the pelvic bone with a flexible 
tape and with the child breathing normally. Offspring obesity was classified using 









7.2.3 Statistical Analysis  
 
 
Linear and logistic regression models were used to examine the associations between 
birthweight and cord blood measures and offspring BMI, waist circumference, fat 
mass, and risk of obesity at age 9 and 17 years. Offspring BMI, waist circumference, 
and fat mass were log-transformed to produce approximately normal distributions 
of residuals. Fat mass and waist circumference z-scores were created internally 
using log outcomes adjusted for sex and age. In addition, BMI z-scores were created 
using the UK 1990 British growth reference for centiles (Cole et al., 2000).  
  
 
Figure 7.1 shows the DAG representing the direction of associations examined as 









1) Maternal Age 
2) Maternal Smoking 
3) Parity 
4) Maternal occupational 
social class 
5) Maternal education 





7) Gestational age at birth 
8) Mode of delivery 
9) Gestational weight gain 
10) Hypertensive disorders of 
pregnancy 





Cord blood leptin 
Adjusted cord blood leptin 
Cord blood adiponectin 
Birthweight adjusted for gestational 
age 
Offspring Outcome 
Age 9 (+11) 
Fat mass 
Waist circumference  
BMI 
≥95th percentile BMI (obesity) 








Age (15+) 17 
Fat mass 
Waist circumference  
BMI 








Model 1: Sex 
Model 2: Adjusted for sex and 
confounders 1-6 






Birthweight was adjusted for sex, gestational age, and number of offspring 
(singletons or twins) using nonlinear regression fitting a Gompertz curve. 
Associations with leptin and with birthweight-adjusted leptin were examined to 
account for differential fat mass for any given birthweight; log-leptin was adjusted 
for log-birthweight using linear regression followed by extracting the residual and 
adding the mean value; birthweight-adjusted leptin was hence generated by 
exponentiation. Among those participants with assessments at both clinics, 
measurements at each clinic were highly correlated (Pearson’s correlation 
coefficient was 0.93 for BMI and 0.93 for fat mass).   
 
 
Three incremental analyses were performed in order to adjust for potential 
confounders. The basic model (model 1) adjusted for offspring sex alone (and 
offspring height when fat mass is the outcome). In model 2 for maternal confounders 
(age, smoking, parity, occupational social class, education, and pre-pregnancy BMI) 
were additionally adjusted for. In the fully adjusted model (model 3) pregnancy 
confounders (gestational age at birth, mode of delivery, gestational weight gain, 
hypertensive, and diabetic disorders of pregnancy) were additionally adjusted for. 
 
 
There were small amounts of missing data on some co-variables included in the 
multivariable models. Twenty imputation data sets were generated by chained 
equations (White, Royston and Wood, 2011), with measurements from the 11-year 
clinic and 15-year clinic informing imputation of missing values in the 9-year clinic 






















Core ALSPAC cohort 
14541 pregnancies 
14676 offspring 
4797 offspring with paired 
cord blood sample 
Exclusions 
13 triplet and 
quadruplet 
pregnancies 
9866 cord blood 
sample unavailable 
214 pregnancies re-
engaged in cohort follow 
up 
Exposure data available 
Birthweight 4753 
Cord blood leptin 5008 
Cord blood adiponectin 4964 
Attended the 9 or 11 year clinic assessment 
 
N = 2775 
Complete data on exposures, confounders 
and outcomes varies by exposures between 
1853 and 1895 
  
 
Total 5011 mother-offspring pairs with cord 
blood sample included 
2547 males             2464 females 
 Attended the 15 or 17 year clinic 
assessment 
N = 2138 
Complete data on exposures, confounders 
and outcomes varies by exposures between 








Table 7.1 summarises the maternal and offspring characteristics for those 









 Attended at least one clinic assessment (n=2955)  
N obs (%)  Median (IQR)  
Maternal Characteristics    
Age  2914  29 (26, 32)  
Smoking  
Never   
Before, not during  
During pregnancy  
  
2103 (73.8)  
212 (7.4)  
533 (18.7)  
  








1274 (45.5)  
1011 (36.1)  
383 (13.7)  
101 (3.6)  




Education    
Left school at 16  
A level   
Degree  
  
1713 (61.3)  
689 (24.8)  
391 (14.0)  
  
  
Social Class  
I (least)  
II  
IIIa   
IIIb   
IV  
V (most disadvantaged)  
  
140 (5.9)  
807 (33.7)  
1038 (43.5)  
162 (6.8)  
203 (8.5)  
40 (1.7)  
  
  
Pregnancy Characteristics  
 
  




40 (39, 41)  








2253 (77.9)  
36 (1.3)  
249 (8.6)  
167 (5.8)  
154 (5.3)  
32 (1.1)  
  
GWG (kg)  2668  12.5 (9.5, 15.2)  





 Attended at least one clinic assessment (n=2955)  




2449 (84.5)  
420 (13.9)  
49 (1.7)  
Diabetic disorders  





2651 (95.8)  
10 (0.4)  
16 (0.6)  
91 (3.3)  
  





1414 (47.9)  
1541 (52.2)  
  
Birthweight (kg) 2891   3.5 (3.1, 3.8)  
Cord blood  
Leptin (pg/ml)   
 
2952   
 
6.4 (3.6, 12.1)  
Adiponectin (µg/ml)  2927  75.7 (53.6, 98.4)  
Height (cm)  
  
Age 9: 2561  
Age 11: 2363  
Age 15: 1816  
Age 17: 1648  
140 (136, 144)  
151 (146, 156)  
169 (163, 175)  
170(164, 178)  
FM (kg)  
  
Age 9: 2460  
Age 11: 2327  
Age 15: 1716  
Age 17: 1594   
7.3 (4.9, 11.2)  
10.0 (6.8, 15.7)  
13.7 (8.6, 20.6)  
16.7 (11.0, 23.5)  
WC (cm)  
  
Age 9: 2574  
Age 11: 2362  
Age 15: 1475  
61.1 (57.4, 66.6)  
66.0 (61.8, 73.5)  
75.4 (71.0, 81.5)  
BMI (kg/m2)   
  
Age 9: 2560  
Age 11: 2359  
Age 15: 1811  
Age 17: 1647  
17.0 (15.7, 19.1)  
18.4(16.6, 21.0)  
20.7 (19.0, 23.1)  
22.0 (20.2, 24.7)  
Obese   
  
Age 9: 102 (4.0)  
Age 11:116 (4.9)  
Age 15: 78 (4.3)  
Age 17:105 (6.4)   
  
Age at clinic attendance 
(years)  
Age 9: 2583  
Age 11: 2378  
Age 15: 1838  
Age 17: 1695  
9.8 (9.6, 10.0)  
11.8 (11.6, 11.8)  
15.4 (15.3, 15.6)  
17.8 (17.6, 17.9)  
 





Table 7.2 shows the Spearman correlation between leptin, adiponectin, and 
birthweight. Birthweight was positively correlated with cord blood leptin (n=4751, 
r=0.33, p<0.001) and, to a lesser degree, with cord blood adiponectin (n=4707, 
r=0.14, p<0.001). Cord blood leptin and adiponectin were themselves positively 
correlated (n=4962, r=0.11, p<0.001).    
 
 





  Leptin (pg/ml) 
N obs  
R   
Adiponectin (ng/ml) 
N obs  
R   

























Figure 7.3: Offspring anthropometry (height, FM, WC, and BMI (kg/m2) 





















Table 7.3 shows the multivariable associations between cord blood leptin, leptin 
adjusted for birthweight, adiponectin, and birthweight and z-scores of offspring fat 
mass, waist circumference, BMI, and the risk of obesity at age 9 years.  
 
 
Cord blood leptin (both total and adjusted for birth weight) was positively associated 
with z-scores of fat mass, waist circumference, and BMI at age 9, however, the 
effect size was largely attenuated with adjustment for maternal and pregnancy 
characteristics. Cord blood adiponectin was not associated with any measures of 
adiposity at age 9. 
 
 
Birthweight was positively associated with z scores of fat mass, waist circumference, 
and BMI at age 9 years and showed a weak relationship with obesity. After 
adjustment for maternal and pregnancy characteristics increasing birthweight 
remained associated with greater waist circumference and BMI, with the association 






Table 7.3: Associations of birthweight and cord blood analyte with FM, WC, and BMI z-scores, and obesity outcome at age 9 
years. N= 2775  
 
Outcome       FM z-score *  WC z-score  BMI z-score  Obesity   
Exposure  Model Coefficient 95% CI  P  Coefficient 95% CI  P   Coefficient 95% CI  P   OR   95% CI   P  
Leptin 






































































































































































Models 1: Adjusted for offspring sex, 2: Adjusted for offspring sex and maternal confounders (age, smoking, parity, occupational 
social class, education, and pre-pregnancy BMI), 3: Adjusted for offspring sex and maternal confounders plus pregnancy 
confounders (gestational age at birth, mode of delivery, gestational weight gain, hypertensive disorders and diabetic disorders 
of pregnancy). * Fat mass adjusted for height † Leptin adjusted for birthweight ‡ Birthweight adjusted for sex, gestational age 






Table 7.4 shows a similar but weaker pattern for cord blood leptin examined at 
ages 15 and 17 where there was a significant association with z-scores of fat mass, 
waist circumference, and BMI and with the risk of obesity. These associations were 
however absent after adjustment for potential confounders. 
 
 
In contrast to the lack of association identified at age 9, cord blood adiponectin was 
positively associated with z-scores of fat mass and waist circumference at age 17, 




Birthweight remained positively associated with z-scores of fat mass, waist 
circumference, and BMI at 17 years and showed a weak relationship with obesity. 
After adjustment for maternal and pregnancy characteristics increasing birthweight 
remained associated with greater waist circumference and BMI, with the association 







Table 7.4: Associations of birthweight and cord blood analyte with FM, WC, BMI z-scores and obesity outcomes at age 17 
years. N= 2138  
 
Outcome       FM z-score *  WC z-score  BMI z-score  Obesity   
Exposure  Model Coefficient 95% CI  P  Coefficient 95% CI  P   Coefficient 95% CI  P   OR   95% CI   P  
Leptin 






0.02   
0.03, 0.11  
-0.02, 0.06  
-0.02, 0.05  
<0.001  
0.263  




0.02, 0.10  
-0.03, 0.05  






0.02   
0.04, 0.14  
-0.02, 0.07  
-0.03, 0.06  
<0.001  
0.272  




0.99, 1.28  
0.83. 1.12  













0.01, 0.09  
-0.03, 0.06  







-0.03, 0.06  
-0.07, 0.02  







0.00, 0.10  
-0.04, 0.05  







0.94, 1.26  
0.81, 1.14  












0.00, 0.03  
0.00, 0.03  







0.00, 0.03  
0.00, 0.03  







-0.01, 0.02  
0.00, 0.03  







0.98, 1.08  
0.99, 1.10  












0.02, 0.03  
0.00, 0.02  







0.03, 0.05  
0.02, 0.04  







0.03, 0.05  
0.01, 0.03  







1.02, 1.09  
0.98, 1.06  






Models 1: Adjusted for offspring sex, 2: Adjusted for offspring sex and maternal confounders (age, smoking, parity, occupational 
social class, education, and pre-pregnancy BMI), 3: Adjusted for offspring sex and maternal confounders plus pregnancy 
confounders (gestational age at birth, mode of delivery, gestational weight gain, hypertensive disorders and diabetic disorders 






Figure 7.4 shows the odds of obesity per 10 pg/ml rise in cord blood leptin using the 
simplest model of analysis. 
 
 
Figure 7.4: Odds of obesity (model 1) at age 9 and 17 per 100g rise in offspring 
birthweight and per 10pg/ml rise in cord blood leptin 
 
 









The distributions of observed and imputed variables were similar, as shown in Table 7.5. 
 
 
Table 7.5: Characteristics of observed and imputed data at age 9 and 17 years 
 
 
 Observed at 9 Multiply Imputed at 9 Observed at 17 Multiply Imputed at 17 
N missing (%) N obs (%) Median IQR N obs (%) Median IQR N missing (%) N obs (%) Median IQR N obs (%) Median IQR 
Maternal Characteristics           
Age  
  
221 (8.0)  2554 29 
26, 32 
2775  29 
26, 32 
465 (21.7) 1673  29 
26, 32 
2138  29 
26, 32 
Smoking  































BMI   483 (17.4) 2292  22.2 
20.5, 24.4 
2775  22.4 
20.5, 24.7 
630 (29.5) 1508 22.0 
20.5, 24.2 





































Left school 16  
A level   
Degree  




















Social Class  
I (least)  
II  
IIIa   
























 Observed at 9 Multiply Imputed at 9 Observed at 17 Multiply Imputed at 17 
N missing (%) N obs (%) Median IQR N obs (%) Median IQR N missing (%) N obs (%) Median IQR N obs (%) Median IQR 






















         
Sex            Male           
              Female 
192 (6.9) 1243 (48.1) 
1340 (51.9) 
 
1343 (48.4)  
1432 (51.6) 
 







         
Gestational age 
at birth (weeks)  




















































































































The percentage missing data for each co-variable is presented in Figure 7.5.  
 






Associations, expressed as percentage change rather than as a coefficient, between 
birthweight and cord blood measures with fat mass, waist circumference, and BMI 
at age 9 and 17 are presented in the Appendix, Table 7. Results did not differ 
substantially when non-imputed (observed) data was used to examine associations 
between birthweight and cord blood measures and offspring adiposity at ages 9 and 


































In this Chapter, cord blood leptin, adiponectin, and birthweight were examined in 
relation to offspring adiposity in childhood and adolescence. Within this prospective 
birth cohort study, cord blood leptin, a marker of neonatal fat mass, exhibited 
relatively weak relationships with later measures of adiposity. These were largely 
attenuated by adjustment for maternal factors, particularly in later childhood. In 
contrast cord blood adiponectin showed no relationship with measures of fat mass 
at age 9 but showed robust relationships with fat mass and waist circumference at 
ages 15 and 17. Taken together the evidence in this cohort would suggest that 
neonatal fat mass per se did show a relationship with later fat mass as late as age 
17 however it was not possible to distinguish between effects of fat mass in utero 
and later shared environmental effects as these effects were attenuated by 
maternal factors, notably maternal BMI.   
  
 
It was hypothesised that adiponectin would be positively associated with later fat 
mass. Although this was the case, the fact that the relationship would be mediated 
by an increased (and persistent) fat mass through childhood was not supported by 
the data, where relationships were only observed at age 15 and 17. More robust 
relationships of birth weight to later BMI and waist in both age groups were also 
observed but it was expected that this was mediated by effects on linear growth, 
given that birthweight was associated with height at both ages 9 and 15 years.    
  
 
To date birthweight, as a proxy for intrauterine growth, and its relation to adult BMI 
has been extensively studied. Studies principally have demonstrated a robust 
positive association between birthweight and fat mass, BMI, and waist 
circumference in childhood and adult life (Brisbois, Farmer and McCargar, 2012), 
and this was similar to the findings from the current study. To try to examine 
whether birthweight was simply acting as a surrogate for neonatal fat mass, ponderal 





associations between the ponderal index and lean body mass, total body fat, and 
the fat-to-lean mass ratio at age 9 years old (Rogers et al., 2006). Although this 
raised the possibility that neonatal fat mass was related to later adiposity, the 
ponderal index was a relatively poor measure of neonatal total body fat (De Bruin 
et al., 1995).   
 
 
To overcome this deficiency the current study utilised cord blood leptin, a strong 
correlate of neonatal fat mass as assessed by skinfolds or total body electrical 
conductivity (Okereke et al., 2002). That cord blood leptin was positively correlated 
with birthweight, would be consistent with it reflecting neonatal fat mass, a major 
determinant of birthweight. Furthermore, that cord blood leptin was positively 
associated with several adiposity measures and specifically fat mass z-score at age 
9 years, suggested that there was an accretion of adipose tissue during intrauterine 
life that was maintained throughout childhood. To examine this further and attain a 
proxy for percentage body fat at birth, adjusted leptin was used as a marker of 
neonatal fat mass for birthweight.  In these analyses, adjusted cord blood leptin was 
still weakly associated with fat mass z-score at age 9, suggesting that neonates with 
a greater percentage of fat at birth continued to have a greater fat mass at age 9. 
In contrast at age 15 and 17 years, all adiposity associations for leptin were lost after 
adjustment for maternal and pregnancy characteristics. This suggests that by the 
time the offspring reached adolescence the biological significance of this long-term 
tracking of adiposity may be minimal or reflect alternative biological pathways.   
  
 
The contribution of adiponectin to long-term adiposity is contentious. In mice, 
transgenic overexpression of adiponectin increases adipose tissue mass, while 
adiponectin deficiency decreases neonatal fat mass and reduces fetal fat deposition 
in response to maternal overnutrition in a maternal obesity model (Qiao, Yoo, et al., 
2012). However, the effect of adiponectin depletion on body weight or body fat was 
no longer evident by the 15th postnatal day or in adult life (Qiao, Yoo, et al., 2012). 
In accordance with some, but not all previous studies, adiponectin was weakly 





Mantzoros et al., 2009), potentially reflecting the greater statistical power in the 
current study. Given this association with birthweight, and known influence on body 
neonatal composition, it was anticipated that cord blood adiponectin would be 
positively associated with later adiposity. However, this was only evident at age 15 
and 17.  Why this was not apparent at age 9, as was observed for leptin, was not 
clear and may reflect that there was age dependence to these associations as at the 
earlier time point children were pre-pubertal, with puberty known to have a major 
impact on body composition and adipocyte number (Knittle et al., 1979).   
 
 
As previously discussed, this study has a number of strengths including its size, 
duration of follow-up, and the availability of data on a range of maternal, 
pregnancy, and social factors pregnancy characteristics to facilitate a robust 
analysis. This was also one of the very few studies with DXA measurements of body 
composition at different time points, thereby overcoming the potential increase in 
overall mass attributed to the expected increase in bone density that results from 
increased adiposity.  
 
 
Limitations of the study include the number of children who were overweight or 
obese were smaller than many contemporary populations, with a similar lean 
maternal population identified, as described in Chapters 3 and 4. That birthweight 
and cord blood measures were not associated with the risk of being obese or 
overweight may reflect this, despite the positive associations with fat mass. In 
addition, offspring lifestyle factors such as uptake of exercise and consumption of 
food and drink were not accounted for and these may have influenced the overall 
adiposity outcomes. Another limitation of the study was the loss to follow-up. 
However, results would be biased only if associations were substantially different 








As previously discussed in Chapter 2, cord blood sample degradation may have 
contributed to the variability, but leptin and adiponectin did appear to be stable 
with long-term storage (Flower et al., 2000; Shih et al., 2000; Boyanton and Blick, 
2002; Paltiel et al., 2008; Gislefoss, Grimsrud and Mørkrid, 2009; Brinc et al., 2012). 
This was in stark contrast to c-peptide, the preferred index of fetal glucose 
exposure, which could not be measured accurately due to significant degradation 
with long-term storage, a phenomenon also previously reported by others (Gislefoss, 
Grimsrud and Mørkrid, 2009).    
 
 
In conclusion, increased cord blood leptin and adiponectin, known surrogates of fetal 
fat mass, were weakly positively associated with increased fat mass in late childhood 
and adolescence, respectively. That these associations were robust to a wide range 
of confounders that may reflect intrauterine, maternal, and shared environmental 
exposures suggests that maternal overnutrition may have a direct effect on fetal fat 
accretion which sets a trajectory for enhanced adiposity throughout later life. 
However, replication of these findings in cohorts with a different risk profile is 
critical, and it was acknowledged that the magnitude of the observed associations 
in this study was small, potentially limiting the impact that neonatal life adiposity 





Chapter 8: Adolescent non-alcoholic fatty liver disease (NAFLD): Association 
with birth weight and cord blood adipokines 
 
 
8.1 Introduction  
 
 
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease 
in children and adults in the developed world (Loomba et al., 2009; Younossi et al., 
2011; Anderson et al., 2014). The identification of NAFLD in children and adolescents 
led to the speculation that intrauterine events may contribute to its early 
pathogenesis (Alisi et al., 2012; Brumbaugh and Friedman, 2014). Intrauterine 
growth restriction and low birth weight have been associated with liver cirrhosis-
related mortality (A.-M.N. and M., 2004) and markers of liver damage and function 
in adults (Fraser et al., 2008). Although the causal effect of the supply of excess 
nutrients to the fetus, as observed in maternal obesity and diabetes, on increasing 
birthweight and neonatal adiposity is clear (Metzger et al., 2008; Tyrrell et al., 
2016), the influence on long-term liver function is less well defined. Mouse and 
primate models of a maternal high-fat diet during pregnancy exhibit offspring 
obesity and hepatic lipid accumulation (McCurdy et al., 2009; Oben et al., 2010). 
Increasing maternal BMI has also been associated with increased neonatal liver fat 
deposition (Modi et al., 2011). Long-term human studies are, however, less 
consistent with birthweight positively associated with adverse liver function or a 
diagnosis of NAFLD at age 17 years in some (Anderson et al., 2014), but not all studies 
(Ayonrinde et al., 2015). These findings suggest that intrauterine exposure to 
maternal over-nutrition increases fetal hepatic steatosis which may predispose to 
NAFLD in the long-term (Modi et al., 2011). However, the fetal origins of NAFLD are 
not well-understood, and poorer intrauterine nutrition, as reflected by lower birth 
weight, has been associated with elevated liver transaminases and NAFLD in 
adolescence and adulthood (Nobili et al., 2006; Fraser et al., 2008; Faienza et al., 
2013; Anderson et al., 2014) as a result of impeded organ development (Andersen 






The differences may reflect that assessments of the intrauterine contribution to the 
onset of metabolic disease in the offspring have primarily used birth weight, which 
reflects both fetal and lean mass. Umbilical cord blood leptin is now widely 
recognised as an accurate biomarker for neonatal fat mass (Hauguel-de Mouzon, 
Lepercq and Catalano, 2006), with higher levels associated with greater fat mass. 
Cord blood adiponectin is also positively associated with birthweight (Mantzoros et 
al., 2009). In mouse studies, over-expression of fetal adiponectin increased the size 
of fat depots in early life, while adiponectin knockout fetuses display lower body 
weight and lower fat content (Qiao, Yoo, et al., 2012). In addition, cord blood lipids 
are increased in the offspring of obese mothers and the presence of NAFLD (Neuman, 
Cohen and Nanau, 2014). The nature of the association of these cord blood 
adipokines and lipids with childhood NAFLD is unknown. Associations in later life are 
however more established as circulating leptin concentrations and dyslipidaemia are 
positively associated with NAFLD activity, while adiponectin is negatively associated 
(Zelber-Sagi et al., 2012).   
  
 
In this Chapter, the relationship between neonatal fat mass (cord blood leptin, 
adiponectin, and lipids) and blood and USS-based markers of liver health in 
adolescence was examined. To make this a comprehensive assessment, birth weight 
was additionally examined in relation to adolescent liver outcomes. In comparison 
with earlier studies, potential confounding was adjusted for and included maternal 









8.2.1 Study Population  
 
 
A total of 14,541 women were initially enrolled and cord blood samples were 
available for 5,011 mother-offspring pairs as previously discussed in Chapter 2. 
Details of all participants that attended the 17-18 follow up clinic (n=5,081), 
provided blood-based indicators of liver function (n=3,188), and participated in the 
liver ultrasound sub-study (n=1,887) have previously been reported in detail by 
ALSPAC (Patel et al., 2012; Anderson et al., 2014). Participants in the current study 
were included if they had a cord blood sample and they attended the 17 to 18-year 
follow-up study and had blood-based indicators of liver function (n=1,037) or 
participated in the sub-study with liver ultrasound measurement (n=541).  Details of 
cord blood sample collection and analysis were presented in Chapter 2. Details of 
obstetric and perinatal abstraction of data from patient case-notes and 
questionnaires completed were also presented in Chapter 2.   
 
 
8.2.2 Assessment of liver outcomes  
 
The protocol for USS assessment by ALSPAC has been published previously (Anderson 
et al., 2014)a. Briefly, the upper abdominal USS was completed by one of four 
trained sonographers using a Siemens Acuson S2000 USS system. Echogenicity, a 
marker of liver fat, was assessed during deep inspiration and recorded as present, 
absent, or uncertain according to established protocols. A longitudinal image, in the 
sagittal plane, with juxtaposition of the right lobe of the liver and the right kidney, 
was viewed and echogenicity was determined by a comparison between the liver 
and kidney. Levels of agreement in identifying echogenicity between the four 
sonographers were 98% or greater, both immediately after training and at 6-month 
intervals throughout data collection. Acoustic radiation force impulse-imaging (ARFI) 





protocols. ARFI, measured as sheer velocity in meters/second (m/s), was assessed 
six times with a gap of at least 1 min between each measurement. The highest and 
lowest of these measurements were excluded and the Siemens Acuson S2000 system 
produced a mean of the remaining four measurements. If this mean was greater than 
four m/s, a further six measurements were taken from the left lobe. When both 
right and left lobe values were available, the lowest mean of the two has been used 
in analyses.   
  
 
Fasting blood samples (minimum of 6-hours) were immediately spun and frozen at -
80 ºC by ALSPAC. Measurements were assayed shortly (3– 9 months) after samples 
were taken with no previous freeze-thaw cycles. All assays were completed in the 
same laboratory at the University of Glasgow. ALT, GGT, and AST were measured by 
an automated analyser with enzymatic methods. Those with a value of >30 U/L ALT 
were defined as having abnormally high ALT levels, using the most common blood-
based indicator and the threshold that has been used previously in adolescent/ 
childhood populations. All inter-and intra-coefficients of variation for these blood-
based assays were <5%.  
  
 
8.2.3 Assessment of covariates and offspring anthropometry 
 
 
Figure 8.1: DAG displays the direction of associations examined as well as the 
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Model 1: Adjusted confounders 
1-2 






Potential confounders included maternal age, pre-pregnancy body mass index, 
smoking status (categorised as never smoked, smoked before but not during and 
smoked during pregnancy), parity, occupational social class, complications during 
pregnancy (hypertensive or diabetic disorders), gestational age at birth, mode of 
delivery and offspring’s sex. Height, BMI, and fat mass at age 17.8 years were 
considered as potential mediators if any confounder-adjusted associations were 
observed. As discussed in Chapter 2: Methods, offspring weight, and height at the 
17-year clinic assessment were measured using standard procedures in light clothing, 
without shoes, and used to calculate BMI. Weight was measured to the nearest 0.1kg 
using Tanita scales. Height was measured to the nearest 0.1cm using a Harpenden 
stadiometer. A narrow fan-beam densitometer (Lunar Prodigy; GE Healthcare Lunar 
Ltd., Cambridge, UK.) was used to perform a whole-body dual-energy X-ray 
absorptiometry scan from which fat mass was measured.  
  
 
8.2.4 Statistical Analysis  
 
 
Offspring liver volume, fibrosis, and liver function tests were log-transformed to 
produce the approximately normal distribution of residuals. Birthweight was 
adjusted for sex and gestational age using nonlinear regression fitting a Gompertz 
curve.  As human and animal studies have demonstrated opposing inverse relations 
between birthweight and risk of NAFLD, a potential departure from linearity was 
explored. By comparing a model in which the exposure was entered in thirds as two 
indicator variables and a model in which a linear relationship was assumed across 
the thirds using a likelihood ratio test, there was no evidence to support a departure 
from linearity. Multivariable linear and logistic regression models were used to 
examine the associations between cord blood measures, birthweight and fatty liver, 
liver volume, fibrosis, and liver function tests at age 17 years. Sex-exposure 
interactions were tested for and as there was no evidence to support these, results 







A series of multivariable regression models were constructed in order to adjust for 
potential confounders and mediators. The basic model (model 1) was adjusted for 
offspring sex and age at outcome assessment. In model 2 for potential confounders 
were additionally adjusted for: maternal age, smoking in pregnancy, parity, 
occupational social class, education, pre-pregnancy BMI, and alcohol consumption 
in pregnancy. In order to examine for any potential mediation, offspring BMI, fat 
mass, height, and height squared at age 17 were further adjusted for in any 
confounder adjusted associations that were not null.  
  
 
There were small amounts of missing data on some co-variables included in the 
multivariable models. In order to deal with the missing data (any exposure, 
outcome, or confounder), twenty imputation data sets were generated by chained 
equations (White, Royston and Wood, 2011), with measurements from the 15-year 
clinic informing imputation of missing values in the 17-year clinic respectively. Up 
to 541 (all participants with a liver scan and paired cord blood sample) and up to 
1037 (participants with LFTs and paired cord blood samples) sets were imputed. The 
distributions of observed and imputed variables were similar, as discussed in the 







Figure 8.2 displays the ALSPAC participant flow chart and the inclusion and 
exclusion criteria.  
 
  






Core ALSPAC cohort 
14541 pregnancies 
14676 offspring 
4797 offspring with paired 
cord blood sample 
Exclusions 
13 triplet and 
quadruplet 
pregnancies 
9866 cord blood 
sample unavailable 
214 pregnancies re-
engaged in cohort follow 
up 
1678 attended the 17–18-year 
clinic follow up 
541 participants with 
liver scan outcomes 
 
Total 4947 singletons 











Table 8.1 summarises the maternal and offspring characteristics for those who 
attended the clinic at age 17 and had liver function tests and/or a liver ultrasound 
scan. In most cases, the proportion of missing data for each variable was less than 
5%. The variables maternal BMI and social class were missing however in 11.5% and 
16.5% of those attending for liver scan.  
 
 
Baseline characteristics for the mothers and their young adult offspring were similar 
for those who had just the blood measures and those who had USS. Of the 541 who 
were assessed by ultrasound, only 10 (1.8%) were categorised as having a fatty 
liver. Cohort characteristics for the observed versus the imputed data were similar, 





Table 8.1: Characteristics of those who had a liver scan (n=541) and/or liver 




Liver scan  Liver function tests   
Median or 
% N obs 






% N obs 
(IQR or N) 
N obs % missing (N) 
Maternal Characteristics  
Age (years)  29 
(26, 32) 




1023 1.3  
(14) 
Smoking  

















BMI  22.3 
(20.5, 24.4) 


























991  4.4 
(46) 
Social Class  





























Left school 16  

























>1 glass/wk  











1009  2.7 
(28) 
Offspring Characteristics  






















Liver scan  Liver function tests   
Median or 
% N obs 






% N obs 
(IQR or N) 





















































































541  0.0 
(0) 





500  7.9 
(41) 
   
Fatty liver  1.8 (10) 371 31.4(170) 
   
LFT’s at age 
17 
      







1037  0.0 (0)  







1037  0.0 (0)  







1004  3.1 (33)  
Anthropometry at age 17      








1011  2.5 (26)  
































The percentage of missing data from the complete case, compared to those used in the multiple imputation analysis, is 
displayed in Figure 8.3.  
 
Figure 8.3: Percentage missing data from the complete case for each co-variable compared to multiple imputation analysis 




















There was no association between birthweight or any of the cord blood measures 
and the diagnosis of a fatty liver in adolescence, as shown in Table 8.2.  
 
 
Table 8.2: Association of birthweight and cord blood measures with NAFLD in 
adolescence (using multiple imputation datasets) N=541  
 
Outcome Age 17:      Diagnosis of Fatty liver (yes/no)  
Exposure:  Model OR  CI  P  
Cord blood     
Leptin  





0.26, 1.73  









0.70, 1.04  









0.36, 1.83  









0.09, 5.94  









0.04, 5.87  









0.33, 2.05  
0.48, 2.15  
0.67  
0.96  
Birthweight †  





0.88, 1.13  




Adjustments for confounders  
Models 1: offspring sex and age, 2: offspring sex and age, maternal age, smoking, 
parity, occupational social class, education, pre-pregnancy BMI and alcohol 
consumption during pregnancy † Birthweight is adjusted for gestational age and 






In the adjusted analyses, there were two out of 42 associations at conventional 5% 
levels of significance. Birthweight was positively associated with liver volume (1.0% 
greater per 100g, 95% CI: 0.5, 2.0%) and cord blood HDLc was positively associated 
with ALT (11.6% higher per 1mmol/l, 95% CI 0.3, 23.4), as shown in Table 8.3.  
 
 
Examining the shape of associations demonstrated that there was no significant 
deviation from the linear trend. To examine the potential impact of offspring 
mediation, BMI, fat mass, height and height squared at age 17 were also adjusted 
for. There was no evidence of mediation where birthweight and liver volume were 
examined as a positive association remained (1.0% greater per 100g, 95% CI: 0.1, 
1.0%). Offspring mediation was however evident in the association between cord 
blood HDLc and ALT as there was a change in the strength and direction of 





Table 8.3: Association of birthweight and cord blood measures with markers of liver health in adolescence (using multiple 
imputation datasets) N=541 for liver scans, N=1037 for LFTs  
 
Outcome 
Age 17:  




logALT (U/l) logAST (U/l) logGGT (U/l) 
Exposure         %           CI P  %  CI  P  %  CI  P  %  CI  P  %  CI  P  
Cord blood Model                
Leptin  















































































































































































































































Adjustments for confounders  
Models 1: offspring sex and age, 2: offspring sex and age, maternal age, smoking, parity, occupational social class, education, 
pre-pregnancy BMI, and alcohol consumption during pregnancy  






The distributions of observed (complete case) and imputed variables were similar. 
Results from those with complete data are also presented, for comparison to the 
imputed data sets, in Tables 8.4 (reflecting Table 8.2) and 8.5 (reflecting Table 8.3).  
 
 
Tables 10 and 11 in the Appendix also display the data presented in Tables 8.4 and 
8.5 respectively but include the coefficient (β) of association rather than the 
percentage association between the exposure and the outcome variables.  
 
 
Table 8.4: Association of birthweight and cord blood measures with NAFLD in 
adolescence (complete case) N=196-233 
  
Outcome Age 17:     Diagnosis of Fatty liver (yes/no)  
Exposure:  OR  CI  P  
Cord blood  
Leptin  
(per 10 pg/ml)   










(per 10µg/ml)  
  0.54  
  





(per 1 mmol/l)  
  1.23  
  





(per 1 mmol/l)  
  0.56  
  





(per 1 mmol/l)  
  2.22  
  





(per 1 mmol/l)  
  1.22  
  




Birthweight †  
(per 100g)  





Adjustments for confounders  
Model 2: Complete case confounders: offspring sex and age, maternal age, 
smoking, parity, occupational social class, education, pre-pregnancy BMI, and 
alcohol consumption in pregnancy  
† Birthweight is adjusted for gestational age and sex, therefore not additionally 





Table 8.5: Association of birthweight and cord blood analyte with measures of liver health in adolescence (complete case)  
  
Outcome Age 




velocity (m/s)  
logALT (U/l)  logAST (U/l)  logGGT (U/l)  
Exposure:  %  CI  P  %  CI  P  %  CI  P  %  CI  P  %  CI  P  
Cord blood 
leptin  
(per 10 pg/ml)   
  1.0  -1.0, 
2.0  
N=402 
0.47  -0.05  -2.0, 
1.0  
N=374 
0.95  -0.8  -3.0, 
2.0  
N=813  
0.54  -0.5  -2.0, 
1.0  
N=813  






(per 10µg/ml)  
-0.1  -1.0, 
1.0  
N=396 
0.71  0.04  -0.6, 
0.7  
N=396 
0.89  -0.7  -2.0, 
0.1  
N=804  
0.09  0.2  -0.4, 
0.7  
N=804  






(per 1 mmol/l)   
0.4  -2.0, 
2.0  
N=392 
0.71  -1.0  -3.0, 
0.5  
N=364 
0.18  2.0  -0.1, 
5.1  
N=800  
0.06  0.1  -2.0, 
2.0  
N=800  






(per 1 mmol/l)   
-2.0  -7.7, 
4.1  
N=388 
0.55  -3.0  -7.7, 
2.0  
N=361 
0.25  3.0  -3.9, 
9.4  
N=796  
0.46  -0.4  -4.9, 
4.1  
N=796  




Cord blood  
HDLc  
(per 1 mmol/l)   
5.0  -3.0, 
13.9  
N=383 
0.25  0.4  -5.8, 
7.3  
N=355 
0.90  18.5  5.1, 
32.3  
N=785  
0.004  5.0  -3.0, 
13.9  
N=785  






(per 1 mmol/l)  
-0.2  -2.0, 
2.0  
N=383 
0.89  -2.0  -3.0, 
0.2  
N=355 
0.08  2.0  -1.0, 
5.1  
N=785  
0.21  -0.3  -2.0, 
2.0  
N=785  




Birthweight †  
(per 100g)  
1.0  0.5, 
2.0  
N=398 
0.000  0.4  -0.03, 
0.8  
N=370 
0.07  -0.7  -1.0, -
0.1  
N=806  
0.04  -0.6  -1.0, -
0.2  
N=806  





Adjustments for confounders  
Model 2: Complete case confounders: offspring sex and age, maternal age, smoking, parity, occupational social class, education, pre-
pregnancy BMI, and alcohol consumption in pregnancy  





8.4 Discussion   
 
 
In this chapter, prospective associations of birthweight and cord blood measures of 
leptin, adiponectin, and lipids with markers of adolescent liver structure and 
function were examined. Out of a total of 42 confounder adjusted tests, only two 
were significant at conventional 5% levels; a positive association of birthweight with 
adolescent liver volume and of cord blood HDLc with adolescent ALT. Overall these 
results did not suggest that birthweight, birth fat (as assessed by cord leptin and 
adiponectin), or cord lipids were associated with later offspring markers of liver 
health when adjustment was made for maternal pregnancy characteristics that were 
likely to confound these associations.  
  
 
Human and animal models demonstrate opposing directions of association of 
birthweight and offspring liver outcomes, perhaps reflecting birthweight as a crude 
marker of fat and lean mass. Whilst lower birth weight has been associated with 
elevated liver transaminases and NAFLD in adolescence and adulthood (Nobili et al., 
2006; Fraser et al., 2008; Faienza et al., 2013; Anderson et al., 2014), offspring 
exposed to an obesogenic environment may also display greater hepatic lipid content 
(McCurdy et al., 2009; Oben et al., 2010; Modi et al., 2011; Brumbaugh et al., 2013). 
Furthermore, a greater rate of weight gain in childhood has also been associated 
with adverse liver outcomes in adolescence (Anderson et al., 2014), which was 
largely mediated by the degree of adiposity in adolescence. That a positive 
association between birthweight and liver volume has been identified may simply 
reflect tracking of greater organ size rather than a relation to hepatic dysfunction 
itself, especially as there was no evidence of offspring mediation at age 17.  
  
 
Adipokines have previously been implicated in the aetiology of NAFLD (Paschos and 
Paletas, 2009; M.S., 2011; Ouchi et al., 2011), with low adiponectin and high leptin 
levels being demonstrated in children (Manco et al., 2007; Fitzpatrick et al., 2010; 





was no observed prospective longitudinal association of cord blood leptin with 
markers of liver function in adolescence, suggests that the contribution of leptin at 
birth to the pathogenesis of childhood NAFLD was limited. Similarly, that 
adiponectin was not associated with multiple measures of liver function 17 years 
later suggested that intrauterine derived adiponectin had minimal impact. Serum 
lipids exhibited strong positive associations with adverse liver function in cross-
sectional analyses (Zelber-Sagi et al., 2012; Orešič et al., 2013). However, in this 
study, no consistent prospective longitudinal associations between cord blood 
lipoproteins and adolescent NAFLD were identified. That cord blood HDLc was 
positively associated with ALT at age 17, may have been a chance finding, 
particularly as there was evidence of mediation by offspring adiposity and height 
measures. Collectively this suggests that although leptin and adiponectin reflected 
neonatal mass, the disease in adolescence may be primarily driven by childhood 
behaviour rather than intrauterine exposures.   
  
 
Whilst previous studies of birthweight with later liver outcomes have been larger 
than this study, this was one of the largest studies to examine cord blood measures 
in relation to subsequent liver outcomes, including measurements assessed by USS. 
The prospective design, long duration of follow-up, detailed anthropometric 
measures, and appropriate adjustment for maternal characteristics that could 
confound the associations were substantive strengths. There were several 
limitations of the study, however.  Ultrasound to assess liver pathology was 
employed as it has been shown to detect moderate to severe steatosis with similar 
accuracy as the gold standard liver biopsy, whilst avoiding an unethical and invasive 
procedure (Shannon et al., 2011). For lesser degrees of hepatic fat mass, however, 
ultrasound may not be as sensitive a tool. The absence of associations in this study 
may reflect this, particularly as a young adolescent population was more likely to 
exhibit subtle changes in hepatic structure as the disease process itself may still be 
in its infancy. Many studies have examined the sensitivity and specificity of 
ultrasound in the detection of liver steatosis compared to the alternative, more 
accurate measures. Where there is moderate to severe hepatic steatosis, the 





89% respectively when all grades of hepatic steatosis are considered (Palmetieri et 
al., 2006; Lee et al., 2010; van Werven et al., 2010; Bril et al., 2015). Alternative 
modes of diagnosing hepatic steatosis include liver biopsy, CT, and MRI. Liver biopsy 
may be observer-dependent and as it is an invasive procedure the patient may 
experience pain or procedure-related complications such as infection or bleeding. 
CT scan exposes the patient to ionising radiation and, like ultrasound, is not a 
reliable method of detecting mild hepatic steatosis. MRI offers the most sensitive 
and specific method of detection (Paige et al., 2017), but is considerably more 
expensive and the environment required to obtain the images may be less well 
tolerated than ultrasound, particularly in younger age groups. Analyses were limited 
to those with an available cord blood sample and to those participants who attended 
the 17-year-old clinic, however, it wass unlikely that this should bias results.  
 
 
Multiple imputation methods were used to account for missing confounder data, with 
similar findings in those with complete data on all confounders. The ALSPAC cohort 
was mainly of white European origin and as a result, this study may not reflect other 
ethnicities that have previously been strongly linked with hepatic dysfunction and 
elevated ALT levels (Fraser, Longnecker and Lawlor, 2007).  
  
 
In animal models, insulin resistance, hyperleptinemia, and hepatic steatosis were 
all features of male but not female offspring of obese mice (Dahlhoff et al., 2014) 
and there have been inconsistent reports of gender-specific predispositions to 
NAFLD. In the current study, the majority of offspring participating in this study 
were female (60.3%) and this may account for the low numbers with evidence of 
NAFLD. Examining offspring outcomes in adolescence may be too early in life to 
identify those who go on to develop metabolic disorders such as NAFLD and type 2 
diabetes. The low prevalence of the disease in adolescence may account for the lack 
of associations in this study and it would be beneficial to repeat the study in an older 
age group where the prevalence of the disease may be greater and more accurately 
assessed. Cord blood sample degradation may have also contributed to variability 





long-term storage (Shih et al., 2000; Paltiel et al., 2008; Gislefoss, Grimsrud and 
Mørkrid, 2009; Brinc et al., 2012).   
  
 
In conclusion, there was no consistent evidence that birth weight, neonatal 
adiposity, or cord blood lipids were associated with liver dysfunction in adolescence. 
This indicates that the disease may be primarily driven by adolescent behaviours and 
phenotype rather than intrauterine exposures or adiposity at birth. The association 
between birthweight and adolescent liver volume may reflect the contribution of 
greater organ size to birthweight and tracking of organ size, rather than any relation 
to hepatic dysfunction itself. The association of maternal adiposity to later offspring 
NAFLD was likely to be a consequence of later environmental effects or in utero 









The DOHaD paradigm was based on earlier pioneering work by Professor David Barker 
(Barker, 2007), who proposed that exposure to an unfavourable intrauterine 
environment may cause permanent re-programming of fetal physiological systems 
and a greater propensity to ill-health in later life. In this thesis, the extent to which 
disturbed maternal metabolism during pregnancy, as a result of greater maternal 
adiposity, diabetes, or HDP, may impact cord blood lipids, adipokines, and 
birthweight has been examined. Tracking of repeat analyte measurements, as well 
as the associations of cord blood analytes at birth and offspring adiposity or 
adolescent development of NAFLD, have also been presented.  
 
 
Specifically, this study has demonstrated that more than fifty percent of overweight 
or obese women gained weight excessively, even though they may have gained less 
weight overall compared to lean women. Maternal BMI during pregnancy, rather than 
GWG alone, was however associated with a wider range of metabolic markers in the 
offspring, with evidence of dyslipidaemia in the cord blood at birth but both BMI and 
GWG were positively associated with birthweight and cord blood leptin. Mid-
pregnancy GWG demonstrated the strongest positive association with birthweight 
whereas late pregnancy GWG displayed a greater positive association with cord 
blood leptin at birth. There was a limited association between mothers with GDM 
and offspring cord blood biomarkers at birth. In contrast, mothers with PGDM 
demonstrated more variability in the cord blood at birth suggesting that the offspring 
of those with known diabetes prior to pregnancy may be at greater risk of metabolic 
disruption, particularly dyslipidaemia. This study has also explored the 
demographics of those that developed HDP and demonstrated that the BP at booking 
was higher in those that later developed HDP, compared to the healthy group. The 
offspring of mothers with PE had overall a lower birthweight, shorter gestational 
period, and higher cord blood leptin and cholesterol at birth, suggesting that these 





Limited evidence of tracking of repeated analytes from birth through to childhood 
and adolescence has been presented. Whilst cord blood lipids, GGT, and adiponectin 
demonstrated a positive association with the repeated analyte measured at age 9, 
GGT was the only analyte that tracked from birth (cord blood) through to 
adolescence. Strong associations were however demonstrated between lipids and 
LFTs obtained at age 9 and repeat measures of the same analyte at age 17. Overall 
this suggests that tracking of analytes may become more progressively defined with 
time but measurement of GGT at birth may be of interest as a biomarker of future 
metabolic health. Lastly, this study has demonstrated that birthweight and cord 
blood adipokines and lipids, reflecting offspring anthropometry at birth, were 
weakly positively associated with offspring fat mass in childhood and adolescence 
but were not associated with adolescent development of NAFLD. Whilst the 
association with later offspring adiposity was robust to a range of confounders, it is 
likely that offspring lifestyle and behaviour may be more likely to account for the 
development of NAFLD rather than any intrauterine exposure alone.  
 
 
Maternal obesity in pregnancy is of growing concern, with a greater risk of obstetric 
and puerperal complications. (Poston, Harthoorn and Van Der Beek, 2011; Poston et 
al., 2016). Fetal complications are also more common in maternal obesity (Gaillard 
et al., 2017), although this risk may not be simply confined to the neonatal period. 
Inappropriate GWG in pregnancy may pose additional risk to the offspring with a 
positive association being identified between GWG and offspring birthweight (Fraser 
et al., 2010; Ludwig and Currie, 2010). GWG has also been positively associated with 
BMI in childhood (Oken et al., 2007; Fraser et al., 2010; Ludwig and Currie, 2010; 
Ludwig, Rouse and Currie, 2013), and in later life (Oken et al., 2008; Mamun et al., 
2009; Schack-Nielsen et al., 2010; Hochner et al., 2012). It is unclear whether 
epigenetic processes may account for these associations and changes in DNA 
methylation have been identified as a plausible mediating mechanism (Sharp et al., 
2015), although shared socioeconomic and lifestyle factors have also been 
implicated (Silventoinen et al., 2016; Tyrrell et al., 2016). Previous reports from 
ALSPAC however suggested that these associations were weak and that maternal BMI 





metabolic markers (Fraser et al., 2010). There was therefore the need to examine 
the causal relationship between maternal BMI and GWG, reflecting fetal 
overnutrition, and offspring adiposity, as measured by birthweight, and the impact 
on the cardio-metabolic cord blood profile at birth.  
 
 
Given the direction of association that exists amongst obese adult subjects, it was 
anticipated that greater GWG and maternal adiposity would be positively associated 
with cord blood leptin and lipids and negatively associated with cord blood 
adiponectin. Whilst GWG was associated with higher cord blood leptin and 
birthweight, pre-pregnancy BMI however was associated with a wider range of 
cardio-metabolic markers at birth, including birthweight. Umbilical cord blood 
leptin is an established biomarker of fat mass and increases with advanced gestation 
mass (Hauguel-de Mouzon, Lepercq and Catalano, 2006). Birthweight is also a crude 
marker of offspring anthropometry at birth that correlates positively with child and 
adult adiposity (Evensen et al., 2017). Although birthweight was positively 
associated with GWG throughout the entire gestational period, in keeping with 
previous reports (Tobi et al., 2009; Fraser et al., 2010), the strongest effect of the 
association was evident during mid-pregnancy. This highlighted that inappropriate 
GWG during specific periods of pregnancy may pose the greatest risk of offspring 
programming, and this has also been demonstrated previously by others (Fraser et 
al., 2010; Hivert et al., 2016). 
 
 
Over half of overweight or obese mothers included in the study exceeded the IOM 
recommendations (even though they may have gained less weight overall than 
normal-weight women). This inappropriate GWG may therefore have exaggerated 
the altered metabolism already present in obese pregnancy which collectively has 
the potential to translate on to the fetus via fuel-mediated teratogenesis.  Whilst 
neonatal adiponectin has been positively associated with offspring birthweight, in 
contrast to associations seen in later life, it is not thought to be associated with 





maternal adiposity, which may account for the lack of associations identified in the 
current study.  
 
 
GDM is a common complication of pregnancy and poses a significant long-term risk 
to the mother (Catalano et al., 2003; Egan et al., 2014; Gante et al., 2015). The 
fetus is also at greater risk of obstetric complications, birth injury, and stillbirth. 
Macrosomia may be detected in mid-pregnancy and may reflect progressive insulin 
resistance, inadequate glucose control, and greater transmission of nutrients to the 
fetus. The HAPO study suggested that the risk of offspring macrosomia was 
exponentially higher when maternal diabetes was combined with maternal obesity  
(Catalano et al., 2012), suggesting that the offspring of obese diabetic mothers may 
be at the greatest risk of inheriting this phenotype and maternal BMI may contribute 
to the causal pathway. Offspring risk may extend into adolescence as maternal 
diabetes has been also associated with offspring fasting glucose levels at age 15 
(Patel et al., 2012). Although dyslipidaemia and hypoadiponectinemia may be 
evident amongst mothers with diabetes, there is less consistent evidence of altered 
lipid profile in the offspring, however (Patel et al., 2012). It was, therefore, 
proposed that maternal diabetes in pregnancy would not be associated with elevated 
cord blood lipids levels but would be associated with lower neonatal adiponectin 
levels in the offspring at birth.  
 
 
GDM may have only a limited influence on offspring programming at birth, as 
demonstrated by the fact that GDM, in addition to GWG, positively influences the 
offspring anthropometry but not the cardiometabolic profile at birth. Offspring of 
those with PGDM displayed cord blood dyslipidaemia however and as such, chronic 
exposure to hyperglycaemia may confer greater risk to the fetus at birth. The lack 
of associations in this study may be due to the low prevalence of the disease in this 
relatively lean cohort, but may also reflect successful intervention during pregnancy 







There is an increasing prevalence of HDP amongst the contemporary population, 
partly due to maternal obesity but also because of greater maternal age at the index 
pregnancy. PE is a multi-system disorder of endothelial dysfunction and systemic 
inflammation and as such,  long-term maternal sequelae include a greater risk of 
chronic hypertension, hyperinsulinemia, and dyslipidaemia (Khatua et al., 1989; 
Vanessa A. Rodie et al., 2004; Ophir et al., 2006; Fraser et al., 2012) as well as the 
greater risk of cardiovascular dysfunction in later life (Bellamy et al., 2007; 
McDonald et al., 2008; Wan Sulaiman et al., 2016). HDP may also impose abnormal 
intrauterine exposure to the offspring. Lower associated birthweight, shorter 
gestational age or preterm delivery, and the associated placental dysfunction may 
all lead to more pronounced endothelial dysfunction throughout life. Increased 
oxidative stress and altered placental lipid transport during pregnancy with PE may 
also lead to dyslipidaemia in the offspring (Vanessa A. Rodie et al., 2004; 
Romanowicz and Bańkowski, 2009). Given these existing associations,  it was further 
hypothesised that pregnancy affected by PE would be associated with higher cord 
blood triglyceride and LDLc, as well as lower HDLc levels.  
 
 
Examining the cohort, it was identified that women who later developed HDP, in 
particular PE, were in general younger, nulliparous non-smokers with a higher BMI 
at booking, and this was in keeping with national guidance (NICE, 2010). Booking 
blood pressure was also more likely to be higher with DBP specifically rising more 
sharply in the third trimester.  
 
 
The offspring of mothers with PE had a lower birthweight and were delivered earlier 
than healthy subjects, both of which are risk factors for cardio-metabolic 
dysfunction in later life. Amongst the offspring of those with PE, higher cord blood 
leptin and cholesterol levels were identified, suggesting that HDP may compete in 
the causal pathway. Maternal BP was also examined across each gestational period 
in relation to cord blood analytes and birthweight. In particular, SBP at booking and 
changes in SBP in the third trimester was positively associated with cord blood HDLc 





greater risk to the mother but the study also suggests that the offspring may be at 
greater risk of metabolic dysfunction as well.  
 
 
Whilst there is limited evidence of tracking of analytes in early life, studies have 
suggested that serum lipoproteins show evidence of tracking over 12 years (Porkka 
et al., 1994) and that lipids, in particular, have been associated with cardiovascular 
disease occurring more than 20 years later (Klag et al., 1993; Raitakari et al., 2003). 
It has therefore been proposed that lipids may act as surrogate markers of future 
cardiovascular risk. LFTs have also displayed evidence of tracking in adulthood (Patel 
et al., 2007; Nguyen et al., 2011), and may be used as indicators of future disorder 
metabolism. There is limited evidence that adipokines, such as leptin however show 
evidence of tracking and it remains unclear if an association, if any, begins in utero 
and persists throughout life. Whilst leptin is a recognised biomarker of fat mass and 
ponderal index in the neonatal period (Hauguel-de Mouzon, Lepercq and Catalano, 
2006; Karakosta et al., 2011, 2013), cord blood leptin has not been associated with 
later repeat measures of leptin in childhood (Volberg, Heggeseth, et al., 2013). 
Leptin obtained in childhood however has displayed evidence of tracking into late 
childhood (Nishimura et al., 2009; Volberg, Heggeseth, et al., 2013), and it appears 
that reproducible tracking of such analytes may strengthen with time. 
 
 
As positive associations have previously been demonstrated between LFTs, lipids, 
and adipokines in later life, it was anticipated that cord blood measures would also 
be positively associated with repeated measures of the same analyte in childhood 
and adolescence.  This study has demonstrated that lipids, as well as adiponectin 
and markers of liver function, may track from birth (cord blood) through to 
childhood, but that the association was lost between birth and age 17.  Associations 
with repeated ‘like for like’ measures of GGT however persisted from birth to age 
17, demonstrating that certain cord blood measures may have the potential for use 
as clinical predictors. In keeping with previous reports, this study also demonstrated 
that lipids and LFTs, measured at age 9, are strongly associated with repeat analytes 





marked between childhood and adolescence, these associations may offer greater 
clinical value with advancing age.   
 
 
Given the positive associations that exist between cord blood leptin and fat mass at 
birth and in early childhood, as well as the direct effect adiponectin has on body 
composition and fat deposition, it was further hypothesized that higher cord blood 
leptin and lower cord blood adiponectin, would be associated with greater adiposity 
in later childhood and adolescence. Birthweight and cord blood adipokines, 
reflecting the intrauterine environment at birth, were used to examine the long-
term metabolic function of the offspring, as measured by adiposity in late childhood 
and adolescence.   
 
 
This study has shown that neonatal fat mass (as determined by surrogate markers 
cord blood leptin and adiponectin), was weakly associated with greater fat mass in 
late childhood and adolescence. Maternal factors, however, mainly maternal BMI, 
did appear to attenuate these associations and may have contributed to the causal 
pathway. This study also added to previous literature showing that adiponectin 
positively correlated with birthweight and leptin, and supported neonatal leptin as 
a valid marker of neonatal fat mass (Hauguel-de Mouzon, Lepercq and Catalano, 
2006). The association between adiponectin and adolescent measures of adiposity 
however were robust to adjustments for confounders, which accounted for a range 
of maternal and shared environmental exposures. Maternal over-nutrition may 
therefore have a direct effect on fetal fat accretion which sets a trajectory for 
enhanced offspring adiposity throughout later life. 
 
 
In line with the global trend in obesity, there has been an increasing prevalence of 
NAFLD worldwide. The identification of NAFLD in children and adolescents has led 
to the speculation that intrauterine events may contribute to its early pathogenesis 
(Alisi et al., 2012; Brumbaugh and Friedman, 2014). Whilst animals fed high-fat diets 





et al., 2009; Oben et al., 2010), evidence amongst human subjects remains less 
clear, with birthweight being positively associated with later development of NAFLD 
in some (Anderson et al., 2014), but not all studies (Ayonrinde et al., 2015). In this 
study, it was hypothesized that cord blood leptin and lipids would be positively, and 
adiponectin negatively associated with NAFLD in adolescence, given the already 
established associations between these measures and NAFLD activity in later life. 
 
 
There was no consistent evidence however that birth weight, neonatal adiposity, or 
cord lipids were associated with liver dysfunction in adolescence. The development 
of NAFLD may therefore be mainly driven by adolescent behaviours and phenotype 
rather than intrauterine exposures or adiposity at birth.  
 
 
Whilst the detailed anthropometric markers and long duration of follow-up added to 
the strength of this prospective study, it was subject to limitations. The low 
prevalence of disease amongst this relatively lean population may have accounted 
for the lack of associations seen with offspring adiposity. The cohort included a 
mainly Caucasian population, so it was difficult to translate these findings across 
other ethnicities. Finally, sample degradation with long-term storage may have 
contributed to the variability within the samples. Significant degradation was 
evident for cord blood c-peptide, hence its exclusion from the study.  
 
 
9.2 Final Conclusions 
 
 
This thesis has examined the disordered maternal metabolism in pregnancy and how 
this may have influenced offspring birthweight and cord blood biomarkers at birth. 
In addition, the extent to which cord blood markers tracked from birth into 





and birthweight, reflecting anthropometric markers at birth, on long-term adiposity 
outcomes, were determined.  
  
 
As detailed in each of the Chapters, this study may draw several conclusions. Firstly, 
it has demonstrated that pre-pregnancy BMI, rather than GWG alone, was more 
consistently associated with a range of offspring cardio-metabolic markers in the 
cord blood at birth, namely offspring dyslipidaemia, and this was in keeping with 
current literature. Both BMI and GWG were however positively associated with 
greater offspring birthweight and cord blood leptin. There was limited evidence of 
metabolic dysfunction in the offspring of mothers with GDM compared to offspring 
of those with PGDM who displayed more variability in the cord blood, specifically 
evidence of dyslipidaemia. Offspring of mothers who developed PE during pregnancy 
may also have been at greater risk of metabolic dysfunction, as lower birthweight 
and higher cord blood leptin and cholesterol were evident amongst this population.   
 
 
Whilst there was evidence of tracking of cord blood adipokines, lipids, and LFTs from 
birth to age 9, the association beyond that was lost for all but GGT. As GGT has been 
implicated in metabolic disorders in later life, this novel finding may highlight the 
use of clinical biomarkers obtained at birth as potential predictors of longer-term 
health, although replication of the findings would be required in future studies. 
Tracking of analytes obtained at age 9 then again at age 17 was more consistent and 
overall this suggested that tracking may become more progressively defined with 
time. This study also demonstrated that cord blood leptin was weakly, and 
adiponectin strongly related to adiposity in childhood and adolescence respectively. 
Using cord blood leptin as a reflection of fetal fat mass, these associations 
demonstrated that maternal overnutrition may therefore have had a direct effect 
on fetal fat accretion, determining a trajectory for enhanced offspring adiposity in 
later life. The fact that neither birthweight, nor adiposity at birth were related to 
offspring markers of liver health in adolescence indicated that the onset of NAFLD 
was mainly driven by behavioural and environmental factors rather than triggered 





Whilst it was difficult to account for environmental and lifestyle influences, 
adjustment for a wide range of pregnancy, maternal and offspring characteristics 
has contributed to the robust analysis and interpretation of the findings. 
Reproducing this study using a more contemporary and diverse cohort may also add 
to its validity. Lastly, analysis of blood samples at serial time points would have 
eliminated the risk and extent of blood sample degradation, and contributed to the 
reliability of the findings from this study. Future work may also include optimising 
maternal pre-pregnancy BMI for all women of reproductive age as well as improving 
glycaemic control amongst those with PGDM, given the potential metabolic 
implications for the offspring. In addition, examining tracking of blood analytes from 
childhood onwards may be of clinical value in predicting future metabolic 
dysfunction. Lastly, given the global obesity pandemic, future work should also be 
considered to determine the long-term implications of cord blood adipokine 
disruption at birth on the risk of offspring adiposity and if this in itself poses any 
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 1 2    
1 13.94 15.18 14.56 0.88 0.06 
2 14.15 15.31 14.73 0.82 0.06 
3 13.45 14.58 14.02 0.80 0.06 
4 10.90 13.74 12.32 2.01 0.16 
5 14.96 16.12 15.54 0.81 0.05 
6 13.74 14.73 14.24 0.70 0.05 
7 15.09 15.55 15.32 0.33 0.02 
8 13.85 15.40 14.63 1.10 0.08 
9 14.76 14.72 14.74 0.03 0.00 
10 15.63 15.40 15.51 0.16 0.01 
11 16.29 17.54 16.92 0.88 0.05 
12 14.49 15.87 15.18 0.98 0.06 
13 14.52 15.19 14.86 0.47 0.03 
14 15.80 18.21 17.00 1.70 0.10 
15 15.35 15.86 15.61 0.36 0.02 
16 15.33 16.26 15.80 0.66 0.04 
17 13.08 14.10 13.59 0.72 0.05 
18 14.83 15.93 15.38 0.77 0.05 
19 12.46 14.04 13.25 1.12 0.08 
20 12.83 14.41 13.62 1.12 0.08 
21 13.94 15.05 14.50 0.78 0.05 
22 14.92 16.12 15.52 0.85 0.05 
23 13.91 14.36 14.13 0.32 0.02 
24 13.36 14.44 13.90 0.76 0.05 
25 12.73 14.00 13.37 0.90 0.07 
26 15.09 13.47 14.28 1.14 0.08 
27 12.93 11.98 12.45 0.67 0.05 
28 13.18 14.88 14.03 1.20 0.09 
29 14.77 15.81 15.29 0.74 0.05 
30 13.23 14.36 13.79 0.80 0.06 
31 12.96 14.90 13.93 1.38 0.10 
32 14.32 15.62 14.97 0.92 0.06 
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56 13.28 14.82 14.05 1.09 0.08 
57 14.38 15.47 14.94 0.77 0.05 
58 13.93 15.26 14.59 0.94 0.06 
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61 13.59 14.85 14.22 0.89 0.06 
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64 13.35 14.46 13.90 0.78 0.06 
      
Mean (µg/ml)    14.41   
SD (µg/ml)    0.47  
CV Inter-assay     0.03 



























































1 1.11 4.09 2.49 43.7 52.6 1.27 53.0 1.91 (0.01) 
0.00  
(0.5) 9.70 (0.01) 
0.00 
(0.1) 






















6 1.08 3.92 2.46 42.6 49.3 1.23 52.0 1.82  9.38  
7 1.05 3.98 2.48 43 49.8 1.25 53.0 1.88  9.26  
8 1.09 4.00 2.5 43.6 49.5 1.23 52.0 1.74  9.09  
9 1.16 3.98 2.52 44.3 49.6 1.24 53.0 1.73  9.08  










12 1.12 3.87 2.51 43.7 49.7 1.24 52.0 2.22  9.73  
13 1.16 4.00 2.5 44.7 51.6 1.28 54.0 1.52  8.03  
14 1.16 4.00 2.5 44.7 51.6 1.28 54.0 1.52  8.03  
15 1.11 3.99 2.48 46.8 50.6 1.24 52.0 2.22  9.73  
16 1.11 3.99 2.48 46.8 50.6 1.24 52.0 1.82  9.38  
17 0.98 3.97 2.43 41.3 47.7 1.22 50.0 2.22  9.73  





19 1.15 3.92 2.48 41.3 50.6 1.23 50.0 2.05  9.81  















23 1.1 3.93 2.48 41.1 49.6 1.24 50.0 1.86  10.95  
24 1.1 3.93 2.48 41.1 49.6 1.24 50.0 1.86  10.95  
25 1.1 3.93 2.48 42.2 50.7 1.24 50.0 1.83  9.85  
26 1.1 3.93 2.48 42.2 50.7 1.24 50.0 1.83  9.85  
27 1.17 3.66 2.58 42.2 50.7 1.27 50.0 1.83  9.85  
28 1.13 3.95 2.49 42.2 50.2 1.22 50.0 2.00  7.24  
29 1.13 3.95 2.49 42.2 50.2 1.22 50.0 2.00  12.28  















33 1.14 4.00 2.48 40.5 47.7 1.23 51.0 1.92  10.14  
34 1.13 3.97 2.53 40.5 47.7 1.24 51.0 1.92  10.14  
35 1.13 3.97 2.53 40.5 47.7 1.24 51.0 1.92  10.14  
36 1.13 3.95 2.59 39.4 44.9 1.25 50.0 2.00  12.27  
37 1.13 3.95 2.59 40.9 44.6 1.25 50.0 2.19  11.1  
38 1.11 3.85 2.51 43.5 49.9 1.27 52.0 2.19  11.1  
39 1.13 3.91 2.49 42.1 49.1 1.23 52.0 2.36  9.08  




















44 1.13 3.98 2.64 45.1 51.5 1.28 53.0 1.66  10.77  
45 1.11 3.94 2.53 43.1 51.3 1.23 52.0 1.86  8.67  
46 1.11 3.94 2.53 43.1 51.3 1.23 52.0 1.82  9.01  
47 1.11 3.99 2.5 42.4 48.9 1.23 51.0 1.82  9.01  
48 1.2 3.95 2.52 46.7 53.7 1.31 54.0 1.65  9.03  
49 1.1 3.94 2.39 41.4 49.7 1.24 51.0 1.92  10.57  
50 1.2 3.95 2.52 46.7 53.7 1.31 54.0 1.77  9.59  















54 1.11 3.96 2.62 42.9 51.7 1.3 53.0 1.87  8.38  
55 1.11 3.96 2.62 42.9 51.7 1.3 53.0 1.97  8.9  
56 1.1 3.95 2.61 41.1 51 1.3 52.0 1.97  8.9  
57 1.09 3.97 2.64 42.3 51.1 1.32 52.0 1.91  8.66  
58 1.09 3.97 2.64 42.3 51.1 1.32 52.0 1.91  8.66  
59 1.09 3.97 2.64 42.3 51.1 1.32 52.0 1.69  8.68  










62 1.09 3.95 2.59 44.2 50.4 1.28 52.0 1.82  8.21  
63 1.09 3.95 2.59 44.2 50.4 1.28 52.0 1.82  8.21  
64 1.09 3.95 2.59 44.2 50.4 1.28 52.0 1.8  9.03  
Mean 1.11 3.95 2.52 42.82 50.03 1.25 51.56 1.90  9.51  





(1.0) 0.03 (3.0) 
0.04 
(4.0) 0.04 (4.0) 0.03 (3.0) 
0.03 





























ALSPAC 0.1 11.4 14.4 1.3 2.5 1.1 50.0 3.4 51.5 
(Popova et al., 
2018) Mean (SD) 
0.9 (0.4)  10.6 (10.4)  18.3 (14.3)        
(Kim, Lim and Oh, 
2017) Mean (SD)  
        156.7 
± 98.2  
(Rifas-Shiman et 
al., 2017) Mean 
(SD)  
1.0 (0.6)  9.0 (6.6)  28.7 (6.8)        
(Lemas et al., 
2015) Mean (SD) 
 14.3 (13.2)   49.1 (40.5)   26.3 (7.5)     
(Hou et al., 2014) 
Median (IQR) 
0.31  
(0.23, 0.42)  
  0.29  
(0.23, 0.37)  
1.60  
(1.38, 1.88)  
0.79  
(0.66, 0.96)  
   
(Melkie et al., 
2012) Mean (95% 
CI)  







(Regnault et al., 
2011) Mean (SD)  
1.0 (0.49)          
(Inoue et al., 2008) 
Mean (SD)  
  14.9 ± 5.8        
(Metzger et al., 
2008) Mean (SD)  





Chapter 6, Table 5: Spearman correlations between birthweight and cord blood measures (N obs, R) 
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Chapter 6, Table 6: Spearman correlations between BMI, FM and analyte measures at age 17 (N obs, R) 
 
  











































































Chapter 7, Table 7: Associations (%) of birthweight and cord blood analyte with FM, WC and BMI at age 9, 15 and 17 years  
Outcome  FM*  WC  BMI  
  Age 9 Age 17 Age 9 Age 15 Age 9 Age 17 
Exposure  Model %  Change 
(95% CI) 
P %  Change 
(95% CI) 
P % Change 
(95% CI) 
P % Change 
(95% CI) 
P %  Change 
(95% CI) 













































































































































































































































































































Models 1: Adjusted for offspring sex, 2: Adjusted for sex and maternal confounders (age, smoking, parity, occupational social class, education and pre-
pregnancy BMI), 3: Adjusted for offspring sex and maternal confounders plus pregnancy confounders (gestational age at birth, mode of delivery, GWG, 
hypertensive disorders and diabetic disorders of pregnancy). * FM adjusted for height † Leptin adjusted for birthweight ‡ Birthweight adjusted for sex, 





Chapter 7, Table 8: Associations of birthweight and cord blood analyte with FM and BMI at age 9 and 17 years (using non-
imputed data)   
 
 
Outcome                             Fat mass*  BMI  
 Age 9 Age 17 Age 9 Age 17 
Exposure  %  Change  
(95% CI) 
P  %  Change  
(95% CI) 
P  %  Change  
(95% CI) 
P    %  Change  
(95% CI) 
P   
Leptin (10pg/ml)   
  
0.7  
(-1.8, 3.2)  
0.015  2.0  
(-1.2, 5.3) 
0.222  0.3  
(-0.5, 1.1)  
0.452  0.6  
(-0.4, 1.6)  
0.227  
Adjusted Leptin† (10pg/ml)   
  
0.9  
(-1.7, 3.6)  
0.482  1.2  
(-2.1, 4.7) 
0.475  -0.2  
(-1.0, 0.6)  
0.618  0.2  
(-0.8, 1.3)  
0.633  
Adiponectin (10µg/ml)   
  
1.4 
(-2.6, 5.5)   
0.495  2.3  
(-0.3, 7.8) 
0.399  0.5  
(-0.8, 1.7)  
0.464  0.9  
(-0.8, 2.5)  
0.299  
Birthweight‡ (100g)  
  
-5.1  
(-21.6, 14.8)  
0.589  22.0  
(-4.5, 55.9) 
0.111  13.8  
(7.6, 20.3)  
<0.001  9.4  




Adjusted for offspring sex and maternal confounders plus pregnancy confounders (gestational age at birth, mode of delivery, 
gestational weight gain, hypertensive disorders and diabetic disorders of pregnancy. * Fat mass adjusted for height. † Leptin 
adjusted for birthweight, ‡ Birthweight adjusted for sex, gestational age and singleton/twin pregnancy, % refers to percentage 





Chapter 8, Table 9: Characteristics of those who had a liver scan and/or LFT’s 
performed at age 17 using imputed and observed data  
  Liver scans Liver Function Tests 
  MI Data Observed data MI Data Observed data 
  Median or % 




Median or % 












Median or % 







Maternal Characteristics          
Age (yrs)  29 (26, 32) 541 29 (26, 32) 535 1.1 (6) 29 (26, 32) 1037 29 (26, 32) 1023 1.3 
(14) 
Smoking  
Never   
Before, 
















































































Social Class  





















































































>1 glass/wk  




























Offspring characteristics   



























Age   17.8 (17.6, 
18.3) 
















Chapter 8, Table 10: Association of birthweight and cord blood measures with markers of liver health in adolescence 
(multiple imputation datasets) N=541 for liver scans, N=1037 for LFTs   
Outcome Age 17:  logLiver volume (ml)  logLiver sheer velocity 
(m/s)  
 logALT (U/l)  logAST (U/l)  logGGT (U/l)  
Exposure   
Model (1,2)  
β  CI  P  β CI  P  β CI  P  β CI  P  β CI  P  
Cord blood                 
Leptin  





-0.01, 0.03  





-0.02, 0.01  






-0.02, 0.03  





-0.01, 0.02  





-0.02, 0.02  










-0.01, 0.01  





-0.01, 0.01  






-0.01, 0.01  





-0.00, 0.01  





0.00, 0.01  










-0.02, 0.02  





-0.03, 0.01  






-0.01, 0.04  





-0.02, 0.01  





-0.02, 0.02  









-0.06, 0.07  





-0.08, 0.03  






-0.04, 0.08  





-0.05, 0.04  





-0.07, 0.03  









-0.08, 0.09  





-0.05, 0.09  






-0.01, 0.20  





-0.04, 0.10  





-0.07, 0.11  









-0.02, 0.02  





-0.03, 0.00  






-0.01, 0.04  





-0.02, 0.01  





-0.03, 0.02  
-0.02, 0.02  
0.81  
0.83  
Birthweight †  





0.01, 0.02  





0.00, 0.01  






-0.01, 0.00  





-0.01, 0.001  





-0.01, 0.003  




Adjustments for confounders  
Models 1: offspring sex and age, Model 2: offspring sex and age, maternal age, smoking, parity, occupational social class, education, pre-
pregnancy BMI and alcohol consumption during pregnancy † Birthweight is adjusted for gestational age and sex, therefore not additionally 





Chapter 8, Table 11: Association of birthweight and cord blood analyte with measures of liver health in adolescence 
(complete case)  
Outcome Age 
17:     
logLiver volume (ml)  logLiver sheer velocity 
(m/s)  
logALT (U/l)  logAST (U/l)  logGGT (U/l)  
Exposure:  β  CI  P  β CI  P  β CI  P  β  CI  P  β CI  P  
Cord blood                
Leptin  
(per 10 
pg/ml)   
0.01  -0.01, 0.02 
N=402 
0.47 0.00 -0.02, 0.01 
N=374 
0.95 -0.01 -0.03, 0.02 
N=813 
0.54 -0.01 -0.02, 0.01 
N=813 









0.71 0.00 -0.01, 0.01 
N=396 
0.89 -0.01 -0.02, 0.00 
N=804 
0.09 0.00 0.00, 0.01 
N=804 





mmol/l)   
0.00  -0.02, 0.02 
N=392 
0.71 -0.01 -0.03, 0.01 
N=364 
0.18 0.02 0.00, 0.05 
N=800 
0.06 0.00  -0.02, 0.02 
N=800 





mmol/l)   
-0.02  -0.08, 0.04 
N=388 
0.55 -0.03 -0.08, 0.02 
N=361 
0.25 0.03 -0.04, 0.09 
N=796 
0.46 0.00 -0.05, 0.04 
N=796 





mmol/l)   
0.05  -0.03, 0.13 
N=383 
0.25 0.00 -0.06, 0.07 
N=355 
0.90 0.17 0.05, 0.28 
N=785 
0.004 0.05 -0.03, 0.13 
N=785 




(per 1 mmol/l)  
0.00 -0.02, 0.02 
N=383 
0.89 -0.02 -0.03, 0.00 
N=355 
0.08 0.02 -0.01, 0.05 
N=785 
0.21 0.00 -0.02, 0.02 
N=785 
0.74 0.00 -0.03, 0.02 
N=785 
0.79 
Birthweight†   
(per 100g)  
0.01 0.01, 0.02 
N=398 
0.00 0.00 0.00, 0.01 
N=370 
0.07 -0.01 -0.01, 0.00 
N=806 
0.04 -0.01 -0.01,0.00 
N=806 




Adjustments for confounders  
Models 1: offspring sex and age, 2: offspring sex and age, maternal age, smoking, parity, occupational social class, education, pre-
pregnancy BMI and alcohol consumption during pregnancy † Birthweight is adjusted for gestational age and sex, therefore not additionally 





Nuclear Magnetic Resonance Spectroscopy (NMR) 
 
Introduction and Aim 
 
To provide an overview of metabolic and inflammatory pathways evident at birth we 
aimed to collect and analyse cord blood samples using 1H-NMR spectroscopy, 
developed by the team at the University of Oulu, Finland. This is also an established 
facility at the Glasgow Polyomics Unit at the University of Glasgow. These resources 
permit accurate quantification of 216 metabolomic traits. These are grouped as: (1) 
lipoprotein lipids (LIPO) consisting of lipids (cholesterol compounds, phospholipids 
and the –CH3 group of Tg), serum albumin and albumin-bound fatty acid resonances; 
(2) low molecular weight molecules (LMWM) encompassing pyruvic acid, amino acids, 
ketone bodies, creatinine, and small molecules that are proxies for fundamental 
metabolic processes including glycolysis, citric acid and urea cycles; and (3) serum 
lipid constituents (LIPID) with detailed molecular information on serum lipid extracts 
including free and esterified cholesterol, sphingomyelin, degree of saturation and 
ω-3 fatty acids.  
 
Methods (Please refer to the Research Protocol (Supporting documents) 
 
Ethical approval was obtained, and 100 cord blood samples were obtained along with 
maternal and offspring co-variables. Please refer to the Appendix for example of the 










There are quite large differences in the cord blood samples analysed by NMR, as 
shown in Figure 1, which was provided by the University of Oulu, Finland. In NMR 
spectroscopy the signal intensity is directly proportional to the concentration of an 
identified compound. Thus, the larger the peak, the larger the concentration.  The 
majority of analyte data are reported as a molar concentration, but derived 
variables are reported as ratios. 
 
In the LMWM window, there is a clear difference e.g. in alanine concentration, and  
in the LIPID window, for example there are large differences in PUFAs. For the LIPO 
window, the peaks on the right are used e.g. to quantify the different lipoprotein 
subclasses. Here the shape is related to quantity of different lipoprotein subclasses. 
For example, there are two samples that have somewhat sharper signals that reflect 




The cord blood samples used in NMR analysis showed large variability within the 





spectroscopy with cord blood samples, this provides some insight into future 







Table 7: Summary of cord blood collection maternal and offspring 
characteristics (N=100) 
 Mean (range) N (%) 
Age (years) 31 (19 – 42)  
BMI (kg/m2) 25.6 (19 – 43)  
Gestation (weeks) 40 (33 – 42)  
Parity    

















Birthweight (kg) 3.3 (1.2 – 5.2)  
Sex                                 
Female 
Male 
 52 (52) 
48 (48) 



























West of Scotland Research Ethics Service  
             
  
  West of Scotland REC 5  
  Ground  Floor - Tennent Building  
Professor Scott Nelson  Western Infirmary 38 Church Street  
Muirhead Chair in Reproductive & and Maternal  Glasgow   
Medicine  G11  6NT  
University of Glasgow      
2nd Floor McGregor Building  Date  27 March 2013  
Western Infirmary  
Glasgow  
G11 6NT  
  
  
Dear Professor Nelson  
  
    
 Direct line  0141 211 2102  
 E-mail  sharon.macgregor@ggc.scot.nhs.uk  
  
Study title:  Collection of Umbilical Cord Blood Samples for NMR Assay 
Development   
REC reference:  13/WS/0072  
IRAS project ID:  126334  
  
The Research Ethics Committee reviewed the above application at the meeting held on 20 
March 2013. Thank you to Dr Simpson for attending to discuss the application.  
  
We plan to publish your research summary wording for the above study on the NRES 
website, together with your contact details, unless you expressly withhold permission to do 
so. Publication will be no earlier than three months from the date of this favourable opinion 
letter. Should you wish to provide a substitute contact point, require further information, or 
wish to withhold permission to publish, please contact the Co-ordinator Mrs Sharon 
Macgregor, sharon.macgregor@ggc.scot.nhs.uk.  
  
Ethical opinion  
  
Ethical issues, raised by the Committee in private discussion, together with 
responses given by the researcher when invited into the meeting  
  
It was noted in the Participant Information Sheet that if the patient withdraws, the samples 
will be destroyed.  However, if they are in another country, how feasible will this be?  
Dr Simpson confirmed that the samples will be linked anonymously so they could be 
identified and removed for destruction.  
  
The members of the Committee present gave a favourable ethical opinion of the above 
research on the basis described in the application form, protocol and supporting 








Ethical review of research sites  
  
NHS Sites  
  
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see “Conditions of the favourable opinion” below).   
  
Conditions of the favourable opinion  
  
The favourable opinion is subject to the following conditions being met prior to the start of 
the study.  
  
Management permission or approval must be obtained from each host organisation prior to 
the start of the study at the site concerned.  
  
Management permission (“R&D approval”) should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements.  
  
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk.    
  
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity.  
  
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.   
  
Sponsors are not required to notify the Committee of approvals from host organisations  
  
It is responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable).  
  
Approved documents  
  
The documents reviewed and approved at the meeting were:  
   
Document     Version     Date     
Covering Letter      28 February 2013   
Investigator CV      28 February 2013   
Other: Student CV   Feb 2013       
Participant Consent Form   2   28 February 2013   
Participant Information Sheet   2   28 February 2013   
Protocol   2   28 February 2013   
REC application   2   28 February 2013   
  






The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet.  
  
Statement of compliance   
  
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK.  
  
After ethical review  
  
Reporting requirements  
  
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including:  
  
• Notifying substantial amendments  
• Adding new sites and investigators  
• Notification of serious breaches of the protocol  
• Progress and safety reports  
• Notifying the end of the study  
  
The NRES website also provides guidance on these topics, which is updated in the light of 




You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views 
known please use the feedback form available on the website.  
  
Further information is available at National Research Ethics Service website > After Review  
  
13/WS/0072  Please quote this number on all correspondence 
  
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/   
  
With the Committee’s best wishes for the success of this project.  
  











Enclosures:  List of names and professions of members who were present 
at the meeting and those who submitted written comments 
“After ethical review – guidance for researchers”   
  
Copy to:  Dr Joy Simpson, NHS Greater Glasgow and Clyde  






R&D Management Office 
Western Infirmary 
Tennent Institute 
1 st Floor, 38 Church Street Greater Glasgow 
Glasgow, Gil 6NT 
Coordinator/Administrator: JMcG/LR 




16th April 2013 
Professor Scott Nelson 
Professor of Obstetrics & Gynaecology 




NHS GG&C Board Approval 
Dear Professor Nelson 
Study Title: Collection of Umbilical Cord Blood Samples for NMR Assay 
Development 
Chief Investigator/ Academic Supervisor: Professor Scott Nelson 
Student: Dr Joy Simpson 
GG&C HB site: SGH, PRMH 
Sponsor: NHS GG&C Health Board 
Reference: GN130B157 
REC Ref: 13/WS/0072 
Protocol no: V2 dated 28/02/13 
I am pleased to confirm that Greater Glasgow & Clyde Health Board is now able to grant 
Approval for the above study. 
Conditions of Approval 
1 For Clinical Trials as defined by the Medicines for Human Use 
Clinical Trial Regulations, 2004 
a. During the life span of the study GGHB requires the following 
information related solely to this site 
i. Notification of any potential serious 
breaches. ii. Notification of any 
regulatory inspections. 
It is your responsibility to ensure that all staff involved in the study at this site 





(www.nhsqqc.org.uk/content/default.asp?paqe=s141 1), evidence of such training to 
be filed in the site file. 
2 For all studies the following information is required during their 
lifespan. 
a. Recruitment Numbers on a monthly basis 
b. Any change of staff named on the original SSI form 
c. Any amendments — Substantial or Non-Substantial 
Delivering better health nhsggc. 
 NoncommApproval 041010 V3 
d. Notification of Trial/study end including final recruitment 
figures 
e. Final Report & Copies of Publications/Abstracts 
Please add this approval to your study file as this letter may be subject 
to audit and monitoring. 
Your personal information will be held on a secure national web-based NHS 
database. 











Dr Joy Simpson 







Centre Number:  
Study Number:  




Title of Project: Umbilical Cord Blood Sampling for the Purpose of Nuclear Magnetic Resonance Machine 
Calibration 
Name of Researcher: Dr Joy Simpson 
Please initial box  
 
1. I confirm that I have read and understand the information sheet dated 28/02/13  
(version 2) for the above study. I have had the opportunity to consider the  
 information, ask questions and have had these answered satisfactorily.  
 
2.  I understand that my participation is voluntary and that I am free to withdraw at any time  
without giving any reason, without my medical care or legal rights being affected.  
 
3. I understand that relevant sections of my medical notes and data collected during the study,  
may be looked at by individuals from the University of Glasgow or from NHS Greater Glasgow  
and Clyde and it is relevant to my taking part in this research. I give permission for these  
individuals to have access to my records. I understand that non-identifiable information will  
then be sent along with the linked cord blood sample to the University of Eastern Finland and  
to Skylight Biotech, Japan. 
 
5.  I agree to take part in the above study which will involve cord blood samples being taken from  
the umbilical cord after birth for the purpose of Nuclear Magnetic Resonance assay  
development. I understand that the samples will be kept in storage after this.   
 
_____________________ ________________  __________________________  
Name of Patient   Date    Signature  
 
 
_____________________  ________________  __________________________  
Name of Person   Date    Signature  
taking consent  
 












                                                                                                                                                                                
 
 
Please reply to: Dr Joy Simpson 
                           Research office, 3rd Floor McGregor Building 
                           Western Infirmary 
                           University of Glasgow, G11 6NT 
                           E-mail:joy.simpson@glasgow.ac.uk 
 
                         
                   VOLUNTEER INFORMATION LEAFLET 
 
Collection of umbilical cord blood samples for NMR assay development. 
 
Lay title: Collection of umbilical cord blood samples for the measurement of 
biochemical indices.  
 
Study Doctor: Dr Joy Simpson  
Chief Investigator: Professor Scott Nelson 
Other Investigators: Professor Ala-Koppel, Professor Lawlor, Professor Sattar 
 
We would like to invite you to take part in a research study. Before you decide you need to 
understand why the research is being done and what it would involve. Please take time to read 
the following information carefully. Talk to others about the study if you wish. Ask us if there 
is anything that is not clear or if you wish further information. Please, take time to decide 
whether you would like to participate or not.  
 
1. What is the purpose of the study?  
 
The purpose of the study is to collect blood samples from the umbilical cord after birth from 
100 different patients. This blood can then be used to run tests on a machine called Nuclear 
Magnetic Resonance (NMR) machine so that it can be scientifically prepared for future 
research projects. This process is called calibration and method development.  
 
As cord blood has not previously been analysed on a NMR machine before, it is important that 
this process is carried out so that future samples can be analysed with greater accuracy. This 
process will be carried out by experts at the University of Eastern Finland and by a company 
called Skylight Biotech in Japan. Therefore, once the samples have been collected, they will 
be split into smaller samples, frozen and sent by courier to Finland and then to Japan to 
complete this calibration process. Following this the samples will be returned to our Biobank 
at the Glasgow British Heart Foundation building. It is anticipated that the calibration process 
will take up to 12 months to complete but the samples will be kept in storage for longer.  
 
It is important that we collect detailed information for each participant and send this to our 
collaborators in Finland and Japan. This information will include your age, smoking status, 





your current pregnancy, gestation at delivery, mode of delivery and the birthweight of your 
baby. This information will be given a coded number so that it can be anonymous but linked to 
the cord blood sample. All of this will be non-identifiable and won’t contain any of your 
personal details.  
  
2. Why have I been chosen? 
 
We are asking pregnant patients who deliver their baby at the Southern General 
Hospital/Princess Royal Maternity Hospital to take part. We are planning to collect blood 
samples from the umbilical cord from a cross section of pregnancy and birth outcomes.  Once 
the blood samples and the information from your case notes has been collected you will have 
no further input in the Study.  
 
3. Do I have to take part? 
 
It is up to you whether or not to take part. If you decide to participate you will be given this 
information leaflet for your records and you will be asked to sign a consent form. You are free 
to withdraw from the study any time without giving a reason. 
 
4. What is my part in the study? 
 
If you agree to take part and meet the inclusion criteria, you will be asked to complete a consent 
form. Following the birth of your baby, your midwife will clamp the umbilical cord in three 
places, cut and deliver the placenta and cord as is performed routinely. Prior to the placenta 
and umbilical cord being disposed of, a blood sample will then be taken from the umbilical 
cord once it is completely separate from you and your baby so it will not harm you or your 
baby in any way. The Study Doctor will then complete a short questionnaire using your hospital 
case notes so you do not need to fill this in yourself.   
 
5. What do I have to do? 
 
If you are happy with the information provided and agree to participate, you will have the 
opportunity to discuss any questions with the Study Doctor. If you are satisfied with this, you 
will be asked to complete a consent form. There is no alteration of routine midwifery/medical 
care.  
 
Following delivery of your baby your midwife/doctor will deliver the placenta and umbilical 
cord as normal. Only following this will the blood sample from the baby’s cord be taken by the 
Study Doctor. It is standard procedure for the placenta, membranes and umbilical cord to be 
disposed of (by incineration) after it has been delivered. Participants will not require any active 
involvement and do not require to do anything for this. Again, a questionnaire will be 
completed by the Study Doctor using information in your case notes and so you do not need to 
do anything for this either.   
 
 
6. What are the possible disadvantages and risks of taking part? 
 
Taking blood samples from the baby’s cord will not harm you or your baby in any way. It will 





It will not affect whether or not you wish to take your placenta home with you when you are 
discharged.  
The blood samples are being used to prepare a machine for future scientific research, so they 
are not being used to determine a result such as ‘high’ or ‘low’ level. You will not be informed 
of these outcomes.  
 
7. What are the possible benefits of participating? 
 
The information gained during the study will enable sufficient preparation of the NMR 
machine. Following this we will be able to begin formal scientific research on umbilical cord 
blood using the NMR machine. 
 
8. What if there is a problem? 
 
The cord blood samples are being used to prepare the NMR machine for future research. 
Therefore the results will not be reported individually and you will not receive/require any 
follow up in this study. 
 
8. What if something goes wrong?    
 
If you have concerns about the study or the way is conducted, you are welcomed to contact the 
researchers (contact details at the end of the leaflet) and discuss these with them. Should you 
wish to make a formal complaint you can do so through the NHS complaints procedure.  Details 
can be obtained from the hospital.   
 
9. Expenses and payment 
 
You will not receive explicit payment for this study. You will not need to pay anything that you 
would require reimbursement for.  
 
10. Will my taking part in this study be kept confidential? 
 
Yes. All information collected about you during the course of the research will be kept strictly 
confidential and only be handled by the individuals listed above or any staff that work under 
their supervision.  Your GP will not be informed of your participation in the study. 
11. What will happen to my samples after the study has finished? 
 
Samples will initially be sent to the University of Eastern Finland and then transferred for 
analysis in Japan. Following this, residual samples will be returned for storage in our Biobank 
at the Glasgow British Heart Foundation Building.  
 
 
13. What will happen if I don’t want to carry on with the study? 
 
You can withdraw any time from the study. If you wish to withdraw from the study, we will 
retain the data that has been collected up to your withdrawal. However, should you wish for 
samples and data to be destroyed we will comply with this request. 
 






NHS Greater Glasgow and Clyde is sponsoring the Study. 
 
15. Who has reviewed the study? 
 
This study has been reviewed by the Greater Glasgow and Clyde Research and Development 
Management Office. 
 
16. Further Information 
 
If you wish to ask any questions about the study now or at any time, please contact the 
Study Doctor.  
Dr Joy Simpson can be contacted by phone on 0141-211 2327 (research office) or email 
joy.simpson@glasgow.ac.uk  
 
If you wish to ask more questions about the study from an individual scientist who has a 
thorough understanding of the area of research but is not directly related to the project, please 
contact: 
 
Dr David Preiss (Clinical Senior Lecturer) 


















Dear Joy [This message is automatically generated by the UKCRN Portfolio and Accrual 
System.] crncc.servicedesk.nihr.ac.uk 
 
This is confirmation that a successful upload of the following studies has occurred for the 
period up to the end of May 2013: 
 
Collection of Umbilical Cord Blood Samples V2 
 
If you have any questions relating to the process of uploading your data you should, in the 
first instance, contact your network contact (or Board R&D Office in Scotland). However if 
you have any further queries the UKCRN IS Team (at https://portal.ukcrn.org.uk/helpdesk) 
will be happy to help. 
 
 
Study 14440 - Collection of Umbilical Cord Blood Samples 
V2 
Previous total rows uploaded 0 
Number of new rows in current upload 100 
Projected total rows (following processing) 100 
    
Previous total unique participants uploaded 0 
Number of new unique participants in current upload 100 
Projected total unique participants (following processing) 100 
    
Previous running total 0 











Research Protocol  
Title 
Umbilical Cord Blood Sampling for the Purpose of Nuclear Magnetic Resonance Machine 
Calibration 
Introduction 
The purpose of this Study is to collect 100 umbilical cord blood samples and corresponding 
information on maternal and fetal characteristics. This is required to aid the development of 
the methodology and calibration process of a Nuclear Magnetic Resonance (NMR) machine, 
specifically for cord blood. NMR has already been used to process blood samples from the 
adult non pregnant population. It provides in depth information on metabolites (lipoproteins, 
lipids and low molecular weight metabolites). It has not yet been used to process umbilical 
cord bloods. Once the calibration process is complete, it will then allow detailed and accurate 
analysis of cord bloods from a separate study and much larger cohort – the Avon Longitudinal 
Study of Parent’s and Children (ALSPAC).  
Background 
The phenotype at birth is related to long-term outcomes and this concept is strengthened by 
observations that birth weight has been positively associated with mean infant, childhood and 
adulthood BMI and adiposity in a number of studies1-4.  Inflammatory markers and lipids have 
been shown to track through childhood and predict later obesity, metabolic and vascular 
disease respectively5-10 This is not fixed as pregnancy complications like excessive gestational 
weight gain, diabetes, glycosuria and the hypertensive disorders of pregnancy can all 
influence offspring fat mass, inflammatory and lipid profile at age 9 and 15 years11-16.   
We seek to address this unique challenge by addition of comprehensive high-resolution 
metabolomics data to an established prospective birth cohort (ALSPAC). This cohort has pre-
existing information on pregnancy characteristics and complications, genotype and childhood 
development. This includes repeat measures of growth, adiposity, cardiovascular and 
metabolic risk factors and cognitive function.  
To provide an overview of metabolic and inflammatory pathways evident at birth we will use 
1H-NMR spectroscopy and analysis developed by one of our collaborators Mika Ala-Korpela 
(MAK; University of Eastern Finland) and now established at Glasgow University Polysomic 
Unit. This platform is already well established and validated in the adult non pregnant 
population. The method and calibration process specifically for umbilical cord blood will 







Patients will be approached to take part in the study in Maternity assessment, the antenatal 
ward or labour ward at the Southern General Hospital/Princess Royal Maternity Hospital, 
Glasgow. They will be provided with a patient information leaflet and given >1hour to read 




Consent will be completed by each patient following consultation with Dr Joy Simpson. 
 
Umbilical Cord Blood Collection 
 
Following delivery of the child, the midwife will clamp the umbilical cord in 3 separate places. 
After the placenta and cord has been delivered and separated from mother and child, a 10ml 
sample of venous and 5ml sample of arterial blood from the umbilical cord will be obtained. 
This will be performed by the Study Doctor using a 10ml and 5ml syringe and 21 gauges 
needles. These samples will then be transferred into yellow biochemistry bottles and 
anonymously labelled (sample number 1 to 100, venous or arterial). 
 
The samples will be obtained within 30 minutes of delivery of the placenta and cord. 
Following this, the samples will be taken to the lab at the Glasgow British Heart Foundation 
Cardiovascular Research Centre to be centrifuged and the serum and plasma split into 
aliquots. For each patient's cord blood sample, aliquots of 100 microlitres will be obtained 
and stored (in 1.5ml micro-centrifuge tubes) in the freezer at -80°C. These aliquots will then 
be labelled 1a, b, c, d etc for each patient's sample. The remaining serum will be stored in 
separate containers suitable for freezing. 
  
Information on maternal and fetal characteristics will be obtained from the case notes and 
also labelled sample 1-100 so that it is anonymous and corresponds to the appropriate 
patient's cord blood sample. This information will include: age, body mass index (at 
booking), smoking status, ethnicity, parity, gestational age at delivery, pregnancy 
complications (pre-eclampsia, gestational diabetes), mode of delivery (eg caesarean section, 
forceps delivery etc) and baby’s birthweight.  
  
The calibration process and development of the methodology will be carried out by Professor 
Ala-Korpela's team, University of Eastern Finland, Finland. It will also require secondary 
calibration which will be performed by Skylight Biotech, Tokyo, Japan. Therefore the serum 
cord blood aliquots will be transferred to their department by courier in boxed containers of 
dry ice. The  corresponding information on maternal and fetal characteristics will be sent to 
Professor Ala-Korpela's team via electronic mail. All of this information will be anonymous 
and will not include any personal details. Therefore the patient has no further input in the 
study beyond consenting to the Study and the collection of umbilical cord blood. After the 
calibration process is completed (<12months anticipated from transfer of cord blood) any 
remaining samples would be returned to the original Biobank at the BHF Glasgow 
Cardiovascular Research Centre.  Therefore the patient has no further input in the study 








Benefits and Risks 
 
There are no immediate benefits or risks anticipated. Once the NMR platform is developed 
specifically for cord blood, this will then allow processing of the ALSPAC cord blood.  
 
Inclusion Criteria 
Female pregnant patients age 18 to 45 years old. 
Consent obtained 
Deliver in Southern General Hospital/Glasgow Royal Infirmary 
Speak English/interpreter present 
Placenta clamped and already delivered by midwife/doctor. 
Cord blood sample taken <30minutes of delivery of placenta 
Corresponding information on maternal/fetal characteristics available for documentation  
Exclusion Criteria 
Pregnant patients <18 and >45 years old 
Consent not obtained 
Deliver out with Southern General Hospital/Glasgow Royal Infirmary  
Do not speak English/interpreter not present 
Placenta not clamped appropriately/not yet delivered 
Blood sample obtained >30minutes after delivery of placenta 














Participants will be approached by the Research Doctor (Dr Joy Simpson) and information 
given in the form of a patient information leaflet. This will take place in either the antenatal 
wards, labour ward or the maternity assessment areas. Patients will be given >1hour to read 
the leaflet and also have the opportunities to ask questions. The consent form will be 
completed by the patient and the Research Doctor. The patient will have no active 
involvement in the Study beyond this. There will be no follow up.  
Duration 
We plan to collect 100 umbilical cord blood samples. This is expected to take place over a 4-
week period. The Study itself however will commence on the 27thth March 2013. It is 
anticipated that the cord blood samples can be collected over a 4-week basis. However as 
the Study is part of a much larger PhD project (using the ALSPAC cohort) then it is expected 
this to run until August 2015. 
Medication 
No medication is being tested/trialled. 
Criteria for Discontinuation 
Patient withdraws consent.  
Does not fulfil inclusion criteria/meets exclusion criteria.  
Data Collection 
Data will be collected from the case notes by the Study Doctor. This will include patient age, 
parity, smoking status, BMI, ethnicity, pregnancy complications, gestation at delivery, mode 
of delivery and baby's birthweight. 
Information will be transferred to an excel file and stored securely on University of 
Glasgow/NHS Greater Glasgow and Clyde password protected software.  
Sample Size 
100 cord blood samples are required for the NMR platform calibration. This sample size is 
recommended by Professor Korpela's team.  
Ethics 
The study will be carried out in accordance with the ethical principles in the Research 
Governance Framework for Health and Community Care, Second Edition, 2006 and 






Finance and Indemnity 
NHS Greater Glasgow and Clyde will sponsor this Study. 
NHS employed researchers will be covered for negligent harm through the NHS CNORIS 
indemnity scheme. 
Publications 
The results of the study will be disseminated by publishing in peer reviewed scientific journals, 
internal reports and presentation at conferences.  
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